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Abstract
Contrast-enhanced ultrasound using SonoVue® (sulphur 
hexafluoride microbubbles) compared with contrast-
enhanced computed tomography and contrast-enhanced 
magnetic resonance imaging for the characterisation of 
focal liver lesions and detection of liver metastases: a 
systematic review and cost-effectiveness analysis
M Westwood,1* M Joore,2 J Grutters,3 K Redekop,4 N Armstrong,1 
K Lee,1 V Gloy,5 H Raatz,5 K Misso,1 J Severens6 and J Kleijnen7
1Kleijnen Systematic Reviews Ltd, York, UK
2Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University 
Medical Centre, Maastricht, Netherlands
3Department of Health Services Research, Maastricht University, Maastricht, Netherlands
4Institute for Medical Technology Assessment, Erasmus University, Rotterdam, Netherlands
5Basel Institute of Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland
6Institute of Health Policy and Management, Erasmus University, Rotterdam, Netherlands
7School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands
*Corresponding author
Background: Medical imaging techniques are important in the management of many patients with liver 
disease. Unenhanced ultrasound examinations sometimes identify focal abnormalities in the liver that may 
require further investigation, primarily to distinguish liver cancers from benign abnormalities. One 
important factor in selecting an imaging test is the ability to provide a rapid diagnosis. Options for 
additional imaging investigations include computed tomography (CT) and/or magnetic resonance imaging 
(MRI) and biopsy when the diagnosis remains uncertain. CT and MRI usually require referral with 
associated waiting time and are sometimes contraindicated. The use of contrast agents may improve the 
ability of ultrasound to distinguish between liver cancer and benign abnormalities and, because it can be 
performed at the same appointment as unenhanced ultrasound, more rapid diagnoses may be possible.
Objective: To compare the clinical effectiveness and cost-effectiveness of contrast-enhanced ultrasound 
(CEUS) using SonoVue® with that of contrast-enhanced computed tomography (CECT) and contrast-
enhanced magnetic resonance imaging (CEMRI) for the assessment of adults with focal liver lesions (FLLs) 
in whom previous liver imaging is inconclusive.
Data sources: Eight bibliographic databases including MEDLINE, EMBASE, Cochrane Database of 
Systematic Reviews and Database of Abstracts of Reviews of Effects were searched from 2000 to 
September/October 2011. Research registers and conference proceedings were also searched.
Review methods: Systematic review methods followed published guidance. Risk of bias was assessed 
using a modified version of the QUADAS-2 tool. Results were stratified by clinical indication for imaging 
(characterisation of FLLs detected on ultrasound surveillance of cirrhosis patients, detection of liver 
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metastases, characterisation of incidentally detected FLLs, assessment of treatment response). For 
incidental FLLs, pooled estimates of sensitivity and specificity, with 95% CIs, were calculated using a 
random-effects model. For other clinical indications a narrative summary was used. The cost-effectiveness 
of CEUS was modelled separately for the three main clinical applications considered [characterisation of 
FLLs detected on ultrasound surveillance of cirrhosis patients, detection of liver metastases in patients with 
colorectal cancer (CRC), characterisation of incidentally detected FLLs].
Results: Of the 854 references identified, 19 (describing 18 studies) were included in the review. Hand 
searching of conference proceedings identified a further three studies. Twenty of the 21 studies included in 
the systematic review were diagnostic test accuracy studies. Studies in cirrhosis patients reported varying 
estimates of test performance. There was no consistent evidence of a significant difference in performance 
between imaging modalities. It was unclear whether or not CEUS alone is adequate to rule out 
hepatocellular carcinoma (HCC) for FLLs of < 30 mm; one study indicated that CEUS may be better at ruling 
out HCC for FLLs of 11–30 mm [very small FLLs (< 10 mm) excluded]. There was no consistent evidence of a 
difference in test performance between imaging modalities for the detection of metastases; CEUS alone 
may be adequate to rule out liver metastases in colorectal cancer. In patients with incidentally detected 
FLLs, the pooled estimates of sensitivity for any malignancy using CEUS and CECT were 95.1% and 94.6%, 
respectively, and the corresponding specificity estimates were 93.8% and 93.1% respectively. One study 
comparing CEUS with CEMRI reported similar sensitivity and lower specificity for both modalities. In the 
surveillance of cirrhosis, CEUS was as effective as but £379 less costly than CECT. CEMRI was £1063 more 
costly than CEUS and gained 0.022 QALYs. In the detection of liver metastases from CRC, CEUS cost £1 
more than CECT, and at a lifetime time horizon they yielded equal QALYs. CEMRI was dominated by CECT. 
In the characterisation of incidentally detected FLLs, CEUS was slightly more effective than CECT and CEMRI 
(by 0.0002 QALYs and 0.0026 QALYs respectively) and less costly (by £52 and £131 respectively).
Limitations: There were a number of methodological issues specific to the studies included in this review. 
The main indication for liver imaging in the populations considered is likely to be to rule out primary liver 
cancer or metastases. Therefore, patient-level analyses of test performance are of particular interest. Some 
of the studies included in this review reported per-patient analyses; however, no study clearly stated how 
results were defined (e.g. was the presence of any positive lesion regarded as a positive test for the whole 
patient). In addition, a number of studies reported data for one lesion per patient (treated as per-patient 
data in this assessment). These studies generally selected the largest lesion or the lesion ‘most suspicious 
for malignancy’ for inclusion in analyses, with the consequence that estimates of test performance may 
have been exaggerated. The applicability of studies included in this review may be limited, as the majority 
of imaging studies were interpreted by multiple, experienced operators and the prevalence of malignancy 
in included studies appeared higher than might be expected in clinical practice. The cost-effectiveness 
analyses did not take into account the potential benefits of reduced anxiety that may arise from potentially 
shorter waiting times associated with SonoVue CEUS.
Conclusions: SonoVue CEUS could provide similar diagnostic performance to other imaging modalities 
(CECT and CEMRI) for the assessment of FLLs. Economic analyses indicated that CEUS was a cost-effective 
replacement for CEMRI. The use of CEUS instead of CECT was considered cost-effective in the surveillance 
of cirrhosis and the characterisation of incidentally detected FLLs, with similar costs and effects for the 
detection of liver metastases from CRC. Further research is needed to compare the effects of different 
imaging modalities (SonoVue CEUS, CECT, CEMRI) on therapeutic planning, treatment and clinical 
outcomes. Future test accuracy studies should provide standardised definitions of a positive imaging test, 
and compare all three imaging modalities in the same patient group.
Study registration: PROSPERO: CRD42011001694.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Cholangiocarcinoma Cancer of the bile ducts, which drain bile from the liver into the small intestine.
Cirrhosis A consequence of liver disease, most commonly alcoholism, hepatitis B and C, or fatty liver 
disease. It is characterised by replacement of liver tissue with fibrosis and scar tissue, leading to loss of 
liver function.
Computed tomography A medical imaging technique using tomography created by computer 
processing to generate a three-dimensional internal image from a series of two-dimensional 
radiographic images.
Contrast-enhanced ultrasound The application of a contrast agent to conventional ultrasonography. 
Ultrasound contrast agents rely on the different ways that sound waves are reflected from interfaces 
between substances, for example microbubbles and human tissue. The difference in echogenicity (ability 
to reflect ultrasound waves) between microbubbles and surrounding tissues is very high and intravenous 
contrast injection can be used to visualise blood perfusion and to distinguish between benign and 
malignant tissue.
Cost-effectiveness analysis An economic analysis that converts effects into health terms and describes 
the costs for additional health gain.
Decision modelling A theoretical construct that allows the comparison of the relationship between costs 
and outcomes of alternative health-care interventions.
False-negative Incorrect negative test result – number of diseased persons with a negative test result.
False-positive Incorrect positive test result – number of non-diseased persons with a positive test result.
Focal nodular hyperplasia A benign, usually asymptomatic tumour of the liver, which rarely grows or 
bleeds and has no malignant potential. It is often characterised by a central stellate scar.
Haemangioma The most common benign tumour of the liver, usually of mesenchymal origin and 
comprising masses of atypical blood vessels.
Hepatocellular carcinoma The most common type of liver cancer, usually secondary to scarring of the 
liver (cirrhosis) or hepatitide viral infection (hepatitis B or C).
Incremental cost-effectiveness ratio The difference in the mean costs of two interventions in the 
population of interest divided by the difference in the mean outcomes in the population of interest.
Index test The test whose performance is being evaluated.
Magnetic resonance imaging A medical imaging technique that uses nuclear magnetic resonance to 
image the nuclei of atoms inside the body. It provides good contrast between the different tissues of the 
body and can be useful in distinguishing malignant from benign tumours.
Markov model An analytical method particularly suited to modelling repeated events or the progression 
of a chronic disease over time.
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xii
Meta-analysis Statistical techniques used to combine the results of two or more studies and obtain a 
combined estimate of effect.
Meta-regression Statistical technique used to explore the relationship between study characteristics and 
study results.
Metastasis The spread of a disease from one organ or part to another non-adjacent organ or part.
Opportunity cost The cost of forgone outcomes that could have been achieved through 
alternative investments.
Publication bias Bias arising from the preferential publication of studies with statistically 
significant results.
Quality of life An individual’s emotional, social and physical well-being and his or her ability to perform 
the ordinary tasks of living.
Quality-adjusted life-year A measure of health gain used in economic evaluations in which survival 
duration is weighted or adjusted by the patient’s quality of life during the survival period.
Radiofrequency ablation A medical procedure in which tumour tissue is ablated using the heat 
generated from the high-frequency alternating current.
Receiver operating characteristic curve A graph that illustrates the trade-offs between sensitivity and 
specificity that result from varying the diagnostic threshold.
Reference standard The best currently available diagnostic test against which the index test 
is compared.
Sensitivity Proportion of people with the target disorder who have a positive test result.
Specificity Proportion of people without the target disorder who have a negative test result.
Transarterial chemoembolisation A minimally invasive medical procedure to restrict blood flow to the 
tumour; frequently used to treat hepatocellular carcinoma.
True-negative Correct negative test result – number of non-diseased persons with a negative test result.
True-positive Correct positive test result – number of diseased persons with a positive test result.
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List of abbreviations
AASLD American Association for the 
Study of Liver Diseases
AFP alpha-fetoprotein
ALD alcoholic liver disease
CCC cholangiocarcinoma
CEA carcinoembryonic antigen
CECT contrast-enhanced 
computed tomography
CEMRI contrast-enhanced magnetic 
resonance imaging
CEUS contrast-enhanced ultrasound
CI confidence interval
CRC colorectal carcinoma
CRD Centre for Reviews 
and Dissemination
CT computed tomography
DARE Database of Abstracts of Reviews 
of Effects
DTA diagnostic test accuracy
EASL European Association for the 
Study of the Liver
EFSUMB European Federation of Societies 
for Ultrasound in Medicine 
and Biology
FDG-PET fluorodeoxyglucose positron 
emission tomography
FLL focal liver lesion
FNB fine-needle biopsy
Gd-CEMRI gadolinium contrast-enhanced 
magnetic resonance imaging
Gd-EOB- gadolinium ethoxybenzyl 
DTPA  diethylenetriamine 
penta-acetic acid
HBV hepatitis B virus
HCC hepatocellular carcinoma
HCV hepatitis C virus
HTA Health Technology Assessment
ICER incremental 
cost-effectiveness ratio
MDCT multidetector 
computed tomography
MRI magnetic resonance imaging
NHS EED NHS Economic 
Evaluation Database
NICE National Institute for Health and 
Care Excellence
NIHR National Institute for 
Health Research
OR odds ratio
PEI percutaneous ethanol injection
PenTAG Peninsula Technology 
Assessment Group
PRESS EBC Peer Review of Electronic 
Search Strategies 
Evidence-Based Checklist
QALY quality-adjusted life-year
RFA radiofrequency ablation
ROC receiver operating characteristic
RON Romanian new leu
SCI Science Citation Index
SPIO- superparamagnetic iron oxide 
CEMRI  contrast-enhanced magnetic 
resonance imaging
SROC summary receiver 
operating characteristic 
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TAE transarterial embolisation
TACE transarterial chemoembolisation
TNM tumour, lymph node, metastases
US ultrasound
All abbreviations that have been used in this report are listed here unless the abbreviation 
is well known (e.g. NHS), or it has been used only once, or it is a non-standard 
abbreviation used only in figures/tables/appendices, in which case the abbreviation is 
defined in the figure legend or in the notes at the end of the table.
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Executive summary
Background
Ultrasound (US) scanning and other imaging technologies [e.g. computed tomography (CT) and magnetic 
resonance imaging (MRI)] are important in the management of many patients with liver disease. Imaging 
sometimes identifies focal abnormalities in the liver that cannot be characterised initially and may 
need further investigation, the main aim of which is to distinguish between liver cancers and benign 
abnormalities not likely to require further treatment. One important factor in selecting an imaging test is 
the ability to provide a rapid diagnosis, both to facilitate prompt treatment in patients who do have cancer 
and to minimise anxiety in the majority who do not. Most liver lesions are found at an initial unenhanced 
US scan. If the liver abnormality is not characterised by this test, the patient is usually referred for 
additional imaging (MRI and/or CT) and may require biopsy when additional imaging remains uncertain. 
CT and MRI can require additional waiting time, CT uses ionising radiation and the intravenous contrast 
agent can, on rare occasions, cause kidney damage, and some patients cannot undergo MRI (e.g. because 
of pacemakers or claustrophobia). The use of contrast agents may improve the ability of US to distinguish 
between liver cancer and benign abnormalities and, because it can be performed at the same appointment 
as unenhanced US, more rapid diagnoses may be possible and some CT and MRI examinations may 
be avoided.
Objectives
To compare the clinical effectiveness and cost-effectiveness of contrast-enhanced ultrasound (CEUS) using 
SonoVue® (Bracco UK Ltd, High Wycombe, UK) with that of contrast-enhanced CT (CECT) and contrast-
enhanced MRI (CEMRI) for the assessment of adults with focal liver lesions (FLLs) in whom previous liver 
imaging is inconclusive.
Methods
A systematic review was conducted to summarise the evidence on the clinical effectiveness of CEUS 
using the contrast agent SonoVue compared with the clinical effectiveness of CECT and CEMRI for the 
assessment of adults with FLLs in whom previous liver imaging has been inconclusive. Search strategies 
were based on the target condition (primary or secondary liver cancer) and intervention (SonoVue 
CEUS), as recommended in current methodological guidance (www.york.ac.uk/inst/crd/SysRev/!SSL!/
WebHelp/SysRev3.htm). Eight bibliographic databases including MEDLINE, EMBASE, Cochrane Database 
of Systematic Reviews and Database of Abstracts of Reviews of Effects were searched from 2000 to 
September/October 2011. Research registers and conference proceedings were also searched. Systematic 
review methods followed published guidance (www.york.ac.uk/inst/crd/SysRev/!SSL!/WebHelp/SysRev3.
htm). The risk of bias in diagnostic test accuracy (DTA) studies was assessed using a modified version 
of the QUADAS-2 tool, and in the single controlled clinical trial was assessed using an adaptation of 
The Cochrane Collaboration’s risk of bias tool. Accuracy results were summarised in tables and the text, 
stratified by clinical indication for imaging [characterisation of FLLs detected on US surveillance of cirrhosis 
patients, detection of liver metastases, characterisation of incidentally (US) detected FLLs, assessment of 
response to treatment of liver malignancy] and further stratified by target condition [primary hepatocellular 
carcinoma (HCC), liver metastases or ‘any liver malignancy’] and/or comparator test(s) (CECT, CEMRI, both), 
as appropriate. The review included only one group of four similar studies (comparable clinical indication, 
index test and comparator, target condition and diagnostic criteria). Pooled estimates of sensitivity and 
specificity, with 95% confidence intervals (CIs), were calculated using a random-effects model and a 
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sensitivity analysis was undertaken to assess the effect of excluding one large study that used a suboptimal 
reference standard. Between-study clinical heterogeneity was assessed qualitatively.
The health economic analysis focused on populations in whom clinical opinion indicated that there was 
most likely to be a benefit from the use of CEUS. These were also the populations with most data on test 
performance. Specifically, most data on the detection of metastases were available from patients with 
colorectal cancer (CRC). In addition, clinical opinion confirmed that liver metastases from CRC were the 
main focus of testing. Therefore, the health economic analysis used three models to assess the value of 
CEUS in the following three populations:
 z characterisation of FLLs detected on routine surveillance of patients with cirrhosis
 z detection of liver metastases in patients with CRC
 z characterisation of incidentally detected FFLs.
In each model, CEUS was compared with CECT, CEMRI using gadolinium contrast agent (Gd-CEMRI) and/
or CEMRI using superparamagnetic iron oxide contrast agent (SPIO-CEMRI). The average costs, expected 
life-years and expected quality-adjusted life-years (QALYs) per patient were calculated for each comparator, 
if accuracy data were available.
The cirrhosis surveillance model was a modified version of a model produced by the Health Economics 
Group, Peninsula Technology Assessment Group (PenTAG), Institute of Health Service Research, Peninsula 
Medical School (the PenTAG cirrhosis surveillance model) [Thompson Coon J, Rogers G, Hewson P, 
Wright D, Anderson R, Cramp M, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic 
review and economic analysis. Health Technol Assess 2007;11(34)]. The population of interest was 
those with a diagnosis of compensated cirrhosis deemed eligible to enter a surveillance programme. It 
was a probabilistic state transition (Markov) cohort model constructed using Microsoft Excel (Microsoft 
Corporation, Redmond, WA, USA). The model used a lifetime time horizon and the cycle duration was 
1 month. Patients in the model can develop HCC. In the base-case analysis surveillance is every 6 months 
and stops at age 70 years. During this surveillance (US, combined with CEUS, CECT or CEMRI when 
inconclusive), the probability of identifying a small (< 2 cm) or medium (2–5 cm) HCC depends on test 
accuracy. In the base case, accuracy was taken from Leoni et al. (Leoni S, Piscaglia F, Golfieri R, Camaggi V, 
Vidili G, Pini P, et al. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small 
hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol 2010;105:599–609). 
Large (> 5 cm) tumours are always identified at surveillance. If the tumour is not identified (false-negatives), 
it grows and may be identified at the next surveillance or when symptomatic. Patients without HCC who 
are incorrectly diagnosed (false-positives) were assumed to be rapidly discovered before treatment.
The liver metastases from CRC model is a modified version of the metastatic model developed by 
Brush et al., adapted to assess the cost-effectiveness of CEUS compared with CECT and CEMRI in 
detecting metastases from CRC after inconclusive US [Brush J, Boyd K, Chappell F, Crawford F, Dozier 
M, Fenwick E, et al. The value of FDG positron emission tomography/computed tomography (PET/
CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation. Health 
Technol Assess 2011;15(35)]. The population of interest was patients who had previously had surgical 
treatment for primary CRC and who, during routine follow-up, were identified as potentially having a 
metastatic recurrence. A decision tree combined with a probabilistic state transition (Markov) cohort 
model, constructed using Microsoft Excel, was used. The model used a lifetime time horizon and the 
cycle duration was 1 year. The probability of correctly detecting metastases depends on test accuracy. In 
the base case, accuracy was taken from Mainenti et al. (Mainenti PP, Mancini M, Mainolfi C, Camera L, 
Maurea S, Manchia A, et al. Detection of colorectal liver metastases: prospective comparison of contrast 
enhanced US, multidetector CT, PET/CT, and 1.5 Tesla MR with extracellular and reticulo-endothelial cell 
specific contrast agents. Abdom Imaging 2010;35:511–21). It was assumed that patients with undetected 
metastases (false-negatives) would be identified within a year if they were still alive. These patients are 
expected to have a lower quality of life and prognosis, but only in the first year. In the base-case analysis, 
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patients who are inaccurately diagnosed as having metastases (false-positives) are identified, because it 
is considered likely that clinicians will require confirmatory biopsy before initiating treatment. They are 
therefore not unnecessarily treated.
Patients with incidentally detected FLLs can have a variety of underlying diseases, for example HCC, 
metastases and various benign lesions. The prognosis and costs for patients with HCC were modelled using 
the cirrhosis model, and the prognosis and costs for patients with liver metastases were modelled using 
the liver metastases model. The FLL model used was a decision-analytic model with a lifetime time horizon. 
Test accuracy data were taken from the findings of the systematic review. The sensitivity and specificity 
of CEUS and CECT in identifying any malignancy were based on the results of a meta-analysis of four 
studies. CEUS and CEMRI could be compared using only one study. For different reasons it was assumed 
that patients with an incorrect test result (i.e. false-positive and false-negative results) would be correctly 
identified within 1 year. This was a conservative assumption biased against CEUS.
The impact of uncertainty about the various input parameters on the outcomes was explored through 
sensitivity analyses.
Results
Of the 854 references identified, 19 (describing 18 studies) were included in the review. Hand searching 
of conference proceedings identified a further three studies. Twenty of the 21 studies included in the 
systematic review were DTA studies. The majority of these were judged to be at low or unclear risk of bias 
with respect to the ‘index test’, ‘comparator test’ and ‘reference standard’ domains. Reporting quality 
was poor and a number of studies were reported only as conference abstracts. High risk of bias ratings 
for the ‘patient selection’ domain arose from retrospective study design or inappropriate exclusions (e.g. 
patients with a low probability of malignancy). High risk of bias ratings for the ‘flow and timing’ domain 
most frequently arose from exclusion of > 10% of patients from analyses. Test accuracy studies varied in 
terms of target condition, definitions of a positive imaging test and lesion size assessed. Overall, there was 
no clear indication that any of the imaging modalities considered (CEUS, CECT or CEMRI) offered superior 
performance for any of the populations or clinical applications considered.
Studies conducted in cirrhosis patients undergoing routine surveillance all concerned the differentiation 
of HCC from other lesion types. The definition of a positive test varied across studies and estimates of 
sensitivity and specificity were inconsistent, even when studies used similar definitions. There was no 
consistent evidence for any significant difference in performance between the three imaging modalities 
and three MRI contrast media assessed. It is unclear whether or not CEUS alone is adequate to rule out 
HCC for FLLs of < 30 mm in this population; one study indicated that CEUS may be better at ruling out HCC 
for FLLs of 11–30 mm, with very small FLLs (< 10 mm) not considered.
Studies of the diagnosis of liver metastases using contrast-enhanced imaging with vascular contrast media 
(CEUS, CECT and Gd-CEMRI) gave similar definitions of a positive test when reported. Two studies reported 
data for SPIO-CEMRI. There was no consistent evidence for any difference in test performance between the 
three imaging modalities and different contrast media assessed. The limited data available indicate that 
CEUS alone may be adequate to rule out liver metastases in patients with CRC.
Studies of patients with incidentally detected FLLs mainly reported data on diagnosis of ‘any malignancy’. 
Studies were consistent in their definitions of the criteria for HCC, which were similar to those reported in 
published guidelines. Studies reported per-patient or equivalent data. All studies reported no significant 
difference in the accuracy of CEUS and CECT or CEMRI for the characterisation of focal FLLs. The pooled 
estimates of sensitivity for the identification of ‘any liver malignancy’ using CEUS and CECT were 95.1% 
(95% CI 93.3% to 96.6%) and 94.6% (95% CI 92.7% to 96.1%), respectively, and the corresponding 
specificity estimates were 93.8% (95% CI 90.4% to 96.3%) and 93.1% (95% CI 89.6% to 95.8%), based 
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on data from four studies. The single study comparing CEUS with CEMRI reported similar sensitivity 
and lower specificity for both modalities. High estimates of sensitivity indicate that CEUS alone may be 
adequate to rule out liver malignancy in this population.
In the surveillance of cirrhosis, CEUS was found to be as effective as but £379 (95% CI £324 to £1060) 
less costly than CECT. This indicates that CEUS dominates CECT. Gd-CEMRI was found to be £1063 (95% 
CI £449 to £1492) more costly than CEUS and gained 0.022 (95% CI –0.002 to 0.050) more QALYs. This 
resulted in an incremental cost-effectiveness ratio (ICER) of £48,545 per QALY gained. This ICER would 
be deemed unacceptable given a willingness-to-pay threshold of £20,000 per additional QALY. CEUS 
can therefore be considered the most cost-effective option when used after inconclusive US. Changing 
the source of accuracy data corroborated the dominance of CEUS over CECT. CEUS was cost-effective 
compared with Gd-CEMRI in most sensitivity analyses.
In the diagnosis of liver metastases from CRC, CEUS was found to cost £1 (95% CI –£1.26 to £1.28) more 
than CECT and at a lifetime time horizon they yielded equal QALYs per patient. Both Gd-CEMRI and SPIO-
CEMRI were dominated by CECT because they were more costly and equally as effective. When increasing 
the proportion of patients with metastases or changing the source of accuracy data, CEUS was found to 
dominate CECT. In these additional analyses, Gd-CEMRI was not cost-effective compared with CEUS, or 
dominated by CEUS. If it is not assumed that patients incorrectly diagnosed with metastases are identified 
by biopsy before any unnecessary treatment, the lower specificity of CEUS has greater consequences. 
CEUS is then the most costly and the least effective option, and Gd-CEMRI dominates. However, it is 
questionable whether or not this would happen in practice.
In the characterisation of incidentally detected FLLs, CEUS was found to be very slightly more effective 
(0.0002 QALYs; 95% CI –0.00110 to 0.00140) than CECT and £52 (95% CI –£81 to –£22) less costly. 
Compared with CEMRI, CEUS was also slightly more effective (0.0026 QALYs; 95% CI –0.0058 to 
0.0135 QALYs) and less costly (–£131; 95% CI –£194 to –£69). An increased prior probability of malignant 
lesions increased the QALYs gained by CEUS compared with both CECT and CEMRI, thereby confirming its 
dominance. When the consequences of an incorrect diagnosis of HCC and metastases were made more 
or less severe, CEUS dominated CECT and CEMRI. When the data source for the performance of CEUS and 
CECT was switched from the meta-analysis to one of the four studies used in the meta-analysis, the cost-
effectiveness results changed only slightly, and did not alter the dominance of CEUS over CECT.
Conclusions
The results of our systematic review suggest that SonoVue CEUS could provide similar diagnostic 
performance to other imaging modalities (CECT and CEMRI) for the three main clinical applications 
considered: characterisation of FLLs detected on US surveillance of cirrhosis patients, detection of liver 
metastases in patients with CRC and characterisation of incidentally detected FLLs. However, some caution 
is required in the interpretation of these findings as studies were generally small and heterogeneous 
with respect to the target condition (HCC, liver metastases or ‘any malignancy’), definitions of a positive 
imaging test and lesion size assessed.
The cost-effectiveness analysis indicated that the use of CEUS instead of CEMRI was cost-effective. 
The use of CEUS instead of CECT was considered cost-effective in the surveillance of cirrhosis and the 
characterisation of incidentally detected FLLs, with similar costs and effects for the detection of liver 
metastases from CRC. Although conclusions can be very dependent on the management of incorrectly 
diagnosed lesions, it is expected that CEUS can reduce costs without reducing quality of life and survival. It 
should be noted that, although no data were available on this issue, experience with CEUS could have an 
important impact on diagnostic accuracy; availability of experienced operators and training requirements 
are likely to be important considerations for the implementation of this technology.
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If the main use of liver imaging is considered to be the rapid rule-out of malignancy, equivalent diagnostic 
performance may be sufficient for SonoVue CEUS to be preferred over other imaging modalities. A 
potential advantage of using SonoVue CEUS would be the option of completing the assessment at 
the same time as the initial unenhanced US. Although this would be unlikely to reduce waiting times 
(compared with other imaging modalities) sufficiently to change clinical outcome, the potential to provide 
more rapid diagnosis without repeat hospital visits is likely to be preferred by patients and may also 
reduce costs.
Suggested research priorities
The ideal study to address questions of clinical effectiveness would be a large multicentre RCT in which 
patients are randomised to receive further testing/monitoring, therapeutic planning and/or treatment 
based on different imaging strategies (SonoVue CEUS, CECT, CEMRI). Long-term observational studies 
assessing the clinical consequences of incorrect initial diagnoses may also be informative for future cost-
effectiveness analyses. Standardisation of the definition of a positive imaging test for each target condition 
(HCC, liver metastases) followed by further, high-quality DTA studies is needed to confirm our findings on 
test accuracy. Future DTA studies should ideally compare the performance of all three imaging modalities 
(SonoVue CEUS, CECT and CEMRI) in the same patient group and report numbers of non-diagnostic 
images and imaging-related adverse events. Studies comparing all three imaging modalities could provide 
a useful vehicle for the collection of information on patients’ preferences. Further investigation of the 
potential role of CEMRI, using newer ‘combined’ vascular and hepatocyte-specific contrast agents, may 
also be warranted. The practicality and effectiveness of SonoVue CEUS in the assessment of multiple 
lesions in both lobes of the liver should also be considered.
Study registration
This study is registered as PROSPERO: CRD42011001694.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National 
Institute for Health Research.
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Chapter 1 Objective
To compare the clinical effectiveness and cost-effectiveness of contrast-enhanced ultrasound (CEUS) using the contrast agent SonoVue® (Bracco UK Ltd, High Wycombe, UK) with that of contrast-enhanced 
computed tomography (CECT) and contrast-enhanced magnetic resonance imaging (CEMRI) for the 
assessment of adults with focal liver lesions (FLLs) in whom previous liver imaging has been inconclusive.
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Chapter 2 Background and definition of the 
decision problem
Conditions and aetiologies
The indication for this assessment is the characterisation of FLLs and detection of liver metastases in 
adults and the target conditions are malignancies of the liver [primary hepatocellular carcinoma (HCC) or 
liver metastases].
In the context of this assessment, the term ‘focal lesion in the liver’ refers to any focal area of perceived 
difference seen on an imaging study and occurring in one specific area of the liver. FLLs can be broadly 
classified as benign (e.g. haemangioma, focal nodular hyperplasia, focal fatty infiltration or sparing and 
adenoma) or malignant [e.g. primary HCC, cholangiocarcinoma (CCC) or liver metastases], with the 
identification or exclusion of malignancy being the primary aim of diagnostic imaging. The distinction 
between benign and malignant determines the individual’s prognosis and the subsequent treatment 
strategy. Benign, asymptomatic FLLs usually do not require any treatment. Depending on the specific type 
of lesion, the individual may be monitored and the lesion rescanned in 6–12 months. Once a malignant 
lesion is identified it is important to distinguish between primary and secondary cancers as this is likely to 
impact on how the individual is managed. Malignant lesions may be treated by a range of interventions 
including chemotherapy, liver resection (surgery) and local ablative therapy. The treatment of primary HCC 
has been addressed in published guidelines1,2 and the National Institute for Health and Care Excellence 
(NICE) has issued guidance on a number of individual interventions for primary HCC and liver metastases 
(see Appendix 6). However, expert opinion suggests that practice within the NHS may vary significantly 
across regions based on clinician preference.
Although liver cancer is rare in the UK (age-standardised rates are 4.7 per 100,000 men and 2.9 per 
100,000 women),3 it is the second most rapidly increasing cancer in men and the third in women 
(increases of 38% and 28%, respectively, in the last decade).4 However, as 70–75% of FLLs assessed in 
the NHS may be benign, one possible benefit of CEUS may be the rapid rule-out of malignancy with 
an associated reduction in anxiety for patients and families. The current practice of referring patients 
with inconclusive unenhanced ultrasound (US) for CEMRI and/or CECT may result in a wait of up to 
several months.
Because SonoVue CEUS should be used only when unenhanced US is inconclusive, we consider its primary 
application to be for the characterisation of lesions (benign or malignant) in patients with known FLLs; 
most patients who have already undergone unenhanced US and who have proceeded to CEUS are 
likely to have FLLs (seen at unenhanced US), the nature of which remains uncertain. Detection of FLLs at 
unenhanced US may be ‘incidental’ (FLLs detected in patients undergoing abdominal US for symptoms 
and/or biochemistry suggestive of possible liver disease or for other reasons unrelated to possible liver 
disease) or the result of routine surveillance of patients with cirrhosis. CEUS may also identify additional 
FLLs over and above those detected on unenhanced US. Other relevant applications include the detection 
of specific types of malignant FLLs [e.g. liver metastases from colorectal carcinoma (CRC), recurrent or 
residual disease following treatment of a known malignancy]. A recent systematic review reported ranges 
for the sensitivity and specificity of SonoVue CEUS for the detection of liver metastases from CRC of 
79–100% and 95–100%, respectively,5 but this review did not provide any comparison with the accuracy 
of other imaging techniques.
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Description of technologies under assessment (SonoVue)
SonoVue is a second-generation contrast agent that uses sulphur hexafluoride microbubbles for CEUS 
imaging in adults. It is used to enhance the echogenicity of the blood and can thus improve the signal-
to-noise ratio in US. SonoVue should be used only in patients for whom unenhanced US is inconclusive.6 
Low solubility gas contrast agents such as SonoVue allow imaging at low mechanical index, which in turn 
leads to effective tissue signal suppression.6 First-generation agents have now been superseded by second-
generation agents and are no longer available in Europe.
The SonoVue product information lists its applications as:
 z echocardiography – provision of opacification of cardiac chambers and enhancement of left ventricular 
echocardial border delineation in patients with suspected or known cardiovascular disease
 z Doppler US of the macrovasculature – detection or exclusion of abnormalities in the cerebral arteries, 
extracranial carotid arteries or peripheral arteries
 z Doppler US of the microvasculature – visualising the vascularity of liver and breast lesions for 
lesion characterisation.
The focus of this assessment was CEUS of the liver.
SonoVue consists of a kit containing a vial of sulphur hexafluoride gas and phospholipid powder, a 
prefilled syringe of solvent (sodium chloride solution) and a transfer and a separate delivery system. The 
saline is introduced into the vial by the delivery system and, once reconstituted, microbubbles are formed. 
These microbubbles are the contrast agent, which is injected into a peripheral vein at the antecubital fossa. 
When the US probe is placed on the abdomen, US waves cause the microbubbles to resonate so that a 
signal is picked up by a transducer and an image is formed on a screen.
As this contrast agent is a pure blood pool agent it remains within the patient’s blood vessels and, 
depending on the type of lesion, it shows a pattern of uptake similar to that of computed tomography 
(CT) or magnetic resonance imaging (MRI) vascular contrast agents. The contrast agent is broken down 
by the body after a few minutes and the sulphur hexafluoride gas is exhaled through the lungs and 
the phospholipid component of the microbubble shell is metabolised (re-entering the endogenous 
phospholipid metabolic pathway). The adverse event rate associated with the use of SonoVue for liver 
imaging is likely to be similar to or lower than that associated with other imaging modalities (CECT or 
CEMRI). A post-marketing study, published in 2006, included 23,188 abdominal investigations and 
reported adverse events in 29 cases, of which only two were graded as serious.7
The dual blood supply of liver tissue from the hepatic artery (25–30%) and the portal vein (70–75%) 
means that three vascular phases can be visualised using CEUS: the hepatic arterial phase (starting 
approximately 10–20 seconds after injection of the contrast agent into a peripheral vein and lasting for 
approximately 10–15 seconds); the portal venous phase (following the hepatic arterial phase and lasting 
until approximately 2 minutes after the initial injection); and the late phase (following the portal venous 
phase and lasting until clearance of the contrast agent from the hepatic parenchyma, up to 4–6 minutes 
after the initial injection). The arterial phase provides information on the extent and pattern of vascularity 
in the lesion, and the portal venous and late phases provide information on the washout of the contrast 
agent from the lesion compared with that of normal liver tissue.6
The European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) produced 
guidelines and good clinical practice recommendations for CEUS in 2004. The latest version of the 
guidelines was published in 2008 and is currently being updated.6 The 2008 EFSUMB guidelines 
recommend the use of CEUS for the characterisation of FLLs in the following indications:
 z in patients with incidental findings on routine US
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 z for the investigation of lesions or suspected lesions in chronic hepatitis or liver cirrhosis
 z for the investigation of lesions or suspected lesions in patients with a history of malignancy
 z in patients with inconclusive MRI/CT or cytology/histology results
 z for the characterisation of portal vein thrombosis.
The guidelines recommend the use of CEUS for the detection of FLLs in the following indications:
 z to rule out liver metastases
 z in selected cases, when clinically relevant for treatment planning and as a complement to CECT and/or 
CEMRI, to assess the number and location of liver metastases
 z for the surveillance of patients with known malignancy
 z in suspected CCC, when other imaging is inconclusive
 z in suspected liver trauma (in some situations).
The EFSUMB guidelines provide information on the typical enhancement patterns associated with various 
types of benign and malignant liver lesions;6 Table 1 shows the typical enhancement patterns described for 
the malignant lesions considered in this assessment.
When considering the post-treatment assessment of patients who have undergone percutaneous ablation 
therapies, CEUS can potentially provide useful information when unenhanced US cannot. This is because 
assessment of vascularisation and tissue perfusion is essential to enable differentiation of tissue necrosis 
from residual tumour.6
Other similar US contrast agents (e.g. Luminity®, Lantheus Medical Imaging, and Optison®, GE Healthcare) 
are indicated for use in echocardiography only. Therefore, no equivalent alternative technologies were 
considered in this assessment.
Comparators
Patients with inconclusive unenhanced US are currently referred for CECT and/or CEMRI. The comparators 
for this assessment are therefore CECT and CEMRI. Contrast-enhanced MRI generally uses gadolinium-
based vascular contrast agents, which can differentiate between benign and malignant FLLs based on 
vascular enhancement patterns in a similar way to CECT and CEUS. However, CEMRI of the liver can also 
use hepatocyte-specific contrast agents such as superparamagnetic iron oxide (SPIO). Hepatocyte-specific 
contrast agents are taken up by Kupffer cells in the normal liver and benign lesions and may therefore 
aid the identification of malignant lesions, which are generally deficient in Kupffer cells, particularly when 
such lesions are hypervascular.8,9 ‘Combined’ vascular and hepatocyte-specific contrast agents such as 
gadolinium ethoxybenzyl diethylenetriamine penta-acetic acid (Gd-EOB-DTPA) can also be used.10 A recent 
systematic review compared the accuracy of SonoVue CEUS, CECT and CEMRI for the differentiation 
of malignant and benign liver lesions. The reported sensitivities were 88% (95% CI 87% to 90%), 
TABLE 1 Typical enhancement patterns of malignant FLLs
Arterial phase Portal venous phase Late phase
HCC in cirrhosis Hyper-enhancing, complete Iso-enhancing Hypo-/iso-enhancing
Non-enhancing areas Non-enhancing areas
HCC in non-cirrhotic liver Hyper-enhancing Hypo-/non-enhancing Hypo-/non-enhancing
Liver metastases (hypovascular) Rim enhancement Hypo-enhancing Hypo-/non-enhancing
Liver metastases (hypervascular) Hyper-enhancing, complete Hypo-enhancing Hypo-/non-enhancing
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90% (95% CI 88% to 92%) and 86% (95% CI 83% to 88%), respectively, and corresponding specificities 
were 81% (95% CI 79% to 84%), 77% (95% CI 71% to 82%) and 81% (95% CI 76% to 85%).11 However, 
these data were based on indirect comparisons, and estimates for CEMRI combined studies using vascular 
contrast agent with studies using hepatocyte-specific contrast agent.
Contrast-enhanced ultrasound could be included in the diagnostic pathway as a replacement for CECT/
CEMRI (Figure 1) or as a triage step to reduce the use of CECT/CEMRI (Figure 2).
Expert opinion indicated that biopsy would not be performed on the basis of unenhanced US examination 
alone; therefore, biopsy was not considered a relevant comparator for CEUS.
Care pathways/current practice
Focal liver lesions found on unenhanced US may be ‘incidental’ (FLLs detected in patients undergoing 
abdominal US for symptoms and/or biochemistry suggestive of possible liver disease or for other reasons 
unrelated to possible liver disease) or appear as the result of routine surveillance of patients with cirrhosis. 
In both cases investigation is focused upon characterisation of lesions, primarily to determine whether 
they are benign or malignant. Other relevant applications include the detection of specific types of 
malignant FLL such as liver metastases from CRC. The care pathways for each of these applications are 
described below.
In general, care pathways for patients with liver malignancy are guided by prognosis. Prognosis depends 
on both the stage of the tumour and underlying liver function. For any care pathway, survival time of 
the patient is the key variable of interest. Improvements in survival by any therapeutic option are largely 
dependent on the disease stage at diagnosis. The earlier the diagnosis, the greater the chance of a 
successful treatment.
Incidentally detected focal liver lesions
A focal lesion in the liver refers to any tissue abnormality occurring in one specific area of the liver. FLLs can 
be classified into two main categories, namely benign or malignant. Benign FLLs include haemangioma, 
Conventional US
BENIGN
Characterisation? YESNO
INCONCLUSIVE
CEUS
MALIGNANT
OUTCOME
OUTCOME
STOP BENIGN MALIGNANT STAGING
FIGURE 1 Diagnostic algorithm for liver imaging: CEUS as a replacement test for CECT/CEMRI.
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focal nodular hyperplasia, focal fatty sparing and adenoma. Malignant FLLs include primary cancer of 
the liver, known as HCC, and secondary cancers of the liver (metastases) resulting from primary cancers 
occurring elsewhere in the body (e.g. CRC, breast cancer, lung cancer and pancreatic cancer).
Once a lesion has been incidentally detected in an individual the foremost concern is to differentiate 
between benign and malignant lesions. This distinction determines the individual’s prognosis and the 
subsequent treatment strategy. Benign liver lesions, because of their asymptomatic nature, often require 
no treatment. In such cases it is common for the individual to be monitored and the lesion rescanned 
in 6–12 months. Once a malignant lesion is identified it is important to distinguish between primary 
and secondary cancers, as this is likely to impact how the individual is managed. Malignant lesions may 
be treated by a range of interventions including chemotherapy, liver resection (surgery), radiofrequency 
ablation (RFA) and transarterial therapies such as selective internal radiation therapy for metastatic lesions 
secondary to CRC. A fine needle aspiration biopsy to assist in the diagnosis is not always needed and 
involves the risk of bleeding and the seeding of neoplastic cells (along the needle tract). It has been argued 
that the biopsy provides little additional information beyond what can be established from a patient 
history, medical examination, laboratory testing and imaging.12
Cirrhosis surveillance
Guidelines from the UK Hepatocellular Group advise that, for all patients with cirrhosis who might be 
suitable candidates for treatment for HCC, surveillance using abdominal US and alpha-fetoprotein (AFP) 
estimation should be considered.2 If surveillance is offered it should involve abdominal US assessments in 
combination with serum AFP estimation at 6-month intervals. US is used for surveillance because it is low 
risk, non-invasive and has good acceptance by patients. However, fibrous septa and regenerative nodules 
characteristic of cirrhosis produce a coarse US pattern that can inhibit detection of small HCCs.13 If the 
US is inconclusive, confirmatory testing will take place using CECT or CEMRI. The decision about whether 
to use CEMRI or CECT as the next imaging modality following the initial US scan is highly dependent 
on clinician preferences and local availability. Although CEMRI in general has a better sensitivity and 
specificity than CECT for the detection and characterisation of FLLs, the main disadvantage of MRI is the 
often long waiting times; it can sometimes take up to 6 months for the presence or absence of a FLL to 
be confirmed. A focal lesion in the liver of a patient with cirrhosis is highly likely to be HCC.2 Biopsy is 
Conventional US
CE-CT/MR
INCONCLUSIVEBENIGN MALIGNANT
BENIGN
Characterisation? YESNO
INCONCLUSIVE
CEUS
MALIGNANT
OUTCOME
OUTCOME
STOP BENIGN MALIGNANT STAGING
FIGURE 2 Diagnostic algorithm for liver imaging: CEUS as a triage test to reduce the use of CECT/CEMRI.
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rarely required for diagnosis as this can usually be established radiologically, and seeding of tumour in 
the needle tract occurs in 1–3% of cases. Therefore, it is advised to avoid biopsy of potentially operable 
lesions when possible. Clinical practice guidelines from the European Association for the Study of the Liver 
(EASL) state that non-invasive diagnostic criteria for HCC (hypervascular in the arterial phase with washout 
in the portal venous or delayed phases) can be applied in cirrhotic patients; one imaging technique is 
needed for lesions of > 1 cm diameter while two techniques are recommended in suboptimal settings and 
biopsy is recommended only when a diagnosis cannot be reached using non-invasive criteria.13 HCC can 
be curatively treated with surgery, either hepatic resection or liver transplantation.2 Palliative treatments 
include percutaneous ethanol injection (PEI), RFA and transarterial chemoembolisation (TACE).
Surgical resection is the treatment of choice for HCC in non-cirrhotic patients. Cirrhotic patients need to be 
carefully selected for resection because they are especially prone to postoperative liver failure and increased 
risk of death. Survival after resection improves if the disease is diagnosed during the very early stages when 
liver function is preserved, the patient is asymptomatic and the nodule size is small (single, < 2 cm); it can 
then exceed 50% at 5 years. Taking liver function into account can help to identify patients in whom the 
resection could lead to decompensation of the liver and death, when resection might not be the treatment 
of choice. In contrast, more advanced liver tumours preclude resection. Commonly, the indication for 
resection is limited to patients with single tumours in the liver, without signs of vascular invasion and 
dissemination by the tumour. Benefits from other treatment options, such as adjuvant chemotherapy, are 
uncertain. Recurrence of HCC is very frequent and exceeds 70% at 5 years. Repeated resection is possible 
if intrahepatic dissemination of the tumour has not occurred. Liver transplantation is an option for early-
stage HCC (< 5 cm or with up to three nodules < 3 cm) but is not recommended for more advanced stages. 
If resection or transplantation is not appropriate, percutaneous ablation (local tumour cell destruction by 
chemicals or temperature) can be applied to patients with early-stage HCC.
Non-curative (palliative) treatment options may be considered when disease has progressed to medium or 
more advanced stages and surgery or percutaneous ablation is not considered appropriate. During tumour 
growth the tumour becomes highly arterialised, meaning that most blood that supplies the tumour is from 
the hepatic artery. During transarterial embolisation (TAE), acute arterial obstruction is provoked, which 
causes ischaemic tumour necrosis. If TAE is combined with a chemotherapeutic agent, which is injected 
into the hepatic artery prior to the procedure, the procedure is called TACE. TACE is indicated if the tumour 
has multiple nodules, without affecting blood vessels or dissemination outside the liver. Complete necrosis 
of the tumour is rarely achieved after one treatment, thus treatment needs to be repeated several times. 
Response to treatment improves survival, which varies from 20% to 60% at 2 years depending on tumour 
stage, liver function and general health status. Systemic chemotherapy in treating HCC is sometimes used 
although it is not recommended by the American Association for the Study of Liver Diseases (AASLD).1 
EASL clinical practice guidelines recommend sorafenib (Nexavar, Bayer Schering) as the standard systemic 
therapy in patients with well-preserved liver function (Child–Pugh class A), advanced HCC or tumours 
progressing after locoregional therapies.13
Patients at an advanced stage of the disease, characterised by failure of liver function, tumour growth and 
dissemination or physical impairment, will not benefit from the above treatments and might therefore be 
enrolled in trials of new agents. In the terminal stage symptomatic treatment is appropriate.1
Liver metastases for colorectal cancer
For cancers of both the colon and the rectum, surgical resection is the mainstay of definitive treatment.14 
After surgical resection, patients may present with metastases. Metastases often first occur in the liver and 
this may be the only site of spread in 30–40% of patients with advanced disease.15 For a patient discovered 
to have isolated liver metastases, CT of the chest, abdomen and pelvis should be performed to determine 
whether or not metastases at multiple sites are present. Isolated liver metastases of colorectal origin are 
commonly resected, with or without preoperative chemotherapy. In cases of small liver metastases, colon 
and liver resection might be combined in one surgery. Metastases at multiple sites may also be resected, 
with or without chemotherapy, or will be palliatively treated. If resection is not appropriate, systemic 
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treatments such as chemotherapy in combination with other medication may be used; however, response 
to treatment is generally poor. Ablative therapy may also be considered; however, this is recommended 
only in the context of randomised controlled trials. As with HCC, recurrence of metastases after liver 
resection occurs in up to 60% of patients.15
Patients without metastases are advised to undergo regular surveillance with a minimum of two CTs of 
the chest, abdomen and pelvis in the first 3 years and regular serum carcinoembryonic antigen (CEA) tests 
(at least every 6 months in the first 3 years).14 Follow-up after liver resection is very dependent on local 
protocols but may include CT of the chest and liver and CEA testing for 5 years.
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Chapter 3 Assessment of clinical effectiveness
A systematic review was conducted to summarise the evidence on the clinical-effectiveness of SonoVue CEUS for the assessment of FLLs in adults with previously inconclusive liver imaging. Systematic review 
methods followed the principles outlined in the Centre for Reviews and Dissemination (CRD) guidance 
for undertaking reviews in health care,16 the NICE Diagnostic Assessment Programme interim methods 
statement17 and the Cochrane Handbook for DTA Reviews.18
Inclusion and exclusion criteria
Participants
Study populations eligible for inclusion were adults (≥ 18 years) in whom previous liver imaging has been 
inconclusive, including patients being assessed for:
 z suspected primary HCC
 z suspected secondary malignancy (liver metastases)
 z response to treatment/recurrence of known liver malignancy.
Setting
Relevant settings were secondary or tertiary care.
Interventions
The intervention (index test) was SonoVue CEUS.
Comparators
Comparator tests eligible for inclusion were:
 z CECT
 z CEMRI.
Reference standard
Studies reporting the diagnostic accuracy of SonoVue CEUS for the characterisation of FLLs (identification 
of liver malignancy) or the detection of liver metastases were required to use histology, following biopsy 
or surgical excision, to confirm the diagnosis in patients with positive index test results. Patients who test 
negative on the index test will generally not undergo biopsy or surgical treatment; clinical/radiological 
follow-up for a minimum of 6 months was therefore considered an acceptable reference standard in 
these patients.
Protocol modification
The reference standard criteria were extended for studies on the characterisation of FLLs only (suspected 
HCC) to include studies that use EASL/AASLD non-invasive diagnostic criteria (two concordant imaging 
test results) as the reference standard.1,13 This modification does not apply to test accuracy studies on the 
detection of liver metastases. This extension of the inclusion criteria was made because clinical opinion 
indicated that biopsy of small, test-positive lesions may be considered unethical in this population and that 
the original criterion (biopsy for imaging test-positive patients/lesions and 6-month follow-up for imaging 
test-negative patients/lesions) may result in important studies being excluded.
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Outcomes
Studies reporting the following outcomes were considered relevant:
 z effect of testing on treatment plan (e.g. surgical or medical management, or palliative care), when 
information on the appropriateness of the final treatment plan is also reported
 z effect of pretreatment testing on clinical outcome (e.g. overall survival, progression-free survival)
 z prognosis – the ability of the test result to predict clinical outcome (e.g. overall survival, progression-
free survival, response to treatment)
 z test accuracy and number of patients/lesions classified as non-diagnostic by SonoVue CEUS.
For included studies reporting any of the above outcome measures, the following outcomes were 
considered, if reported:
 z the acceptability of tests to patients or surrogate measures of acceptability (e.g. waiting time and 
associated anxiety)
 z adverse events associated with testing (e.g. claustrophobia, reaction to contrast media)
 z additional FLLs detected by CEUS, over and above those seen on unenhanced US.
Radiation exposure was not considered a relevant outcome as the population is mostly older adults in 
whom additional incident cancers due to imaging-related radiation are likely to be minimal. In addition, a 
previous technology assessment (new-generation CT for cardiac imaging) showed that including radiation 
exposure in modelling did not influence the results of cost-effectiveness analyses.19
Study design
The following study designs were eligible for inclusion:
 z Randomised or non-randomised controlled trials in which participants are assigned to the intervention 
or comparator test, for treatment planning, and outcomes are compared at follow-up.
 z Observational studies that report the results of multivariable regression modelling, with clinical 
outcome (e.g. survival, response to treatment) as the dependent variable and the index test result as 
an independent variable. Included studies should control adequately for potential confounders (e.g. 
age, tumour stage, previous treatment, results of other imaging).
 z Test accuracy studies in which the index test is compared with one or more of the comparators and 
the reference standard. Test accuracy studies of the index test alone were included when these were 
conducted in patients who had previously undergone one or more of the comparator tests (e.g. a 
study of the accuracy of SonoVue for the diagnosis of HCC in patients with inconclusive findings 
on CECT).
Included test accuracy studies were required to report the absolute numbers of true-positive, 
false-negative, false-positive and true-negative index test results or sufficient information to allow 
their calculation.
The following study/publication types were excluded:
 z preclinical and animal studies
 z reviews, editorials and opinion pieces
 z case reports
 z studies reporting only technical aspects of the test or image quality
 z studies with < 10 participants.
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Search strategy
Search strategies were based on target condition and intervention, as recommended in the CRD’s 
Guidance for Undertaking Reviews in Health Care and the Cochrane Handbook for DTA Reviews.16,18,20
The following databases were searched for relevant studies from 2000 to September/October 2011:
 z MEDLINE (2000–September 2011 Week 4) (OvidSP)
 z MEDLINE In-Process & Other Non-Indexed Citations and Daily Update (2000–5 October 2011) (OvidSP)
 z EMBASE (2000–2011 Week 39) (OvidSP)
 z Cochrane Database of Systematic Reviews (CDSR) (The Cochrane Library Issue 10, 2011) (Wiley)
 z Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 4, 2011) (Wiley)
 z Database of Abstracts of Reviews of Effects (DARE) (2000–6 October 2011) (via The Cochrane Library)
 z Health Technology Assessment (HTA) database (2000–6 October 2011) (via The Cochrane Library)
 z DARE (1 January 2011–6 October 2011) (CRD website)
 z HTA database (1 January 2011–6 October 2011) (CRD website)
 z Science Citation Index (SCI) (2000–6 October 2011) (Web of Science)
 z National Institute for Health Research (NIHR) HTA database (2000–2011) (internet).
Supplementary searches were undertaken on the following resources to identify grey literature and 
completed and ongoing trials:
 z National Institutes of Health ClinicalTrials.gov (2000–7 October 2011) (www.clinicaltrials.gov/)
 z Current Controlled Trials (2000–7 October 2011) (www.controlled-trials.com/)
 z World Health Organization International Clinical Trials Registry Platform (ICTRP) (2000–7 October 
2011) (www.who.int/ictrp/en/)
 z EU Clinical Trials Register (EU CTR) (2000–8 October 2011) (www.clinicaltrialsregister.eu/).
Searches were undertaken to identify studies of SonoVue/sulphur hexafluoride CEUS in the diagnosis 
of liver cancer (primary and metastases). The main EMBASE strategy for each set of searches was 
independently peer reviewed by a second information specialist using the PRESS EBC (Peer Review of 
Electronic Search Strategies Evidence-Based Checklist).21 Search strategies were developed specifically for 
each database and the keywords associated with liver cancer (primary and metastases) were adapted 
according to the configuration of each database. Searches took into account generic and other product 
names for the intervention. No restrictions on language or publication status were applied. Limits were 
applied to remove animal studies. Full search strategies are reported in Appendix 1.
Electronic searches were undertaken on the following conference abstracts:
 z EFSUMB (EUROSON):
 | 2011: www.wfumb2011.org/index.php?pid=70
 | 2008: www.thieme-connect.com/ejournals/toc/ultraschall/33697/grouping/54161
 | 2007: www.interplan.de/pages/euroson2007/front_content.php?idcat=82
 z Radiological Society of North America (RSNA)
 | 2010: http://rsna2010.rsna.org/search/search.cfm
 | 2009: http://rsna2009.rsna.org/search/search.cfm
 | 2008: http://rsna2008.rsna.org/program.cfm
 | 2007: http://rsna2007.rsna.org/rsna2007/v2007/conference/track.cvn
 | 2006: http://rsna2006.rsna.org/rsna2006/v2006/conference/track.cvn
 z European Congress of Radiology (ESR)
 | 2011: www.myesr.org/cms/website.php?id=/en/past_congresses/ecr_2011/ecr_2011_book_of_
abstracts.htm
 | 2010: www.myesr.org/cms/website.php?id=/en/ecr_2010/book_of_abstracts.htm
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 | 2009: www.myesr.org/cms/website.php?id=/en/ecr_2009/ecr_2009_book_of_abstracts.htm
 | 2008: www.abstractsonline.com/viewer/?mkey={9AF35541-5128-444B-9D15-447022358A3F}
 | 2007: www.abstractsonline.com/viewer/?mkey={9A26688A-5BBE-4366-AE14-5AC99DF8F8E4}
 | 2006: www.abstractsonline.com/viewer/?mkey={6748FA35-D7A5-44B0-B8D4-4E2E51850B06}.
We planned to search the British Medical Ultrasound Society (BMUS) conference abstracts (2006–11) but 
these were not available online.
Identified references were downloaded into EndNote X4 software (Thomson Reuters, CA, USA) for further 
assessment and handling.
References in retrieved articles were checked for additional studies.
Inclusion screening and data extraction
Two reviewers (MW and VG) independently screened the titles and abstracts of all reports identified by 
searches and any discrepancies were discussed and resolved by consensus. Full copies of all studies deemed 
potentially relevant were obtained and the same two reviewers independently assessed these for inclusion; 
any disagreements were resolved by consensus. Details of studies excluded at the full-paper screening 
stage are presented in Appendix 5.
Studies listed in submissions from the manufacturer of SonoVue, Bracco UK Ltd, were first checked against 
the project reference database in EndNote X4; any studies not already identified by our searches were 
screened for inclusion following the process described above. Studies referenced by the manufacturer 
and excluded at the full-paper screening stage are noted in Appendix 5. Appendix 5 also includes a list of 
studies referenced by the manufacturer that were excluded at title and abstract screening.
When there was insufficient information for full inclusion assessment, study authors were contacted 
for clarification.
Data were extracted on study details (study design, participant recruitment, setting, funding, stated 
objective and clinical indication for testing relevant to this assessment for which data were reported), 
study participants (total number of participants and total number of FLLs, study inclusion criteria, study 
exclusion criteria, participant age and gender distribution, participant characteristics relevant to liver 
cancer risk, lesion size and final diagnoses), details of the index test, comparator(s) and reference standard 
(technical details of the test, details of who interpreted tests and how, threshold used to define a positive 
test) and study results. All but one of the studies included in the review were diagnostic test accuracy 
(DTA) studies and the results extracted from these studies were unit of analysis (patient or lesion); numbers 
of true-positive, false-negative, false-positive and true-negative test results; numbers of patients or 
lesions classified as non-diagnostic by SonoVue CEUS and/or comparator(s). The remaining study was a 
controlled trial that compared assessment with conventional imaging (CECT or CEMRI) plus unenhanced 
US with assessment with conventional imaging (CECT or CEMRI) plus SonoVue CEUS prior to RFA; data 
were extracted from this study to calculate odds ratios (ORs) and mean differences for dichotomous and 
continuous patient-relevant outcomes respectively. Data were extracted by one reviewer using a piloted, 
standard data extraction form and checked by a second (MW and VG); any disagreements were resolved 
by consensus. Chinese-language studies were extracted by one reviewer (MW) working with a native 
speaker (KL) and the only German language study was extracted by one reviewer and checked by a second 
(VG and HR) Full data extraction tables are provided in Appendix 4.
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Quality assessment
The evidence-based QUADAS tool22–24 is recommended for assessing the methodological quality of test 
accuracy studies.16,18 A revised version of QUADAS (QUADAS-2) has recently been published25 (www.
QUADAS.org). QUADAS-2 more closely resembles the approach and structure of the Cochrane risk of 
bias tool. It is divided into four key domains covering participant selection, index test, reference standard 
and the flow of patients through the study (including the timing of tests). Each domain is rated for risk 
of bias (low, high or unclear) and the tool provides signalling questions in each domain to aid reviewers 
in reaching a judgement. The participant selection, index test and reference standard domains are also 
separately rated for concerns regarding the applicability of the study to the review question (low, high or 
unclear). Thus, QUADAS-2 separates bias from external validity (applicability) and does not include any 
items that assess only reporting quality. The QUADAS-2 tool does not currently include domains specific 
to the assessment of studies comparing multiple index tests, such as those included in this assessment. 
Further development of QUADAS-2 in this area is planned. A modified version of the QUADAS-2 tool, 
which includes an additional domain for the comparator test and additional signalling questions in the 
flow and timing domain, has been used in this assessment. Review-specific guidance was produced for the 
use of the modified version of QUADAS-2 and is reported in Appendix 2.
The results of the quality assessment are summarised and presented in tables and graphs in the results 
section of the systematic review and are presented in full, by study, in Appendix 3. No diagnostic accuracy 
data set included in this assessment was of sufficient size to allow statistical exploration of between-study 
heterogeneity based on aspects of risk of bias. The findings of the quality assessment were used to inform 
recommendations for future research.
The risk of bias in the controlled clinical trial was assessed using a table based on The Cochrane 
Collaboration’s tool for assessing risk of bias.26
Methods of analysis/synthesis
The results of the DTA studies included in this review were summarised by clinical indication for imaging 
(characterisation of FLLs detected on routine surveillance of cirrhosis patients using unenhanced US, 
detection of liver metastases in patients with known primary malignancy, characterisation of incidentally 
detected FLLs visualised on unenhanced US, assessment of response to treatment in known liver 
malignancy) and further stratified by target condition (HCC, liver metastases or ‘any liver malignancy’) and/
or comparator test(s) (CECT, CEMRI, both), as appropriate. For all included studies the absolute numbers of 
true-positive, false-negative, false-positive and true-negative test results, as well as sensitivity and specificity 
values, with 95% confidence intervals (CIs) were presented in results tables for index test, comparator and 
target condition reported. When multiple data sets were reported (e.g. for per-patient and per-lesion data, 
different diagnostic criteria, different lesion sizes) these were extracted in full. Data on the number of non-
diagnostic tests were also included in the results tables and described in text summaries. No study reported 
data on patient preferences and one study reported absence of index test-associated adverse events; the 
latter was recorded in the relevant results table.
When groups of similar studies (comparable clinical indication, index test and comparator, target condition 
and diagnostic criteria) included four or more data sets, we planned to construct summary receiver 
operating characteristic (SROC) curves and calculate summary estimates of sensitivity and specificity 
with 95% CIs using the bivariate modelling approach;27–29 four data sets are the minimum requirement 
to fit models of this type. However, the review included only one group of four similar studies and 
this group included one study that used a suboptimal reference standard (as described in the protocol 
modification noted in Inclusion and exclusion criteria). Pooled estimates of sensitivity and specificity with 
95% CIs were therefore calculated using a random-effects model and forest plots were constructed 
showing the sensitivity and specificity estimates from each study together with pooled estimates. A 
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sensitivity analysis was undertaken to assess the effect of excluding the large study that used a suboptimal 
reference standard; these analyses were conducted using MetaDiSc 1.4 (www.hrc.es/investigacion/
metadisc_en.htm).30
Between-study clinical heterogeneity was assessed qualitatively. Statistical heterogeneity was assessed for 
the one meta-analysis undertaken using the chi-squared test and inconsistency was quantified using the 
I2 statistic,31 although these measures are of limited value given the small number of studies involved. 
There were no data sets of sufficient size (minimum 10) to allow statistical exploration of sources of 
heterogeneity by including additional covariables in the SROC model.
Where meta-analysis was considered unsuitable for the data identified (e.g. because of heterogeneity and/
or small number of studies), studies were summarised using a narrative synthesis. Text and tables were 
stratified by clinical indication and target condition, as described above. Where appropriate, the results of 
individual studies were plotted in the receiver operating characteristic (ROC) plane.
Results of the assessment of clinical effectiveness
The literature searches of bibliographic databases identified 854 references. After initial screening of titles 
and abstracts, 175 were considered to be potentially relevant and ordered for full-paper screening. No 
additional papers were ordered based on screening of the industry submission; all studies submitted had 
already been identified by the bibliographic database searches. No additional studies were identified from 
searches of clinical trials registries. Of the 175 publications considered potentially relevant, three32–34 could 
not be obtained within the time scale of this assessment; these were held in British Library stacks that 
are currently closed for asbestos removal or were not held by the British Library. Four studies, reported as 
conference abstracts, did not contain sufficient information to complete inclusion assessment and authors 
were contacted for additional information;35–38 one response was received and all four studies were finally 
excluded. Figure 3 shows the flow of studies through the review process and Appendix 5 provides details 
of all publications excluded at the full-paper screening stage with reasons for exclusion.
Based on the searches and inclusion screening described above, 19 publications of 18 studies were 
included in the review. Hand searching of conference proceedings resulted in the inclusion of a further 
three studies, which were published in abstract form only.39–41 A total of 21 studies in 22 publications were 
therefore included in the review.
All but one of the included studies were test accuracy studies; of the 20 test accuracy studies, seven 
concerned the use of SonoVue CEUS for the characterisation of FLLs detected at routine surveillance of 
patients with cirrhosis,42–48 four assessed the performance of SonoVue CEUS for the detection of liver 
metastases in patients with known primary cancers (CRC),39,49–51 six concerned the use of SonoVue CEUS 
for the characterisation of incidentally detected FLLs41,52–56 and three considered the use of SonoVue CEUS 
to assess response to treatment in patients with liver cancer.40,57,58 The remaining study was a controlled 
trial that compared assessment with conventional imaging (CECT or CEMRI) plus unenhanced US with 
assessment with conventional imaging (CECT or CEMRI) plus SonoVue CEUS prior to RFA.59 This study 
reported the following patient-relevant outcomes: successful ablation, tumour progression, incidence 
of new HCC, incidence of repeat RFA, local progression-free survival, new tumour-free survival and 
post-therapy complications.
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All included studies were published in 2006 or later. Sixteen of the 21 included studies were conducted in 
Europe (the majority in Italy or Spain) and the remaining five studies were conducted in China (including 
two Chinese-language publications). Two studies reported funding from the manufacturer of SonoVue55,56 
and 13 studies did not report any information on funding sources.
Table 2 shows the details of the included studies, the clinical indication for imaging for which they 
reported data and the target conditions (primary HCC, liver metastases, ‘any liver malignancy’ or response 
to treatment) and comparator tests assessed. Further details of the characteristics of study participants and 
the technical details of the conduct of the index test (SonoVue CEUS), comparator test(s) and reference 
standard (where applicable) and their interpretation are reported in the data extraction tables presented in 
Appendix 4.
Industry submission
n = 23
(All previously identified
by bibliographic
database searches)
Titles and abstracts identified
from bibliographic databases
and screened for potential
relevance
n = 854
Total potentially relevant
publications obtained as full
text
n = 172
Could not be obtained
n = 3
Excluded at title and
abstract screening
n = 679
Potentially relevant
publications
n = 175
Total number of studies
included in the review
n = 21 (22 publications)
Excluded at full-paper
screening
n = 149
Conference abstracts
included after screening
n = 3
Authors contacted for
further information
n = 4
FIGURE 3 Flow of studies through the review process.
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TABLE 2 Included studies
Study ID Study design Objective
US (CCTs 
and RCTs 
only)
Combined 
imaging
 
Comparator 
CECT
Comparator 
CEMRI
Any liver 
malignancy
Primary 
HCC Metastases
Treatment 
success
Study design and 
outcome extracted
Blondin 201148 Retrospective analysis based 
on a search of the radiological 
information system between 
January 2007 and March 2009
To compare the diagnostic accuracy 
of CEUS and hepatobiliary contrast-
enhanced MRI of the liver in 
evaluating FLLs in patients with 
liver cirrhosis
ü ü DTA
Accuracy data 
(characterisation of FLLs 
detected at cirrhosis 
surveillance): HCC vs benign
Catala 200752 Prospective cohort of adult patients 
(≥ 18 years) with FLLs detected on 
US
December 2002–August 2003
Single centre, Spain
One author supported in part by a 
grant from the Carolina Foundation
To compare the diagnostic accuracy 
of real-time evaluation by CEUS 
using SonoVue vs SCT in the 
characterisation of FLLs and to 
determine the degree of correlation 
between the two techniques
ü ü ü ü ü DTA
Accuracy data 
(characterisation of 
incidentally detected FLLs): 
separate data for HCC, liver 
metastases and any liver 
malignancy
Chen 200759
Related 
publication60 
excluded as 
duplicate
Prospective CCT of patients with 
HCC who were being assessed 
before RFA treatment
July 2002–March 2005
Single centre, China
Funding NR
To evaluate the use of CEUS in 
assessing patients for RFA and to 
compare the efficacy of RFA after 
CEUS with the efficacy of RFA after 
US
ü ü ü CCT
Clevert 200951 Prospective cohort of consecutive 
patients with suspected liver 
malignancya
Recruitment dates NR
Two centre, Germany
Funding NR
To assess the diagnostic 
performance of CHI with SonoVue 
compared with biphasic multislice 
CECT for the detection of 
malignant liver lesions
ü üa DTA
Accuracy data (detection of 
liver metastases)
Dai 200843 Prospective cohort of consecutive 
patients with confirmed cirrhosis, 
without extrahepatic malignancy, 
who had indeterminate liver 
nodules on surveillance US
March 2004–March 2005
Single centre, China
Funding NR
To investigate the diagnostic value 
for indeterminate small (1–2 cm) 
hepatic nodules detected by 
surveillance US in patients with 
cirrhosis using CEUS compared 
with helical CECT
ü ü DTA
Accuracy data 
(characterisation of FLLs 
detected at cirrhosis 
surveillance): HCC vs benign
Feng 200757 
(Chinese 
language)
Prospective cohort of patients 
with known liver malignancy (21 
HCC, 3 metastases), undergoing 
cryosurgery
November 2004–February 2006
Single centre, China
Funding NR
To evaluate the role of CEUS 
in assessing the short-term 
therapeutic response of hepatic 
carcinoma with cryosurgery
ü ü DTA
Accuracy data (detection of 
treatment success)
Flor 200939 
(abstract only)
Prospective cohort of patients 
with known primary cancer and 
indeterminate liver lesions on 
MDCT
Recruitment dates NR
Single centre, Italy
Funding NR
To evaluate the role of plain US 
and CEUS in characterising small 
indeterminate MDCT-detected FFLs 
in patients with known primary 
cancer
ü DTA
Accuracy data (detection of 
liver metastases)
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TABLE 2 Included studies
Study ID Study design Objective
US (CCTs 
and RCTs 
only)
Combined 
imaging
 
Comparator 
CECT
Comparator 
CEMRI
Any liver 
malignancy
Primary 
HCC Metastases
Treatment 
success
Study design and 
outcome extracted
Blondin 201148 Retrospective analysis based 
on a search of the radiological 
information system between 
January 2007 and March 2009
To compare the diagnostic accuracy 
of CEUS and hepatobiliary contrast-
enhanced MRI of the liver in 
evaluating FLLs in patients with 
liver cirrhosis
ü ü DTA
Accuracy data 
(characterisation of FLLs 
detected at cirrhosis 
surveillance): HCC vs benign
Catala 200752 Prospective cohort of adult patients 
(≥ 18 years) with FLLs detected on 
US
December 2002–August 2003
Single centre, Spain
One author supported in part by a 
grant from the Carolina Foundation
To compare the diagnostic accuracy 
of real-time evaluation by CEUS 
using SonoVue vs SCT in the 
characterisation of FLLs and to 
determine the degree of correlation 
between the two techniques
ü ü ü ü ü DTA
Accuracy data 
(characterisation of 
incidentally detected FLLs): 
separate data for HCC, liver 
metastases and any liver 
malignancy
Chen 200759
Related 
publication60 
excluded as 
duplicate
Prospective CCT of patients with 
HCC who were being assessed 
before RFA treatment
July 2002–March 2005
Single centre, China
Funding NR
To evaluate the use of CEUS in 
assessing patients for RFA and to 
compare the efficacy of RFA after 
CEUS with the efficacy of RFA after 
US
ü ü ü CCT
Clevert 200951 Prospective cohort of consecutive 
patients with suspected liver 
malignancya
Recruitment dates NR
Two centre, Germany
Funding NR
To assess the diagnostic 
performance of CHI with SonoVue 
compared with biphasic multislice 
CECT for the detection of 
malignant liver lesions
ü üa DTA
Accuracy data (detection of 
liver metastases)
Dai 200843 Prospective cohort of consecutive 
patients with confirmed cirrhosis, 
without extrahepatic malignancy, 
who had indeterminate liver 
nodules on surveillance US
March 2004–March 2005
Single centre, China
Funding NR
To investigate the diagnostic value 
for indeterminate small (1–2 cm) 
hepatic nodules detected by 
surveillance US in patients with 
cirrhosis using CEUS compared 
with helical CECT
ü ü DTA
Accuracy data 
(characterisation of FLLs 
detected at cirrhosis 
surveillance): HCC vs benign
Feng 200757 
(Chinese 
language)
Prospective cohort of patients 
with known liver malignancy (21 
HCC, 3 metastases), undergoing 
cryosurgery
November 2004–February 2006
Single centre, China
Funding NR
To evaluate the role of CEUS 
in assessing the short-term 
therapeutic response of hepatic 
carcinoma with cryosurgery
ü ü DTA
Accuracy data (detection of 
treatment success)
Flor 200939 
(abstract only)
Prospective cohort of patients 
with known primary cancer and 
indeterminate liver lesions on 
MDCT
Recruitment dates NR
Single centre, Italy
Funding NR
To evaluate the role of plain US 
and CEUS in characterising small 
indeterminate MDCT-detected FFLs 
in patients with known primary 
cancer
ü DTA
Accuracy data (detection of 
liver metastases)
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Study ID Study design Objective
US (CCTs 
and RCTs 
only)
Combined 
imaging
 
Comparator 
CECT
Comparator 
CEMRI
Any liver 
malignancy
Primary 
HCC Metastases
Treatment 
success
Study design and 
outcome extracted
Forner 200844 Prospective cohort of asymptomatic 
patients with Child–Pugh A/B 
cirrhosis and no history of HCC, 
with a new liver nodule detected 
on surveillance US
November 2003–August 2006
Two centre, Spain and USA
Supported by grants from Instituto 
de Salud Carlos III, Spain; BBVA 
Foundation; Fundación Cientifica 
de la Asociación Española de 
Ayuda contra el Cáncer, Spain, 
grant nos PI 05/150, 06/132 and 
05/645; NIH-NIDDK grant no. 
1R01DK076986–0
To evaluate the accuracy of CEUS 
and dynamic MRI for the diagnosis 
of nodules of ≤ 20 mm detected 
during US surveillance
ü ü DTA
Accuracy data 
(characterisation of FLLs 
detected at cirrhosis 
surveillance): HCC vs benign
Gierblin´ski 200853 Prospective cohort of patients with 
incidentally detected solid liver 
lesions, referred for biopsy
June 2005–March 2006
Single centre, Poland
Funding NR
To determine whether or not 
CEUS is an accurate method to 
differentiate FLLs and reduce the 
need for fine-needle biopsy
ü DTA
Accuracy data 
(characterisation of 
incidentally detected FLLs): 
any malignancy vs benign
Giorgio 200745 Prospective study of consecutive 
patients with cirrhosis and a single 
liver nodule of ≤ 30 mm identified 
on surveillance US
September 2003–June 2004
Single centre, Italy
Funding NR
To evaluate the role of low 
mechanical index CEUS for the 
characterisation of small HCC in 
cirrhotic patients compared with 
ultrafast gadolinium-enhanced MRI
ü ü DTA
Accuracy data 
(characterisation of FLLs 
detected at cirrhosis 
surveillance): HCC vs benign
Jonas 201150 
(abstract only)
Prospective study of consecutive 
patients with CRC metastases 
who were considered candidates 
for curative surgery and who 
underwent complete preoperative 
workup
2005–7
Single centre, Sweden
Funding NR
To assess the sensitivity and 
specificity of four imaging 
modalities (CEUS, CECT, CEMRI 
and FDG-PET) in detecting liver 
metastases in patients with CRC
ü ü ü DTA
Accuracy data (detection of 
liver metastases)
Leoni 201042 Retrospective analysis of a study of 
consecutive patients with cirrhosis 
with one to three liver nodules 
(1–3 cm) detected at surveillance 
US
September 2003–November 2005
Single centre, Italy
No financial support
To assess the diagnostic 
contribution of vascular contrast-
enhanced techniques and the 
possible additional contribution of 
SPIO MRI for the diagnosis of HCC 
in cirrhosis
ü ü ü DTA
Accuracy data 
(characterisation of FLLs 
detected at cirrhosis 
surveillance): HCC vs benign
 continued
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Study ID Study design Objective
US (CCTs 
and RCTs 
only)
Combined 
imaging
 
Comparator 
CECT
Comparator 
CEMRI
Any liver 
malignancy
Primary 
HCC Metastases
Treatment 
success
Study design and 
outcome extracted
Forner 200844 Prospective cohort of asymptomatic 
patients with Child–Pugh A/B 
cirrhosis and no history of HCC, 
with a new liver nodule detected 
on surveillance US
November 2003–August 2006
Two centre, Spain and USA
Supported by grants from Instituto 
de Salud Carlos III, Spain; BBVA 
Foundation; Fundación Cientifica 
de la Asociación Española de 
Ayuda contra el Cáncer, Spain, 
grant nos PI 05/150, 06/132 and 
05/645; NIH-NIDDK grant no. 
1R01DK076986–0
To evaluate the accuracy of CEUS 
and dynamic MRI for the diagnosis 
of nodules of ≤ 20 mm detected 
during US surveillance
ü ü DTA
Accuracy data 
(characterisation of FLLs 
detected at cirrhosis 
surveillance): HCC vs benign
Gierblin´ski 200853 Prospective cohort of patients with 
incidentally detected solid liver 
lesions, referred for biopsy
June 2005–March 2006
Single centre, Poland
Funding NR
To determine whether or not 
CEUS is an accurate method to 
differentiate FLLs and reduce the 
need for fine-needle biopsy
ü DTA
Accuracy data 
(characterisation of 
incidentally detected FLLs): 
any malignancy vs benign
Giorgio 200745 Prospective study of consecutive 
patients with cirrhosis and a single 
liver nodule of ≤ 30 mm identified 
on surveillance US
September 2003–June 2004
Single centre, Italy
Funding NR
To evaluate the role of low 
mechanical index CEUS for the 
characterisation of small HCC in 
cirrhotic patients compared with 
ultrafast gadolinium-enhanced MRI
ü ü DTA
Accuracy data 
(characterisation of FLLs 
detected at cirrhosis 
surveillance): HCC vs benign
Jonas 201150 
(abstract only)
Prospective study of consecutive 
patients with CRC metastases 
who were considered candidates 
for curative surgery and who 
underwent complete preoperative 
workup
2005–7
Single centre, Sweden
Funding NR
To assess the sensitivity and 
specificity of four imaging 
modalities (CEUS, CECT, CEMRI 
and FDG-PET) in detecting liver 
metastases in patients with CRC
ü ü ü DTA
Accuracy data (detection of 
liver metastases)
Leoni 201042 Retrospective analysis of a study of 
consecutive patients with cirrhosis 
with one to three liver nodules 
(1–3 cm) detected at surveillance 
US
September 2003–November 2005
Single centre, Italy
No financial support
To assess the diagnostic 
contribution of vascular contrast-
enhanced techniques and the 
possible additional contribution of 
SPIO MRI for the diagnosis of HCC 
in cirrhosis
ü ü ü DTA
Accuracy data 
(characterisation of FLLs 
detected at cirrhosis 
surveillance): HCC vs benign
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Study ID Study design Objective
US (CCTs 
and RCTs 
only)
Combined 
imaging
 
Comparator 
CECT
Comparator 
CEMRI
Any liver 
malignancy
Primary 
HCC Metastases
Treatment 
success
Study design and 
outcome extracted
Li 200754 Prospective study of patients 
with FLLs detected at US and 
unenhanced CT
Recruitment dates NR
Single centre, China
Supported by the Clinical 
New Technology Foundation 
of Southwest Hospital 
(SWH2005A004)
To compare the efficacy of 
contrast-enhanced pulse-inversion 
harmonic sonography for the 
characterisation of FLLs with that of 
contrast-enhanced helical CT
ü ü DTA
Accuracy data 
(characterisation of 
incidentally detected FLLs): 
any malignancy vs benign
Lüttich 200640 
(abstract only)
Cohort of patients with HCC 
undergoing RFA treatment
Recruitment dates NR
Single centre, Spain
Funding NR
ü ü DTA
Accuracy data (detection of 
treatment success)
Mainenti 201049 Prospective study of consecutive 
patients with histologically proven 
CRC who were scheduled for 
surgery
July 2005–March 2007
Single centre, Italy
Funding NR
To compare CEUS, MDCT, MRI 
with extracellular contrast agent 
(Gd-CEMRI), MRI with intracellular 
contrast agent (SPIO-CEMRI) and 
PET/CT in the detection of hepatic 
metastases from CRC
ü ü ü DTA
Accuracy data (detection of 
liver metastases)
Quaia 200946 Prospective study of patients with 
cirrhosis who had at least one 
hepatocellular nodule detected on 
surveillance US
Recruitment dates NR
Two centre, Italy
Funding NR
To assess the added diagnostic 
value of CEUS combined with 64-
row MDCT in the assessment of 
hepatocellular nodule vascularity in 
patients with liver cirrhosis
ü ü ü DTA
Accuracy data 
(characterisation of FLLs 
detected at cirrhosis 
surveillance): HCC vs benign
Sangiovanni 
201047,61
Prospective study of patients with 
cirrhosis who had at least one 
hepatocellular nodule detected on 
surveillance US
April 2006 to NR
Single centre, Italy
Funded by grant no. PUR 2008, 
University of Milan and a personal 
donation (Dr Aldo Antognozzi)
To assess the sensitivity, specificity 
and economic impact of all 
possible sequential combinations 
of contrast imaging techniques in 
patients with cirrhosis with 1- to 
2-cm liver nodules undergoing US 
surveillance
ü ü ü ü DTA
Accuracy data 
(characterisation of FLLs 
detected at cirrhosis 
surveillance): HCC vs benign
 continued
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Study ID Study design Objective
US (CCTs 
and RCTs 
only)
Combined 
imaging
 
Comparator 
CECT
Comparator 
CEMRI
Any liver 
malignancy
Primary 
HCC Metastases
Treatment 
success
Study design and 
outcome extracted
Li 200754 Prospective study of patients 
with FLLs detected at US and 
unenhanced CT
Recruitment dates NR
Single centre, China
Supported by the Clinical 
New Technology Foundation 
of Southwest Hospital 
(SWH2005A004)
To compare the efficacy of 
contrast-enhanced pulse-inversion 
harmonic sonography for the 
characterisation of FLLs with that of 
contrast-enhanced helical CT
ü ü DTA
Accuracy data 
(characterisation of 
incidentally detected FLLs): 
any malignancy vs benign
Lüttich 200640 
(abstract only)
Cohort of patients with HCC 
undergoing RFA treatment
Recruitment dates NR
Single centre, Spain
Funding NR
ü ü DTA
Accuracy data (detection of 
treatment success)
Mainenti 201049 Prospective study of consecutive 
patients with histologically proven 
CRC who were scheduled for 
surgery
July 2005–March 2007
Single centre, Italy
Funding NR
To compare CEUS, MDCT, MRI 
with extracellular contrast agent 
(Gd-CEMRI), MRI with intracellular 
contrast agent (SPIO-CEMRI) and 
PET/CT in the detection of hepatic 
metastases from CRC
ü ü ü DTA
Accuracy data (detection of 
liver metastases)
Quaia 200946 Prospective study of patients with 
cirrhosis who had at least one 
hepatocellular nodule detected on 
surveillance US
Recruitment dates NR
Two centre, Italy
Funding NR
To assess the added diagnostic 
value of CEUS combined with 64-
row MDCT in the assessment of 
hepatocellular nodule vascularity in 
patients with liver cirrhosis
ü ü ü DTA
Accuracy data 
(characterisation of FLLs 
detected at cirrhosis 
surveillance): HCC vs benign
Sangiovanni 
201047,61
Prospective study of patients with 
cirrhosis who had at least one 
hepatocellular nodule detected on 
surveillance US
April 2006 to NR
Single centre, Italy
Funded by grant no. PUR 2008, 
University of Milan and a personal 
donation (Dr Aldo Antognozzi)
To assess the sensitivity, specificity 
and economic impact of all 
possible sequential combinations 
of contrast imaging techniques in 
patients with cirrhosis with 1- to 
2-cm liver nodules undergoing US 
surveillance
ü ü ü ü DTA
Accuracy data 
(characterisation of FLLs 
detected at cirrhosis 
surveillance): HCC vs benign
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Study ID Study design Objective
US (CCTs 
and RCTs 
only)
Combined 
imaging
 
Comparator 
CECT
Comparator 
CEMRI
Any liver 
malignancy
Primary 
HCC Metastases
Treatment 
success
Study design and 
outcome extracted
Seitz 200955 
(linked to Seitz 
201056)
Cohort of 267 patients who 
underwent SCT from a prospective 
study of 1349 consecutive patients 
with newly detected solid liver 
mass visible during routine US. 
Data extracted for the subgroup of 
patients (158) in whom diagnosis 
was histologically confirmed (2 × 2 
data could not be extracted for the 
remaining patients)
May 2004–December 2006
Multicentre, Germany, Austria and 
Switzerland
Funded by Bracco Research 
(Konstanz, Germany) for the 
online data forms, quality control, 
calculations and statistical analyses
To evaluate the diagnostic value of 
CEUS for the characterisation of 
FLLs in a prospective multicentre 
study in clinical practice. For this 
purpose CEUS was compared with 
SCT, the standard radiological 
method
ü ü ü DTA
Accuracy data 
(characterisation of 
incidentally detected FLLs): 
separate data for HCC, liver 
metastases and any liver 
malignancy
Seitz 201056 
(linked to Seitz 
200955)
Cohort of 269 patients who 
underwent MRI from a prospective 
study of 1349 consecutive patients 
with newly detected FLLs identified 
on US. Data extracted for the 
subgroup of patients (84) in 
whom diagnosis was histologically 
confirmed (2 × 2 data could not 
be extracted for the remaining 
patients)
May 2004–December 2006
Multicentre, Germany
Funding by Bracco Research 
(Konstanz, Germany) for the 
online data forms, quality control, 
calculations and statistical analyses
To assess the diagnostic 
performance of CEUS (compared 
with MRI) in a large patient cohort 
with FLLs recently discovered by US 
but not yet characterised
ü ü ü DTA
Accuracy data 
(characterisation of 
incidentally detected FLLs): 
separate data for HCC, liver 
metastases and any liver 
malignancy
Solbiati 200641 
(abstract only)
Retrospective analysis of data from 
patients with incidentally detected 
FLLs
5-year experience, dates not 
specified
Single centre, Italy
Funding NR
To assess the diagnostic 
performance and cost-effectiveness 
of CEUS in the characterisation of 
FLLs
ü ü DTA
Accuracy data 
(characterisation of 
incidentally detected FLLs): 
any malignancy vs benign
Zhou 200758 
(Chinese 
language)
Retrospective analysis of data from 
patients undergoing non-surgical 
treatment for HCC
June 2005–June 2006
Single centre, China
Funding NR
To investigate the value of CEUS for 
non-surgical treatment response 
in HCC
ü ü DTA
Accuracy data (detection of 
treatment success) 
CCT, controlled clinical trial; CHI, contrast-enhanced harmonic imaging; FDG-PET, fluorodeoxyglucose positron 
emission tomography; Gd-CEMRI, gadolinium contrast-enhanced magnetic resonance imaging; MDCT, multidetector 
computed tomography; NR, not reported; PET, positron emission tomography; SCT, spiral computed tomography; US, 
unenhanced ultrasound.
a 52 of the 59 positive diagnoses were liver metastases; therefore, this study was classified as ‘detection of metastases’.
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Study ID Study design Objective
US (CCTs 
and RCTs 
only)
Combined 
imaging
 
Comparator 
CECT
Comparator 
CEMRI
Any liver 
malignancy
Primary 
HCC Metastases
Treatment 
success
Study design and 
outcome extracted
Seitz 200955 
(linked to Seitz 
201056)
Cohort of 267 patients who 
underwent SCT from a prospective 
study of 1349 consecutive patients 
with newly detected solid liver 
mass visible during routine US. 
Data extracted for the subgroup of 
patients (158) in whom diagnosis 
was histologically confirmed (2 × 2 
data could not be extracted for the 
remaining patients)
May 2004–December 2006
Multicentre, Germany, Austria and 
Switzerland
Funded by Bracco Research 
(Konstanz, Germany) for the 
online data forms, quality control, 
calculations and statistical analyses
To evaluate the diagnostic value of 
CEUS for the characterisation of 
FLLs in a prospective multicentre 
study in clinical practice. For this 
purpose CEUS was compared with 
SCT, the standard radiological 
method
ü ü ü DTA
Accuracy data 
(characterisation of 
incidentally detected FLLs): 
separate data for HCC, liver 
metastases and any liver 
malignancy
Seitz 201056 
(linked to Seitz 
200955)
Cohort of 269 patients who 
underwent MRI from a prospective 
study of 1349 consecutive patients 
with newly detected FLLs identified 
on US. Data extracted for the 
subgroup of patients (84) in 
whom diagnosis was histologically 
confirmed (2 × 2 data could not 
be extracted for the remaining 
patients)
May 2004–December 2006
Multicentre, Germany
Funding by Bracco Research 
(Konstanz, Germany) for the 
online data forms, quality control, 
calculations and statistical analyses
To assess the diagnostic 
performance of CEUS (compared 
with MRI) in a large patient cohort 
with FLLs recently discovered by US 
but not yet characterised
ü ü ü DTA
Accuracy data 
(characterisation of 
incidentally detected FLLs): 
separate data for HCC, liver 
metastases and any liver 
malignancy
Solbiati 200641 
(abstract only)
Retrospective analysis of data from 
patients with incidentally detected 
FLLs
5-year experience, dates not 
specified
Single centre, Italy
Funding NR
To assess the diagnostic 
performance and cost-effectiveness 
of CEUS in the characterisation of 
FLLs
ü ü DTA
Accuracy data 
(characterisation of 
incidentally detected FLLs): 
any malignancy vs benign
Zhou 200758 
(Chinese 
language)
Retrospective analysis of data from 
patients undergoing non-surgical 
treatment for HCC
June 2005–June 2006
Single centre, China
Funding NR
To investigate the value of CEUS for 
non-surgical treatment response 
in HCC
ü ü DTA
Accuracy data (detection of 
treatment success) 
CCT, controlled clinical trial; CHI, contrast-enhanced harmonic imaging; FDG-PET, fluorodeoxyglucose positron 
emission tomography; Gd-CEMRI, gadolinium contrast-enhanced magnetic resonance imaging; MDCT, multidetector 
computed tomography; NR, not reported; PET, positron emission tomography; SCT, spiral computed tomography; US, 
unenhanced ultrasound.
a 52 of the 59 positive diagnoses were liver metastases; therefore, this study was classified as ‘detection of metastases’.
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Accuracy of SonoVue contrast-enhanced ultrasound for the 
characterisation of focal liver lesions detected on surveillance of patients 
with cirrhosis
Seven studies reported comparisons of SonoVue CEUS with other imaging techniques for the 
characterisation of FLLs detected on unenhanced US surveillance of patients with known cirrhosis.42–48 One 
study, by Sangiovanni et al., was reported as both a full paper47 and a conference abstract.61 All of the 
studies in this section reported accuracy data for the differentiation of HCC from other liver lesions only 
and one study45 reported that there were no imaging-related adverse events. In total, the seven studies 
in this section reported 369 diagnoses of malignant liver lesions, of which 366 were HCC; the remaining 
lesions comprised two CCC and one liver metastasis. All studies in this section reported per-lesion data; 
three studies reported data for one lesion per patient, equivalent to per-patient test performance.44,45,47 
Studies generally focused on the characterisation of small to medium FLLs. Four studies prespecified the 
size of FLLs considered: ≤ 30 mm42,45,46 or ≤ 20 mm.47 In two studies the mean size was 15 ± 3 mm43 and 
14 mm (range 7–20 mm).44 The remaining study did not specify lesion size as an inclusion criterion or 
report mean lesion size.48 Two studies explicitly excluded lesions of < 10 mm42,47 and one study reported 
stratified data for different lesion sizes (≤ 10 mm and 11–30 mm).45 Two studies compared SonoVue CEUS 
with CECT,43,46 three studies compared SonoVue CEUS with CEMRI45,48,62 and the remaining two studies 
compared SonoVue CEUS with both CECT and CEMRI.42,47 One study included in this section explicitly 
reported that patients had an uncertain diagnosis following unenhanced US.43 Five studies had previous 
unenhanced US examination as an inclusion criterion, and the ‘concern regarding applicability’ criterion 
for quality assessment was rated ‘unclear’ for these studies (see Table 3).42,44–47 The remaining study was 
a retrospective analysis of information derived from a radiology database; inclusion criteria specified only 
that patients should have received both CEUS and CEMRI and histological confirmation of diagnosis 
(examinations prior to contrast-enhanced imaging were not specified), and the ‘concern regarding 
applicability’ criterion was therefore rated ‘high’ risk of bias for this study.48 Comparators and imaging 
criteria used to define a positive test for HCC varied across studies and no meta-analyses were therefore 
undertaken. All but one42 of the studies in this section used histological confirmation in all patients or 
histological confirmation of imaging-positive patients and follow-up of imaging-negative patients as the 
reference standard.
All studies in this section were rated as ‘low’ or ‘unclear’ risk of bias for the ‘index test’ and ‘comparator 
test’ domains of the quality assessment tool. Two studies recruited consecutive samples of patients without 
inappropriate exclusions and were rated as ‘low’ risk of bias for ‘patient selection’.43,45 Four studies were 
rated as ‘high’ risk of bias for the ‘patient selection’ domain because of the retrospective study design48 
or inappropriate exclusions.42,46,47 Two studies excluded very small lesions (< 10 mm);42,47 as these lesions 
may be more difficult to characterise, their exclusion may result in overestimations of test performance. 
One study excluded lesions with peripheral enhancement on CECT, which was considered to be indicative 
of a high probability of haemangioma.46 Two of the three studies were also rated as ‘high’ risk of bias 
for the ‘flow and timing domain’ of the assessment, in one case because the reference standard used 
was not independent of the imaging test results42 and in the other because a high proportion of lesions 
(approximately 40%) were excluded because a histopathological reference standard was not performed.46 
One study was also rated as ‘high’ risk of bias for the ‘reference standard’ domain because a suboptimal 
reference standard (concordance between at least two imaging test results) was used in the majority 
of cases.42
The two studies that compared CEUS and CECT had slightly differing definitions of a positive imaging test 
(hyperenhancement in the arterial phase followed by portal venous washout43 and hyperenhancement 
in the arterial phase with or without portal venous washout).46 Neither study reported a significant 
difference in performance between imaging modalities for the differentiation of HCC from other liver 
lesions and neither study specified exclusion of very small FLLs. However, no data for very small FLLs were 
reported; in one study 46% of lesions were 10–15 mm and 54% were 16–20 mm43 and in the other study 
all lesions were in the range 10–30 mm.46 The study by Dai et al.43 reported slightly higher estimates of 
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test performance, particularly for CECT specificity (see Table 4). The sensitivity estimates for CEUS and 
CECT were 91.1% (95% CI 80.4% to 97.0%) and 80.4% (95% CI 67.6% to 89.8%), respectively, and the 
corresponding specificities were 87.2% (95% CI 74.3% to 95.2%) and 97.9 (95% CI 88.7% to 99.9%).43 
The definition of HCC used by this study corresponded most closely with that reported in the EFSUMB 
guidelines on the use of CEUS.6 Table 1 summarises the typical enhancement patterns seen in various 
malignant FLLs. Quaia et al.46 reported sufficient data to allow calculation of sensitivity and specificity for 
the combination of CEUS and CECT, with a positive finding on either imaging technique treated as ‘test 
positive’; they reported an increase in sensitivity for combined imaging compared with either CEUS or CECT 
alone with no change in specificity.
Three studies compared CEUS and CEMRI; two used gadolinium contrast-enhanced magnetic resonance 
imaging (Gd-CEMRI)44,45 and one used Gd-EOB-DTPA-CEMRI,48 a ‘combined’ vascular and hepatocyte-
specific contrast agent. The two studies that compared CEUS and Gd-CEMRI used different definitions 
of a positive imaging test result and only Forner et al.44 reported data for a definition of HCC, which 
corresponded with that given in the EFSUMB guidelines,6 which they described as ‘conclusive’ HCC. Forner 
et al.44 also reported data for a definition of ‘suspicious’ HCC (hyperenhancement in the arterial phase 
without portal venous washout). Sensitivity and specificity were similar for CEUS and Gd-CEMRI using 
either criterion. Specificity tended to increase and sensitivity to decrease for both imaging modalities when 
the stricter ‘conclusive’ definition of HCC was used. This study did not stratify data by lesion size; however, 
very small lesions (≤ 10 mm) were included (15% of lesions were < 10 mm, 49% were 10–15 mm and 36% 
were 16–20 mm). The authors also stated that use of the AASLD criteria (concordant, ‘conclusive’ findings 
on CEUS and CEMRI) resulted in 100% specificity but low sensitivity (33%) (data not reported). Giorgio et 
al.45 used (arterial phase) hypervascularity as the definition of a positive test and stratified data by lesion 
size. There was no significant difference in the performance of CEUS and Gd-CEMRI for the differentiation 
of HCC from benign lesions, for FLLs between 11 and 30 mm, and both techniques had sensitivity and 
specificity values > 85% (see Table 4). For very small FLLs (≤ 10 mm), the sensitivity of CEUS was lower than 
that of CEMRI (27% vs 73%); for both imaging techniques, sensitivity was poor when the analysis was 
restricted to very small FLLs.45 Imaging test performance estimates were similar for the ‘all lesion’ data set 
from Georgio et al.45 and the ‘suspicious’ diagnostic criteria data set from Forner et al.;44 these data sets 
were similar in terms of diagnostic criteria and distribution of lesion size. The study that used Gd-EOB-
DTPA-CEMRI did not report any information on lesion size.48 The criteria used to define a positive imaging 
test result matched the definition of HCC given in the EFSUMB guidelines.6 Sensitivity estimates were 
similar and high (> 90%) for both CEUS and Gd-EOB-DTPA-CEMRI (see Table 4). Specificity appeared lower 
for CEUS than for Gd-EOB-DTPA-CEMRI; however, the small number of patients with benign lesions in this 
study resulted in high imprecision in specificity estimates: 50% (95% CI 42% to 88%) for CEUS and 83% 
(95% CI 36% to 100%) for Gd-EOB-DTPA-CEMRI.
The two studies that assessed all three imaging modalities42,47 both reported data using a definition of HCC 
that broadly corresponded to that given in the EFSUMB guidelines,6 although Leoni et al.42 stated ‘typical 
enhancement pattern’ without specifying portal venous/late phase washout and Sangiovanni et al.47 also 
reported data using arterial hyperenhancement and portal venous washout separately as the definitions 
of HCC. Both studies assessed Gd-CEMRI and one study also assessed CEMRI using SPIO, a contrast agent 
that is selectively taken up by Kupffer cells in the normal liver and benign lesions and can therefore be used 
to identify HCCs, which are generally deficient in Kupffer cells.47 When the EFSUMB-consistent definition 
of HCC was used, the two studies reported similar specificity estimates for all imaging modalities and for 
both MRI contrast agents; however, Leoni et al.42 tended to report higher estimates of sensitivity. Sensitivity 
estimates from these studies were generally lower than those from studies with an EFSUMB-consistent 
definition of HCC that compared only CECT with CEUS43 or CEMRI with CEUS.44,48 Leoni et al.42 reported 
that Gd-CEMRI had the highest sensitivity of the imaging modalities assessed [81.8% (95% CI 69.1% to 
90.9%)]. Both studies reported sufficient data to allow calculation of sensitivity and specificity estimates, 
with a positive result on any of the three imaging modalities treated as index test positive. Data from Leoni 
et al.42 indicated that combining the three imaging modalities in this way could increase sensitivity [98.2% 
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(95% CI 90.3% to 100%)] and decrease specificity [75.0% (95% CI 50.9% to 91.3%)] relative to any of the 
three imaging modalities alone. By contrast, combined imaging modality data from Sangiovanni et al.47 
did not appear to indicate significant improvements in sensitivity.
Table 3 provides a summary of the QUADAS-2 assessments for studies in this section and Table 4 
summarises individual study results.
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State 
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17160 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 16
29
TA
B
LE
 3
 Q
U
A
D
A
S-
2 
re
su
lt
s 
fo
r 
st
ud
ie
s 
on
 t
he
 a
cc
ur
ac
y 
of
 S
on
oV
ue
 C
EU
S 
fo
r 
th
e 
ch
ar
ac
te
ri
sa
ti
on
 o
f 
FL
Ls
 d
et
ec
te
d 
on
 s
ur
ve
ill
an
ce
 o
f 
pa
ti
en
ts
 w
it
h 
ci
rr
ho
si
s
St
u
d
y 
ID
R
is
k 
o
f 
b
ia
s
A
p
p
lic
ab
ili
ty
 
co
n
ce
rn
s
Pa
ti
en
t 
se
le
ct
io
n
In
d
ex
 t
es
t
C
o
m
p
ar
at
o
r 
te
st
R
ef
er
en
ce
 s
ta
n
d
ar
d
Fl
o
w
 a
n
d
 t
im
in
g
Pa
ti
en
t 
se
le
ct
io
n
Bl
on
di
n 
20
11
48
L
?
?
J
J
L
D
ai
 2
00
84
3
J
J
J
?
J
J
Fo
rn
er
 2
00
84
4
?
?
J
?
?
?
G
io
rg
io
 2
00
74
5
J
J
J
J
J
?
Le
on
i 2
01
04
2
L
J
J
L
L
?
Q
ua
ia
 2
00
94
6
L
J
J
?
L
?
Sa
ng
io
va
nn
i47
,6
1
L
?
?
J
J
?
J
, l
ow
 r
is
k;
 L
, h
ig
h 
ris
k;
 ?
, u
nc
le
ar
 r
is
k.
NIHR Journals Library
ASSESSMENT Of CLINICAL EffECTIVENESS
30
TABLE 4 Accuracy of SonoVue CEUS compared with other imaging techniques for the characterisation of FFLs 
detected during routine surveillance of patients with known cirrhosis
Study ID
Patient or 
lesion data Index test or comparator
Reference 
standard TP FN FP TN
Sensitivity  
(95% CI) (%)a
Specificity  
(95% CI) (%)a Non-diagnostic
Adverse 
events
Acceptability 
to patients
HCC
SonoVue CEUS compared with CECT
Dai 200843 n = 103 FLLs 
in 72 patients 
(per-lesion 
data)
CEUS SonoVue
HCC = positiveb
Histopathology 
following biopsy, 
with negative 
biopsy confirmed 
by a minimum of 
6 months’ follow-up
51 5 6 41 91.1 (80.4 to 97.0) 87.2 (74.3 to 95.2) None NR NR
CECT with Somatom Plus 4 
(Siemens Medical Systems, 
Erlangen, Germany)
HCC = positiveb
45 11 1 46 80.4 (67.6 to 89.8) 97.9 (88.7 to 99.9)
Quaia 200946 n = 121 FLLs 
(≤ 30 mm) in 
106 patients 
(per-lesion 
data)
CEUS sulphur hexafluoride-filled 
microbubbles
HCC = positivec (readers 1 and 2)
FNB in all lesions 64 8 15 34 88.9 (79.3 to 95.1) 69.4 (54.6 to 81.7) n = 4 inadequate CEUS 
examinations excluded from 
study
NR NR
63 9 18 31 87.5 (77.6 to 94.1) 63.3 (48.3 to 76.6)
CECT with Aquilion (Toshiba 
Medical Systems, Tochigi-ken, 
Japan) or Brilliance (Philips, 
Cleveland, OH, USA)
HCC = positivec (readers 1&2)
53 19 14 35 73.6 (61.9 to 83.3) 71.4 (56.7 to 83.4) n = 10 inadequate CECT 
examinations excluded from 
study51 21 14 35 70.8 (58.9 to 81.0) 71.4 (56.7 to 83.4)
CEUS + CECT
HCC = either test positive 
(readers 1 and 2)
70 2 14 35 97.2 (90.3 to 99.7) 71.4 (56.7 to 83.4) See above
70 2 15 34 97.2 (90.3 to 99.7) 69.4 (54.6 to 81.7)
SonoVue CEUS compared with CEMRI
Blondin 
201148
n = 47 FLLs in 
33 patients
CEUS SonoVue
HCC = positiveb
Histology (surgery or 
biopsy) in all lesions
38 3 3 3 93 (80 to 98) 50 (42 to 88) None NR NR
Gd-EOB-DTPA CEMRI with 
MAGNETOM Avanto (Siemens)
HCC = positiveb
37 4 1 5 90 (77 to 97) 83 (36 to 100)
Forner 200844 n = 89 
patients (one 
lesion per 
patient)
CEUS SonoVue
HCC suspiciousd or 
conclusiveb = positive
FNB for test positive, 
imaging follow-up 
for test negative
47 13 4 25 78.3 (65.8 to 87.9) 86.2 (68.3 to 96.1)
CEUS SonoVue
HCC conclusiveb = positive
31 29 2 27 51.7 (38.4 to 64.8) 93.1 (77.2 to 99.2)
Gd-CEMRI with Symphony system 
(Siemens)
HCC suspiciousd or 
conclusiveb = positive
51 9 3 26 85.0 (73.4 to 92.9) 89.7 (72.6 to 97.8)
Gd-CEMRI 
HCC conclusiveb = positive
37 23 1 28 61.7 (48.2 to 73.9) 96.6 (82.2 to 99.9)
 continued
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TABLE 4 Accuracy of SonoVue CEUS compared with other imaging techniques for the characterisation of FFLs 
detected during routine surveillance of patients with known cirrhosis
Study ID
Patient or 
lesion data Index test or comparator
Reference 
standard TP FN FP TN
Sensitivity  
(95% CI) (%)a
Specificity  
(95% CI) (%)a Non-diagnostic
Adverse 
events
Acceptability 
to patients
HCC
SonoVue CEUS compared with CECT
Dai 200843 n = 103 FLLs 
in 72 patients 
(per-lesion 
data)
CEUS SonoVue
HCC = positiveb
Histopathology 
following biopsy, 
with negative 
biopsy confirmed 
by a minimum of 
6 months’ follow-up
51 5 6 41 91.1 (80.4 to 97.0) 87.2 (74.3 to 95.2) None NR NR
CECT with Somatom Plus 4 
(Siemens Medical Systems, 
Erlangen, Germany)
HCC = positiveb
45 11 1 46 80.4 (67.6 to 89.8) 97.9 (88.7 to 99.9)
Quaia 200946 n = 121 FLLs 
(≤ 30 mm) in 
106 patients 
(per-lesion 
data)
CEUS sulphur hexafluoride-filled 
microbubbles
HCC = positivec (readers 1 and 2)
FNB in all lesions 64 8 15 34 88.9 (79.3 to 95.1) 69.4 (54.6 to 81.7) n = 4 inadequate CEUS 
examinations excluded from 
study
NR NR
63 9 18 31 87.5 (77.6 to 94.1) 63.3 (48.3 to 76.6)
CECT with Aquilion (Toshiba 
Medical Systems, Tochigi-ken, 
Japan) or Brilliance (Philips, 
Cleveland, OH, USA)
HCC = positivec (readers 1&2)
53 19 14 35 73.6 (61.9 to 83.3) 71.4 (56.7 to 83.4) n = 10 inadequate CECT 
examinations excluded from 
study51 21 14 35 70.8 (58.9 to 81.0) 71.4 (56.7 to 83.4)
CEUS + CECT
HCC = either test positive 
(readers 1 and 2)
70 2 14 35 97.2 (90.3 to 99.7) 71.4 (56.7 to 83.4) See above
70 2 15 34 97.2 (90.3 to 99.7) 69.4 (54.6 to 81.7)
SonoVue CEUS compared with CEMRI
Blondin 
201148
n = 47 FLLs in 
33 patients
CEUS SonoVue
HCC = positiveb
Histology (surgery or 
biopsy) in all lesions
38 3 3 3 93 (80 to 98) 50 (42 to 88) None NR NR
Gd-EOB-DTPA CEMRI with 
MAGNETOM Avanto (Siemens)
HCC = positiveb
37 4 1 5 90 (77 to 97) 83 (36 to 100)
Forner 200844 n = 89 
patients (one 
lesion per 
patient)
CEUS SonoVue
HCC suspiciousd or 
conclusiveb = positive
FNB for test positive, 
imaging follow-up 
for test negative
47 13 4 25 78.3 (65.8 to 87.9) 86.2 (68.3 to 96.1)
CEUS SonoVue
HCC conclusiveb = positive
31 29 2 27 51.7 (38.4 to 64.8) 93.1 (77.2 to 99.2)
Gd-CEMRI with Symphony system 
(Siemens)
HCC suspiciousd or 
conclusiveb = positive
51 9 3 26 85.0 (73.4 to 92.9) 89.7 (72.6 to 97.8)
Gd-CEMRI 
HCC conclusiveb = positive
37 23 1 28 61.7 (48.2 to 73.9) 96.6 (82.2 to 99.9)
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Study ID
Patient or 
lesion data Index test or comparator
Reference 
standard TP FN FP TN
Sensitivity  
(95% CI) (%)a
Specificity  
(95% CI) (%)a Non-diagnostic
Adverse 
events
Acceptability 
to patients
Giorgio 
200745
n = 73 FLLs 
(one lesion 
per patient)
CEUS SonoVue
HCC = positivee 
US-guided FNB in all 
patients
37 11 1 24 77.1 (62.7 to 88.0) 96.0 (79.6 to 99.9) None No side 
effects 
observed in 
any patients
NR
n = 21 FLLs 
(≤ 10 mm)
3 8 0 10 27.3 (6.0 to 61.0) 100 (69.2 to 100)
n = 52 FLLs 
(11–30 mm)
34 3 1 14 91.9 (78.1 to 98.3) 93.3 (68.1 to 99.8)
n = 73 FLLs 
(one lesion 
per patient)
Gd-CEMRI with Symphony system
HCC = positivef 
43 5 3 22 89.6 (77.3 to 96.5) 88.0 (68.8 to 97.5) NR
n = 21 FLLs 
(≤ 10 mm)
8 3 1 9 72.7 (39.0 to 94.0) 90.0 (55.5 to 99.7)
n = 52 FLLs 
(11–30 mm)
35 2 2 13 94.6 (81.8 to 99.3) 86.7 (59.5 to 98.3)
SonoVue CEUS compared with CECT and CEMRI
Leoni 201042 n = 75 FLLs in 
60 patients 
(10–30 mm) 
CEUS SonoVue
HCC = positiveg 
Two or more 
concordant imaging 
results (n = 44), FNB 
(n = 14) or follow-up 
at 3-month intervals 
(n = 1) for positive 
test
FNB (n = 7) or 
follow-up at 
3-month intervals 
(n = 9) for test 
negative
37 18 2 18 67.3 (53.3 to 79.3) 90.0 (68.3 to 98.8) None NR NR
CECT with Emotion 6 (Siemens)
HCC = positiveg
37 18 2 18 67.3 (53.3 to 79.3) 90.0 (68.3 to 98.8)
Gd-CEMRI with Signa (GE Medical 
Systems, WI, USA)
HCC = positiveg
45 10 1 19 81.8 (69.1 to 90.9) 95.0 (75.1 to 99.9)
n = 68 FLLs 
(10–30 mm)
SPIO-CEMRI with Signa
HCC = positiveg
35 15 1 17 70.0 (55.4 to 82.1) 94.4 (72.7 to 99.9) Seven FLLs not assessed with 
SPIO-MRI
n = 75 FLLs 
(10–30 mm)
CEUS + CECT + CEMRI
HCC = any test positive
54 1 5 15 98.2 (90.3 to 100) 75.0 (50.9 to 91.3) None
Sangiovanni 
201047,61
n = 55 FLLs 
selected from 
67 FLLs in 
64 patients 
(10–20 mm)
CEUS SonoVue
HCC = positiveb
FNB in all lesions 9 25 0 21 26.5 (12.9 to 44.4) 100 (83.9 to 100) None NR NR
CEUS SonoVue
HCC = positiveh 
23 11 5 16 67.6 (49.5 to 82.6) 76.2 (52.8 to 91.8)
CEUS SonoVue
HCC = positivei 
13 21 1 20 38.2 (22.2 to 56.4) 95.2 (76.2 to 99.9)
CECT with Definition system 
(Siemens)
HCC = positiveb
16 18 0 21 47.1 (29.8 to 64.9) 100 (83.9 to 100)
CECT
HCC = positiveh
22 12 4 17 64.7 (46.5 to 80.3) 81.0 (58.1 to 94.6)
CECT
HCC = positivei 
18 16 0 21 52.9 (35.1 to 70.2) 100 (83.9 to 100)
 continued
TABLE 4 Accuracy of SonoVue CEUS compared with other imaging techniques for the characterisation of FFLs 
detected during routine surveillance of patients with known cirrhosis (continued)
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Study ID
Patient or 
lesion data Index test or comparator
Reference 
standard TP FN FP TN
Sensitivity  
(95% CI) (%)a
Specificity  
(95% CI) (%)a Non-diagnostic
Adverse 
events
Acceptability 
to patients
Giorgio 
200745
n = 73 FLLs 
(one lesion 
per patient)
CEUS SonoVue
HCC = positivee 
US-guided FNB in all 
patients
37 11 1 24 77.1 (62.7 to 88.0) 96.0 (79.6 to 99.9) None No side 
effects 
observed in 
any patients
NR
n = 21 FLLs 
(≤ 10 mm)
3 8 0 10 27.3 (6.0 to 61.0) 100 (69.2 to 100)
n = 52 FLLs 
(11–30 mm)
34 3 1 14 91.9 (78.1 to 98.3) 93.3 (68.1 to 99.8)
n = 73 FLLs 
(one lesion 
per patient)
Gd-CEMRI with Symphony system
HCC = positivef 
43 5 3 22 89.6 (77.3 to 96.5) 88.0 (68.8 to 97.5) NR
n = 21 FLLs 
(≤ 10 mm)
8 3 1 9 72.7 (39.0 to 94.0) 90.0 (55.5 to 99.7)
n = 52 FLLs 
(11–30 mm)
35 2 2 13 94.6 (81.8 to 99.3) 86.7 (59.5 to 98.3)
SonoVue CEUS compared with CECT and CEMRI
Leoni 201042 n = 75 FLLs in 
60 patients 
(10–30 mm) 
CEUS SonoVue
HCC = positiveg 
Two or more 
concordant imaging 
results (n = 44), FNB 
(n = 14) or follow-up 
at 3-month intervals 
(n = 1) for positive 
test
FNB (n = 7) or 
follow-up at 
3-month intervals 
(n = 9) for test 
negative
37 18 2 18 67.3 (53.3 to 79.3) 90.0 (68.3 to 98.8) None NR NR
CECT with Emotion 6 (Siemens)
HCC = positiveg
37 18 2 18 67.3 (53.3 to 79.3) 90.0 (68.3 to 98.8)
Gd-CEMRI with Signa (GE Medical 
Systems, WI, USA)
HCC = positiveg
45 10 1 19 81.8 (69.1 to 90.9) 95.0 (75.1 to 99.9)
n = 68 FLLs 
(10–30 mm)
SPIO-CEMRI with Signa
HCC = positiveg
35 15 1 17 70.0 (55.4 to 82.1) 94.4 (72.7 to 99.9) Seven FLLs not assessed with 
SPIO-MRI
n = 75 FLLs 
(10–30 mm)
CEUS + CECT + CEMRI
HCC = any test positive
54 1 5 15 98.2 (90.3 to 100) 75.0 (50.9 to 91.3) None
Sangiovanni 
201047,61
n = 55 FLLs 
selected from 
67 FLLs in 
64 patients 
(10–20 mm)
CEUS SonoVue
HCC = positiveb
FNB in all lesions 9 25 0 21 26.5 (12.9 to 44.4) 100 (83.9 to 100) None NR NR
CEUS SonoVue
HCC = positiveh 
23 11 5 16 67.6 (49.5 to 82.6) 76.2 (52.8 to 91.8)
CEUS SonoVue
HCC = positivei 
13 21 1 20 38.2 (22.2 to 56.4) 95.2 (76.2 to 99.9)
CECT with Definition system 
(Siemens)
HCC = positiveb
16 18 0 21 47.1 (29.8 to 64.9) 100 (83.9 to 100)
CECT
HCC = positiveh
22 12 4 17 64.7 (46.5 to 80.3) 81.0 (58.1 to 94.6)
CECT
HCC = positivei 
18 16 0 21 52.9 (35.1 to 70.2) 100 (83.9 to 100)
 continued
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Study ID
Patient or 
lesion data Index test or comparator
Reference 
standard TP FN FP TN
Sensitivity  
(95% CI) (%)a
Specificity  
(95% CI) (%)a Non-diagnostic
Adverse 
events
Acceptability 
to patients
n = 53j FLLs 
(10–20 mm)
Gd-CEMRI with Avanto system 
(Siemens)
HCC = positiveb
14 18 0 21 43.8 (26.4 to 62.3) 100 (83.9 to 100)
Gd-CEMRI
HCC = positiveh
21 11 8 13 65.6 (46.8 to 81.4) 61.9 (38.4 to 81.9)
Gd-CEMRI
HCC = positivei
19 13 1 20 59.4 (40.6 to 76.3) 95.2 (76.2 to 99.9)
CEUS + CECT + CEMRI
HCC = at least one test positiveb
22 12 0 21 64.7 (46.5 to 80.3) 100 (83.9 to 100)
Liver metastases
No studies identified
Any malignancy
No studies identified
FN, false-negative; FNB, fine-needle biopsy; FP, false-positive; ND, non-diagnostic; NR, not reported; TN, true-negative; 
TP, true-positive.
a Calculated values.
b Hyperenhancement in the arterial phase and hypoenhancement in the portal venous and late phases (portal 
venous washout).
c Hyperenhancement in the arterial phase and iso- or hyperenhancement in the portal venous and late phases with 
evidence of peripheral rim-like enhancement, or hyperenhancement in the arterial phase and hypoenhancement in the 
portal venous and late phases with or without peripheral vascular rim.
d Hyperenhancement in the arterial phase without washout in the venous phase.
e Hyper-echogenicity related to hypervascularity on US.
f Typical pattern of round area of hypervascularity and lack of portal supply.
g Hyperenhancement in the arterial phase, ‘typical enhancement pattern for HCC’.
h Arterial hypervascularity.
i Portal venous washout.
j Two patients were excluded from analyses because they could not undergo CEMRI.
TABLE 4 Accuracy of SonoVue CEUS compared with other imaging techniques for the characterisation of FFLs 
detected during routine surveillance of patients with known cirrhosis (continued)
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Study ID
Patient or 
lesion data Index test or comparator
Reference 
standard TP FN FP TN
Sensitivity  
(95% CI) (%)a
Specificity  
(95% CI) (%)a Non-diagnostic
Adverse 
events
Acceptability 
to patients
n = 53j FLLs 
(10–20 mm)
Gd-CEMRI with Avanto system 
(Siemens)
HCC = positiveb
14 18 0 21 43.8 (26.4 to 62.3) 100 (83.9 to 100)
Gd-CEMRI
HCC = positiveh
21 11 8 13 65.6 (46.8 to 81.4) 61.9 (38.4 to 81.9)
Gd-CEMRI
HCC = positivei
19 13 1 20 59.4 (40.6 to 76.3) 95.2 (76.2 to 99.9)
CEUS + CECT + CEMRI
HCC = at least one test positiveb
22 12 0 21 64.7 (46.5 to 80.3) 100 (83.9 to 100)
Liver metastases
No studies identified
Any malignancy
No studies identified
FN, false-negative; FNB, fine-needle biopsy; FP, false-positive; ND, non-diagnostic; NR, not reported; TN, true-negative; 
TP, true-positive.
a Calculated values.
b Hyperenhancement in the arterial phase and hypoenhancement in the portal venous and late phases (portal 
venous washout).
c Hyperenhancement in the arterial phase and iso- or hyperenhancement in the portal venous and late phases with 
evidence of peripheral rim-like enhancement, or hyperenhancement in the arterial phase and hypoenhancement in the 
portal venous and late phases with or without peripheral vascular rim.
d Hyperenhancement in the arterial phase without washout in the venous phase.
e Hyper-echogenicity related to hypervascularity on US.
f Typical pattern of round area of hypervascularity and lack of portal supply.
g Hyperenhancement in the arterial phase, ‘typical enhancement pattern for HCC’.
h Arterial hypervascularity.
i Portal venous washout.
j Two patients were excluded from analyses because they could not undergo CEMRI.
NIHR Journals Library
ASSESSMENT Of CLINICAL EffECTIVENESS
36
Accuracy of SonoVue contrast-enhanced ultrasound for the detection of 
liver metastases in patients with known primary malignancy
Two studies compared SonoVue CEUS with both CECT and CEMRI (SPIO-CEMRI in one study and both 
SPIO-CEMRI and Gd-CEMRI in the other study) for the detection of liver metastases in patients with 
known CRC.49,50 Both studies reported per-lesion accuracy data and one study49 also reported per-patient 
data. These two studies reported a total of 46 diagnoses of metastatic liver lesions. One of these studies 
included only patients with known liver metastases who were being considered for curative surgery and 
was therefore rated as having ‘high’ concerns regarding applicability.50 One study, which compared 
CEUS and CECT and reported data on the detection of any liver malignancy, was included in this section 
because the diagnostic status of participants at baseline was unclear and 52 of the 59 positive final 
diagnoses were liver metastases (primary tumours: colon 43, breast 5, neuroendocrine 2, renal 2); this 
study was rated ‘unclear’ for concerns regarding applicability.51 One further study, which did not include a 
comparator test, was included in this section.39 This study was included in the review because it reported 
an inclusion criterion of ‘indeterminate MDCT [multidetector computed tomography]-detected FLLs in 
patients with known primary cancers’ (various locations) and could therefore provide information on 
how SonoVue CEUS performs in patients who have had previous imaging other than US and in whom 
the diagnosis remains uncertain. All studies in this section used histological confirmation in all patients or 
histological confirmation of imaging-positive patients and follow-up of imaging-negative patients as the 
reference standard.
Two of the four studies included in this section were reported only as conference abstracts,39,50 resulting in 
a frequent judgement of ‘unclear’ risk of bias on quality assessment domains (see Table 5). Of the two full 
papers in this section,49,51 Clevert et al.51 was rated ‘high’ risk of bias for the ‘flow and timing’ domain of 
QUADAS-2 because 21% of participants were excluded from the CECT analysis; both studies were judged 
to be at ‘low’ or ‘unclear’ risk of bias for all other domains. The study by Jonas et al.50 was rated as ‘high’ 
risk of bias for the ‘patient selection’ domain because it aimed to assess the ability of imaging modalities 
to detect liver metastases while including only patients with known liver metastases.
When definitions of a positive imaging test were reported, studies that assessed imaging tests using 
vascular contrast media (CEUS, CECT and Gd-CEMRI) gave various descriptions of peripheral rim 
enhancement as the criteria for liver metastases. In addition, two studies reported data for CEMRI using 
the hepatocyte-specific contrast agent SPIO.49,50 Jonas et al.50 reported 100% specificity and, similarly, 
high (83–97%) estimates of sensitivity for all three imaging modalities (CEUS, CECT and SPIO-CEMRI). 
Mainenti et al.49 also reported high (83–100%) specificity values for all imaging modalities and for both 
per-lesion and per-patient data. Per-patient sensitivity estimates were also consistent across all imaging 
modalities (83% in all cases);49 however, for both CEUS and CECT, the sensitivity estimates appeared lower 
for per-lesion data (50% and 69% respectively) than for per-patient data.49 For both CEMRI methods, the 
per-lesion estimate of sensitivity (81%) was similar to the per-patient estimate.49 By contrast, Clevert et 
al.51 reported per-patient data and found similarly high (> 95%) estimates of sensitivity for both CEUS and 
CECT; however, specificity appeared lower for CECT than for CEUS [71.4% (95% CI 47.8% to 88.7%) and 
97.6% (95% CI 87.1% to 99.9%) respectively] and images were non-diagnostic in approximately 15% of 
CT examinations.
Table 5 provides a summary of the QUADAS-2 assessments for studies in this section and Table 6 
summarises individual study results.
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Accuracy of SonoVue contrast-enhanced ultrasound for the 
characterisation of incidentally detected focal liver lesions
Five studies reported comparisons of SonoVue CEUS with other imaging techniques for the 
characterisation of incidentally detected liver lesions identified by unenhanced US.41,52,54–56 All of these 
studies reported accuracy data for the differentiation of malignant from benign liver lesions and 
three studies also provided stratified data for the identification of HCC and the identification of liver 
metastases.52,55,56 All but one of the studies in this section reported data on one lesion per patient and 
the remaining study41 reported per-lesion data for 694 lesions in 686 patients. Therefore, although data 
are reported per lesion, all results reported in this section can be considered equivalent to per-patient test 
performance. Four studies compared SonoVue CEUS with CECT41,52,54,55 and one of these52 also reported 
data on the combined performance of SonoVue CEUS and CECT, with a positive result on either test 
treated as positive. One study compared SonoVue CEUS with CEMRI.55 No study reported comparative 
accuracy data for all three imaging modalities. None of the comparative accuracy studies described in this 
section explicitly stated that patients had an uncertain diagnosis following unenhanced US, although all 
patients had a prior unenhanced US examination and therefore the applicability criterion for the quality 
assessment was rated ‘unclear’ in all cases.
One further study, which did not include a comparator test, was included in this section.53 This study 
was included in the review because it reported an inclusion criterion of ‘previous US and/or CT that 
had suggested the possibility of malignant liver lesions (not sufficiently proven benignancy)’ and could 
therefore provide information on how SonoVue CEUS performs in patients who have had previous imaging 
other than US and in whom the diagnosis remains uncertain. Altogether, the six studies included in this 
section reported 805 diagnoses of malignant liver lesions; these included 459 HCC, 333 liver metastases 
and 13 CCC. It should be noted that overlap between the study populations of Seitz et al.55 and Seitz et 
al.56 is highly likely as these two publications by the same group reported a very similar study design and 
identical recruitment periods; Seitz et al.55 reported a comparison of SonoVue CEUS with CECT and Seitz 
et al.56 reported a comparison of SonoVue CEUS with CEMRI in a smaller group of patients. All but one41 
of the studies in this section used histological confirmation in all patients or histological confirmation of 
imaging-positive patients and follow-up of imaging-negative patients as the reference standard.
Studies were generally poorly reported, resulting in a judgement of ‘unclear’ risk of bias for many of the 
QUADAS-2 domain assessments. No study in this section reported recruiting a consecutive or random 
sample of participants and the ‘patient selection’ domain of QUADAS-2 was consequently rated ‘high’ or 
‘unclear’ risk of bias in all cases. In addition, one study53 excluded patients who were unable to undergo 
biopsy and both Seitz et al. studies55,56 divided participants into two subgroups based on probable 
diagnoses after unenhanced US (‘suspected benign’ and ‘suspected malignant’). For the Seitz et al. 
studies, accuracy data could be extracted only for the ‘suspected malignant’ subgroup; this may have 
resulted in a higher than usual prevalence of malignancy and possible overestimation of test performance. 
Two studies were also rated as ‘high’ risk of bias for the ‘flow and timing’ domain, in one case52 because 
more than half of the participants initially recruited were excluded from the analyses (either because 
more than 1 month had elapsed between SonoVue CEUS and CECT or because positive lesions could 
not be confirmed by pathology) and in the second case41 because the reference standard used was 
not independent of the index test results. This study was also rated ‘high’ risk of bias for the ‘reference 
standard’ domain because a suboptimal reference standard (concordance between at least two imaging 
modalities) was used in the majority of cases.
All of the comparative accuracy studies in this section reported no significant difference in the accuracy 
of CEUS and CECT or CEMRI for the characterisation of focal FLLs.41,52,54–56 The primary analysis in all 
studies was for the differentiation of malignant from benign lesions. Studies used similar criteria to define 
HCC (hyperenhancement in the arterial phase followed by portal venous/late phase washout) and liver 
metastases (peripheral rim enhancement in the arterial phase, decreasing in the portal venous and late 
phases). These criteria are consistent with the typical enhancement patterns described in the EFSUMB 
guideline on the use of CEUS6 (see Table 1). Pooled estimates of test performance for distinguishing 
malignant from benign FLLs, derived from the four studies that compared CEUS with CECT,41,52,54–56 
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indicated that sensitivity and specificity were similar for the two imaging modalities. The pooled estimates 
for the sensitivity of CEUS and CECT were 95.1% (95% CI 93.3% to 96.6%) and 94.6% (95% CI 92.7% 
to 96.1%) respectively. The pooled estimates for the specificity of CEUS and CECT were 93.8% (95% CI 
90.4% to 96.3%) and 93.1% (95% CI 89.6% to 95.8%) respectively. I2 values were moderate (50–75%) 
for CEUS and high (> 75%) for CECT. Figures 4 and 5 illustrate the sensitivity and specificity values for each 
study comparing CEUS and CT, with pooled estimates. Sensitivity analyses excluding the study that used a 
suboptimal reference standard41 showed a trend towards lower estimates of test performance and reduced 
heterogeneity (I2 values were low, < 50%, in all cases). The new pooled estimates for the sensitivity of 
CEUS and CECT were 92.3% (95% CI 88.2% to 95.3%) and 87.4% (95% CI 82.7% to 91.3%), respectively, 
and the new pooled estimates for specificity were 88.2% (95% CI 79.8% to 93.9%) and 82.8% (95% CI 
73.6% to 89.8%) respectively. It should be noted that exclusion of the study by Solbiati41 resulted in a large 
reduction in sample size (694 FLLs from a total sample size of 1038 FLLs) and hence greater imprecision 
(wider CIs) in the estimates of sensitivity and specificity.
The single study that compared CEUS with CEMRI found no significant difference between the 
performance of the two imaging modalities for the differentiation of malignant from benign FLLs. The 
reported sensitivities were 90.0% (95% CI 80.0% to 97.0%) and 81.8% (95% CI 69.1% to 90.9%), 
respectively, and the reported specificities were 66.7% (95% CI 46.3% to 83.5%) and 63.0% (95% CI 
42.4% to 80.6%) respectively. This study used gadolinium-enhanced MRI in all patients, with the addition 
of SPIO-MRI in an unspecified number of patients.
One study reported sufficient data to allow calculation of sensitivity and specificity for the combination of 
CEUS and CECT, with a positive finding on either imaging technique treated as ‘test positive’.52 These data 
indicated that the addition of CECT to the imaging workup would not increase the accuracy of diagnosis 
over that obtained by CEUS alone; the sensitivity and specificity of CEUS for differentiating malignant from 
benign lesions were 91.1% (95% CI 78.8% to 97.5%) and 93.8% (95% CI 79.2% to 99.2%), respectively, 
and for CEUS and CECT combined were 93.3% (95% CI 81.7% to 98.6%) and 93.8% (95% CI 79.2% 
to 99.2%) respectively. Three studies reported sufficient data to derive estimates of test performance by 
lesion type (HCC and liver metastases), two comparing CEUS and CECT52,55 and one comparing CEUS and 
CEMRI.56 The sensitivity and specificity of CEUS and CECT were similar for the characterisation of HCC; 
however, one study indicated that CEUS may be more sensitive than CECT for the characterisation of 
metastases [92.9% (95% CI 82.7% to 98.0%) compared with 67.9% (95% CI 54.0% to 79.7%)].55 The 
sensitivity and specificity of CEUS and CEMRI were similar for both HCC and liver metastases.56
Table 7 provides a summary of the QUADAS-2 assessments for studies in this section and Table 8 
summarises individual study results. Figure 6 shows the results for differentiation of malignant from benign 
FLLs for all studies in this section, plotted in the ROC plane.
TABLE 7 QUADAS-2 results for studies of the accuracy of SonoVue CEUS for the characterisation of incidentally 
detected FLLs
Study ID
Risk of bias Applicability concerns
Patient 
selection
Index 
test
Comparator 
test
Reference 
standard
Flow and 
timing Patient selection
Catala 200752 L J J ? L ?
Gierblin´ski 200853 L ? NA J ? ?
Li 200754 ? J J ? J ?
Seitz 200955 L ? ? ? ? ?
Seitz 201056 L ? ? ? ? ?
Solbiati 200641 (abstract only) L ? ? L L ?
J, low risk; L, high risk; ?, unclear risk; NA, not applicable (no comparator test).
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TABLE 8 Accuracy of SonoVue CEUS compared with other imaging techniques for the characterisation of incidentally 
detected FLLs
Study ID Patient or lesion data Index test or comparator Reference standard TP FN FP TN
Sensitivity (95% 
CI) (%)a
Specificity (95% 
CI) (%)a
Non-
diagnostic
Adverse 
events
Acceptability to 
patients
HCC
SonoVue CEUS compared with CECT
Catala 200752 n = 77 patients (one 
lesion per patient)
CEUS SonoVue
HCC = positiveb
Histology following biopsy or surgery for test 
positive, MRI and follow-up ≥ 12 months for 
test negative
41 4 2 30 91.1 (78.8 to 97.5) 93.8 (79.2 to 99.2) None NR NR
CECT with Somatom Plus 4 
(Siemens)
HCC = positiveb
39 6 2 30 86.7 (73.2 to 94.9) 93.8 (79.2 to 99.2)
CEUS + CECT
HCC=either test positive
42 3 2 30 93.3 (81.7 to 98.6) 93.8 (79.2 to 99.2)
Seitz 200955 
(related 
publication 
Seitz 201056)
Subgroup B (suspected 
malignant lesion)c
n = 158 FLLs (one lesion 
per patient) 
CEUS SonoVue
HCC = positive
FNB n = 154 (remaining four lesions 
excluded)
34 6 4 110 85.0 (70.2 to 94.3) 96.5 (91.3 to 99.0) None NR NR
CECT (device not specified)
HCC = positive
28 12 6 108 70.0 (53.5 to 83.4) 94.7 (88.9 to 98.0)
SonoVue CEUS compared with CEMRI
Seitz 201056 
(related 
publication 
Seitz 200955)
Subgroup B (suspected 
malignant lesion)c
n = 84 FLLs (one lesion 
per patient)
CEUS SonoVue
HCC = positive
FNB n = 82 (two lesions excluded) 23 6 11 42 79.3 (60.3 to 92.0) 79.2 (65.9 to 89.2) NR NR NR
Gd-CEMRI and SPIO-CEMRI 
in some cases (number 
unspecified) (device not 
specified)
HCC = positive
24 5 13 40 82.8 (64.2 to 94.2) 75.5 (61.7 to 86.2)
SonoVue CEUS following inconclusive CECT/CEMRI
Gierblin´ski 
200853
n = 100 patients (one 
lesion per patient)
CEUS SonoVue
HCC = positiveb 
FNB with clinical and imaging follow-up for 
biopsy-negative patients
7 2 1 90 77.8 (40.0 to 97.2) 98.9 (94.0 to 100) None NR NR
Liver metastases
SonoVue CEUS compared with CECT
Catala 200752 n = 77 patients (one 
lesion per patient)
CEUS SonoVue
M = positived
Histology following biopsy or surgery for test 
positive, MRI and follow-up ≥ 12 months for 
test negative
11 1 0 65 91.7 (61.5 to 99.8) 100 (94.5 to 100) None NR NR
CECT with Somatom Plus 4 
(Siemens)
M = positived pattern
11 1 0 65 91.7 (61.5 to 99.8) 100 (94.5 to 100)
CEUS +  CECT
M = either test positive
11 1 0 65 91.7 (61.5 to 99.8) 100 (94.5 to 100)
Seitz 200955 
(related 
publication 
Seitz 201056)
Subgroup B (suspected 
malignant lesion)c
n = 158 FLLs (one lesion 
per patient)
CEUS SonoVue
M = positive
FNB n = 154 (four lesions excluded) 52 4 17 81 92.9 (82.7 to 98.0) 82.7 (73.7 to 89.6) None NR NR
CECT (device not specified)
M = positive
38 18 23 75 67.9 (54.0 to 79.7) 76.5 (66.9 to 84.5)
 continued
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State 
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17160 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 16
43
TABLE 8 Accuracy of SonoVue CEUS compared with other imaging techniques for the characterisation of incidentally 
detected FLLs
Study ID Patient or lesion data Index test or comparator Reference standard TP FN FP TN
Sensitivity (95% 
CI) (%)a
Specificity (95% 
CI) (%)a
Non-
diagnostic
Adverse 
events
Acceptability to 
patients
HCC
SonoVue CEUS compared with CECT
Catala 200752 n = 77 patients (one 
lesion per patient)
CEUS SonoVue
HCC = positiveb
Histology following biopsy or surgery for test 
positive, MRI and follow-up ≥ 12 months for 
test negative
41 4 2 30 91.1 (78.8 to 97.5) 93.8 (79.2 to 99.2) None NR NR
CECT with Somatom Plus 4 
(Siemens)
HCC = positiveb
39 6 2 30 86.7 (73.2 to 94.9) 93.8 (79.2 to 99.2)
CEUS + CECT
HCC=either test positive
42 3 2 30 93.3 (81.7 to 98.6) 93.8 (79.2 to 99.2)
Seitz 200955 
(related 
publication 
Seitz 201056)
Subgroup B (suspected 
malignant lesion)c
n = 158 FLLs (one lesion 
per patient) 
CEUS SonoVue
HCC = positive
FNB n = 154 (remaining four lesions 
excluded)
34 6 4 110 85.0 (70.2 to 94.3) 96.5 (91.3 to 99.0) None NR NR
CECT (device not specified)
HCC = positive
28 12 6 108 70.0 (53.5 to 83.4) 94.7 (88.9 to 98.0)
SonoVue CEUS compared with CEMRI
Seitz 201056 
(related 
publication 
Seitz 200955)
Subgroup B (suspected 
malignant lesion)c
n = 84 FLLs (one lesion 
per patient)
CEUS SonoVue
HCC = positive
FNB n = 82 (two lesions excluded) 23 6 11 42 79.3 (60.3 to 92.0) 79.2 (65.9 to 89.2) NR NR NR
Gd-CEMRI and SPIO-CEMRI 
in some cases (number 
unspecified) (device not 
specified)
HCC = positive
24 5 13 40 82.8 (64.2 to 94.2) 75.5 (61.7 to 86.2)
SonoVue CEUS following inconclusive CECT/CEMRI
Gierblin´ski 
200853
n = 100 patients (one 
lesion per patient)
CEUS SonoVue
HCC = positiveb 
FNB with clinical and imaging follow-up for 
biopsy-negative patients
7 2 1 90 77.8 (40.0 to 97.2) 98.9 (94.0 to 100) None NR NR
Liver metastases
SonoVue CEUS compared with CECT
Catala 200752 n = 77 patients (one 
lesion per patient)
CEUS SonoVue
M = positived
Histology following biopsy or surgery for test 
positive, MRI and follow-up ≥ 12 months for 
test negative
11 1 0 65 91.7 (61.5 to 99.8) 100 (94.5 to 100) None NR NR
CECT with Somatom Plus 4 
(Siemens)
M = positived pattern
11 1 0 65 91.7 (61.5 to 99.8) 100 (94.5 to 100)
CEUS +  CECT
M = either test positive
11 1 0 65 91.7 (61.5 to 99.8) 100 (94.5 to 100)
Seitz 200955 
(related 
publication 
Seitz 201056)
Subgroup B (suspected 
malignant lesion)c
n = 158 FLLs (one lesion 
per patient)
CEUS SonoVue
M = positive
FNB n = 154 (four lesions excluded) 52 4 17 81 92.9 (82.7 to 98.0) 82.7 (73.7 to 89.6) None NR NR
CECT (device not specified)
M = positive
38 18 23 75 67.9 (54.0 to 79.7) 76.5 (66.9 to 84.5)
 continued
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Study ID Patient or lesion data Index test or comparator Reference standard TP FN FP TN
Sensitivity (95% 
CI) (%)a
Specificity (95% 
CI) (%)a
Non-
diagnostic
Adverse 
events
Acceptability to 
patients
SonoVue CEUS compared with CEMRI
Seitz 201056 
(related 
publication 
Seitz 200955)
Subgroup B (suspected 
malignant lesion)c
n = 84 FLLs (one lesion 
per patient)
CEUS SonoVue
M = positive
FNB n = 82 (two lesions excluded) 17 5 15 45 77.3 (54.6 to 92.2) 75.0 (62.1 to 85.3) NR NR NR
Gd-CEMRI and SPIO-CEMRI 
in some cases (number 
unspecified) (device not 
specified)
HCC = positive
14 8 14 46 63.6 (40.7 to 82.8) 76.7 (64.0 to 86.6)
SonoVue CEUS following inconclusive CECT/CEMRI
Gierblin´ski 
200853
n = 100 patients (one 
lesion per patient)
CEUS SonoVue
M = positivee 
FNB with clinical and imaging follow-up for 
biopsy-negative patients
13 1 2 84 92.9 (66.1 to 99.8) 97.7 (91.9 to 99.7) None NR NR
Any malignancy
SonoVue CEUS compared with CECT
Catala 200752 n = 77 patients (one 
lesion per patient)
CEUS SonoVue
Any malignancy (HCCb or 
Md) = positive 
Histology following biopsy or surgery for 
index test positive, MRI and follow-up 
≥ 12 months for index test negative
52 5 2 18 91.2 (80.7 to 97.1) 90.0 (68.3 to 98.8) None NR NR
CECT with Somatom Plus 4 
(Siemens)
Any malignancy (HCCb or 
Md) = positive
50 7 2 18 87.7 (76.3 to 94.9) 90.0 (68.3 to 98.8)
CEUS + CECT
Either test positive = positive
53 4 2 18 93.0 (83.0 to 98.1) 90.0 (68.3 to 98.8)
Li 200754 n = 109 patients (one 
lesion per patient)
CEUS SonoVue
Any malignancy (HCC,f CCC,g 
Mh) = positive
Histopathology following surgical resection 
or FNB
72 9 2 26 88.9 (80.0 to 94.8) 92.9 (76.5 to 99.1) Three 
lesions not 
visualised. 
All were 
malignant 
and are 
classified 
as FN
NR NR
CECT with Somatom 
Sensation (Siemens)
Any malignancy (HCC, CCC, 
M) = positive
67 14 6 22 82.7 (72.7 to 90.2) 78.6 (59.0 to 91.7) Seven 
lesions not 
visualised. 
Five were 
malignant 
and are 
classified 
as FN; 
two were 
benign 
and are 
classified 
as TN
Seitz 200955 
(related 
publication 
Seitz 201056)
Subgroup B (suspected 
malignant lesion)c
n = 158 FLLs (one lesion 
per patient)
CEUS SonoVue
Any malignancy = positivei
FNB n = 154 (four lesions excluded) 104 5 7 38 95.4 (89.6 to 98.5) 84.4 (70.5 to 93.5) None NR NR
CECT (device not specified)
Any malignancy = positive
99 10 8 37 90.8 (83.8 to 95.5) 82.2 (67.9 to 92.0)
 continued
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Study ID Patient or lesion data Index test or comparator Reference standard TP FN FP TN
Sensitivity (95% 
CI) (%)a
Specificity (95% 
CI) (%)a
Non-
diagnostic
Adverse 
events
Acceptability to 
patients
SonoVue CEUS compared with CEMRI
Seitz 201056 
(related 
publication 
Seitz 200955)
Subgroup B (suspected 
malignant lesion)c
n = 84 FLLs (one lesion 
per patient)
CEUS SonoVue
M = positive
FNB n = 82 (two lesions excluded) 17 5 15 45 77.3 (54.6 to 92.2) 75.0 (62.1 to 85.3) NR NR NR
Gd-CEMRI and SPIO-CEMRI 
in some cases (number 
unspecified) (device not 
specified)
HCC = positive
14 8 14 46 63.6 (40.7 to 82.8) 76.7 (64.0 to 86.6)
SonoVue CEUS following inconclusive CECT/CEMRI
Gierblin´ski 
200853
n = 100 patients (one 
lesion per patient)
CEUS SonoVue
M = positivee 
FNB with clinical and imaging follow-up for 
biopsy-negative patients
13 1 2 84 92.9 (66.1 to 99.8) 97.7 (91.9 to 99.7) None NR NR
Any malignancy
SonoVue CEUS compared with CECT
Catala 200752 n = 77 patients (one 
lesion per patient)
CEUS SonoVue
Any malignancy (HCCb or 
Md) = positive 
Histology following biopsy or surgery for 
index test positive, MRI and follow-up 
≥ 12 months for index test negative
52 5 2 18 91.2 (80.7 to 97.1) 90.0 (68.3 to 98.8) None NR NR
CECT with Somatom Plus 4 
(Siemens)
Any malignancy (HCCb or 
Md) = positive
50 7 2 18 87.7 (76.3 to 94.9) 90.0 (68.3 to 98.8)
CEUS + CECT
Either test positive = positive
53 4 2 18 93.0 (83.0 to 98.1) 90.0 (68.3 to 98.8)
Li 200754 n = 109 patients (one 
lesion per patient)
CEUS SonoVue
Any malignancy (HCC,f CCC,g 
Mh) = positive
Histopathology following surgical resection 
or FNB
72 9 2 26 88.9 (80.0 to 94.8) 92.9 (76.5 to 99.1) Three 
lesions not 
visualised. 
All were 
malignant 
and are 
classified 
as FN
NR NR
CECT with Somatom 
Sensation (Siemens)
Any malignancy (HCC, CCC, 
M) = positive
67 14 6 22 82.7 (72.7 to 90.2) 78.6 (59.0 to 91.7) Seven 
lesions not 
visualised. 
Five were 
malignant 
and are 
classified 
as FN; 
two were 
benign 
and are 
classified 
as TN
Seitz 200955 
(related 
publication 
Seitz 201056)
Subgroup B (suspected 
malignant lesion)c
n = 158 FLLs (one lesion 
per patient)
CEUS SonoVue
Any malignancy = positivei
FNB n = 154 (four lesions excluded) 104 5 7 38 95.4 (89.6 to 98.5) 84.4 (70.5 to 93.5) None NR NR
CECT (device not specified)
Any malignancy = positive
99 10 8 37 90.8 (83.8 to 95.5) 82.2 (67.9 to 92.0)
 continued
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Study ID Patient or lesion data Index test or comparator Reference standard TP FN FP TN
Sensitivity (95% 
CI) (%)a
Specificity (95% 
CI) (%)a
Non-
diagnostic
Adverse 
events
Acceptability to 
patients
Solbiati 200641 
(abstract only)
n = 694 FLLs in 686 
patients, one lesion 
missing from analysis 
(per-lesion data)
CEUS SonoVue
Any malignancy (HCC, M, 
CCC) = positive
Concordant CEUS and CT result (n = 656) or 
FNB when results were discordant (n = 38)
478 17 7 191 96.6 (94.6 to 98.0) 96.5 (92.9 to 98.6) One (results 
missing for 
one lesion)
NR NR
CECT (device not specified)
Any malignancy (HCC, M, 
CCC) = positive
486 9 4 194 98.2 (96.6 to 99.2) 98.0 (94.9 to 99.4)
SonoVue CEUS compared with CEMRI
Seitz 201056 
(related 
publication 
Seitz 200955)
Subgroup B (suspected 
malignant lesion)c
n = 84 FLLs (one lesion 
per patient)
CEUS SonoVue
Any malignancy = positivee
FNB n = 82 (two lesions excluded) 50 5 9 18 90.9 (80.0 to 97.0) 66.7 (46.3 to 83.5) Nine lesions 
(six benign 
and three 
malignant); 
these were 
classified as 
FP and FN 
respectively
NR NR
Gd-CEMRI and SPIO-CEMRI 
in some cases (number 
unspecified) (device not 
specified)
HCC = positive
45 10 10 17 81.8 (69.1 to 90.9) 63.0 (42.4 to 80.6) Nine lesions 
(three 
benign 
and six 
malignant); 
these were 
classified as 
FP and FN 
respectively
SonoVue CEUS following inconclusive CECT/CEMRI
Gierblin´ski 
200853
n = 100 patients (one 
lesion per patient)
CEUS SonoVue
Any malignancy (HCCb or 
Me) = positive
FNB with clinical and imaging follow-up for 
biopsy-negative patients
21 2 3 74 91.3 (72.0 to 98.9) 96.1 (89.0 to 99.2) None NR NR
FN, false-negative; FNB, fine-needle biopsy; FP, false-positive; M, metastases; ND, non-diagnostic; NR, not reported; SCT, 
spiral computed tomography; TN, true-negative; TP, true-positive.
a Calculated values.
b Hyperenhancement in the arterial phase and hypo- or iso-enhancement in the portal venous and late phases.
c Subgroup A (suspected benign lesions) excluded.
d Hypo- to high enhancement in the arterial phase; hypoenhancement, quick washout or rim-like enhancement in the 
portal venous phase; hypoenhancement in the late phase.
e Rim-like enhancement in the arterial phase and hypoenhancement in the portal venous and late phases.
f Tortuous intratumoural vessels and diffuse enhancement in the arterial phase, decreasing in the portal venous and 
late phases.
g Variable intratumoural vessels and heterogeneous peripheral enhancement in the arterial phase, decreasing in the 
portal venous and late phases. Dilatation of the bile ducts near the tumour many be accentuated after enhancement.
h Enhancing peripheral rim, variable intratumoural enhancement in the arterial phase, decreasing in the portal venous 
and late phases.
i Hypoenhancement in the late phase.
TABLE 8 Accuracy of SonoVue CEUS compared with other imaging techniques for the characterisation of incidentally 
detected FLLs (continued)
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Study ID Patient or lesion data Index test or comparator Reference standard TP FN FP TN
Sensitivity (95% 
CI) (%)a
Specificity (95% 
CI) (%)a
Non-
diagnostic
Adverse 
events
Acceptability to 
patients
Solbiati 200641 
(abstract only)
n = 694 FLLs in 686 
patients, one lesion 
missing from analysis 
(per-lesion data)
CEUS SonoVue
Any malignancy (HCC, M, 
CCC) = positive
Concordant CEUS and CT result (n = 656) or 
FNB when results were discordant (n = 38)
478 17 7 191 96.6 (94.6 to 98.0) 96.5 (92.9 to 98.6) One (results 
missing for 
one lesion)
NR NR
CECT (device not specified)
Any malignancy (HCC, M, 
CCC) = positive
486 9 4 194 98.2 (96.6 to 99.2) 98.0 (94.9 to 99.4)
SonoVue CEUS compared with CEMRI
Seitz 201056 
(related 
publication 
Seitz 200955)
Subgroup B (suspected 
malignant lesion)c
n = 84 FLLs (one lesion 
per patient)
CEUS SonoVue
Any malignancy = positivee
FNB n = 82 (two lesions excluded) 50 5 9 18 90.9 (80.0 to 97.0) 66.7 (46.3 to 83.5) Nine lesions 
(six benign 
and three 
malignant); 
these were 
classified as 
FP and FN 
respectively
NR NR
Gd-CEMRI and SPIO-CEMRI 
in some cases (number 
unspecified) (device not 
specified)
HCC = positive
45 10 10 17 81.8 (69.1 to 90.9) 63.0 (42.4 to 80.6) Nine lesions 
(three 
benign 
and six 
malignant); 
these were 
classified as 
FP and FN 
respectively
SonoVue CEUS following inconclusive CECT/CEMRI
Gierblin´ski 
200853
n = 100 patients (one 
lesion per patient)
CEUS SonoVue
Any malignancy (HCCb or 
Me) = positive
FNB with clinical and imaging follow-up for 
biopsy-negative patients
21 2 3 74 91.3 (72.0 to 98.9) 96.1 (89.0 to 99.2) None NR NR
FN, false-negative; FNB, fine-needle biopsy; FP, false-positive; M, metastases; ND, non-diagnostic; NR, not reported; SCT, 
spiral computed tomography; TN, true-negative; TP, true-positive.
a Calculated values.
b Hyperenhancement in the arterial phase and hypo- or iso-enhancement in the portal venous and late phases.
c Subgroup A (suspected benign lesions) excluded.
d Hypo- to high enhancement in the arterial phase; hypoenhancement, quick washout or rim-like enhancement in the 
portal venous phase; hypoenhancement in the late phase.
e Rim-like enhancement in the arterial phase and hypoenhancement in the portal venous and late phases.
f Tortuous intratumoural vessels and diffuse enhancement in the arterial phase, decreasing in the portal venous and 
late phases.
g Variable intratumoural vessels and heterogeneous peripheral enhancement in the arterial phase, decreasing in the 
portal venous and late phases. Dilatation of the bile ducts near the tumour many be accentuated after enhancement.
h Enhancing peripheral rim, variable intratumoural enhancement in the arterial phase, decreasing in the portal venous 
and late phases.
i Hypoenhancement in the late phase.
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FIGURE 4 Forest plot of sensitivity and specificity of CEUS for the identification of any liver malignancy in patients with 
incidentally detected FLLs.
FIGURE 5 Forest plot of sensitivity and specificity of CECT for the identification of any liver malignancy in patients with 
incidentally detected FLLs.
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FIGURE 6 Receiver operating characteristic plane plot comparing performance of imaging tests for the differentiation 
of malignant from benign lesions in patients with incidentally detected FLLs.
Accuracy of SonoVue contrast-enhanced ultrasound for the determination 
of treatment success in patients with known liver malignancy
Three studies reported comparisons of SonoVue CEUS with other imaging modalities for the assessment 
of treatment success (complete response) in patients with malignant liver lesions (mainly HCC).40,57,58 Two 
were Chinese-language publications57,58 and the other was published only as a conference abstract.40 The 
two Chinese studies reported per-lesion data, with one57 reporting only one lesion per patient, and the 
remaining study reported only per-patient data.40 The studies assessed patients following cryosurgery,57 
RFA40 and ‘non-surgical treatment’.58 Sample sizes were small: in total, studies reported data for 
105 lesions (102 HCC and three liver metastases) in 97 patients. All three studies included only patients 
who were undergoing treatment for known liver malignancies and all studies were therefore rated as 
having ‘low’ concerns regarding applicability.
Studies were generally poorly reported and all QUADAS-2 risk of bias domains were rated ‘unclear’.
One of the two Chinese studies compared CEUS with CECT or CEMRI (numbers of patients receiving CECT 
and CEMRI, respectively, were not specified)57 and the other compared CEUS with CECT.58 Both studies 
reported similar, high sensitivity (95.5–100%) and specificity (83.3–100%) for all imaging modalities, 
although small sample sizes resulted in wide CIs. One study reported sufficient data to allow the 
calculation of sensitivity and specificity for the combination of CEUS and CECT, with a negative finding on 
either imaging technique treated as ‘test negative’ for complete response.58 These data indicated that the 
addition of CECT would not increase the accuracy of the assessment of response to treatment over that 
obtainable by CEUS alone; the sensitivity and specificity of CEUS for detecting complete response were 
97.8% (95% CI 88.5% to 99.9%) and 94.4% (95% CI 72.7% to 99.9%), respectively, and for CEUS and 
CECT combined were 97.8% (95% CI 88.5% to 99.9%) and 100% (95% CI 81.5% to 100%) respectively. 
The remaining study compared CEUS with Gd-CEMRI and included only 15 patients undergoing RFA, with 
five final diagnoses of ‘complete ablation’.40 The results of the two techniques were identical; sensitivity for 
the detection of complete ablation was 80% (95% CI 28.4% to 99.5%) and there were nine false-positives, 
resulting in a very low estimate of specificity [10.0% (95% CI 3.0% to 44.5%)].
Table 9 provides a summary of the QUADAS-2 assessments for studies in this section and Table 10 
summarises individual study results.
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TABLE 9 QUADAS-2 results for studies of the accuracy of SonoVue CEUS for the determination of treatment success in 
patients with known liver malignancy
Study ID
Risk of bias
Applicability 
concerns
Patient 
selection Index test
Comparator 
test
Reference 
standard
Flow and 
timing
Patient 
selection
Feng 200757 ? ? ? ? ? J
Lüttich 200640 
(abstract only)
? ? ? ? ? J
Zhou 200758 ? ? ? ? ? J
J, low risk; L, high risk; ?, unclear risk.
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Effectiveness of SonoVue contrast-enhanced ultrasound for treatment 
planning in patients with known liver malignancy
One controlled clinical trial compared SonoVue CEUS with unenhanced US (control) when added to 
routine imaging (CECT or CEMRI) for pretreatment assessment of patients undergoing RFA for HCC.59 
This study assessed the effect of CEUS on treatment effectiveness (successful ablation) as the primary 
outcome measure. Secondary outcomes were incidence of tumour progression, new HCC, repeat RFA and 
post-therapy complications, and duration of local progression-free survival and new tumour-free survival. 
The CEUS and control groups were similar at baseline in terms of age, gender distribution, numbers who 
had CECT and numbers who had CEMRI, TNM (tumour, lymph node, metastases) stage, tumour size and 
number, and numbers who had Child–Pugh class A cirrhosis.
This non-randomised study was considered to have ‘risk of bias’ in a number of areas. Alternate allocation 
of patients to the CEUS and control groups means that clinicians could predict patient allocation before 
recruitment. The nature of the study precluded the blinding of patients, and the blinding of assessors and/
or clinicians planning RFA protocols was not clear. Finally, 14 patients who were considered unsuitable for 
RFA after imaging assessment (nine in the CEUS group and five in the control group) were excluded from 
the analyses.
There were no significant differences in the rates of successful ablation (primary outcome) or post-therapy 
complications between the CEUS group and the control group. Use of CEUS in the pretreatment imaging 
protocol was found to significantly reduce incidence of tumour progression, new HCC and repeat RFA over 
a 2-year follow-up period; ORs were 0.35 (95% CI 0.13 to 0.95), 0.34 (95% CI 0.16 to 0.72) and 0.33 
(95% CI 0.17 to 0.66) respectively. The use of CEUS also increased local progression-free survival [mean 
difference 7.2 months (95% CI 6.6 months to 7.8 months)] and new tumour-free survival [mean difference 
11.7 months (95% CI 11.1 months to 12.3 months)].
Table 11 provides a summary of the risk of bias assessment for this study and Table 12 summarises 
the results.
TABLE 11 Risk of bias assessment for studies of the effectiveness of SonoVue CEUS for treatment planning in patients 
with known liver malignancy
Item Judgement Description
Adequate sequence generation? Yes Alternate allocation 
Allocation concealment? No Alternate allocation means that assignment of an individual 
patient to a test group can be easily predicted
Blinding? No Patients could not be blinded to the tests being undertaken 
and it was not clear whether or not those assessing the efficacy 
of treatment were aware of test allocations. It was not clear if 
those who designed the RFA protocol knew the results of CEUS 
and US or of only one of the tests
Were patient characteristics 
comparable at baseline?
Yes
Incomplete outcome data 
addressed?
Yes All outcomes assessed appear to be reported for all patients
Free of selective reporting? Yes All outcomes assessed appear to be reported for all patients
Free of other bias? No Patients in both groups who were judged to be unsuitable for 
RFA were excluded from the analyses
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Summary of clinical effectiveness results
Twenty of the 21 studies included in the systematic review were DTA studies: seven compared the 
performance of imaging modalities for the characterisation of FLLs detected on surveillance of cirrhosis 
patients using unenhanced US; four compared the performance of imaging modalities for the detection of 
liver metastases in patients with known primary cancer (CRC); six compared the performance of imaging 
modalities for the characterisation of incidentally detected FLLs identified by unenhanced US; and three 
compared the performance of imaging modalities for the determination of treatment response in patients 
with liver cancer.
The majority of included test accuracy studies were judged to be at ‘low’ or ‘unclear’ risk of bias with 
respect to the ‘index test’, ‘comparator test’ and ‘reference standard’ domains. ‘Unclear’ ratings for these 
domains most frequently arose from insufficient detail in the reporting of how tests were interpreted, 
particularly blinding of interpreters to other test results. Reporting quality was generally poor and a 
number of studies were reported only as conference abstracts, resulting in a high proportion of ‘unclear’ 
risk of bias ratings across domains (Figure 7). ‘High’ risk of bias ratings for the ‘patient selection’ domain 
arose from the use of a retrospective study design or from inappropriate exclusions of particular patient 
groups (e.g. exclusion of patients with a low probability of malignancy). ‘High’ risk of bias ratings for the 
‘flow and timing’ domain arose from exclusion of > 10% of patients from analyses or, in two cases, from 
incorporation of index test results in the reference standard. The last two studies were also rated as ‘high’ 
risk of bias for the ‘reference standard’ domain.
Studies varied in terms of target condition (HCC, liver metastases or ‘any malignancy’), definitions of a 
positive imaging test in studies of the same target condition, and lesion size assessed. Overall, there was 
no clear indication that any of the imaging modalities (CEUS, CECT or CEMRI) or contrast media considered 
offered superior performance for any of the clinical applications assessed.
Studies conducted in cirrhosis patients undergoing routine surveillance all concerned the differentiation 
of HCC from other lesion types in small to medium (< 30 mm) FLLs. The definition of a positive test for 
HCC varied, including arterial enhancement followed by portal venous washout, arterial enhancement 
alone and portal venous washout alone. There was no consistent evidence for any significant difference 
in test performance between the three imaging modalities and three MRI contrast media assessed. 
Results were inconsistent for the studies that reported an EFSUMB-consistent definition of HCC (arterial 
phase enhancement followed by portal venous/late phase washout). One study comparing CEUS and 
CECT reported high per-lesion sensitivity (91% and 80% respectively) and specificity (87% and 98% 
respectively) estimates; all lesions in this study were between 10 and 20 mm. Two studies comparing 
CEUS and Gd-CEMRI reported inconsistent sensitivity estimates for CEUS (93% and 52%), with the lower 
Reference standard
Flow and timing
20 30 50Patient selection
Index test 40 60 0
50 50 0
15 75 10
25
0%
Low risk of bias
Unclear risk of bias
High risk of bias
20% 40% 60% 80% 100%
45 30
Comparator test
FIGURE 7 Summary of QUADAS-2 assessments.
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sensitivity estimate arising from a study that included very small (≤ 10 mm) FLLs. Two studies comparing all 
three imaging modalities reported similar, high specificity estimates (> 90% in most cases) for all imaging 
modalities; however, sensitivity estimates were inconsistent between the two studies. Sensitivity estimates 
were 67% and 27% for CEUS; 67% and 47% for CECT; and 82% and 44% for Gd-CEMRI. Sensitivity 
estimates from these two studies were generally lower than those in studies that compared only two 
imaging modalities using a similar definition of HCC and similar lesion size. There was some evidence 
from one study comparing CEUS and Gd-CEMRI that these techniques may be better at ruling out HCC 
in FLLs between 11 and 30 mm (sensitivities for CEUS and CEMRI were 92% and 95% respectively) than 
in small FLLs of ≤ 10 mm (sensitivities 27% and 73% respectively); however, this study did not use an 
EFSUMB-consistent definition of HCC. There was also some evidence from two studies that combined 
imaging using CEUS and CECT or all three imaging modalities, in which any positive imaging result was 
treated as ‘test positive’, that combined imaging may increase sensitivity. Overall, inconsistent estimates of 
sensitivity mean that it is unclear whether or not CEUS alone is adequate to rule out HCC for FLLs < 30 mm 
in this population; CEUS alone may be adequate to rule out HCC for FLLs 11–30 mm, with very small FLLs 
(< 10 mm) not considered.
Studies of the diagnosis of liver metastases using imaging with vascular contrast media (CEUS, CECT 
and Gd-CEMRI) in which definitions of a positive imaging test were reported gave various descriptions 
of peripheral rim enhancement as the criterion for liver metastases. Two studies reported data for SPIO-
CEMRI. There was no consistent evidence for any significant difference in test performance between 
the three imaging modalities assessed and different MRI contrast media assessed. Both per-patient and 
per-lesion sensitivity estimates were generally high in all studies [> 83% for all imaging modalities and both 
MRI contrast agents in two studies of patients with CRC and > 95% for both CEUS and CECT in a third 
study of patients with various primary cancers (majority CRC)]. The limited data available indicate that 
CEUS alone may be adequate to rule out liver metastases in patients with known primary malignancies.
The primary outcome measure reported by studies conducted in patients with incidentally detected FLLs 
was test accuracy for the differentiation of malignant from benign liver lesions. Studies used arterial 
enhancement followed by portal venous washout to define a positive test for primary liver cancer (HCC) 
and peripheral rim enhancement to define a positive test for liver metastases; these criteria are consistent 
with those defined in the EFSUMB guidelines on the use of CEUS6 (see Table 1). All studies reported no 
significant difference in the accuracy of CEUS and CECT or CEMRI for the characterisation of focal FLLs. 
All but one study reported data for one lesion per patient and the remaining study reported data for 
694 lesions in 686 patients; data were therefore treated as per patient. The pooled estimates of sensitivity 
for the detection of ‘any liver malignancy’ were approximately 95% for both CEUS and CECT and the 
pooled estimates of specificity were 94% and 93%, respectively, based on data from four studies. The 
single study comparing CEUS with CEMRI used Gd-CEMRI in all patients, with the addition of SPIO-CEMRI 
in an unspecified number of cases, and reported sensitivity estimates of 91% and 82%, respectively, and 
specificity estimates of 67% and 63% respectively. Data from one study indicated that combined imaging 
using both CEUS and CECT, in which a positive result on either modality was treated as ‘test positive’, did 
not increase sensitivity. High estimates of sensitivity indicate that CEUS alone may be adequate to rule out 
liver malignancy in this population.
Two Chinese-language studies compared imaging modalities for the assessment of response to treatment 
(cryosurgery and non-surgical treatment) in patients with HCC. One study compared CEUS and CECT 
in the same patients and the other compared CEUS and CECT or CEMRI. All sensitivity estimates were 
> 95% and all specificity estimates were > 80%. These very limited data indicate that CEUS may provide 
information on response in patients treated for HCC. However, these data are very limited and may not be 
directly applicable to UK clinical practice; further studies, ideally conducted in a UK setting, are required to 
confirm findings.
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One controlled clinical trial indicated that the inclusion of CEUS in pretreatment imaging protocols for 
patients undergoing RFA for HCC may result in reduced incidence of disease progression, new HCC and 
repeat RFA, and increased local progression- and new tumour-free survival compared with unenhanced 
US. However, no difference was found in the primary outcome, successful ablation. High-quality RCTs are 
needed to determine the relative effectiveness of different imaging strategies for treatment planning.
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Chapter 4 Assessment of cost-effectiveness
Search strategy
Searches were undertaken to identify cost-effectiveness studies of US, MRI and CT in the diagnosis of liver 
cancer. As with the clinical effectiveness searching, the main EMBASE strategy for each set of searches was 
independently peer reviewed by a second information specialist using the PRESS EBC checklist.21 Search 
strategies were developed specifically for each database and searches took into account generic and other 
product names for the intervention. No restrictions on language or publication status were applied. Limits 
were applied to remove animal studies. Full search strategies are reported in Appendix 1.
The following databases were searched for relevant studies from 2000 to October/November 2011:
 z MEDLINE (2000–September 2011 Week 4) (OvidSP)
 z MEDLINE In-Process & Other Non-Indexed Citations and Daily Update (2000–10 October 2011) 
(OvidSP)
 z EMBASE (2000–11 Week 40) (OvidSP)
 z NHS Economic Evaluation Database (NHS EED) (2000–11) (via The Cochrane Library)
 z NHS EED (1 January 2011–12 October 2011) (CRD website)
 z Health Economic Evaluations Database (HEED) (2000–12 October 2011) (Wiley) (http://onlinelibrary.
wiley.com/book/10.1002/9780470510933)
 z SCI (2000–7 October 2011) (Web of Science).
Supplementary searches on FLLs and liver cancers were undertaken on the following resources to identify 
guidelines and guidance:
 z National Guidelines Clearinghouse (NGC) (2005–10 November 2011) (www.guideline.gov/)
 z Guidelines International Network (GIN) (2005–10 November 2011) (www.g-i-n.net)
 z NICE guidance (up to 10 November 2011) (http://guidance.nice.org.uk/)
 z TRIP database (limited to guidelines) (2005–10 November 2011) (www.tripdatabase.com/)
 z HTA database (2005–10 November 2011) (CRD website).
Identified references were downloaded in EndNote X4 software for further assessment and handling.
References in retrieved articles were checked for additional studies.
Review of economic analyses of SonoVue
A total of 1194 titles and abstracts were screened from which 40 papers were selected. After full-paper 
screening 36 studies were excluded and four that met the inclusion criteria were included. A summary of 
each of these studies is provided in Table 13, with a quality checklist based on Drummond and Jefferson63 
provided in Table 14.
Faccioli et al.64 developed a decision model to assess the costs of testing for benign FLLs after the 
introduction of CEUS. In total, 398 benign FLL patients (angiomas, focal nodular hyperplasias and 
pseudolesions) with suspicious lesions at baseline US from the radiology department of a hospital in Italy 
between 2002 and 2005 were reviewed and entered into the model. All lesions underwent CEUS and 
98 also underwent CT. The average follow-up was 22 months and none of the CEUS diagnoses changed 
during the follow-up.
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TABLE 14 Economic study quality checklist
Faccioli 
200764
Romanini 
200766
Sangiovanni 
201147
S¸irli 
201067
Zaim 
201168
Study design 
The research question is stated ü ü ü ü ü
The economic importance of the research question is 
stated
ü ü ü ü ü
The viewpoint(s) of the analysis are clearly stated and 
justified
û ü ü û ü
The rationale for choosing alternative programmes or 
interventions compared is stated
ü ü ü ü ü
The alternatives being compared are clearly described ü ü ü ü ü
The form of economic evaluation used is stated ü ü ü ü ü
The choice of form of economic evaluation is justified in 
relation to the questions addressed
ü ü ü ü ü
Data collection
The source(s) of effectiveness estimates used are stated ü ü ü ü û
Details of the design and results of the effectiveness study 
are given (if based on a single study)
ü ü ü ü û
Details of the methods of synthesis or meta-analysis of 
estimates are given (if based on a synthesis of a number of 
effectiveness studies)
NA NA NA NA NA
The primary outcome measure(s) for the economic 
evaluation are clearly stated
ü ü ü ü ü
Methods-to-value benefits are stated ü ü ü ü û
Details of the subjects from whom valuations were 
obtained are given
ü ü ü ü ü
Productivity changes (if included) are reported separately NA NA NA NA NA
The relevance of productivity changes to the study 
question is discussed
û û û û û
Quantities of resource use are reported separately from 
their unit costs
ü û ü ü û
Methods for the estimation of quantities and unit costs are 
described
ü û ü û û
Currency and price data are recorded ü ü ü ü ü
Details of currency of price adjustments for inflation or 
currency conversion are given
û û û û ü
Details of any model used are given NA NA NA NA NA
The choice of model used and the key parameters on 
which it is based are justified
ü ü ü ü ü
Analysis and interpretation of results
Time horizon of costs and benefits is stated ü ü ü ü ü
The discount rate(s) is stated û û û û ü
The choice of discount rate(s) is justified û û û û ü
An explanation is given if costs and benefits are not 
discounted
û û û û NA
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Faccioli 
200764
Romanini 
200766
Sangiovanni 
201147
S¸irli 
201067
Zaim 
201168
Details of statistical tests and CIs are given for stochastic 
data
û û ü û û
The approach to sensitivity analysis is given NA NA NA NA ü
The choice of variables for sensitivity analysis is justified NA NA NA NA û
The ranges over which the variables are varied are justified NA NA NA NA û
Relevant alternatives are compared ü ü ü ü ü
Incremental analysis is reported ü ü û ü ü
Major outcomes are presented in a disaggregated as well 
as aggregated form
ü ü ü ü ü
The answer to the study question is given ü ü ü ü ü
Conclusions follow from the data reported ü ü ü ü ü
Conclusions are accompanied by the appropriate caveats ü ü ü ü ü
ü, yes; û, no; NA, not available.
TABLE 14 Economic study quality checklist (continued)
Equipment costs (purchase and service contract costs), agents and related costs (contrast agents, saline 
solution, medical supplies and films) and human resource costs (radiologists, technicians, nurses and 
administrative staff) were evaluated within the model. The calculation of equipment costs was based on 
utilisation time per examination, considering both purchase price and depreciation; these were all obtained 
from the hospital administrative office with a constant annual depreciation rate. The costs of all medical 
staff and administrators (per minute) were derived from the Società Italiana di Radiologia Medica (SIRM) 
publication.65 The formula for the ‘total saving’ calculation was CT × n – [(CEUS-US) × n], with n representing 
the number of examinations. The cost year was 2006.
For each US examination, the total cost was 46.36 euros and disaggregated costs were 8.43 euros for 
equipment, 5.96 euros for agents and related costs and 31.97 euros for human resource costs. In each 
CEUS examination, equipment costs were 8.43 euros, agents and related costs were 43.04 euros and 
human resources were 50.04 euros, giving a total cost of 101.51 euros. For each CECT examination, the 
aggregate cost was 211.48 euros, calculated by summing 68.27 euros for equipment costs, 62.96 euros 
for agents and related costs and 80.25 euros for human resource costs. The total saving from replacing 
CEUS as the second-line diagnostic procedure for the 398 patients modelled was 47,055.33 euros.
Romanini et al.66 conducted a multicentre prospective study to evaluate the economic and clinical 
outcomes after the introduction of CEUS in diagnostic procedures for incidentally detected FLLs. A total 
of 485 patients presenting with uncharacterised FLLs, without liver cirrhosis, were recruited into the study 
from January 2002 to October 2005. All patients underwent two diagnostic strategies, that is, patients 
were their own control group:
 z US → CEUS → (if inconclusive) CECT/CEMRI
 z US → CECT/CEMRI → (if inconclusive) CEMRI.
Cost items included diagnostic examinations, health-care professional time, pharmaceuticals, laboratory 
tests, medical devices and material for imaging. Reimbursement for baseline US was 51.13 euros, for 
CEUS was 76.13 euros, for CT with or without contrast agent was 164.75 euros and for MRI with or 
without contrast agent was 259.70 euros, according to a regional reimbursement price list. Other variable 
hospital costs were obtained from hospitals joining the study. From the Italian NHS perspective, the 
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conventional diagnostic pathway with CECT and CEMRI cost a total of 134,576.60 euros. A total saving of 
78,902 euros could be made by adopting the CEUS strategy, that is, 162.70 euros per patient. From the 
hospitals’ perspective, the total expenditure incurred by the conventional approach was 147,045 euros, 
compared with 61,979 euros using the CEUS strategy. The reimbursement to the hospital per person for 
the conventional strategy was 277 euros, 26 euros less than the original spending by the hospital; for the 
CEUS strategy the reimbursement agency paid only 114.79 euros to the hospital, 13 euros less than the 
original spending by the hospital.
S¸irli et al.67 conducted a prospective study in the Department of Gastroenterology and Hepatology in a 
hospital in Romania to evaluate the cost differences when CEUS replaced CECT/CEMRI as the first-line 
examination for FLL characterisation. All of the CEUS liver evaluations performed from September 2009 to 
March 2010 were included in the study. The cost of a CEUS positive diagnosis was compared with the cost 
of a CECT and/or CEMRI positive diagnosis. The cost of a CECT/CEUS examination was added when the 
CEUS result was inconclusive:
 z CEUS → (when inconclusive) CECT
 z CEUS → (when inconclusive) CEMRI
 z CECT
 z CEMRI.
Contrast-enhanced ultrasound provided a conclusive diagnosis for 250 of 316 FLLs; the remaining 66 
required further imaging (CECT or CEMRI). Therefore, the total examination cost for CEUS followed 
by CECT when necessary was 75,690 Romanian new leu (RON) [180 RON (cost for single CEUS 
examination) × 316 + 285 RON (cost for single CECT examination) × 66]. The total cost following the second 
strategy was 99,780 RON [180 RON (cost for single CEUS examination) × 316 + 650 RON (cost for single 
CEMRI examination) × 66]. When using CECT only the total cost was 90,060 RON and when using CEMRI 
only the total cost was 205,400 RON. To sum up, by adopting CEUS for first-line FLL characterisation, the 
cost saving per person was 45.5 RON compared with CT as first line and 334.2 RON compared with MRI as 
first line.
Sangiovanni et al.47 conducted a study to assess the diagnostic accuracy and also the economic impact 
of all possible diagnostic strategy combinations in characterising FLLs (including only 1- to 2-cm lesions) 
in Italy. Compensated cirrhosis patients diagnosed with liver nodules under US surveillance were included 
in this study. All possible examinations [CT, MRI, CEUS and US-guided fine-needle biopsy (FNB)] were 
performed until a final diagnosis was obtained. The study assessed costs using two approaches. The first 
was in accordance with AASLD guidelines, with the final diagnosis of HCC needing concordant results 
from at least two imaging techniques; a third examination was recommended only when the previous 
two were discordant. FNB was performed only when the vascular pattern observed was different in the 
first two diagnostic procedures. The second approach was to perform a single scan and then perform 
subsequent scans if the result was inconclusive; although not stated, it appeared that FNB was performed 
only if all three scans were inconclusive.
The AASLD approach implied three possible permutations, that is:
 z CEUS and CT → (when inconclusive) MRI → (if required) FNB
 z CEUS and MRI → (when inconclusive) CT → (if required) FNB
 z CT and MRI → (when inconclusive) CEUS → (if required) FNB.
The study criteria approach implied six possible permutations, that is:
 z CEUS → (when inconclusive) CT → (when inconclusive) MRI → (if required) FNB
 z CEUS → (when inconclusive) MRI → (when inconclusive) CT → (if required) FNB
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 z CT → (when inconclusive) CEUS → (when inconclusive) MRI → (if required) FNB
 z CT → (when inconclusive) MRI → (when inconclusive) CEUS → (if required) FNB
 z MRI → (when inconclusive) CEUS → (when inconclusive) CT → (if required) FNB
 z MRI → (when inconclusive) CT → (when inconclusive) CEUS → (if required) FNB.
Following the AASLD guideline approach, CEUS + CT with MRI and FNB when required was considered the 
cheapest combination, with a total aggregate cost of 26,440 euros, equivalent to 479 euros per person. 
This strategy was 79 euros cheaper per person than CEUS + MRI → CT → FNB and 144 euros cheaper per 
person than CT + MRI → CEUS → FNB. The most inexpensive strategy using the study criteria approach was 
CEUS → CT → MRI → FNB: 535 euros per person, within the range of 9–45 euros cheaper than the rest of 
the strategies.
The study conducted by Zaim et al.68 assessed cost-effectiveness when CEUS was applied as the second-
line imaging technique in FLL characterisation. Patients with a FLL diagnosis were recruited between 
January 2009 and June 2010 in a medical centre in the Netherlands. All participants had at least one 
baseline US and received both the conventional imaging strategy, which was US, followed by MRI or CT, 
and CEUS. Those diagnosed with benign lesions underwent a minimum of 6 months of follow-up. Those 
with malignant lesions underwent curative or palliative treatments. Costs included costs of diagnostic 
techniques (US, CEUS, CT, MRI, laboratory tests and liver biopsy), surgical resection, intensive care stays, 
hospitalisation, outpatient visits and various treatment strategies (RFA, TACE, chemotherapy, palliative care 
and liver transplantation). All unit prices were based on Farmacotherapeutisch Kompas (CVZ) and Dutch 
tariffs and Erasmus Medical Centre (EMC) data at the 2010 rate.69 The time horizon was 24 months with 
a 1.5% discount rate for health outcomes and 4% for costs. Deterministic and probabilistic sensitivity 
analyses were performed in the study. The discounted cost per patient undergoing CEUS was 8309 euros; 
this was less than that for patients following the conventional strategy, which was 8761 euros per person. 
The aggregate cost saving was 452 euros per person, of which 160 euros constituted the diagnostic phase 
and 292 euros the treatment phase. Total discounted life-years gained per patient were 1.538 for the 
CEUS strategy and 1.536 for the conventional strategy. The results of the probabilistic sensitivity analyses 
indicated that, when the cost-effectiveness threshold was 20,000 euros per life-year, the CEUS strategy 
was cost-effective in 90% of the simulation and the MRI/CT strategy was cost-effective in only 10% of 
the simulation.
Although all of the studies were of reasonably good quality, they did not fully address our research 
question. Limitations included restricted information about disease management and progression, choice 
of equipment and administrative procedures in different settings, inclusion of costing elements in the 
calculation and health outcomes. Zaim et al.68 was the only paper that modelled disease management and 
reported relevant health outcomes; however, the follow-up lasted only 24 months.
Model structure and methodology
The aim of the health economic analysis was to investigate the cost-effectiveness of CEUS using the 
contrast agent SonoVue for the assessment of adults with FFLs in whom unenhanced US or other liver 
imaging is inconclusive. In the analysis we focused on the clinical applications for which the most data on 
test performance were available (see previous chapters) and for which we are most likely to see a clinical 
benefit from the use of CEUS. Therefore, the health economic analysis assessed the value of CEUS in the 
following three populations:
 z characterisation of FLLs detected on routine surveillance of patients with cirrhosis
 z detection of liver metastases in patients with CRC
 z characterisation of incidentally detected FLLs.
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The comparators included the following liver imaging techniques:
 z CECT
 z Gd-CEMRI
 z SPIO-CEMRI.
Three separate models were used to assess the cost-effectiveness of CEUS using the contrast agent 
SonoVue in the populations specified above:
 z a cirrhosis surveillance model
 z a liver metastases of CRC model
 z an incidentally detected FLL model.
In all models the mean costs and life-years and quality-adjusted life-years (QALYs) gained per patient 
were calculated for each comparator. Costs and benefits were discounted at 3.5%. The three models are 
described in detail in the following sections.
Cirrhosis surveillance model
The cirrhosis surveillance model is a modified version of a model produced by the Health Economics 
Group, Peninsula Technology Assessment Group (PenTAG), Institute of Health Service Research, Peninsula 
Medical School (the PenTAG cirrhosis surveillance model).70 This model was developed to assess the 
cost-effectiveness of several surveillance strategies in cirrhotic patients to identify HCC, using periodic 
serum AFP testing and/or liver US examination with CT as a confirmatory imaging technique, followed by 
treatment with liver transplantation or resection when appropriate. One of the research recommendations 
made by the authors was to assess the value of CEUS in surveillance strategies for cirrhotic patients. For the 
assessment of the value of CEUS in cirrhosis surveillance, this model required adaptation, because it did 
not allow for a confirmatory test with less than perfect accuracy. Also, the original model did not allow the 
comparison of different confirmatory tests.
The population of interest in the cirrhosis surveillance model in this assessment consisted of those with a 
diagnosis of compensated cirrhosis deemed eligible to enter a surveillance programme [aged ≤ 70 years 
with no pre-existing medical conditions that would preclude treatment with a liver transplant or hepatic 
resection (including current alcohol or intravenous drug abuse)]. The model allowed separate analysis of 
each of three cirrhosis aetiologies: alcoholic liver disease (ALD), hepatitis B virus (HBV) and hepatitis C virus 
(HCV). In the base-case analysis, results were produced for a mixed cohort weighted according to the 
following proportions: 57.6% ALD, 7.3% HBV and 35.1% HCV (expert opinion; as in the PenTAG model70). 
A probabilistic state transition (Markov) cohort model, constructed using Excel (Microsoft Corporation, 
Redmond, WA, USA), was used. The time horizon was lifetime and the cycle duration was 1 month.
The model diagram is shown in Figure 8. States are shown as boxes and allowable state transitions are 
shown as arrows. The basis of the model was the disease process or ‘natural history’ of cirrhosis. Within 
the natural history model, a distinction was made between those with compensated and those with 
decompensated cirrhosis. Those with compensated cirrhosis can progress to decompensated cirrhosis, 
which is irreversible and associated with excess mortality, costs and quality of life decrements. The rate 
of incidence of HCC is the same in those with compensated and decompensated cirrhosis. HCC can be 
either diagnosed or occult. Three classes of tumours were distinguished: small tumours (< 2 cm), medium 
tumours (2–5 cm) and large tumours (> 5 cm). Tumour size was used as a surrogate measure of all 
characteristics of tumour progression. Hence, tumour progression was modelled by a tumour growth rate. 
Both test performance in identifying tumours and treatability of the tumour are dependent on the tumour 
size. For example, for larger tumours there is a greater likelihood of identification. Incidental/symptomatic 
presentation of HCC is possible for those with both compensated and decompensated cirrhosis, for all 
tumour sizes, although with significantly lower probabilities for small and medium-sized tumours.
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The surveillance programme and treatment components are superimposed onto the disease process. The 
technical performance of each testing strategy was modelled using decision trees. The testing strategies 
consisted of unenhanced US followed by CEUS, CECT, Gd-CEMRI or SPIO-CEMRI as a confirmatory imaging 
test. In the base-case analysis surveillance was every 6 months and stopped for people who reached 
the age of 70 years. It was also assumed that compliance was 100%. The decisions trees are shown in 
Figure 9.
The treatments considered in the model are liver transplantation and liver resection. People can enter the 
transplant waiting list following diagnosis of either surgically treatable HCC or decompensated cirrhosis. 
There is no prioritisation of people waiting for a transplant. During the time on the waiting list people are 
subject to the same natural history process as during prelisting. There is no waiting list for liver resection 
for HCC. Some people are deemed unsuitable for surgical treatment, including those whose tumours are 
large or whose tumours become large while on the transplant waiting list. Small tumours are deemed 
more amenable to surgical treatment than medium-sized tumours. People who undergo successful 
liver transplant or resection enter a simplified disease process in which post-transplant or post-resection 
mortality, costs and utilities are taken into account. People with small and medium-sized tumours that 
are deemed to be surgically untreatable enter a series of states to model palliative care. Palliative care 
includes PEI, RFA and TACE and supportive care. Once people progress to untreatable large HCC, an excess 
mortality and associated costs and utilities are applied to reflect the palliation provided by TACE for a 
proportion of these people. An overview of the key structural assumptions is provided in the following 
section. A more detailed description of the model structure can be found in Thompson Coon et al.70
No HCC
Large
HCC
Small
HCC
Medium
HCC
Palliative
medium HCC
Waiting list
small HCC
Resected
HCC
Waiting list
medium HCC
Palliative
small HCC
Decompensated cirrhosis 
Untreatable
HCC
Post transplant
No HCC
Large
HCC
Small
HCC
Medium
HCC
Palliative
medium HCC
Waiting list
small HCC
Resected
HCC
Waiting list
medium HCC
Palliative
small HCC 
Untreatable
HCC
Compensated cirrhosis 
FP FP 
Waiting list
no HCC
FIGURE 8 Model diagram for cirrhosis surveillance, based on Thomson Coon et al.70 Each cycle all patients who are 
alive can stay in the same health state, die from non-HCC related causes, or move according to the shown transitions. 
Patients with compensated cirrhosis can decompensate, by moving to the corresponding decompensated cirrhosis 
health state. Patients who are palliative or untreatable can die from HCC. Light grey states represent occult HCC. 
Dotted lines represent detection of HCC after screening or showing symptoms; stacked lines represent tumour growth; 
solid lines represent transplant.
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Summary of structural assumptions (adapted from Thompson Coon et al.70) 
 z All tumours are uninodular, with diameter used as a surrogate index of all characteristics of 
tumour progression.
 z Progression from compensated to decompensated cirrhosis is irreversible.
 z The rate of incidence of HCC is the same in compensated and decompensated livers.
 z The presence of a HCC tumour has no direct effect on mortality until it becomes ‘large’, at which point 
it becomes symptomatic and is associated with an additional mortality rate.
 z Incidental/symptomatic diagnosis is possible alongside all interventions, including ‘no surveillance’.
 z The ceiling age for surveillance is 70 years.
 z In the base case there is 100% compliance with the surveillance programme.
 z There is a small rate of false-positive diagnoses as a result of surveillance, all of which are assumed 
to be rapidly discovered before treatment, as both resection and transplant involve further 
diagnostic workup.
 z There is no waiting list for liver resection.
 z There is no prioritisation of people on the transplant waiting list.
 z No ablative therapies are applied to patients on the transplant waiting list.
 z Some people are deemed to have surgically untreatable tumours at the time of diagnosis of HCC.
Liver metastases of colorectal cancer model
The CRC metastases model is a modified version of the metastatic model developed by Brush et al.71 This 
model was developed to assess the cost-effectiveness of fluorodeoxyglucose positron emission tomography 
Ultrasound
False-negative
Diagnosed
HCC
No HCC seen
HCC seen
No HCC seen
Return to screening programme
To treatment programme
Incur extra costs and return
to screening programme
HCC present
No HCC present
Confirmatory
testing
HCC seen
Inconclusive
Ultrasound
HCC excluded
False-positive
No HCC seen
HCC seen
No HCC seen
Return to screening programme
Confirmatory
testing
HCC seen
Inconclusive
FIGURE 9 Decision tree structure for the cirrhosis model. Note: The confirmatory tests are the comparators in this 
analysis: CEUS, CECT, Gd-CEMRI and SPIO-CEMRI.
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(FDG-PET)/CT as an add-on device in detecting metastatic cancer compared with conventional imaging 
(CT). The model was adapted to assess the cost-effectiveness of CEUS compared with CECT, Gd-CEMRI 
and SPIO-CEMRI in detecting metastases from CRC after an inconclusive unenhanced US scan. In addition 
to changing the comparators in the model, we added the cost of a whole-body CT scan for all patients 
with a positive test to detect whether or not metastases at extra sites are present. We also changed the 
way that false-positives were handled, and changed the watch and wait strategy to correspond with latest 
guidance. The watch and wait strategy was given not only to patients without metastases but also to 
those patients treated and still alive. A final addition was that we assigned false-negatives poorer survival 
in the first year because they are not treated immediately. These adaptations are described in more detail 
below. A decision tree combined with a probabilistic state transition (Markov) cohort model, constructed 
using Excel, was used. The time horizon was lifetime and the cycle duration was 1 year.
Figure 10 depicts the decision tree structure used for the metastases model. Patients who had previously 
had surgical treatment for primary CRC and in a routine follow-up assessment (involving a clinical 
examination and CEA testing) were found to have rising CEA levels and were identified as potentially 
having a metastatic recurrence received an unenhanced abdominal US scan. When this US scan was 
deemed inconclusive, the patient entered the decision tree and could receive CEUS, CECT, Gd-CEMRI or 
SPIO-CEMRI. Similar to the Brush et al. model,71 the decision tree splits the patient population according to 
true disease status (metastatic recurrence or no metastatic recurrence) before applying the DTA estimates, 
so that accurate and inaccurate diagnoses can be identified.
In this model, imaging (CEUS, CECT, Gd-CEMRI or SPIO-CEMR) will identify either metastases (test positive) 
or no metastases (test negative). After a positive test, patients receive a whole-body CECT scan to identify 
whether there are metastases at one site or at multiple sites. In the base case it was assumed that all 
patients in the model receive a biopsy to confirm the metastases before treatment, and it was assumed 
that biopsy is 100% accurate. Thus, in contrast to the Brush et al. model,71 patients with a false-positive 
test result will not receive treatment. Patients with a positive biopsy (true-positives) receive treatment. 
In line with Brush et al.71 it was assumed that all patients with metastases at a single site will receive 
preoperative chemotherapy and surgery for metastases, and that patients with metastases at multiple sites 
are assumed to be non-curable and will receive either preoperative chemotherapy followed by surgery 
and palliative care, or chemotherapy and palliative care. In line with the Brush et al. model, patients with 
a negative test result are followed up in a watch and wait strategy for 3 years. Also in line with the Brush 
et al. model, for patients who are inaccurately diagnosed as having no metastases (false-negatives), the 
true diagnosis is assumed to be identified within a year if the patient is still alive. These metastases can 
be detected during scans in the watch and wait strategy or because the patient becomes symptomatic. 
This delayed detection involves a second scan (CEUS, CECT, Gd-CEMRI or SPIO-CEMRI, depending on the 
comparator), a whole-body CT and a biopsy.
SurgeryBiopsyMetastases one site (accurate)
Surgery
Palliative care
BiopsyExtra metastases (accurate)
Test positive (TP)
Wait and watchNo metastases (inaccurate)Test negative (FN)
Metastases
Wait and watchBiopsyMetastases one site (accurate)
Wait and watchBiopsyExtra metastases (inaccurate)
Test positive (FP)
Wait and watchNo metastases (accurate)Test negative (TN)
No metastases
CEUS
CECT (as above)
CEMR (as above)
Suspected
metastatic
recurrence,
inconclusive
ultrasound
FIGURE 10 Decision tree structure for the liver metastases from CRC model.
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After the decision tree phase, a state transition (Markov) model was used to follow up the patients 
(Figure 11). After the second year, when every patient is correctly diagnosed, patients can either stay in 
their health state or die. In the first 3 years, patients without metastases and those who were treated were 
assumed to be followed up using the watch and wait strategy.
Summary of structural assumptions
 z For patients who are inaccurately diagnosed as having no metastases, the true diagnosis is identified 
within a year if the patient is still alive, either through regular tests in the watch and wait strategy or 
because the metastases become symptomatic.
 z All patients with a positive test result receive a whole-body CT scan to identify whether or not 
metastases are present at multiple sites. This scan does not detect inaccuracies of the previous 
(positive) test.
 z Patients who are inaccurately diagnosed as having metastases receive a biopsy and are therefore not 
treated for their metastases.
 z All patients with metastases at a single site will receive preoperative chemotherapy and 
metastatic surgery.
 z Patients with both hepatic and extrahepatic metastases are assumed to be non-curable and will 
receive one of two treatment options: preoperative chemotherapy followed by metastatic surgery and 
palliative care or chemotherapy and palliative care.
 z All patients identified as having no metastatic recurrence, as well as patients who have been treated 
for their metastases, would be treated with a watch and wait strategy in which they would be 
followed up annually for 3 years.
 z If there are no metastases at baseline, metastases will not occur. The watch and wait strategy is used 
to detect local recurrences and these are not incorporated in the model.
Incidentally detected focal liver lesion model
Patients with incidentally detected FLLs can have a variety of diseases, ranging from malignant lesions such 
as HCC and metastases to different types of benign lesions. Figure 12 illustrates the different combinations 
of test results and lesion types. The choice of lesion categories was based on similarities and differences in 
treatments, costs and prognosis.
The prognosis, costs and QALYs seen among patients diagnosed with HCC were modelled using the 
cirrhosis model, whereas the prognosis, costs and QALYs among patients with liver metastases were 
Metastases
(inaccurate)
No
metastases
(accurate)
No
metastases
(inaccurate)
Metastases
(accurate)
Death
FIGURE 11 Simplified schematic diagram of the Markov model for follow-up of patients in the CRC metastases model.
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modelled using the liver metastases model. The incidentally detected FLL model therefore incorporated 
elements of the cirrhosis model and elements of the liver metastases model as well as some new elements. 
The cirrhosis model required adjustments before it could be incorporated into these analyses. One 
important issue related to when HCC is diagnosed. In particular, although none of the patients in the 
cirrhosis surveillance model has HCC at the start of the simulation, all HCC patients in the incidentally 
detected FLL model will have HCC at the start of the simulation.
The economic and health consequences of false-positive and false-negative results were modelled in the 
following ways. First, it was assumed that patients with HCC who were not correctly identified at baseline 
would be correctly diagnosed within several months, as essentially all of these patients will have important 
risk factors (e.g. alcohol misuse, newly diagnosed cirrhosis or hepatitis) that are identified at baseline. 
Patients with a false-positive diagnosis (in particular, patients with a benign tumour that was misclassified 
as a malignant tumour) were assumed to undergo one additional follow-up consult as a result of this 
misclassification. This was viewed as a conservative assumption that would bias the assessment against 
CEUS and in favour of the comparators (CECT, CEMRI), as a false-positive result might lead to even greater 
costs than the cost of simply one extra visit and as CEUS was found to have a lower rate of false-positives 
in the DTA studies.
The costs, life-years and QALYs for patients having a malignancy other than HCC or metastases were 
assumed to be equal to those for HCC patients (see Figure 12). These other types of malignant lesions 
(e.g. lymphoma) were infrequently seen among patients with an incidentally detected FLL and the 
studies comparing CEUS with CECT or CEMRI provided little information about these lesions. Given the 
heterogeneity in costs and QALYs within this group (and even among patients with the same malignancy), 
we chose to set the base-case values to the costs and QALYs seen with HCC patients and emphasise that 
this was an assumption. However, it was known in advance that the costs and QALYs of these patients 
would have a limited effect on the cost-effectiveness of CEUS compared with the comparators for two 
reasons: the values for the sensitivity of CEUS and the comparators were very similar and the prior 
Treatment according to adapted cirrhosis model
Treatment according to adapted cirrhosis model
Additional assessment, possible resection,
otherwise no follow-up
Additional assessment,
no follow-up thereafter
Possible resection, otherwise no follow-up
No follow-up
Delayed treatment using adapted cirrhosis model
Delayed treatment using adapted cirrhosis model
Delayed treatment using adapted metastasis model
Treatment according to adapted metastasis model
HCC
Other malignancy
Adenoma
FNH
Haemangioma
Other benign
Haemangioma
Other benign
Adenoma
FNH
HCC
Other malignancy
Metastasis
Metastasis
Positive
‘malignant’
Negative
‘benign’
Test result
True-positive
False-positive
False-negative
True-negative
FIGURE 12 Description of patient categories and their treatments used in the incidentally detected FLL model.
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probability of other malignancies was small. In fact, the only possible way in which the values for costs 
and QALYs of other malignancies could have any effect on the overall cost-effectiveness was if the costs 
and QALYs changed dramatically if the malignancy were to be incorrectly classified as a benign lesion 
(i.e. a false-negative test result). The impact of this false-negative effect was therefore examined using 
sensitivity analysis.
Summary of structural assumptions made in the incidentally detected focal liver 
lesion model
 z Patients with HCC have a small HCC lesion and compensated cirrhosis at the time of assessment. The 
cirrhosis surveillance model made it possible to explore the impact of assuming that these patients 
have a medium lesion and compensated cirrhosis at the time of assessment, and the costs and QALYs 
associated with this alternative were used in a sensitivity analysis.
 z Patients with HCC who are incorrectly diagnosed at baseline will be correctly diagnosed later (within 
several months). This is assumed because these patients will be followed up because of the presence 
of some of the risk factors known to result in HCC (e.g. history of alcohol misuse, hepatitis B or C).
 z Patients diagnosed with an apparently benign lesion do not undergo treatment unless they have a 
(hepatic) adenoma, in which case they may undergo a resection.
 z The mean costs and health outcomes of patients with incidentally detected FLLs that are metastatic 
can be estimated using the model for liver metastases from CRC, because the highest proportion of 
liver metastases will originate from CRC. For example, Catala et al.52 reported that 7 of the 12 patients 
with metastases in their study had CRC, and this corresponds with findings elsewhere in the literature 
as well as frequencies reported by one of the clinicians queried during this study.
Model parameters
Cirrhosis surveillance model
Test performance
It was assumed that the surveillance strategy started with unenhanced US. The test performance of US 
used in the model was based on the study by Bennett et al.,72 as used in the HTA report by Thompson 
Coon et al.70 (Table 15). This study was preferred over other studies because it distinguished between 
small, medium and large tumours and had a relatively large sample size (n = 200).
Additional imaging takes place following an inconclusive unenhanced US scan. The percentage of 
unenhanced US examinations that are inconclusive was estimated to be 43%, based on information 
provided by the manufacturer of SonoVue during the scoping phase of this assessment.
TABLE 15 Test performance of US used in the decision trees for the cirrhosis surveillance model
Parameter Value Distributiona TP FN FP TN
Sensitivity for identifying tumours Small 0.11 Dirichlet 3 25 6 118
Medium 0.29 Dirichlet 2 5 0 2
Large 0.75 Dirichlet 3 1 0 0
False-positive rate US 0.04 Dirichlet See data used to model sensitivity
FN, false-negative; FP, false-positive; TN, true-negative; TP, true-positive.
a The Dirichlet distribution is the multivariate generalisation of the beta distribution. The parameters of the distribution 
are the observed test results (TP, FP, FN, TN), presented in the table.
Source: based on Bennett et al.72
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In the systematic review seven studies42,43–46,48,61 that compared CEUS with at least one of the comparators 
(CECT, Gd-CEMRI or SPIO-CEMR) for the characterisation of FLLs detected during routine surveillance of 
cirrhotic patients were identified. In the base-case analysis the probability of identifying a HCC, as well 
as the proportion of people with a false-positive test result, was taken from the study by Leoni et al.42 
(Table 16). The main reason for using this study was that it used diagnostic criteria matching the EFSUMB 
guidance on the use of CEUS,6 and reported data on the performance of CEUS, CECT and Gd-CEMRI in 
the same population, whereas most other studies compared CEUS with either CECT or CEMRI. A potential 
disadvantage of the Leoni et al. study was that it used a suboptimal reference standard (concordance 
between at least two imaging test results) for the majority of patients. Leoni et al. also reported accuracy 
data for SPIO-CEMRI, which were not incorporated in the base-case analysis. The study included patients 
with liver lesions between 1 and 3 cm; therefore, in the base case we used these results to model the 
diagnostic accuracy for both small (< 2 cm) and medium-sized (2–5 cm) tumours. The sensitivity for 
the identification of large HCCs was assumed to be 100% for all confirmatory imaging tests and this 
assumption was agreed by the clinical experts.
Transition probabilities
The transition probabilities were all taken from the cirrhosis surveillance model reported in Thompson 
Coon et al.70 A detailed description of the estimates of the transition probabilities can be found in this HTA 
report. An overview of the parameters used in the model that affect transition probabilities is provided in 
Table 17.
Costs
The cost of CEUS (in addition to unenhanced US) was based on expert opinion, both from clinicians 
and the manufacturer. The cost of the contrast was assumed to be £48.70 (estimate supplied by the 
manufacturer and agreed by clinicians). This cost includes the cost of cannulation. In addition, we 
expected CEUS to take more time than the unenhanced US scan. Therefore, we used the difference 
between the reference cost of an US scan of < 20 minutes (£55) and the reference cost of an US scan of 
> 20 minutes (£71) as the additional time cost of CEUS.84 The total additional costs of CEUS were therefore 
estimated to be £65. This implies that CEUS is performed in the same appointment as the unenhanced 
US scan. The costs of the other diagnostic tests, outpatient appointments, orthotopic liver transplantation 
(OLT) and resection were based on NHS reference costs (NHSRC).84
All other cost inputs were based on Thompson Coon et al.,70 recalculated to the 2011 price level.85 A 
detailed description of these costs can be found in this HTA report.70 The parameters used in the model 
affecting costs are listed in Table 18.
TABLE 16 Test performance of confirmatory imaging used in the decision tree for the cirrhosis surveillance model
Parameter Value Distributiona TP FN FP TN
Sensitivity for identifying small and 
medium tumours
CEUS 0.67 Dirichlet 37 18 2 18
CECT 0.67 Dirichlet 37 18 2 18
Gd CEMRI 0.82 Dirichlet 45 10 1 19
False-positive rate CEUS 0.03 Dirichlet See data used to model sensitivity
CECT 0.03 Dirichlet See data used to model sensitivity
Gd CEMRI 0.01 Dirichlet See data used to model sensitivity
FN, false-negative; FP, false-positive; TN, true-negative; TP, true-positive.
a The Dirichlet distribution is the multivariate generalisation of the beta distribution. The parameters of the distribution 
are the observed test results (TP, FP, FN, TN), presented in the table.
Source: based on Leoni et al.42
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TABLE 18 Parameters used in the cirrhosis surveillance model: costs
Parameter Cost (£) Source Distribution
Range of values used in 
sensitivity analysis
Lower Upper
Unit costs
US scan 55 Per scan NHSRC84 Beta PERTa 40 65
SonoVue contrast agent 49 Per scan Expert 
opinion
Beta PERTa 40 60
Additional time for CEUS 16 Per scan NHSRC84 Beta PERTa 0 39
CECT (one area) 116 Per scan Beta PERTa 88 126
Gd-CEMRI (one area) 189 Per scan Beta PERTa 137 226
SPIO-CEMRI (one area) 189 Per scan Beta PERTa 137 226
Outpatient appointment 150 Per appointment Beta PERTa 72 228
OLT 26,329 Per operation Beta PERTa 20,169 38,406
Resection 6521 Per operation Beta PERTa 1812 7246
State costs
All compensated cirrhosis 
states
1394 Per year Thompson 
Coon et al.,70 
updated to 
2011
Beta PERTa 867 1961
All decompensated 
cirrhosis states
11,335 Per year Beta PERTa 7738 14,931
All known HCC states 1486 Per yearb Beta PERTa 743 2971
Post OLT (year 1) 11,923 Per patient per 
year
Beta PERTa 5835 18,021
Post OLT (year 2 onwards) 1889 Per patient per 
year
Beta PERTa 992 2796
Post resection 4266 Per patient per 
year
Beta PERTa 2824 5752
Palliative care (small and 
medium tumours)
1955 Per yearb Beta PERTa 977 3909
Palliative care (large 
tumours)
214 Beta PERTa 106 428
Event costs
False-positive diagnosis 618 Per false-positive 
diagnosis
Thompson 
Coon et al.,70 
updated to 
2011
Beta PERTa 419 961
Symptomatic/incidental 
diagnosis
198 Per diagnosis Beta PERTa 94 287
a In the beta PERT distributions, λ (the scale parameter that scales the height of the distribution) equals 4, which means 
that the distribution approximates the normal distribution.
b In addition to the costs of the underlying cirrhosis.
NIHR Journals Library
ASSESSMENT Of COST-EffECTIVENESS
78
Utilities
Utilities were taken from the HTA report by Thompson Coon et al.70 (Table 19)
Liver metastases of colorectal cancer model
Test performance
Chapter 3 reports the results of two studies identified that assessed the accuracy of CEUS compared with 
CECT and/or Gd-CEMRI and/or SPIO-CEMRI in detecting liver metastases in CRC patients after inconclusive 
unenhanced US.49,50 The test performance found in the Mainenti et al. study49 was used in the base case 
as this study compared all three alternative tests (CECT, Gd-CEMRI, SPIO-CEMRI) with CEUS. In this study, 
based on a total of 34 patients, sensitivity was 83% for all comparators. Specificity was lowest for CEUS 
(86%), followed by CECT (96%), SPIO-CEMRI (96%) and Gd-CEMRI (100%). An overview of the test 
performance is presented in Table 20. A Dirichlet distribution based on the observed counts was used to 
assess the uncertainty surrounding these results.
Transition probabilities
All transition probabilities used in the model are listed in Table 21 and are in line with the probabilities 
used in the Brush et al. model.71 The probability of having metastases after CRC is expected to be 40%.88 
Even though the population modelled in the present analysis has already had an inconclusive US scan and 
may therefore be a slightly different population, we expected this figure to also apply to our population. 
Of those patients with metastases, approximately 30% have them at one site.89
In line with Brush et al.71 we assumed that all patients with metastases at a single site receive preoperative 
chemotherapy and metastatic surgery. Patients with extra metastases receive either preoperative 
chemotherapy followed by metastatic surgery and palliative care (20%) or chemotherapy and palliative 
care. All patients without a metastatic recurrence are followed up using a watch and wait strategy.
Five-year overall survival rates were extracted from Brush et al.71 Patients who were inaccurately classified 
as having no metastases and who therefore failed to receive treatment in the first year were expected 
to have a higher probability of dying in this first year than those who were immediately treated for their 
metastases. Therefore, in the first year patients who had undetected metastases at one site had the 
probability of dying of those who were treated for extra metastases with surgery. Similarly, patients who 
had undetected metastases at multiple sites who could have been treated with surgery were assumed 
TABLE 19 Parameters used in the cirrhosis surveillance model: utilities 
Parameter Value Source Distribution
Range of values used in 
sensitivity analysis
Lower Upper
Compensated cirrhosis 0.75 Chong et al.86 Beta PERTb 0.66 0.83
Decompensated cirrhosis 0.66 Chong et al.86 Beta PERTb 0.46 0.86
Untreatable HCC 0.64 Chong et al.86 Beta PERTb 0.44 0.86
Month of OLT 0.50 AAa Beta PERTb 0.30 0.60
Post OLT (year 1) 0.69 Ratcliffe et al.87 Beta PERTb 0.64 0.74
Post OLT (year 2 onwards) 0.73 Ratcliffe et al.87 Beta PERTb 0.67 0.78
Month of resection 0.50 AAa Beta PERTb 0.30 0.60
a Author assumption as reported in Thompson Coon et al.70
b In the beta PERT distributions, λ (the scale parameter that scales the height of the distribution) equals 4, which means 
that the distribution approximates the normal distribution.
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to have the probability of dying of those patients who received palliative care. Patients with undetected 
metastases at multiple sites who would have received palliative care were assumed not to experience 
increased mortality. After 1 year, all patients were assigned the mortality rate that belonged to their type 
of metastases and treatment. The survival rates were converted to yearly probabilities and extrapolated to 
10 years, after which patients were assumed to have survived their disease and returned to the average 
TABLE 20 Test performance of imaging used in the decision tree for the metastases model
Parameter Value Distributiona
Observed counts (n = 34)
TP FN FP TN
Sensitivity CEUS 0.83 Dirichlet 5 1
CECT 0.83 Dirichlet 5 1
Gd-CEMRI 0.83 Dirichlet 5 1
SPIO-CEMRI 0.83 Dirichlet 5 1
Specificity CEUS 0.86 Dirichlet 4 24
CECT 0.96 Dirichlet 1 27
Gd-CEMRI 0.96 Dirichlet 0 28
SPIO-CEMRI 1.00 Dirichlet 1 27
FN, false-negative; FP, false-positive; TN, true-negative; TP, true-positive.
a The Dirichlet distribution is the multivariate generalisation of the beta distribution. The parameters of the distribution 
are the observed test results (TP, FP, FN, TN), presented in the table.
Source: based on Mainenti et al.49
TABLE 21 Parameters used in the metastases model: transition probabilities 
Parameter Value Source Distribution
Cancer prevalence
Probability of having metastases 0.40 Saunders et al.88 Beta SE = 0.1
Probability of having metastases at one site 0.30 Lejeune et al.89 Beta SE = 0.1
Treatments
Metastases: preoperative chemotherapy and 
metastatic surgery
1.00 Assumption based on 
Brush et al.71
Fixed
Extra metastases: preoperative chemotherapy 
and metastatic surgery
0.20 MSAC90 Beta SE = 0.04
Watch and wait 1.00 Assumption based on 
Brush et al.71
Fixed
5-year overall survival
No metastases 0.85 American Cancer Society91 Beta SE = 0.01
Metastases: surgery for cure 0.24 AJCC92 Beta SE = 0.03
Extra metastases: metastatic surgery and 
palliative care
0.12 AJCC92 Beta SE = 0.04
Extra metastases: palliative care 0.06 AJCC92 Beta SE = 0.04
AJCC, American Joint Committee on Cancer; MSAC, Medical Services Advisory Committee.
Source: based on Brush et al.71
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mortality rate for their age.93 To inform this mortality rate, the model assumed a starting age of 50 years 
and a male-to-female ratio of 55 : 45.94
Costs
Both the costs of the imaging techniques and the costs of subsequent treatment were taken into account 
(Table 22). The costs of CEUS were similar to those in the cirrhosis surveillance model. Because all patients 
already received an unenhanced US scan, the costs of CEUS consisted of the cost of the extra time used 
for CEUS as opposed to an unenhanced US scan (£16) and the cost of the contrast (£48.70). CECT 
was assumed to scan three areas (chest, abdomen, pelvis) whereas CEMRI was assumed to scan two to 
three areas. The costs of biopsy, whole-body CT and the watch and wait strategy were based on NHSRC 
reference costs.84 The watch and wait strategy consisted of two CECT scans over 3 years and a serum CEA 
test twice a year for 3 years.14 Costs of treatment were based on the costs used by Brush et al.71
Utilities
All utility scores used in the model were based on Brush et al.71 and are presented in Table 23. Patients 
who were inaccurately diagnosed as having no metastatic recurrence and who therefore failed to receive 
treatment in the first year were assigned a disutility for that year to account for the negative impact 
on their quality of life. Likewise, patients without metastases who unnecessarily received treatment 
(in a sensitivity analysis) were assigned a lower utility score to account for the negative impact of this 
unnecessary treatment on their quality of life.
It was assumed that the average utility experienced by patients in a particular stage was constant for 
5 years post diagnosis. Patients who were still alive 5 years post diagnosis were assigned age-specific utility 
weights based on UK population norms.102
TABLE 22 Parameters used in the metastases model: costs
Parameter Cost (£) Source Distribution
Range of values used in 
sensitivity analysis
Lower Upper
SonoVue contrast agent 49 Expert opinion Beta PERTa λ = 4 40 60
Additional time for CEUS 16 NHSRC84 Beta PERTa λ = 4 0 39
CECT (three areas) 162 NHSRC84 Beta PERTa λ = 4 120 192
Gd-CEMRI (two to three 
areas)
366 NHSRC84 Beta PERTa λ = 4 175 374
SPIO-CEMRI (two to three 
areas)
366 NHSRC84 Beta PERTa λ = 4 175 374
Biopsy 1437 NHSRC84 Beta PERTa λ = 4 989 1798
Whole-body CT 162 NHSRC84 Beta PERTa λ = 4 120 192
Chemotherapy 11,532 BNF 58,95 ISD,96 
Cancer Research UK97
Fixed
Surgery 9134 ISD96 Normal SD = 1827
Palliative care 2468 Guest et al.98 Normal SD = 494
Watch and wait 110 NHSRC,84 NICE14 Beta PERTa 82 130
BNF, British National Formulary; ISD, Information Services Division.
a In the beta PERT distributions, λ (the scale parameter that scales the height of the distribution) equals 4, which means 
that the distribution approximates the normal distribution.
Source: based on Brush et al.71
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Incidentally detected focal liver lesion model
Test performance
As noted earlier, different studies have compared CEUS with CECT and CEMRI in its ability to characterise 
incidentally FLLs. Three different types of diagnostic outcome have been studied: diagnosis of any 
malignancy, diagnosis of HCC and diagnosis of metastases. Of these three, the most common outcome 
has been any malignancy. In addition, most studies have compared CEUS with CECT; only one has 
compared CEUS with CEMRI. These two factors made it impossible to combine all results into one analysis 
without important assumptions (listed in Incidentally detected FLL model). This issue was resolved by 
utilising the test performance results in various ways.
The approach used in the base-case analysis was to take the results from the meta-analysis of four studies 
that compared CEUS with CECT in their ability to differentiate between malignant and benign lesions 
(described in Chapter 3, Accuracy of SonoVue CEUS for the characterisation of incidentally detected FLLs). 
The following results illustrate how similar the performance of CEUS and CECT are (Table 24). The CIs 
shown were calculated using the exact method.
In addition to using the sensitivity and specificity values from the meta-analysis, we also used the results 
from the individual studies (see Chapter 3, Accuracy of SonoVue CEUS for the characterisation of 
incidentally detected FLLs for details). Dirichlet distributions were applied when the results from these 
individual studies were used. Use of these distributions had no influence on the prior probability of the 
different diagnoses as test performance and prior probability were combined to calculate the post-test 
probability using Bayes’ theorem.
In the past, only one study has compared the test accuracy of CEUS with MRI.56 As noted in Chapter 3 
(see Accuracy of SonoVue CEUS for the characterisation of incidentally detected FLLs), this study 
reported that all patients in subgroup B underwent Gd-CEMRI, and that a subset of these patients also 
underwent SPIO-CEMRI. It is therefore difficult to refer to the accuracy of Gd-CEMRI or SPIO-CEMRI in the 
characterisation of incidentally detected FLL. For this reason, in the sections relating to the use of MRI in 
the characterisation of incidentally detected FLL, we refer to CEMRI.
TABLE 23 Parameters used in the metastases model: utilities
Parameter Value Source Distribution
No metastases 0.91 Ramsey et al.99 Beta SE = 0.11 
Metastases at one site 0.84 Ramsey et al.99 Beta SE = 0.12
Extra metastases: surgery for cure 0.74 Langenhoff et al.100 Beta SE = 0.21
Extra metastases: palliative care 0.52 Tengs and Wallace101 Beta SE = 0.08
Patients receiving unnecessary metastatic surgery 0.74 Langenhoff et al.100 Beta SE = 0.14
Patients receiving unnecessary palliative care 0.61 Tengs and Wallace101 Beta SE = 0.20
Disutility for patients who fail to receive surgery 0.30 Assumption based on 
Tengs and Wallace101
Gamma SE = 0.08
Disutility for patients who fail to receive palliative care 0.20 Assumption based on 
Tengs and Wallace101
Gamma SE = 0.08
Source: based on Brush et al.71
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As noted above, some studies examined the ability of imaging tests to correctly identify HCC and 
metastases. While modelling, we made it possible to use these results instead of the results based on 
malignancy compared with no malignancy.
With regard to the outcome of malignancy compared with no malignancy, we assumed that any mistakes 
in diagnosis were made at random and were not associated with any particular lesion type. For example, 
if a malignant lesion was incorrectly classified by CEUS as a benign lesion, the type of benign lesion in that 
instance was determined according to the relative frequencies of the different benign lesion types.
Nevertheless, a number of different probabilities were used in this model. The first set of probabilities 
related to the prior probabilities (or prevalence) of the different types of lesions at the time of assessment 
(Table 25). The prevalence of malignant lesions varied substantially between the diagnostic accuracy 
studies included in the systematic review. In one study the probability of any malignancy was 23%,53 
whereas in another it was 74%.52 In the final protocol for this study it was stated that expert opinion had 
suggested that as many as 70–75% of FLLs assessed in the NHS may be benign. This percentage might 
be higher if the population in question were to be limited to incidentally detected FLLs. The clinicians 
surveyed during the present study were of the opinion that the chance of malignancy was rather low in 
this population. As a consequence, we used a low probability of malignancy in the base-case scenario. The 
values shown in Table 25 were based on the results of Bartolotta et al.,103 who reported a low probability 
of malignancy of 4.3%. As Bartolotta et al. reported no patients with HCC in their study, we increased this 
to 0.05 to introduce a small chance that a patient with HCC would appear on occasion in the analysis.
As noted above, care was taken to ensure that the estimates of test performance were kept separate 
from the prior probabilities of the different malignancies by combining prior probability, sensitivity 
and specificity using Bayes’ theorem. This enabled us to vary the prior probability of malignancy in 
sensitivity analyses.
The incidentally detected FLL model was a decision-analytic model and not a Markov model and therefore 
did not directly involve the modelling of health states. The prognosis of patients following the initial 
diagnostic assessment was estimated using existing disease models and background mortality data 
(national vital statistics). The prognosis associated with the two most important types of malignant lesions 
(HCC and metastases) was estimated using the two other models applied in this HTA (i.e. the cirrhosis 
model and the liver metastases model). The following assumptions were made regarding the prognosis of 
patients with incidentally detected FLLs.
Summary of assumptions made in the incidentally detected focal liver lesion 
model regarding probabilities
 z Patients with HCC have a small HCC lesion and compensated cirrhosis at the time of assessment. The 
cirrhosis surveillance model made it possible to explore the impact of assuming that these patients 
have a medium-sized lesion and compensated cirrhosis at the time of assessment, and the costs and 
QALYs associated with this alternative were used in a sensitivity analysis.
 z Patients with HCC who are incorrectly diagnosed at baseline will be correctly diagnosed later (within 
several months). This is assumed because these patients will be followed up because of the presence 
TABLE 24 Test performance of CEUS and CECT in their ability to characterise any malignancy: incidentally detected FLLs
Estimate (%) 95% CI (exact method) (%)
Sensitivity of CEUS 95.1 93.3 to 96.6
Sensitivity of CECT 94.6 92.7 to 96.1
Specificity of CEUS 93.8 90.4 to 96.3
Specificity of CECT 93.1 89.6 to 95.8
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of one or more risk factors for HCC, such as newly diagnosed cirrhosis and hepatitis. The impact of 
delayed treatment is 1 less life-year, 1 less QALY and 5% extra costs. The impact of delayed treatment 
was varied in sensitivity analyses.
 z Patients diagnosed with an apparent benign lesion do not undergo treatment unless they have a 
(hepatic) adenoma, in which case they may undergo a resection [base-case chance of resection: 50% 
(but varied in sensitivity analyses)].
Costs
The costs of diagnostic tests, outpatient appointments, biopsy, OLT and resection were taken from the 
NHSRC.84 Many of the values used in the incidentally detected FLL analyses were similar to those used in 
the cirrhosis analyses (Table 26). All other cost inputs were based on Thompson Coon et al.,70 recalculated 
to the 2011 price level using the Personal and Social Services Research Unit (PSSRU) unit costs.85
The costs of treating HCC and metastases were based on the calculations in the cirrhosis surveillance 
and liver metastases models (see Table 26). However, adaptations of the cirrhosis model were needed 
before the results could be used for these analyses. In particular, it was assumed that a small tumour 
was found at diagnosis. Therefore, the total costs shown here cannot be compared with the total costs 
reported for cirrhosis surveillance. In contrast, the estimated costs of liver metastases treatment were 
based directly on the base-case results for liver metastases reported later in this chapter. Although it could 
be argued that some cost components (such as the costs of the initial diagnostic assessment) should be 
removed as they are not relevant for the incidentally detected FLL model, we chose to leave the total costs 
unchanged to allow the reader to trace the origin of these cost estimates. Moreover, these costs are greatly 
overshadowed by the other treatment-related costs and the standard error.
Utilities
Patients with an incidentally detected lesion that is benign are expected to lead a normal life in the future. 
For this reason it was assumed that their life expectancy and quality of life would not be different from 
those of the general population. In contrast, patients with a malignant lesion can have a poorer quality of 
life. The impact of disease on health utilities was based on the results of the cirrhosis and liver metastases 
models, as HCC and liver metastases are two important types of malignant lesion that may be identified. 
More information about the impact that these have on utilities is provided in the other sections of 
this chapter.
TABLE 25 Probabilities of the different types of lesions at time of assessment: incidental FLL model
Type of lesion Prior probability Distribution Alpha Beta
Metastases 0.0211 Beta 3 139
HCC 0.0004 Beta 0.05 141.95
CCC 0.0070 Beta 1 141
Other malignancy 0.0004 Beta 0.05 141.95
Haemangioma 0.4993 Beta 70.9 71.1
Focal nodular hyperplasia 0.3169 Beta 45 97
Hepatocellular adenoma 0.0141 Beta 2 140
Focal fatty sparing 0.0704 Beta 10 132
Other benign lesion 0.0704 Beta 10 132
Probability of malignant lesion 0.0289 Beta NA NA
Probability of benign lesion 0.9711 Beta NA NA
NA, not applicable.
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One factor not included in the analysis was the extent of disutility resulting from the anxiety caused by an 
incorrect diagnosis. Another type of disutility not explicitly included in the analysis related to the possible 
disutility from any delay before undergoing the test. Differences in waiting time between CEUS, CECT 
and CEMRI are expected, as CEUS can be performed right after the unenhanced US, as part of the same 
examination. However, it is uncertain how much disutility may be caused by differences in waiting time.
Summary of assumptions made in the incidentally detected focal liver lesion 
model regarding utilities
 z Patients with HCC who are incorrectly diagnosed at baseline will be correctly diagnosed later (within 
several months). This is assumed because these patients will be followed up because of other risk 
factors, such as newly diagnosed cirrhosis and hepatitis. The impact of delayed treatment is 1 
fewer QALY.
 z Patients diagnosed with an apparent benign lesion will have a life expectancy and quality of life equal 
to those seen among people in the general population of the same age and sex.
Additional analyses
First, one-way sensitivity analyses were performed for all key parameters, especially for parameters in the 
models that were based on expert opinion. Next, probabilistic sensitivity analyses were performed using 
parameter distributions instead of fixed values. The chosen distributions are presented for each input 
parameter in Tables 25 and 26. Decision uncertainty regarding mutually exclusive alternatives is reflected 
using cost-effectiveness planes and cost-effectiveness acceptability curves. Specific additional analyses 
(including one-way sensitivity analyses) are listed in the following sections for each model.
TABLE 26 Parameters used in the incidentally detected FLL model: costs
Cost (£) Lower (£) Upper (£) Distribution
Imaging
 US 16 0 39 Beta PERT
 Contrast 48.70 40 60 Beta PERT
 CEUS 65
 CECT 116 88.21 126.33 Beta PERT
 CEMRIa 189 137.27 225.89 Beta PERT
Mean cost (£) Standard error (£) Distribution
HCC (correctly diagnosed) 24,645 3980 Normal
HCC (incorrectly diagnosed) 25,877 3980 Normal
Metastasis (correctly diagnosed) 7518 1808 Normal
Metastasis (incorrectly 
diagnosed)
7894 1808 Normal
Follow-up (total) 150 (min.–max.) 144–156 Beta PERT (when varied)
Resection 6521 (min.–max.) 1812–7246 Beta PERT
max., maximum; min., minimum.
a Type of contrast used in CEMRI not indicated here as both types were used in test accuracy studies.
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Cirrhosis surveillance model
The proportion of patients receiving confirmatory imaging (the proportion of patients with an inconclusive 
unenhanced US scan: 43%) was an uncertain parameter in the model. Therefore, we performed a 
sensitivity analysis in which CEUS, CECT and Gd-CEMRI were used for a proportion of patients equal to 
the proportion of patients with a positive unenhanced US scan (as a minimum estimate of the patients 
requiring confirmatory imaging). Second, we reduced the proportion of inconclusive unenhanced US scans 
considerably (20% instead of 43%). Next, we conducted sensitivity analyses on the age limit of surveillance 
(90 years instead of 70 years), the frequency of screening (every year instead of every 6 months) and the 
tumour sizes for which the accuracy data were applied (small only instead of small and medium-sized).
Finally, scenario analyses were conducted using other sources for the accuracy of the tests. As alternative 
sources we used the articles by Dai et al.,43 Quaia et al.,46 Blondin et al.48 and Giorgio et al.45 (using data 
for 11- to 30-mm lesions). Dai et al. and Blondin et al. were included as other examples of studies that 
used a standard (EFSUMB guidelines6) definition of HCC, and Giorgio et al. and Quaia et al. were included 
to explore the effects of using other definitions of HCC. The study by Forner et al.44 was not used because 
it included a significant proportion of patients with very small (< 10 mm) FLLs and the study by Sangiovanni 
et al.47 was not used because it was considered to be an ‘outlier’ (accuracy results differed substantially 
from those of other, apparently similar studies).
Liver metastases from colorectal cancer model
First, we analysed the impact of not having a biopsy before treatment on the expected costs and effects. 
This would imply that patients who were inaccurately detected as having metastases would receive 
treatment, as was assumed in the Brush et al. model.71 Second, we examined the impact of a 80% instead 
of a 40% probability of having metastases. We did this because our population of patients who have 
already received an unenhanced US scan may be slightly different from the population in Brush et al.71 and 
may consist of more patients with metastases.
Next, we performed scenario analyses using other sources as input for the accuracy of the tests. Although 
the results refer to lesions instead of patients, we used the sensitivity and specificity reported in Jonas et 
al.50 to assess the impact on the expected costs and effects. We also used the sensitivity and specificity 
reported in Clevert et al.;51 this study included some patients with primary cancers other than CRC, but the 
majority (> 80%) of metastases diagnosed were from CRC.
Incidentally detected focal liver lesion model
A number of different parameters were varied to investigate their impact on the cost-effectiveness of 
CEUS. First, we increased the probability of a malignant lesion. We also examined the impact of basing the 
values for the sensitivity and specificity of CEUS and CECT on individual studies rather than on the meta-
analysis. We then examined whether or not assuming that all patients with HCC had medium-sized lesions 
instead of small lesions would have an effect on the results. Lastly, we analysed the impact of changing the 
costs and health loss from an incorrect diagnosis of HCC or metastasis.
Results
Cirrhosis surveillance model
Effectiveness of surveillance
In the base case we compared CEUS, CECT and Gd-CEMRI (Table 27). Based on the accuracy data, as found 
by Leoni et al.,42 we found that the proportion of patients dying from HCC was slightly higher for CEUS 
(17%) and CECT (17%) than for Gd-CEMRI (16%). This resulted in a slightly higher number of expected 
discounted life-years (13.76) and QALYs (10.18) gained by Gd-CEMRI than by CEUS and CECT (13.73 and 
10.15 respectively).
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Costs of surveillance
The total discounted costs were lowest for CEUS (£35,744), followed by CECT (£36,124) and Gd-CEMRI 
(£36,807) (Table 28). The main cost difference was in the imaging costs. Because Gd-CEMRI had a 
higher sensitivity than CEUS and CECT, HCC was identified at an earlier stage, improving the options for 
treatment. This also resulted in higher maintenance and treatment costs for CEMRI compared with CEUS 
and CECT.
Cost-effectiveness of surveillance
Contrast-enhanced ultrasound was found to have the lowest discounted lifetime cost per patient 
(£35,744), followed by CECT (£36,124) and Gd-CEMRI (£36,807) (Table 29). Compared with CEUS, CECT 
was as effective and more costly and was thus considered to be dominated by CEUS. Gd-CEMRI was 
£1063 (95% CI £449 to £1492) more expensive than CEUS per patient, but also yielded 0.022 (95% 
CI –0.002 to 0.050) more QALYs, resulting in an incremental cost-effectiveness ratio (ICER) of £48,454 
per QALY gained. As this is above the typical willingness-to-pay threshold of £30,000 per QALY gained, 
Gd-CEMRI was not deemed cost-effective compared with CEUS.
TABLE 27 Effectiveness of cirrhosis surveillance (discounted)
CEUS CECT Gd-CEMRI
Proportion dying from HCC (%) 17 17 16
Proportion dead by age 75 (%) 54 54 53
Number of total life-years 13.730 13.730 13.764
Number of total QALYs 10.153 10.153 10.175
TABLE 28 Breakdown of discounted costs of cirrhosis surveillance (£)
CEUS CECT Gd-CEMRI
Surveillance 1559 1939 2420
 Imaging 1436 1816 2359
 False-positive 123 123 61
Maintenance 23,631 23,631 23,687
 Symptomatic detection 12 12 11
 Compensated cirrhosis 13,043 13,043 13,014
 Decompensated cirrhosis 2119 2119 2092
 Known HCC 380 380 379
 Post transplant 7822 7822 7931
 Post resection 3 3 56
 Palliative 57 57 59
 Transplant waiting list 195 195 198
Treatment 10,554 10,554 10,700
 Transplantation 10,504 10,504 10,644
 Resection 50 50 56
Total 35,744 36,124 36,807
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Additional analyses for surveillance
Sensitivity analyses
First, we analysed the impact of using CEUS, CECT and CEMRI as confirmatory imaging for a proportion of 
patients equal to the proportion of patients with a positive unenhanced US scan (Table 30). In line with the 
base-case analysis, CEUS was as effective and less costly than CECT. Gd-CEMRI was also more costly (£321) 
and more effective (0.025 QALYs) than CEUS, resulting in an ICER of £12,806 per QALY gained. Based 
on a willingness-to-pay threshold of £20,000–30,000, this indicated that Gd-CEMRI was cost-effective 
compared with CEUS in this analysis.
Second, we changed the proportion of inconclusive US scans from 43% to 20% (Table 31), the age limit of 
surveillance to 90 years instead of 70 years (Table 32), the frequency of screening to every year instead of 
every 6 months (Table 33) and the accuracy data to use only those that applied to small tumours instead of 
small and medium-sized tumours (Table 34). Only when changing the proportion of inconclusive US scans 
was Gd-CEMRI cost-effective compared with CEUS, with an ICER of £16,121 per QALY gained. In all other 
sensitivity analyses CEUS dominated CECT and was cost-effective compared with Gd-CEMRI.
Scenario analyses
Scenario analyses were conducted using other sources for data on the accuracy of the tests. As alternative 
sources we first used the articles by Dai et al.43 and Quaia et al.46 These studies both compared CEUS and 
CECT. Dai et al. used a definition of a positive test for HCC which was comparable with that used in the 
EFSUMB guidelines,6 whereas Quaia et al. did not. Using data from either study, CEUS was found to be less 
costly and more effective than CECT (Tables 35 and 36).
Next, we used Blondin et al.48 and Giorgio et al.45 as sources for input for the accuracy of CEUS and 
Gd-CEMRI (Tables 37 and 38 respectively). Blondin et al. used a definition of a positive test for HCC which 
was comparable with that used in the EFSUMB guidelines,6 whereas Giorgio et al. did not. Based on 
Blondin et al., Gd-CEMRI was found to be more costly and less effective than CEUS. Based on Giorgio et al, 
using only data for lesions between 11 and 30 mm, Gd-CEMRI was found to be more costly, but also more 
effective than CEUS. However, the resulting ICER of £297,695 was very high.
Probabilistic sensitivity analysis
Over 5000 replications, CEUS has the highest probability of being cost-effective for thresholds < £55,000 
(Figure 13). Above this threshold, Gd-CEMRI has the highest probability of being cost-effective. At a 
threshold of £20,000–30,000, the probability that CEUS, CECT or Gd-CEMRI is cost-effective is 99%, 0% 
and 1% respectively.
Table 39 provides an overview of the results of all of the sensitivity and scenario analyses.
Liver metastases of colorectal cancer model
Effectiveness of diagnosing liver metastases
As indicated previously, Mainenti et al.49 found that the sensitivities of CEUS, CECT, Gd-CEMRI and SPIO-
CEMRI were equal. This resulted in an equal number of cases incorrectly diagnosed without metastases 
(false-negatives) in the base-case analysis. Because of a lower specificity, the number of cases incorrectly 
diagnosed with metastases (false-positives) was highest for CEUS, followed by CECT, SPIO-CEMRI and 
Gd-CEMRI. Because false-positive results were assumed to be detected with a biopsy before treatment, 
differences in specificity did not affect the expected life-years and QALYs (Table 40).
Costs of diagnosing liver metastases
An overview of the total discounted costs in the different cost categories per test strategy is given in 
Table 41. Although CEUS is less costly than CECT, the total diagnostic cost in the CEUS strategy is higher 
than that in the CECT strategy. This is because all patients with a positive test result receive a whole-body 
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TABLE 35 Results of scenario analysis for cirrhosis surveillance: Dai et al.43 used as source for accuracy data
Strategy Cost (£) QALYs
Compared with CEUS
Incremental cost (£) Incremental QALYs
Incremental cost 
per QALY (£)
CEUS 36,203 10.188
CECT 36,332 10.184 129 –0.004 Dominated
TABLE 36 Results of scenario analysis for cirrhosis surveillance: Quaia et al.46 used as source for accuracy data
Strategy Cost (£) QALYs
Compared with CEUS
Incremental cost (£) Incremental QALYs
Incremental cost 
per QALY (£)
CEUS 36,479 10.185
CECT 36,767 10.180 288 –0.005 Dominated
TABLE 37 Results of scenario analysis for cirrhosis surveillance: Blondin et al.48 used as source for accuracy data
Strategy Cost (£) QALYs
Compared with CEUS
Incremental cost (£) Incremental QALYs
Incremental cost 
per QALY (£)
CEUS 36,248 10.190
Gd-CEMRI 36,948 10.187 700 –0.003 Dominated
TABLE 38 Results of scenario analysis for cirrhosis surveillance: Giorgio et al.45 used as source for accuracy data
Strategy Cost (£) QALYs
Compared with CEUS
Incremental cost (£) Incremental QALYs
Incremental cost 
per QALY (£)
CEUS 36,034 10.189
Gd-CEMRI 37,078 10.192 1044 0.004 297,695
CT and biopsy, and in the CEUS strategy more patients have a positive test result. This implies that in the 
CEUS strategy, unnecessary additional diagnostic tests are performed. Because patients without metastases 
are not treated, and all metastases are eventually detected, costs of treatment are similar. Because of the 
higher total diagnostic cost, the average total discounted cost of CEUS (£7547) per patient is slightly 
higher than that for CECT (£7545). The average total discounted costs per patient for both Gd-CEMRI 
(£7724) and SPIO-CEMRI (£7758) are higher than those for CEUS and CECT, with SPIO-CEMRI having the 
highest cost because of unnecessary whole-body scans and biopsies.
Cost-effectiveness of diagnosing liver metastases
In the base-case analysis, the different imaging techniques to detect liver metastases from CRC resulted 
in equal expected lifetime QALYs (8.364). CECT was found to be the least costly test, with expected costs 
of £7510 per patient. The expected lifetime cost per patient of CEUS was only slightly more than that 
for CECT (£7511). Gd-CEMRI (£7688) and SPIO-CEMRI (£7722) were both more costly than, and thus 
dominated by, CECT and CEUS. Although technically speaking CECT dominates CEUS, their effectiveness is 
equal and their expected costs are extremely close (Table 42).
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TABLE 39 Overview of the sensitivity and scenario analyses for cirrhosis surveillance
Analysis Comparator
Compared with CEUS
Incremental 
cost (£)
Incremental 
QALYs
Incremental cost 
per QALY (£)
Base-case analysis
CECT 379 0.000 Dominated
Gd-CEMRI 1063 0.022 48,454
Sensitivity analyses
Imaging used as confirmatory after all positive 
non-enhanced US examinations
CECT 39 0.000 Dominated
Gd-CEMRI 321 0.025 12,806
Proportion of inconclusive US scans 20% 
instead of 43%
CECT 176 0.000 Dominated
Gd-CEMRI 624 0.024 16,121
Age limit for screening 90 years instead of 
70 years
CECT 430 0.000 Dominated
Gd-CEMRI 1204 0.023 51,619
Annual screening instead of every 6 months CECT 198 0.000 Dominated
Gd-CEMRI 594 0.016 37,619
Accuracy data for small tumours only instead of 
for small and medium-sized tumours
CECT 378 0.000 Dominated
Gd-CEMRI 913 0.004 244,840
Scenario analyses
Dai et al.43 used as source for accuracy data CECT 129 –0.004 Dominated
Quaia et al.46 used as source for accuracy data CECT 288 –0.005 Dominated
Blondin et al.48 used as source for accuracy data Gd-CEMRI 700 –0.003 Dominated
Giorgio et al.45 used as source for accuracy data Gd-CEMRI 1044 0.004 297,695
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FIGURE 13 Cost-effectiveness acceptability curves: cirrhosis surveillance (effects are QALYs; both costs and effects are 
discounted).
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Additional analyses for diagnosing liver metastases
Sensitivity analyses
When it is assumed that patients with a positive test do not undergo biopsy but are treated for their 
disease, implying that patients without metastases can receive unnecessary treatment, the lower specificity 
of CEUS leads to a loss in QALYs (Table 43). CEUS now yields the lowest number of QALYs (8.343) and is 
most expensive (£8335), while Gd-CEMRI, which is the most accurate, yields the highest number of QALYs 
(8.364) and is the least expensive (£7158). In this sensitivity analysis, Gd-CEMRI dominates the other tests 
because of its better accuracy.
If CEUS is combined with biopsy (see Table 42), and CECT, Gd-CEMRI and SPIO-CEMRI are not followed by 
biopsy (see Table 43), then CEUS and Gd-CEMRI are most effective, both yielding 8.364 QALYS. However, 
CEUS is more costly than, and is thus dominated by, Gd-CEMRI. CECT and SPIO-CEMRI are now dominated 
by Gd-CEMRI.
If it is assumed that, instead of 40%, 80% of the initial population has metastases, the expected number 
of QALYs is 4.078 for all tests (Table 44). CEUS is now the least costly strategy, being £71 less costly than 
CECT. Because there is no difference between the tests in QALYs, the least costly test, CEUS, dominates all 
other tests.
Scenario analyses
We examined the expected costs and effects using different sources for the accuracy of the tests. First, we 
incorporated the accuracy data of Jonas et al.50 (Table 45). This study compared CEUS, CECT and SPIO-
CEMRI and found perfect specificity for all tests, with sensitivities of 87%, 83% and 97% respectively. CECT 
was slightly more costly (£7) and slightly less effective (0.005 QALYs) than CEUS and thus was dominated 
by CEUS. SPIO-CEMRI was more costly and more effective than CEUS, resulting in an ICER of £43,318 per 
QALY gained.
The slightly lower sensitivity and specificity of CECT compared with CEUS found by Clevert et al.51 resulted 
in CEUS being £300 less costly and yielding 0.002 more QALYs than CECT (Table 46).
TABLE 40 Life-years and QALYs for metastases of CRC model
CEUS CECT Gd-CEMR SPIO-CEMRI
Number of discounted total life-years 10.40 10.40 10.40 10.40
Number of discounted total QALYs 8.36 8.36 8.36 8.36
TABLE 41 Breakdown of discounted costs (£): metastases of CRC model
CEUS CECT Gd-CEMRI SPIO-CEMRI
Diagnostics 795 793 971 1006
 Initial imaging 67 169 381 381
 Whole-body scan 75 64 61 64
 Biopsy 653 560 529 560
Treatment 6716 6716 6716 6716
 Surgery/chemotherapy 3583 3583 3583 3583
 Palliative care 2901 2901 2901 2901
 Watch and wait 232 232 232 232
Total 7511 7510 7688 7722
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Probabilistic sensitivity analyses
Based on the probabilistic sensitivity analysis with 5000 replications, we found that CEUS and CECT have 
a similar probability of being cost-effective across all willingness-to-pay thresholds (Figure 14). CEUS 
has a slightly higher probability of being cost-effective up to a threshold of £20,000, after which CECT 
has a somewhat higher probability of being cost-effective. At a threshold of £20,000 per QALY, CECT 
has the highest probability of being cost-effective (48%), followed by CEUS (47%), Gd-CEMRI (3%) and 
SPIO-CEMR (2%).
Incidentally detected focal liver lesion model
Effectiveness
Table 47 shows the effectiveness results from the base-case analysis. Two pairs of results are shown here: 
the first pair shows the results of CEUS compared with CECT, and the second pair shows the results of 
CEUS compared with CEMRI. The two sets are kept separate because four studies compared CEUS with 
CECT whereas one study compared CEUS with CEMRI. Very small differences in effectiveness (life-years 
and QALYs) were seen between CEUS and the two comparators. This was to be expected as the test 
performance results of the tests were not very different.
Costs
As with the effectiveness results, the small differences in test performance results resulted in small 
differences in overall costs (Table 48). The critical factor for any difference in costs is simply the cost of the 
initial test.
Cost-effectiveness
The following results were seen in the base-case analysis (Table 49). As expected, the lower costs of CEUS 
combined with the slightly better test performance meant that CEUS dominated both CECT and CEMRI. 
The main factor in these calculations was the cost of the tests.
Additional analyses
Additional analyses changed the absolute costs and effectiveness of the different strategies; however, this 
did not lead to any dramatic changes in the incremental costs and effectiveness of CEUS compared with 
CECT or CEMRI. The most critical factor in the analyses related to the costs of the tests. The impact of any 
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FIGURE 14 Cost-effectiveness acceptability curves: liver metastases from CRC (effects are QALYs; both costs and effects 
are discounted).
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other elements (e.g. prior probabilities of a particular diagnosis, costs of treatment) was minimal because 
the accuracies of the tests were so similar.
Sensitivity analyses
The first sensitivity analysis involved varying the prior probability of malignancy to a value much higher 
than that used in the base-case scenario. In this analysis, the prior probability was raised from the base-
case value of 2.89% to 94% [based on the highest percentages for HCC and metastasis reported in the 
individual studies (58% of patients with HCC52 and 36% of patients with metastases)].55 Although this 
exceptionally high probability of malignancy was not viewed as realistic in daily practice, it was seen as a 
way to explore the degree of robustness of the results. As expected, the higher probability of malignancy 
reduced the absolute number of QALYs and increased the costs (Table 50). However, it increased the 
incremental QALYs only slightly and had no effect on incremental costs and therefore essentially had no 
effect on the cost-effectiveness of CEUS compared with CECT or CEMRI.
When the data source for the performance of CEUS and CECT was switched from the meta-analysis to one 
of the four studies used in the meta-analysis, the cost-effectiveness results changed only slightly.
TABLE 47 Base-case effectiveness results (discounted) for characterisation of incidentally detected FLLs
Comparisons Life-years QALYs
CEUS (vs CECT) 17.205 13.330
CECT 17.205 13.330
CEUS (vs CEMRI) 17.204 13.329
CEMRI 17.201 13.327
TABLE 48 Base-case cost results (£) for the incidentally detected FLL model
 CEUS (vs CECT) CECT CEUS (vs CEMRI) CEMRI 
Initial assessment 73.5 125 112.6 242
 Initial imaging 64.7 116 64.7 189
 False-positive costs 8.9 9.9 47.9 53
Treatment 397 397 398 400
 Metastases 159 159 160 160
 HCC 9 9 9 9
 Other malignancies 183 183 183 184
 Adenoma 46 46 47 47
Total 471 522 511 642
TABLE 49 Base-case cost-effectiveness results for the incidentally detected FLL model
Comparison Incremental costs (£) Incremental QALYs
Incremental cost per 
QALY (£)
CEUS vs CECT –52 0.0002 Dominant 
CEUS vs CEMRI –131 0.0026 Dominant 
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We also examined the effect on the results of assuming that all patients with HCC had medium-sized 
lesions instead of small lesions. When we applied this in the model and also increased the risk of HCC to 
the highest value seen in the DTA studies (58% of patients with HCC52), there was no effect on the cost-
effectiveness of CEUS compared with CECT or CEMRI.
When the consequences of an incorrectly diagnosed malignant lesion were made more severe (i.e. by 
reducing QALYs or increasing costs), this improved the cost-effectiveness of CEUS compared with CECT 
or CEMRI. For example, if an incorrect diagnosis of HCC and metastases led to a doubling of the costs 
(compared with the costs following a correct diagnosis) and the QALYs were set to zero, CEUS remained 
the dominant strategy. Table 51 shows the results of this analysis.
As expected, when an incorrect diagnosis of HCC or metastases did not result in any health or economic 
consequences, there was no difference in effectiveness between CEUS, CECT and CEMRI. However, because 
a difference in costs was still observed, this could be viewed as a situation of extended dominance in both 
comparisons (Table 52).
Probabilistic sensitivity analyses
Probabilistic sensitivity analyses revealed that there was no uncertainty about the cost savings of CEUS 
compared with CECT (mean difference –£52, 95% CI –£81 to –£22) but some uncertainty about their 
differences in effectiveness (mean difference 0.00014, 95% CI –0.00100 to 0.00130). Note that these CIs 
were based on symmetrical beta PERT distributions for the cost parameters. When the original beta PERT 
distributions were used, a mean difference of –£46 (95% CI –£71 to –£21) was found.
Figure 15 shows the cost-effectiveness acceptability curve comparing CEUS with CECT. This curve shows 
that the probability of CEUS being cost-effective compared with CECT is > 95% at willingness-to-pay 
thresholds of up to £20,000.
When the differences in costs and effects between CEUS and CEMRI are visualised on the cost-effectiveness 
plane, it is clear that there is little doubt about the cost savings of CEUS compared with CEMRI, but some 
uncertainty about their differences in effectiveness.
The results of probabilistic sensitivity analyses comparing CEUS with CEMRI were similar to those shown 
above for CEUS compared with CECT. There was less certainty about the expected amount of cost savings 
of CEUS compared with CEMRI (mean difference –£131, 95% CI –£194 to –£69) and some uncertainty 
about their differences in effectiveness (mean difference 0.0039, 95% CI –0.0058 to 0.0135). Once again, 
these calculations were made using symmetrical beta PERT distributions for cost parameters to ensure 
that the point estimate for the cost difference would correspond with the point estimate based on the 
deterministic analysis. When the original beta PERT distributions were used, a mean difference of –£125 
(95% CI –£183 to –£67) was found.
TABLE 50 Results of sensitivity analysis for the incidentally detected FLL model: prior probability of malignancy 
increased to the maximum observed frequencies of HCC and metastasis (any type)
Comparison QALYs Cost (£)
Incremental 
QALYs
Incremental 
cost (£)
Incremental cost per 
QALY (£)
CEUS (vs CECT) 6.654 17,121 0.005 –56 Dominant 
CECT 6.649 17,177 
CEUS (vs CEMRI) 6.614 17,160 0.086 –202 Dominant 
CEMRI 6.529 17,362 
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TABLE 51 Results of sensitivity analysis for the incidentally detected FLL model: more severe consequences of an 
incorrect diagnosis of HCC and metastases
Comparison QALYs Cost (£)
Incremental 
QALYs
Incremental 
cost (£)
Incremental cost per 
QALY (£)
CEUS (vs CECT) 13.321 486 0.001 –54 Dominant 
CECT 13.320 540    
CEUS (vs CEMRI) 13.312 541 0.020 –162 Dominant 
CEMRI 13.293 702    
TABLE 52 Results of sensitivity analysis for the incidentally detected FLL model: less severe consequences of an 
incorrect diagnosis of HCC and metastases
Comparison QALYs Cost (£)
Incremental 
QALYs
Incremental 
cost (£)
Incremental cost per 
QALY (£)
CEUS (vs CECT) 13.332 469 0.000 –52 Extended dominance
CECT 13.332 521    
CEUS (vs CEMRI) 13.332 509 0.000 –130 Extended dominance
CEMRI 13.332 639    
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FIGURE 15 Cost-effectiveness acceptability curve comparing CEUS with CECT: incidentally detected FLL model (effects 
are QALYs; both costs and effects are discounted).
Figure 16 shows the cost-effectiveness acceptability curve comparing CEUS with CEMRI. Here we see 
that the probability of CEUS being cost-effective compared with CEMRI is > 95% at all willingness-to-pay 
thresholds between £0 and £20,000.
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FIGURE 16 Cost-effectiveness acceptability curve comparing CEUS with CEMRI: incidentally detected FLL model 
(effects are QALYs; both costs and effects are discounted).
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Chapter 5 Discussion
Statement of principal findings
Clinical effectiveness
Twenty of the 21 studies included in the systematic review were DTA studies: seven compared the 
performance of imaging modalities for the characterisation of FLLs detected on surveillance of cirrhosis 
patients using unenhanced US; four compared the performance of imaging modalities for the detection 
of liver metastases in patients with known primary cancers; six compared the performance of imaging 
modalities for the characterisation of incidentally detected FLLs identified by unenhanced US; and three 
compared the performance of imaging modalities for the determination of treatment response in patients 
with liver cancers.
The only controlled clinical trial identified indicated that the inclusion of CEUS in pretreatment imaging 
protocols for patients undergoing RFA for HCC may result in a reduced incidence of disease progression, 
new HCC and repeat RFA, and increased local progression-free and new tumour-free survival, compared 
with unenhanced US. However, this was a small non-randomised study that had a number of 
methodological weaknesses and no difference was found in the primary outcome of successful ablation. 
High-quality RCTs are needed to determine the relative effectiveness of different imaging strategies for 
treatment planning.
Test accuracy studies varied in terms of target condition (HCC, liver metastases or ‘any malignancy’), 
definitions of a positive imaging test used by studies of the same target condition, and lesion size assessed. 
Overall, there was no clear indication that any of the imaging modalities considered (CEUS, CECT or 
CEMRI) offered superior performance for any of the clinical indications assessed. This is consistent with two 
other recently published systematic reviews, which found no significant difference in the performance of 
CEUS, CECT and CEMRI for the characterisation of FLLs.11,104 Neither of these two reviews reported details 
of the clinical application of imaging in the included studies (i.e. were FLLs incidentally detected, detected 
on surveillance or detected during the assessment for liver metastases in patients with known primary 
cancers) or of the target conditions (e.g. HCC, liver metastases or ‘any liver malignancy’), and one review104 
did not specify the use of SonoVue as the contrast agent for CEUS.
The majority of included test accuracy studies were judged to be at ‘low’ or ‘unclear’ risk of bias with 
respect to the ‘index test’, ‘comparator test’ and ‘reference standard’ domains. ‘Unclear’ ratings for these 
domains most frequently arose from insufficient detail in the reporting of how tests were interpreted, 
particularly blinding of interpreters to other test results. Reporting quality was generally poor and a 
number of studies were reported only as conference abstracts, resulting in a high proportion of ‘unclear’ 
risk of bias ratings across QUADAS-2 domains (see Figure 7). ‘High’ risk of bias ratings for the ‘patient 
selection’ domain arose from the use of a retrospective study design or from inappropriate exclusions of 
particular patient groups (e.g. exclusion of patients with a low probability of malignancy); exclusion of 
patients with a low probability of disease might result in underestimations of test accuracy, although this 
was not apparent from the results observed. ‘High’ risk of bias ratings for the ‘flow and timing’ domain 
arose from exclusion of > 10% of patients from analyses or, in two cases, from incorporation of index 
test results in the reference standard. The last two studies were also rated as ‘high’ risk of bias for the 
‘reference standard’ domain.
Test accuracy studies included in this review were grouped by clinical application: characterisation of 
FLLs detected on routine unenhanced US surveillance of patients with known cirrhosis, detection of 
liver metastases in patients with known primary tumours (CRC), characterisation of FLLs in patients with 
incidentally detected lesions and assessment of response in patients treated for liver malignancy.
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Studies conducted in cirrhosis patients undergoing routine surveillance all concerned the differentiation 
of HCC from other lesion types in small to medium-sized (< 30 mm) FLLs. The definition of a positive 
test for HCC varied across studies. Studies assessing CEMRI used three contrast agents: gadolinium, a 
vascular contrast agent; SPIO, a hepatocyte-specific contrast agent which is taken up by Kupffer cells 
in the normal liver and benign lesions and may therefore aid identification of HCC, which are generally 
deficient in Kupffer cells, particularly when such lesions are hypervascular;8,9 and Gd-EOB-DTPA-CEMRI, a 
‘combined’ vascular and hepatocyte-specific contrast agent.10 There was no consistent evidence for any 
significant difference in test performance between the three imaging modalities and three MRI contrast 
media assessed. When a definition of HCC consistent with that given in the EFSUMB guidelines6 (arterial 
phase enhancement followed by portal venous/late phase washout) was used, estimates of the sensitivity 
and specificity of each of the imaging modalities assessed varied across studies. There was some evidence 
from one study that compared CEUS and Gd-CEMRI that these imaging techniques may be better at ruling 
out HCC in FLLs of between 11 and 30 mm (sensitivities for CEUS and Gd-CEMRI were 92% and 95% 
respectively) than in small FLLs of ≤ 10 mm (sensitivities of 27% and 73% respectively), although this study 
did not use an EFSUMB-consistent definition of HCC. It is therefore possible that some of the variation 
in sensitivity estimates seen across studies of FLLs of < 30 mm may be due to differences in the size 
distribution of FLLs included. There was also some evidence from two studies that combined imaging using 
CEUS and CECT or all three imaging modalities, in which any positive imaging result was treated as ‘test 
positive’, that combined imaging may increase sensitivity. Inconsistent estimates of sensitivity mean that it 
is unclear whether or not CEUS alone is adequate to rule out HCC for FLLs of < 30 mm in this population; 
CEUS alone may be adequate to rule out HCC for FLLs of 11–30 mm, with very small FLLs (< 10 mm) 
not considered.
Studies of the diagnosis of liver metastases using imaging with vascular contrast media (CEUS, CECT 
and Gd-CEMRI) in which definitions of a positive imaging test were reported gave various descriptions 
of peripheral rim enhancement as the criteria for liver metastases. Two studies also reported data for 
SPIO-CEMRI. There was no consistent evidence for any difference in test performance between the three 
imaging modalities and the different contrast media assessed. Per-patient sensitivity estimates from two 
studies were generally high [83% for all imaging modalities and both MRI contrast agents in one study of 
patients with CRC and > 95% for both CEUS and CECT in a second study of patients with various primary 
cancers (majority CRC)]. The only previous systematic review identified, which assessed SonoVue CEUS for 
the diagnosis of liver metastases, did not include any comparator tests and reported sensitivities for CEUS 
ranging from 79% to 100%. The limited data available indicate that CEUS alone may be adequate to rule 
out liver metastases in patients with known primary malignancies.
The primary outcome measure reported by studies conducted in patients with incidentally detected FLLs 
was test accuracy for the differentiation of malignant from benign liver lesions. Studies consistently used 
definitions of the imaging criteria for HCC and liver metastases that were similar to those reported in the 
EFSUMB guidelines on the use of CEUS.6 All studies reported no significant difference in the accuracy of 
CEUS and CECT or CEMRI for the characterisation of FLLs. All but one study reported data for one lesion 
per patient and the remaining study reported data for 694 lesions in 686 patients; data were therefore 
treated as per patient. The pooled estimates of sensitivity for the identification of ‘any liver malignancy’ 
were approximately 95% for both CEUS and CECT and the pooled estimates of specificity were 94% 
and 93%, respectively, based on data from four studies. The single study comparing CEUS with CEMRI 
used Gd-CEMRI in all patients, with the addition of SPIO-CEMRI in an unspecified number of cases, and 
reported sensitivity estimates of 91% and 82%, respectively, and corresponding specificity estimates of 
67% and 63%. Data from one study indicated that combined imaging using both CEUS and CECT, in 
which a positive result on either modality was treated as ‘test positive’, did not increase sensitivity. This, 
combined with the high estimates of sensitivity, indicates that CEUS alone may be adequate to rule out 
liver malignancy in this population.
Two Chinese-language studies comparing imaging modalities for the assessment of response to treatment 
(cryosurgery and non-surgical treatment) in patients with HCC reported per-lesion sensitivity estimates of 
> 95% and specificity estimates of > 80% for complete response, using CEUS, CECT and CECT or Gd-CEMRI. 
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These data indicate that CEUS may provide information on response in patients treated for HCC. However, 
these data are very limited and may not be directly applicable to UK clinical practice; further studies, 
ideally conducted in a UK setting, are required to confirm findings. The possibility of the rapid detection 
of residual tumour tissue using CEUS has the potential to allow the immediate extension of interstitial 
therapy; however, no data were identified on any therapeutic consequences of using CEUS to assess 
response to initial treatment.
Cost-effectiveness
The cost-effectiveness analysis of the use of CEUS in patients with an inconclusive unenhanced US test 
indicated that the use of CEUS instead of CEMRI was considered cost-effective. The use of CEUS instead of 
CECT was considered cost-effective in the surveillance of cirrhosis and the characterisation of incidentally 
detected FLLs, whereas the two techniques were similar in terms of costs and effects in the detection of 
liver metastases from CRC.
In the surveillance of cirrhosis, CEUS was found to be as effective as but £379 less costly than CECT. This 
indicates that CEUS dominates CECT. Gd-CEMRI was found to be £1063 more costly than CEUS and 
gained 0.022 more QALYs. This resulted in an ICER of £48,545 per QALY gained. This ICER is deemed 
unacceptable given the currently used willingness-to-pay thresholds of £20,000 and £30,000 per 
additional QALY. CEUS can therefore be considered the most cost-effective option after inconclusive 
unenhanced US. These base-case results were based on one source for accuracy, the study by Leoni et 
al.42 Using the two other studies that compared CEUS and CECT corroborated the dominance of CEUS 
over CECT, showing even lower effectiveness for CECT. Compared with Gd-CEMRI, CEUS was cost-effective 
in most sensitivity analyses, except when all positive unenhanced US examinations were subject to 
confirmatory testing instead of the inconclusive US examinations, and when the proportion of patients 
having an inconclusive US scan was considerably lower (20% instead of 43%). These two analyses resulted 
in acceptable ICERs for Gd-CEMRI compared with CEUS of £12,806 and £16,121 respectively.
In the diagnosis of liver metastases from CRC, CEUS was found to have similar costs and effects to those 
of CECT. Using a lifetime time horizon the two techniques yielded equal QALYs per patient, with CEUS 
costing £1 more than CECT. Both Gd-CEMRI and SPIO-CEMRI were dominated by CECT in this population 
because they were more costly and equally as effective. However, in the base-case analysis it was assumed 
that patients who were incorrectly diagnosed with liver metastases would receive a biopsy before they 
were treated and that this mistake would be discovered. If this is not assumed and patients could receive 
unnecessary treatment, the lower specificity of CEUS had larger consequences. Under this assumption, 
CEUS is both the most costly and the least effective option, and Gd-CEMRI dominates all other tests. 
However, it is questionable whether or not this would occur in practice. If the proportion of patients 
having metastases were higher, CEUS would dominate the other tests. Based on the two other studies 
that reported accuracy data in this population,50,51 CEUS was found to dominate CECT. Gd-CEMRI yielded 
0.014 more QALYs but was also £587 more costly than CEUS, resulting in an ICER of £43,318 per QALY 
gained. As this is above the willingness-to-pay threshold of £30,000 per QALY, Gd-CEMRI is deemed not 
cost-effective compared with CEUS.
The final evaluation involved the comparison of CEUS with CECT and CEMRI in the characterisation of 
incidentally detected FLLs. In the base-case analysis, no large differences in effectiveness were found 
between the three imaging strategies (incremental QALYs: CEUS vs CECT: 0.00016; CEUS vs CEMRI: 
0.0026). However, a difference in costs was found (CEUS vs CECT: –£52; CEUS vs CEMRI: –£131) and 
this resulted in a situation of dominance. Probabilistic sensitivity analysis revealed that there was little 
uncertainty about the cost-effectiveness of CEUS compared with the other two tests. Additional analyses 
changed the absolute costs and effectiveness of the different strategies but did not lead to dramatic 
changes in the incremental costs and effectiveness of CEUS compared with CECT or CEMRI. One critical 
factor in the analyses related to the costs of the tests. This could mean that local conditions may play 
a role in deciding which test is preferable, assuming that the costs of these tests can be influenced by 
local conditions.
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Strengths and limitations of the assessment
Clinical effectiveness
Extensive literature searches were conducted in an attempt to maximise retrieval of relevant studies. 
These included electronic searches of a variety of bibliographic databases, as well as screening of clinical 
trials registers and conference abstracts to identify unpublished studies. Because of the known difficulties 
in identifying test accuracy studies using study design-related search terms,20 search strategies were 
developed to maximise sensitivity at the expense of reduced specificity. Thus, large numbers of citations 
were identified and screened, many of which did not meet the inclusion criteria of the review.
The possibility of publication bias remains a potential problem for all systematic reviews. Considerations 
may differ for systematic reviews of test accuracy studies. It is relatively simple to define a positive result 
for studies of treatment, for example a significant difference between the treatment and control groups 
that favours treatment. This is not the case for test accuracy studies, which measure agreement between 
index test and reference standard. It would seem likely that studies finding greater agreement (high 
estimates of sensitivity and specificity) will be published more often. In addition, test accuracy data are 
often collected as part of routine clinical practice, or by retrospective review of records; test accuracy 
studies are not subject to the formal registration procedures applied to RCTs and are therefore more easily 
discarded when results appear unfavourable. The extent to which publication bias occurs in studies of test 
accuracy remains unclear; however, simulation studies have indicated that the effect of publication bias on 
meta-analytic estimates of test accuracy is minimal.105 Formal assessment of publication bias in systematic 
reviews of test accuracy studies remains problematic and reliability is limited.105 We did not undertake a 
statistical assessment of publication bias in this review; however, our search strategy included a variety of 
routes to identify unpublished studies and resulted in the inclusion of a number of conference abstracts.
Clear inclusion criteria were specified in the protocol for this review and the one protocol modification 
that occurred during the assessment has been documented in Chapter 3 of this report (see Inclusion and 
exclusion criteria). The eligibility of studies for inclusion is therefore transparent. In addition, we have 
provided specific reasons for excluding all of the studies considered potentially relevant at initial citation 
screening (see Appendix 5). The review process followed recommended methods to minimise the potential 
for error and/or bias.16 Studies were independently screened for inclusion by two reviewers and data 
extraction and quality assessment were carried out by one reviewer and checked by a second (MW and 
VG). Any disagreements were resolved by consensus. Chinese-language studies were extracted by one 
reviewer (MW) working with a native speaker (KL) and the only German-language study was extracted by 
one reviewer (VG).
With one exception, all studies included in the review were test accuracy studies. The methodological 
quality of these studies was assessed using a modification of the QUADAS-2 tool.25 The QUADAS tool 
has been recommended for assessing the methodological quality of test accuracy studies16,18 and has 
been widely adopted by researchers and key organisations such as The Cochrane Collaboration, NICE and 
the Institut für Qualität and Wirtschaftlichkeit im Gesundheitswesen (IQWiG) in Germany. It has been 
mentioned in more than 200 abstracts in the DARE database and has been cited more than 500 times. The 
revised version of QUADAS (QUADAS-2) has recently been published.25 QUADAS-2 more closely resembles 
the approach and structure of the Cochrane risk of bias tool. It is structured into four key domains 
covering participant selection, index test, reference standard and the flow of patients through the study 
(including the timing of tests). Each domain is rated for risk of bias (low, high or unclear) and the tool 
provides signalling questions in each domain to help reviewers in reaching a judgement. The participant 
selection, index test and reference standard domains are also separately rated for concerns regarding 
the applicability of the study to the review question (low, high or unclear). However, the QUADAS-2 tool 
does not currently include domains specific to the assessment of studies comparing multiple index tests; 
further development of QUADAS-2 in this area is planned. This assessment used a modified version of 
the QUADAS-2 tool that includes an additional domain for the comparator test and additional signalling 
questions in the flow and timing domain. It should be noted, however, that these components of the tool 
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were not developed using the same rigorous evidence-based approach as for the core QUADAS-2 tool. 
The inclusion criteria for this review were considered to largely match the review question and questions 
of applicability were therefore relevant only to the patient selection domain. The review-specific guidance 
used in our QUADAS-2 assessment is reported in Appendix 2. The results of the risk of bias assessment 
are reported in full for all included studies in Appendix 3 and in summary in Chapter 3 (see Results of 
the assessment of clinical effectiveness). However, the usefulness of this assessment was limited by poor 
reporting of primary study methods, particularly with respect to how the index and comparator tests and 
the reference standard were applied. This issue was exacerbated because four of the 20 test accuracy 
studies (20%) were reported only as conference abstracts.
The systematic review conducted for this assessment represents an improvement on previously published 
systematic reviews11,104,106 in that it focuses on studies that directly compared the performance of SonoVue 
CEUS with at least one other imaging modality, as well as clearly distinguishing between both the clinical 
application and the target condition of imaging.
Hierarchical or bivariate models are considered the optimal methods for estimating SROC curves and 
pooled estimates of sensitivity and specificity.16,27 The bivariate model analyses sensitivity and specificity 
jointly, retaining the paired nature of the original data, and has been shown to produce equivalent results 
to the hierarchical SROC model in the absence of other study-level covariates.28 However, the fitting of this 
model requires a minimum of four data sets. There was only one group of four studies in this assessment 
for which meta-analytic pooling was considered potentially appropriate (similar clinical application, 
target condition and comparator test). One of these studies used a suboptimal reference standard and 
a sensitivity analysis was used to investigate the influence of this study upon the overall estimate of test 
performance, reducing the data set to three studies; for this reason, a random-effects model was used to 
generate pooled estimates of sensitivity and specificity, with 95% CIs.
In addition to the limited potential for meta-analysis and the general methodological quality issues 
outlined above, there were a number of reporting/methodological problems specific to this review. Of 
particular concern for this assessment was the way in which data were reported in terms of the unit of 
analysis. The main reason for undertaking liver imaging in the populations considered is likely to be to 
rule out primary liver cancer or liver metastases. Therefore, patient-level analyses of test performance are 
of particular interest. Some of the studies included in this review reported per-patient analyses; however, 
no study clearly stated how per-patient test results were defined (e.g. was the presence of any positive 
lesion regarded as a positive test for the whole patient). Some of the included studies reported per-lesion 
data (multiple lesions per patient). These type of within-patient ‘clustered’ data are a common feature of 
test accuracy studies and are likely to result in a correlation between results within each patient, which 
should be accounted for in any statistical analysis.107 Uncorrected estimates of sensitivity and specificity 
derived from such data are likely to be accurate, but imprecision will be underestimated.107 Of greater 
concern are those studies that reported data for one lesion per patient (treated as per-patient data in this 
assessment) but in which multiple lesions per patient were present, as was the case for the majority of 
studies evaluating SonoVue CEUS for the characterisation of incidentally detected FLLs.52,54–56 These studies 
generally selected the largest lesion or the lesion ‘most suspicious for malignancy’ for inclusion in analyses, 
with the result that estimates of test performance may have been exaggerated. It might be argued that, 
when considering the ability of a test to rule out malignancy, performance for the characterisation of 
smaller ambiguous lesions is an important consideration.
All assessments of diagnostic accuracy are underpinned by the assumption that the reference standard, 
against which the index and comparator tests are evaluated, is 100% sensitive and 100% specific. The 
inclusion criteria specified by the protocol for this assessment allowed the use of different reference 
standards for test-positive and test-negative patients (histology and clinical follow-up respectively). This 
approach was used because it may be considered unethical to perform biopsy of test-negative patients 
or lesions. However, delayed verification, as represented by clinical follow-up, is inherently flawed in that 
follow-up must be of sufficient duration for any false-positive or false-negative test results to become 
NIHR Journals Library
DISCuSSION
106
apparent, but prolonged follow-up may also result in changes in disease state and hence misclassification 
of test results. In addition, a protocol modification allowed the inclusion of studies on the characterisation 
of FLLs (suspected HCC) that used EASL/AASLD non-invasive diagnostic criteria (two concordant imaging 
test results) as the reference standard. Two additional studies were included in the review as a result 
of this protocol modification.42,41 Studies using this type of reference standard may be subject to 
incorporation bias. However, the implications of this are unclear; the review of sources of variation and 
bias in test accuracy studies, conducted as part of the development of QUADAS, found no evidence on 
the effects of incorporation bias,23 and the update of this review, conducted during the development of 
QUADAS-2, found two contradictory studies, one reporting no effect of incorporation bias on accuracy 
and one reporting increased sensitivity and reduced specificity in the presence of incorporation bias 
(unpublished data).
The clinical applicability of accuracy data included in this review may have some limitations. The inclusion 
criteria for this assessment specified that SonoVue CEUS should be used for the characterisation of 
FLLs when unenhanced US examination was considered inconclusive. Although all study participants 
had imaging-detected FLLs before undergoing SonoVue CEUS, only one study43 explicitly stated that 
unenhanced US was inconclusive. Perhaps more importantly, the prevalence of malignancy appeared 
high in studies assessing the accuracy of CEUS and other imaging modalities for the characterisation of 
incidentally detected FLLs; these study populations may not be representative of the population with 
incidental FLLs seen in clinical practice. When any information on the interpretation of CEUS was reported 
(see Appendix 4), the majority of DTA studies included in this review reported consensus interpretation by 
multiple experienced operators (experience ranging from > 2 years to 20 years). It should be noted that 
operator training and experience may have important effects on the diagnostic performance of CEUS, but 
insufficient data are currently available to explore these potential effects.
The majority of included studies reported no information on funding; two studies reported funding from 
the manufacturer of SonoVue.55,56
Cost-effectiveness
In this study we built three separate models for the three different potential uses of CEUS: surveillance of 
cirrhosis, detection of liver metastases from CRC and characterisation of incidentally detected FLLs. All three 
models were based on existing models that had previously informed NICE guidance.70,71 When necessary 
we updated and improved these models. The model for incidentally detected FLLs was a combination of 
the two updated and improved models.
In each of the three analyses we used evidence to inform parameters that was relevant for the UK and as 
up-to-date and of as high a quality as possible. When evidence was not available from published studies or 
databases, we used the most likely and plausible ranges based on expert opinion.
As expected, the main driver of the models was the accuracy of the different tests. There was only one 
group of four studies in this assessment for which meta-analytic pooling was considered potentially 
appropriate (similar clinical application, target condition and comparator test): the use of CEUS to 
characterise incidentally detected FLLs. As a consequence, the estimated cost-effectiveness of CEUS for 
the surveillance of cirrhosis and the diagnosis of liver metastases from CRC had to be based on single 
studies. Scenario analyses were performed using other available studies and these analyses showed that 
in general the source for accuracy influences the costs and effects of the different tests. However, the use 
of different sources resulted in similar conclusions. CEUS was found to be the most cost-effective test 
for the surveillance of cirrhosis, and the two alternative sources for the liver metastases model produced 
favourable results for CEUS.
In general, the studies used to estimate test accuracy appeared to involve different types of patient 
populations. The studies used for the incidentally detected FLL model, for example, defined incidentally 
detected FLLs in different ways. Interestingly, regardless of the variation in composition of the patient 
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populations, there was never an instance when the test accuracy results of CEUS and CECT were very 
different. All studies concluded that the two tests were comparable in performance.
Another main driver was the clinical pathway of incorrectly diagnosed patients. Although the pathway may 
be straightforward for false-negative patients, as their disease may be correctly diagnosed at a later stage 
of the initial workup, it is not as clear for false-positive patients. In the liver metastases from CRC model we 
assumed that patients who are inaccurately diagnosed as having metastases would receive biopsy before 
treatment. This implies that patients were not unnecessarily treated. However, it is unclear what happens 
to these patients in practice. Therefore, we performed a sensitivity analysis in which patients without 
metastases were treated if they were incorrectly diagnosed. In this sensitivity analysis CEUS was found to 
be the least effective and most costly option. Although we do not expect it to be realistic that patients 
without metastases will actually receive treatment, it is important to note this factor.
Besides being less costly, CEUS has the advantage compared with CECT and especially CEMRI that it is 
highly accessible. All patients already receive an unenhanced US examination and can be immediately 
diagnosed using CEUS as part of the same examination. A potential benefit of CEUS is therefore the 
reduction in anxiety in patients because a malignant lesion is ruled out sooner as a result of not having 
to wait too long for another test. This benefit was not taken into account in the analysis as little evidence 
is available on the effect of anxiety on quality of life. It might be expected that the effects of using CEUS 
are therefore underestimated. Although the length of wait associated with other imaging modalities is 
uncertain, the consideration of this anxiety factor would only further support the use of CEUS over CECT 
or CEMRI.
Uncertainties
Clinical effectiveness
None of the clinical applications of liver imaging considered in this review was evaluated by a large 
number of studies; the maximum was seven studies on the performance of imaging modalities for the 
characterisation of FLLs detected on surveillance of cirrhosis patients using unenhanced US. Although 
this review benefits from focusing on studies that directly compared the performance of SonoVue CEUS 
with that of other imaging modalities, as noted above in the strengths and limitations section, only two 
studies on the characterisation of FLLs detected on surveillance of cirrhosis patients42,47 and two studies 
on the detection of liver metastases in patients with known primary cancers49,50 compared all three 
imaging modalities under assessment (CEUS, CECT and CEMRI). Most studies that assessed CEMRI used 
gadolinium-based vascular contrast agent, which has a comparable mode of operation with that of CEUS 
and CECT. However, CEMRI of the liver can also be conducted using hepatocyte-specific contrast agents 
such as SPIO or ‘combined’ vascular and hepatocyte-specific agents such as Gd-EOB-DTPA; only four 
of the studies included in our systematic review reported data for these types of contrast agent.42,49,48,50 
Studies were generally small (15 of the 20 DTA studies included fewer than 100 participants) and, within 
clinical applications, studies varied in terms of target condition (HCC, liver metastases or ‘any malignancy’), 
definitions of a positive imaging test used by studies of the same target condition, comparator imaging 
technologies and lesion size assessed. In addition, four of the 20 test accuracy studies were reported 
only as conference abstracts,39–41,50 which further limited the available data. These factors meant that, 
as detailed above in the statement of principal findings for the clinical effectiveness assessment, only 
one meta-analysis was undertaken (studies comparing CEUS with CECT for the characterisation of 
incidentally detected FLLs). Based on the available data, SonoVue CEUS appeared to offer similar diagnostic 
performance to that of other imaging modalities (CECT and CEMRI) for all clinical applications considered, 
but data were generally insufficient to support firm conclusions.
SonoVue CEUS is generally used for the characterisation or detection of liver lesions in patients for 
whom unenhanced US examination has proved inconclusive. In addition to test accuracy, it is therefore 
particularly important to assess the proportion of patients in whom US examination remains inconclusive 
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even after contrast-enhancement compared with the proportion in whom comparator imaging 
technologies are inconclusive. Four of the 20 DTA studies included in this review explicitly reported the 
numbers of participants in whom imaging was inconclusive; three studies indicated that SonoVue CEUS 
was inconclusive in slightly fewer patients than CECT (0%,51 3%46 and 3%54 for SonoVue CEUS compared 
with 14%,51 8%46 and 6%54 for CECT). One study reported 11% inconclusive imaging results for both 
SonoVue CEUS and CEMRI.56 Although not explicitly stated, all other included studies appeared to report 
complete data sets and hence may be inferred to have had no inconclusive imaging examinations.
When diagnostic accuracy is comparable across imaging modalities, comparison of adverse event rates 
associated with the different imaging options, as well as consideration of patients’ preferences, are also 
of particular importance. Only one of the DTA studies included in this review reported any information 
on adverse events related to testing; the authors of this study stated that there were no adverse events 
associated with SonoVue CEUS but did not report any information about the comparator technology 
Gd-CEMRI.45 A large, retrospective safety study of SonoVue CEUS in abdominal applications, which did not 
meet the inclusion criteria for this review, reported data from 23,188 investigations in 29 centres in Italy.7 
This study found 29 cases of adverse events, of which two were graded as serious, one as severe, three as 
moderate and 23 as mild. There were no fatal adverse events. One of the serious adverse events occurred 
in a patient with prostate cancer who was being investigated to characterise a liver lesion suspected of 
metastases; this patient complained of dyspnoea with signs of bronchoplasm, slight hypotension and 
bradycardia within 1 minute after injection of SonoVue. The majority of non-serious adverse events 
resolved without intervention and included itching, mild dizziness, moderate hypotension, headache, 
sensation of warmth and nausea and vomiting. None of the studies identified reported any information on 
patient preferences.
Acceptability to patients and the potential for reduced anxiety provided by the ability to conduct CEUS at 
the same appointment as the initial US examination are also likely to be important factors in the choice of 
imaging modality; however, no studies were identified that reported these outcome measures.
It should be further noted that, although this review provides some evidence on the accuracy of SonoVue 
CEUS for the characterisation of FLLs and the detection of liver metastases and response to treatment of 
liver cancers, only one study59 was identified that reported the effects of imaging with SonoVue on patient 
outcomes; the ultimate aim of any research on clinical tests should be to determine impact on patient 
management and clinical outcomes. As described earlier in the statement of principal findings for the 
clinical effectiveness assessment, this study indicated that the inclusion of CEUS in pretreatment imaging 
protocols for patients undergoing RFA for HCC may result in some improved outcomes compared with 
unenhanced US. Overall, the effects, if any, of imaging with SonoVue CEUS on management and outcome 
of patients with FLLs remain uncertain.
Cost-effectiveness
Many studies emphasised that the participating clinicians had years of experience in the use of CEUS. It 
is possible that the diagnostic accuracy of CEUS may be poorer if the user has little experience. However, 
widespread implementation of CEUS might also improve the experience with CEUS and ultimately 
improve accuracy.
The main uncertainty surrounding the cost-effectiveness of CEUS is how patients who are incorrectly 
diagnosed are managed. Arguably, this is very different across locations. In the cirrhosis surveillance 
model, patients are screened twice a year and it is expected that a lesion, although it may have grown 
and therefore be potentially less treatable, will be detected eventually. In the liver metastases from CRC 
model, patients with metastases will have associated symptoms and it is therefore justifiable to assume 
that metastases will be detected within a year. Patients with incidentally detected lesions also often have 
associated risk factors or evidence of liver disease, which may have been the indication for initial testing 
with unenhanced US or which may have been identified at this examination; hence, it is expected that 
their complaints will worsen and that their lesions will be detected within several months. How patients 
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with a false-positive test result are managed might be more complex. We assumed that, in all models, 
these patients would receive additional costs of unnecessary additional diagnostic tests but would not 
undergo inappropriate treatment as the correct diagnosis would be determined after additional diagnostic 
workup. In the liver metastases of CRC model we examined the extreme situation in which all patients who 
were incorrectly diagnosed with metastases would receive treatment for these metastases. As this involves 
the costs of the treatment as well as reduced quality of life, this has a considerable impact on the results.
In the cirrhosis surveillance model, the actual use of CEUS impacted the results. If CEUS were used after all 
positive instead of after all inconclusive unenhanced US examinations, or if the proportion of inconclusive 
unenhanced US tests were lower, Gd-CEMRI would be cost-effective compared with CEUS.
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Chapter 6 Conclusions
Implications for service provision
The results of our systematic review suggest that SonoVue CEUS could provide similar diagnostic 
performance to other imaging modalities (CECT and CEMRI) for the three main clinical applications 
considered: characterisation of FLLs detected on surveillance of cirrhosis patients using unenhanced 
US, detection of liver metastases in patients with known primary cancers (CRC) and characterisation 
of incidentally detected FLLs identified by unenhanced US. However, some caution is required in the 
interpretation of these findings as studies were generally small and heterogeneous with respect to the 
target condition (HCC, liver metastases or ‘any malignancy’), definitions of a positive imaging test used by 
studies of the same target condition, comparator imaging technologies and lesion size assessed. Available 
data were insufficient to draw firm conclusions of the effectiveness of CEUS in treatment planning and the 
determination of treatment response.
The cost-effectiveness analysis of the use of CEUS in patients with an inconclusive unenhanced US test 
indicated that the use of CEUS instead of CEMRI was considered cost-effective. The use of CEUS instead of 
CECT was considered cost-effective in the surveillance of cirrhosis and the characterisation of incidentally 
detected FLLs, whereas the two techniques were similar in terms of costs and effects in the detection of 
liver metastases from CRC. Although these conclusions can be very dependent on the actual management 
of incorrectly diagnosed lesions, it is expected that the use of CEUS can reduce costs without reducing 
quality of life and survival. It should be noted that experience with using CEUS can have an important 
impact on diagnostic accuracy.
If the main use of liver imaging in these populations is considered to be the rapid rule-out of malignancy, 
equivalent diagnostic performance may be sufficient for SonoVue CEUS to be preferred over other 
imaging modalities when unenhanced US is inconclusive. A potential advantage of using SonoVue 
CEUS would be the option of completing the assessment at the same time as the initial unenhanced US 
examination. Although this would be unlikely to reduce waiting times (compared with other imaging 
modalities) sufficiently to change clinical outcome, the potential to provide more rapid diagnosis without 
repeat hospital visits is likely to be preferred by patients and may also reduce costs (e.g. by avoiding the 
administration costs of scheduling new appointments).
Suggested research priorities
All but one of the studies included in our systematic review were DTA studies of liver imaging for the 
clinical applications specified in our protocol: characterisation of FLLs detected on surveillance of cirrhosis 
patients using unenhanced US, detection of liver metastases in patients with known primary cancers (CRC), 
characterisation of incidentally detected FLLs identified by unenhanced US and determination of treatment 
response in patients with liver cancers. The test accuracy study design compares the results of a new test 
(index test) with those of the reference standard (which are assumed always to be correct); it is therefore 
inherently not capable of comparing tests in terms of their ultimate impact on patient outcome. The only 
study included in this review that reported data on patient outcomes considered the impact on clinical 
outcomes following treatment of using SonoVue CEUS for pretreatment assessment. This study had a 
number of methodological limitations and found significant effects of SonoVue CEUS only on secondary 
outcomes. The ideal study to address questions of clinical effectiveness would be a large multicentre 
RCT in which patients are randomised to receive further testing/monitoring, therapeutic planning and/
or treatment based on different imaging strategies (SonoVue CEUS, CECT, CEMRI); evaluation in more 
than one centre is preferred to minimise performance bias. Long-term observational studies assessing the 
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clinical consequences of incorrect initial diagnoses may also provide an important source of information for 
future cost-effectiveness analyses. Other potentially important factors that may affect decision-making in 
the NHS and for which information is currently lacking include patient preferences and the acceptability of 
different imaging modalities, the potential effects of reduced anxiety arising from a more rapid diagnosis 
and the potential effects of operator experience on the diagnostic performance of CEUS.
Test accuracy data identified in this assessment were relatively sparse and studies were heterogeneous 
with respect to the target condition (HCC, liver metastases or ‘any malignancy’), definitions of a positive 
imaging test used by studies of the same target condition, comparator imaging technologies and lesion 
size assessed. Standardisation of the definition of a positive imaging test for each target condition 
followed by further high-quality DTA studies are therefore needed to confirm our findings. Future DTA 
studies should ideally compare the performance of all three imaging modalities (SonoVue CEUS, CECT 
and CEMRI) in the same patient group and should also report the numbers of patients in whom imaging 
with each modality is non-diagnostic as well as any imaging-related adverse events; studies comparing 
all three imaging modalities could provide a useful vehicle for the collection of information on patients’ 
preferences. Further investigation of the potential role of CEMRI using newer ‘combined’ vascular and 
hepatocyte-specific contrast agents may also be warranted. The QUADAS-2 assessment highlighted 
limitations in the reporting of many studies included in our review; future studies should follow the 
STARD (STAndards for the Reporting of Diagnostic accuracy studies) guidelines for reporting test accuracy 
studies.108,109
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Appendix 1 Literature search strategies
Clinical effectiveness search strategies
EMBASE (OvidSP): 2000–11 Week 39
Searched 6 October 2011.
1. metastasis/ (154,939)
2. (Metasta$ or meta-sta$).ti,ab,ot,hw. (394,219)
3. or/1-2 (394,219)
4. (liver or hepato$ or hepatic$).ti,ab,ot,hw. (999,970)
5. 3 and 4 (64,975)
6. exp liver tumor/ (134,843)
7. FLL.ti,ab,ot. (104)
8. FLLs.ti,ab,ot. (41)
9. bile duct carcinoma/ (9888)
10. ((liver$ or hepat$) adj3 (cancer$ or met$ or malignan$ or carcinoma$ or tumo?r$ or neoplas$ or 
adeno$ or angiom$ or sarcoma$ or angiosarcoma$)).ti,ab,ot,hw. (210,520)
11. (hepatoma$ or h?emangiosarcoma$ or h?emangio-sarcoma$).ti,ab,ot,hw. (24,960)
12. (Focal liver lesion$ and (cancer$ or met or mets or metasta$ or malignan$ or carcinoma$ or tumo?r$ 
or neoplas$ or adeno$ or angiom$ or sarcoma$ or angiosarcoma$)).ti,ab,ot,hw. (845)
13. (BFLL or BFLLS).ti,ab,ot. (5)
14. (HCC or HCCs).ti,ab,ot. (25,130)
15. (Cholangiocarcinoma$ or Cholangio-carcinoma$).ti,ab,ot,hw. (6557)
16. (Bile duct$ adj3 (cancer$ or met$ or malignan$ or lesion$ or carcinoma$ or tumo?r$ or neoplas$ or 
adeno$ or angiom$ or sarcoma$)).ti,ab,ot,hw. (18,232)
17. or/5-16 (252,012)
18. Echography/ or Echotomography/ (186,679)
19. ((ultrasonic$ or ultra-sonic$) adj4 (scan or imag$ or echogram$ or sonogra$ or detect$ or diagnos$ or 
exam$)).ti,ot,ab,hw. (7362)
20. (ultraso$ or ultra-so$ or sonogra$ or Echotomogra$ or Echo-tomogra$ or echoscope$ or echosound$ 
or Echogra$ or echogra$ or tomo-echogra$ or tomoechogra$).ti,ot,ab,hw. (413,388)
21. or/18-20 (413,388)
22. Sulfur hexafluoride/ (1199)
23. (hexafluoruro-sulfurico or SF6 or SF-6 or sulphur hexa-fluoride$ or sulphur hexafluoride$ or sulfur 
hexa-fluoride$ or sulfur hexafluoride$).af. (2094)
24. or/22-23 (2094)
25. 21 and 24 (328)
26. Sonovist/ or Sonovue/ (1350)
27. (Sonovue or sono-vue or Sonavoid or Sonogen or sonagen or Sonavist).af. (1507)
28. (CE-US or CEUS).ti,ab,ot. (900)
29. ((Sulfur or Sulphur) adj2 (hexafluoride$ or hexa-fluoride$) adj4 (US or ultraso$ or ultra-so$ or 
sonogra$ or Echotomogra$ or Echo-tomogra$ or echoscope$ or echosound$ or Echogra$ or tomo-
echogra$ or tomoechogra$ or imag$)).af. (30)
30. (SF6US or SF6-US or SF-6US or SF-6-US).af. (0)
31. ((SF6 or SF6 or sulfur hexafluoride$ or sulfur hexafluoride$ or sulphur hexafluoride$ or sulphur 
hexafluoride$) adj4 (bubbl$ or microbubbl$ or micro-bubbl$ or micropartic$ or micro-partic$)).af. 
(153)
32. or/26-31 (2114)
33. 25 or 32 (2203)
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34. 17 and 33 (676)
35. exp Liver Tumor/di (23,736)
36. bile duct carcinoma/di (2943)
37. metastasis/di (11,811)
38. or/35-37 (36,762)
39. 24 and 38 (40)
40. 34 or 39 (676)
41. limit 40 to yr=”2000-Current” (668)
42. limit 41 to embase (613)
43. animal/ or animal experiment/ (3,084,529)
44. (rat or rats or mouse or mice or murine or rodent or rodents or hamster or hamsters or pig or pigs or 
porcine or rabbit or rabbits or animal or animals or dogs or dog or cats or cow or bovine or sheep or 
ovine or monkey or monkeys).mp. (4,773,759)
45. or/43-44 (4,773,759)
46. exp human/ or human experiment/ (12,541,220)
47. 45 not (45 and 46) (3,833,028)
48. 42 not 47 (578)
MEDLINE (OvidSP): 2000–11 September Week 4
Searched 6 October 2011.
1. neoplasm metastasis/ or neoplasm seeding/ or neoplasms, unknown primary/ (79,582)
2. (Metasta$ or meta-sta$).ti,ab,ot,hw. (311,666)
3. or/1-2 (313,877)
4. (liver or hepato$ or hepatic$).ti,ab,ot,hw. (871,423)
5. 3 and 4 (46,193)
6. exp Liver Neoplasms/ (112,995)
7. exp Bile Duct Neoplasms/ (11,958)
8. Carcinoma, Hepatocellular/ (51,056)
9. (FLL or FLLs).ti,ab,ot. (95)
10. Cholangiocarcinoma/ (4146)
11. ((liver$ or hepat$) adj3 (cancer$ or met$ or malignan$ or carcinoma$ or tumo?r$ or neoplas$ or 
adeno$ or angiom$ or sarcoma$ or angiosarcoma$)).ti,ab,ot,hw. (169,576)
12. (hepatoma$ or h?emangiosarcoma$ or h?emangio-sarcoma$).ti,ab,ot,hw. (27,800)
13. (Focal liver lesion$ and (cancer$ or met or mets or metasta$ or malignan$ or carcinoma$ or tumo?r$ 
or neoplas$ or adeno$ or angiom$ or sarcoma$ or angiosarcoma$)).ti,ab,ot,hw. (712)
14. (BFLL or BFLLS).ti,ab,ot. (3)
15. (HCC or HCCs).ti,ab,ot. (18,801)
16. (Cholangiocarcinoma$ or Cholangio-carcinoma$).ti,ab,ot,hw. (6205)
17. (Bile duct$ adj3 (cancer$ or met$ or malignan$ or lesion$ or carcinoma$ or tumo?r$ or neoplas$ or 
adeno$ or angiom$ or sarcoma$)).ti,ab,ot,hw. (14,499)
18. or/5-17 (200,072)
19. ultrasonography/ or ultrasonography, doppler/ or exp ultrasonography, doppler, duplex/ or exp 
ultrasonography, doppler, pulsed/ (89,811)
20. ((ultrasonic$ or ultra-sonic$) adj4 (scan or imag$ or echogram$ or sonogra$ or detect$ or diagnos$ or 
exam$)).ti,ot,ab,hw. (6823)
21. (ultraso$ or ultra-so$ or sonogra$ or Echotomogra$ or Echo-tomogra$ or echoscope$ or echosound$ 
or Echogra$ or tomoechogra$ or tomo-echogra$).ti,ot,ab,hw. (276,299)
22. or/19-21 (280,667)
23. Sulfur Hexafluoride/ (1489)
24. (hexafluoruro-sulfurico or SF6 or SF-6 or sulphur hexa-fluoride$ or sulphur hexafluoride$ or sulfur 
hexa-fluoride$ or sulfur hexafluoride$).af. (2150)
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25. or/23-24 (2150)
26. 22 and 25 (668)
27. (Sonovue or sono-vue or Sonavoid or Sonogen or sonagen or Sonavist).af. (505)
28. (CE-US or CEUS).ti,ab,ot. (524)
29. ((hexafluoruro-sulfurico or SF6 or SF-6) adj4 (US or ultraso$ or ultra-so$ or sonogra$ or Echotomogra$ 
or Echo-tomogra$ or echoscop$ or echosound$ or Echogra$ or tomoechogra$ or tomo-echogra$ or 
imag$)).af. (7)
30. ((Sulfur or Sulphur) adj2 (hexafluoride$ or hexa-fluoride$) adj4 (US or ultraso$ or ultra-so$ or 
sonogra$ or Echotomogra$ or Echo-tomogra$ or echoscop$ or echosound$ or Echogra$ or 
tomoechogra$ or tomo-echogra$ or imag$)).af. (28)
31. (SF6US or SF6-US or SF-6US or SF-6-US).af. (0)
32. ((SF6 or SF6 or sulphur hexafluoride$ or sulphur hexa-fluoride$ or sulfur hexafluoride$ or sulfur hexa-
fluoride$) adj4 (bubbl$ or microbubbl$ or micro-bubbl$ or micropartic$ or micro-partic$)).af. (213)
33. or/27-32 (1002)
34. 26 or 33 (1197)
35. 18 and 34 (367)
36. exp Liver Neoplasms/us (2714)
37. Carcinoma, Hepatocellular/us (1268)
38. exp Bile Duct Neoplasms/us (375)
39. Cholangiocarcinoma/us (137)
40. Neoplasm Metastasis/us (51)
41. Neoplasm Seeding/ra (1)
42. Neoplasms, Unknown Primary/us (21)
43. or/36-42 (3101)
44. 25 and 43 (163)
45. 35 or 44 (368)
46. limit 45 to yr=”2000 -Current” (363)
47. animals/ not (animals/ and humans/) (3,606,824)
48. 46 not 47 (342)
MEDLINE In-Process & Other Non-Indexed Citations (OvidSP): 2000–5 
October 2011
MEDLINE Daily Update (OvidSP): 2000–5 October 2011
Searched 6 October 2011.
1. neoplasm metastasis/ or neoplasm seeding/ or neoplasms, unknown primary/ (66)
2. (Metasta$ or meta-sta$).ti,ab,ot,hw. (12,580)
3. or/1-2 (12,581)
4. (liver or hepato$ or hepatic$).ti,ab,ot,hw. (21,219)
5. 3 and 4 (1428)
6. exp Liver Neoplasms/ (134)
7. exp Bile Duct Neoplasms/ (6)
8. Carcinoma, Hepatocellular/ (99)
9. (FLL or FLLs).ti,ab,ot. (21)
10. Cholangiocarcinoma/ (7)
11. ((liver$ or hepat$) adj3 (cancer$ or met$ or malignan$ or carcinoma$ or tumo?r$ or neoplas$ or 
adeno$ or angiom$ or sarcoma$ or angiosarcoma$)).ti,ab,ot,hw. (4928)
12. (hepatoma$ or h?emangiosarcoma$ or h?emangio-sarcoma$).ti,ab,ot,hw. (482)
13. (Focal liver lesion$ and (cancer$ or met or mets or metasta$ or malignan$ or carcinoma$ or tumo?r$ 
or neoplas$ or adeno$ or angiom$ or sarcoma$ or angiosarcoma$)).ti,ab,ot,hw. (22)
14. (BFLL or BFLLS).ti,ab,ot. (0)
15. (HCC or HCCs).ti,ab,ot. (1356)
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16. (Cholangiocarcinoma$ or Cholangio-carcinoma$).ti,ab,ot,hw. (319)
17. (Bile duct$ adj3 (cancer$ or met$ or malignan$ or lesion$ or carcinoma$ or tumo?r$ or neoplas$ or 
adeno$ or angiom$ or sarcoma$)).ti,ab,ot,hw. (130)
18. or/5-17 (5956)
19. ultrasonography/ or ultrasonography, doppler/ or exp ultrasonography, doppler, duplex/ or exp 
ultrasonography, doppler, pulsed/ (57)
20. ((ultrasonic$ or ultra-sonic$) adj4 (scan or imag$ or echogram$ or sonogra$ or detect$ or diagnos$ or 
exam$)).ti,ot,ab,hw. (349)
21. (ultraso$ or ultra-so$ or sonogra$ or Echotomogra$ or Echo-tomogra$ or echoscope$ or echosound$ 
or Echogra$ or tomoechogra$ or tomo-echogra$).ti,ot,ab,hw. (11,431)
22. or/19-21 (11,432)
23. Sulfur Hexafluoride/ (0)
24. (hexafluoruro-sulfurico or SF6 or SF-6 or sulphur hexa-fluoride$ or sulphur hexafluoride$ or sulfur 
hexa-fluoride$ or sulfur hexafluoride$).af. (316)
25. or/23-24 (316)
26. 22 and 25 (3)
27. (Sonovue or sono-vue or Sonavoid or Sonogen or sonagen or Sonavist).af. (34)
28. (CE-US or CEUS).ti,ab,ot. (82)
29. ((hexafluoruro-sulfurico or SF6 or SF-6) adj4 (US or ultraso$ or ultra-so$ or sonogra$ or Echotomogra$ 
or Echo-tomogra$ or echoscop$ or echosound$ or Echogra$ or tomoechogra$ or tomo-echogra$ or 
imag$)).af. (1)
30. ((Sulfur or Sulphur) adj2 (hexafluoride$ or hexa-fluoride$) adj4 (US or ultraso$ or ultra-so$ or 
sonogra$ or Echotomogra$ or Echo-tomogra$ or echoscop$ or echosound$ or Echogra$ or 
tomoechogra$ or tomo-echogra$ or imag$)).af. (0)
31. (SF6US or SF6-US or SF-6US or SF-6-US).af. (0)
32. ((SF6 or SF6 or sulphur hexafluoride$ or sulphur hexa-fluoride$ or sulfur hexafluoride$ or sulfur hexa-
fluoride$) adj4 (bubbl$ or microbubbl$ or micro-bubbl$ or micropartic$ or micro-partic$)).af. (2)
33. or/27-32 (103)
34. 26 or 33 (104)
35. 18 and 34 (40)
36. exp Liver Neoplasms/us (2)
37. Carcinoma, Hepatocellular/us (1)
38. exp Bile Duct Neoplasms/us (0)
39. Cholangiocarcinoma/us (0)
40. Neoplasm Metastasis/us (0)
41. Neoplasm Seeding/ra (0)
42. Neoplasms, Unknown Primary/us (0)
43. or/36-42 (2)
44. 25 and 43 (0)
45. 35 or 44 (40)
46. limit 45 to yr=”2000 -Current” (40)
47. animals/ not (animals/ and humans/) (2179)
48. 46 not 47 (40)
Cochrane Database of Systematic Reviews (Wiley): Issue 10, 2011
Cochrane Central Register of Controlled Trials (Wiley): Issue 4, 2011
www.thecochranelibrary.com/
Search limited to 2000–11.
Searched 6 October 2011.
#1 MeSH descriptor Neoplasm Metastasis, this term only (1725)
#2 MeSH descriptor Neoplasm Seeding, this term only (25)
#3 MeSH descriptor Neoplasms, Unknown Primary, this term only (32)
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#4 (Metasta* or meta-sta*):ti,ab,kw (10,876)
#5 (#1 OR #2 OR #3 OR #4) (10,908)
#6 (liver or hepato* or hepatic*):ti,ab,kw (30,235)
#7 (#5 AND #6) (1342)
#8 MeSH descriptor Liver Neoplasms explode all trees  (1521)
#9 MeSH descriptor Bile Duct Neoplasms explode all trees (128)
#10 MeSH descriptor Carcinoma, Hepatocellular, this term only (769)
#11 MeSH descriptor Cholangiocarcinoma, this term only (41)
#12 (FLL or FLLs):ti,ab (0)
#13 ((liver* or hepat*) near/3 (cancer* or met* or malignan* or carcinoma* or tumor* or tumour* or 
neoplas* or adeno* or angiom* or sarcoma* or angiosarcoma*)):ti,ab,kw (5985)
#14 (hepatoma* or hemangiosarcoma* or hemangio-sarcoma* or haemangiosarcoma* or haemangio-
sarcoma*):ti,ab,kw (71)
#15 ((Focal NEXT liver NEXT lesion*) and (cancer* or met or mets or metasta* or malignan* 
or carcinoma* or tumor* or tumour* or neoplas* or adeno* or angiom* or sarcoma* or 
angiosarcoma*)):ti,ab,kw (20)
#16 (BFLL or BFLLS or HCC or HCCs):ti,ab (563)
#17 (Cholangiocarcinoma* or Cholangio-carcinoma*):ti,ab,kw (70)
#18 ((Bile NEXT duct*) near/3 (cancer* or met* or malignan* or lesion* or carcinoma* or tumor* or 
tumour* or neoplas* or adeno* or angiom* or sarcoma*)):ti,ab,kw (236)
#19 (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18) 
(6625)
#20 MeSH descriptor Ultrasonography, this term only (743)
#21 MeSH descriptor Ultrasonography, Doppler, this term only (403)
#22 MeSH descriptor Ultrasonography, Doppler, Duplex explode all trees (696)
#23 MeSH descriptor Ultrasonography, Doppler, Pulsed explode all trees (120)
#24 ((ultrasonic* or ultra-sonic*) near/4 (scan or imag* or echogram* or sonogra* or detect* or diagnos* 
or exam*)):ti,ab,kw (141)
#25 (ultraso* or ultra-so* or sonogra* or Echotomogra* or Echo-tomogra* or echoscope* or echosound* 
or Echogra* or tomoechogra* or tomo-echogra*):ti,ab,kw (14,089)
#26 (#20 OR #21 OR #22 OR #23 OR #24 OR #25) (14,122)
#27 MeSH descriptor Sulfur Hexafluoride, this term only (54)
#28 (hexafluoruro-sulfurico or SF6 or SF-6 or (sulphur NEXT hexafluoride*) or (sulphur NEXT 
hexafluoride*) or (sulfur NEXT hexafluoride*) or (sulfur NEXT hexafluoride*)) (125)
#29 (#27 OR #28) (125)
#30 (#26 AND #29) (39)
#31 (Sonovue or sono-vue or Sonavoid or Sonogen or sonagen or Sonavist) (35)
#32 (CE-US or CEUS):ti,ab (16)
#33 ((hexafluoruro-sulfurico or SF6 or SF-6) near/4 (US or ultraso* or ultra-so* or sonogra* or 
Echotomogra* or Echo-tomogra* or echoscop* or echosound* or Echogra* or tomoechogra* or 
tomo-echogra* or imag*)) (2)
#34 ((Sulfur or Sulphur) near/2 (hexafluoride* or hexa-fluoride*) near/4 (US or ultraso* or ultra-so* 
or sonogra* or Echotomogra* or Echo-tomogra* or echoscop* or echosound* or Echogra* or 
tomoechogra* or tomo-echogra* or imag*)) (11)
#35 (SF6US or SF6-US or SF-6US or SF-6-US) (0)
#36 ((SF6 or SF6 or (sulphur NEXT hexafluoride*) or (sulphur NEXT hexa-fluoride*) or (sulfur NEXT 
hexafluoride*) or (sulfur NEXT hexa-fluoride*)) near/4 (bubbl* or microbubbl* or micro-bubbl* or 
micropartic* or micro-partic*)) (4)
#37 (#31 OR #32 OR #33 OR #34 OR #35 OR #36) (56)
#38 (#30 OR #37) (67)
#39 (#19 AND #38) (15)
#40 MeSH descriptor Liver Neoplasms explode all trees with qualifier: US (51)
#41 MeSH descriptor Carcinoma, Hepatocellular, this term only with qualifier: US (23)
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#42 MeSH descriptor Bile Duct Neoplasms explode all trees with qualifier: US (4)
#43 MeSH descriptor Cholangiocarcinoma explode all trees with qualifier: US (1)
#44 MeSH descriptor Neoplasm Metastasis, this term only with qualifier: US (0)
#45 MeSH descriptor Neoplasm Seeding, this term only with qualifier: US (0)
#46 MeSH descriptor Neoplasms, Unknown Primary, this term only with qualifier: US (0)
#47 (#40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46) (55)
#48 (#39 OR #47), from 2000 to 2011 (40)
CDSR search retrieved 1 reference.
CENTRAL search retrieved 31 references.
Database of Abstracts of Reviews of Effects via The Cochrane Library 
(Wiley): 2000–6 October 2011
Health Technology Assessment database via The Cochrane Library (Wiley): 
2000–7 October 2011
www.thecochranelibrary.com/
Search limited to 2000–11.
Searched 6 October 2011.
#1 MeSH descriptor Neoplasm Metastasis, this term only (1725)
#2 MeSH descriptor Neoplasm Seeding, this term only (25)
#3 MeSH descriptor Neoplasms, Unknown Primary, this term only (32)
#4 (Metasta* or meta-sta*):ti,ab,kw (10,876)
#5 (#1 OR #2 OR #3 OR #4) (10,908)
#6 (liver or hepato* or hepatic*):ti,ab,kw (30,235)
#7 (#5 AND #6) (1342)
#8 MeSH descriptor Liver Neoplasms explode all trees (1521)
#9 MeSH descriptor Bile Duct Neoplasms explode all trees (128)
#10 MeSH descriptor Carcinoma, Hepatocellular, this term only (769)
#11 MeSH descriptor Cholangiocarcinoma, this term only (41)
#12 (FLL or FLLs):ti,ab (0)
#13 ((liver* or hepat*) near/3 (cancer* or met* or malignan* or carcinoma* or tumor* or tumour* or 
neoplas* or adeno* or angiom* or sarcoma* or angiosarcoma*)):ti,ab,kw (5985)
#14 (hepatoma* or hemangiosarcoma* or hemangio-sarcoma* or haemangiosarcoma* or haemangio-
sarcoma*):ti,ab,kw (71)
#15 ((Focal NEXT liver NEXT lesion*) and (cancer* or met or mets or metasta* or malignan* 
or carcinoma* or tumor* or tumour* or neoplas* or adeno* or angiom* or sarcoma* or 
angiosarcoma*)):ti,ab,kw (20)
#16 (BFLL or BFLLS or HCC or HCCs):ti,ab (563)
#17 (Cholangiocarcinoma* or Cholangio-carcinoma*):ti,ab,kw (70)
#18 ((Bile NEXT duct*) near/3 (cancer* or met* or malignan* or lesion* or carcinoma* or tumor* or 
tumour* or neoplas* or adeno* or angiom* or sarcoma*)):ti,ab,kw (236)
#19 (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18) 
(6625)
#20 MeSH descriptor Ultrasonography, this term only (743)
#21 MeSH descriptor Ultrasonography, Doppler, this term only (403)
#22 MeSH descriptor Ultrasonography, Doppler, Duplex explode all trees (696)
#23 MeSH descriptor Ultrasonography, Doppler, Pulsed explode all trees (120)
#24 ((ultrasonic* or ultra-sonic*) near/4 (scan or imag* or echogram* or sonogra* or detect* or diagnos* 
or exam*)):ti,ab,kw (141)
#25 (ultraso* or ultra-so* or sonogra* or Echotomogra* or Echo-tomogra* or echoscope* or echosound* 
or Echogra* or tomoechogra* or tomo-echogra*):ti,ab,kw (14,089)
#26 (#20 OR #21 OR #22 OR #23 OR #24 OR #25) (14,122)
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#27 MeSH descriptor Sulfur Hexafluoride, this term only (54)
#28 (hexafluoruro-sulfurico or SF6 or SF-6 or (sulphur NEXT hexafluoride*) or (sulphur NEXT 
hexafluoride*) or (sulfur NEXT hexafluoride*) or (sulfur NEXT hexafluoride*)) (125)
#29 (#27 OR #28) (125)
#30 (#26 AND #29) (39)
#31 (Sonovue or sono-vue or Sonavoid or Sonogen or sonagen or Sonavist) (35
#32 (CE-US or CEUS):ti,ab (16)
#33 ((hexafluoruro-sulfurico or SF6 or SF-6) near/4 (US or ultraso* or ultra-so* or sonogra* or 
Echotomogra* or Echo-tomogra* or echoscop* or echosound* or Echogra* or tomoechogra* or 
tomo-echogra* or imag*)) (2)
#34 ((Sulfur or Sulphur) near/2 (hexafluoride* or hexa-fluoride*) near/4 (US or ultraso* or ultra-so* 
or sonogra* or Echotomogra* or Echo-tomogra* or echoscop* or echosound* or Echogra* or 
tomoechogra* or tomo-echogra* or imag*)) (11)
#35 (SF6US or SF6-US or SF-6US or SF-6-US) (0)
#36 ((SF6 or SF6 or (sulphur NEXT hexafluoride*) or (sulphur NEXT hexafluoride*) or (sulfur NEXT 
hexafluoride*) or (sulfur NEXT hexafluoride*)) near/4 (bubbl* or microbubbl* or micro-bubbl* or 
micropartic* or micro-partic*)) (4)
#37 (#31 OR #32 OR #33 OR #34 OR #35 OR #36) (56)
#38 (#30 OR #37) (67)
#39 (#19 AND #38) (15)
#40 MeSH descriptor Liver Neoplasms explode all trees with qualifier: US (51)
#41 MeSH descriptor Carcinoma, Hepatocellular, this term only with qualifier: US (23)
#42 MeSH descriptor Bile Duct Neoplasms explode all trees with qualifier: US (4)
#43 MeSH descriptor Cholangiocarcinoma explode all trees with qualifier: US (1)
#44 MeSH descriptor Neoplasm Metastasis, this term only with qualifier: US (0)
#45 MeSH descriptor Neoplasm Seeding, this term only with qualifier: US (0)
#46 MeSH descriptor Neoplasms, Unknown Primary, this term only with qualifier: US (0)
#47 (#40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46) (55)
#48 (#39 OR #47), from 2000 to 2011 (40)
DARE search retrieved 2 records.
HTA search retrieved 0 records.
Database of Abstracts of Reviews of Effects (Internet) (top-up search for 
currency)
Health Technology Assessment database (Internet) (top-up search for 
currency)
Records added to CRD databases between 1 January 2011 and 6 October 2011.
www.york.ac.uk/inst/crd/
Searched 7 October 2011.
1. ((hexafluoruro-sulfurico or SF6 or SF-6) ) (414)
2. (US or ultraso* or ultra-so* or sonogra* or Echotomogra* or Echo-tomogra* or echoscop* or 
echosound* or Echogra* or tomoechogra* or tomo-echogra* or imag*) (17,021)
3. #1 and #2 (155)
4. (CE-US or CEUS):ti,ab (188)
5. ((Sonovue or sono-vue or Sonavoid or Sonogen or sonagen or Sonavist)) (0)
6. (SF6US or SF6-US or SF-6US or SF-6-US) (0)
7. (Sulfur or Sulphur) AND (hexafluoride* or hexa-fluoride*) AND (US or ultraso* or ultra-so* or sonogra* 
or Echotomogra* or Echo-tomogra* or echoscop* or echosound* or Echogra* or tomoechogra* or 
tomo-echogra* or imag*) (4)
8. (SF6 or SF6) AND (bubbl* or microbubbl* or micro-bubbl* or micropartic* or micro-partic*) (0)
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9. (sulphur NEXT hexafluoride*) AND (bubbl* or microbubbl* or micro-bubbl* or micropartic* or micro-
partic*) (0)
10. (sulfur NEXT hexafluoride*) AND (bubbl* or microbubbl* or micro-bubbl* or micropartic* or micro-
partic*) (0)
11. #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 (346)
12. (liver or hepato* or hepatic* or FLL or FLLs) (1877)
13. (hepatoma* or hemangiosarcoma* or hemangio-sarcoma* or haemangiosarcoma* or haemangio-
sarcoma*) (7)
14. (BFLL or BFLLS or HCC or HCCs) (70)
15. (Cholangiocarcinoma* or Cholangio-carcinoma*) (20)
16. (Bile NEXT duct*) (140)
17. #12 OR #13 OR #14 OR #15 OR #16 (1965)
18. #11 AND #17 (19)
19. * IN DARE WHERE PD FROM 01/01/2011 TO 07/10/2011 (3108)
20. #18 AND #19 (2)
21. * IN HTA WHERE PD FROM 01/01/2011 TO 07/10/2011 (1418)
22. #18 AND #21 (0)
Science Citation Index (Web of Science): 2000–11
Search limited to 2000–6 October 2011.
Searched 7 October 2011.
#25 416 #23 not #24
#24 1,035,565 TS=(cat or cats or dog or dogs or animal or animals or rat or rats or hamster or 
hamster or feline or ovine or canine or bovine or sheep)
#23 450 #9 AND #22
#22 1281 #21 OR #14
#21 1273 #20 OR #19 OR #18 OR #17 OR #16 OR #15
#20 144 TS=((SF6 or SF6 or (sulphur SAME hexafluoride*) or (sulphur SAME hexafluoride*) 
or (sulfur SAME hexafluoride*) or (sulfur SAME hexafluoride*)) SAME (bubbl* or 
microbubbl* or micro-bubbl* or micropartic* or micro-partic*))
#19 0 TS=(SF6US or SF6-US or SF-6US or SF-6-US)
#18 36 TS=((Sulfur or Sulphur) SAME (hexafluoride* or hexa-fluoride*) near/4 (US or 
ultraso* or ultra-so* or sonogra* or Echotomogra* or Echo-tomogra* or echoscop* 
or echosound* or Echogra* or tomoechogra* or tomo-echogra* or imag*))
#17 213 TS=((hexafluoruro-sulfurico or SF6 or SF-6) SAME (US or ultraso* or ultra-so* or 
sonogra* or Echotomogra* or Echo-tomogra* or echoscop* or echosound* or 
Echogra* or tomoechogra* or tomo-echogra* or imag*))
#16 576 TS=(CE-US or CEUS)
#15 546 TS=(Sonovue or sono-vue or Sonavoid or Sonogen or sonagen or Sonavist)
#14 135 #12 AND #13
#13 3932 TS=(hexafluoruro-sulfurico or SF6 or SF-6 or (sulphur SAME hexafluoride*) or 
(sulphur SAME hexa-fluoride*) or (sulfur SAME hexafluoride*) or (sulfur SAME 
hexa-fluoride*))
#12 166,385 #11 OR #10
#11 166,385 TS=(ultraso* or ultra-so* or sonogra* or Echotomogra* or Echo-tomogra* or 
echoscope* or echosound* or Echogra* or tomoechogra* or tomo-echogra*)
#10 14,050 TS=((ultrasonic* or ultra-sonic*) SAME (scan or imag* or echogram* or sonogra* or 
detect* or diagnos* or exam*))
#9 239,703 #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#8 9832 TS=((Bile SAME duct*) SAME (cancer* or met* or malignan* or lesion* or 
carcinoma* or tumor* or tumour* or neoplas* or adeno* or angiom* or sarcoma*))
#7 4831 TS=(Cholangiocarcinoma* or Cholangio-carcinoma*)
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#6 1966 TI=(BFLL or BFLLS or HCC or HCCs)
#5 1584 TS=((Focal SAME liver SAME lesion*) SAME (cancer* or met or mets or metasta* or 
malignan* or carcinoma* or tumor* or tumour* or neoplas* or adeno* or angiom* 
or sarcoma* or angiosarcoma*))
#4 10,317 TS=(hepatoma* or hemangiosarcoma* or hemangio-sarcoma* or 
haemangiosarcoma* or haemangio-sarcoma*)
#3 230,065 TS=((liver* or hepat*) SAME (cancer* or met* or malignan* or carcinoma* 
or tumor* or tumour* or neoplas* or adeno* or angiom* or sarcoma* 
or angiosarcoma*))
#2 224 TS=(FLL or FLLs)
#1 24,460 TS=((Metasta* or meta-sta*) AND (liver or hepato* or hepatic*))
ClinicalTrials.gov (Internet)
http://clinicaltrials.gov/ct2/search/advanced
Searched 7 October 2011.
Advanced search option – search terms box
Search terms Condition Results
Sonovue OR sono-vue OR Sonavoid OR Sonogen OR sonagen OR 
Sonavist
22
CE-US OR CEUS 18
SF6US OR SF6-US OR SF-6US OR SF-6-US 0
(SF6 OR SF6) AND (liver OR hepato* OR hepatic* OR FLL OR 
FLLS OR BFLL OR BFLLS OR HCC OR HCCs OR hepatoma* 
OR hemangiosarcoma* OR hemangio-sarcoma* OR 
haemangiosarcoma* OR haemangio-sarcoma*)
0
SF6 OR SF6 0/11
(sulphur hexafluoride*) OR (sulphur hexafluoride*) OR (sulfur 
hexa-fluoride*) OR (sulfur hexa-fluoride*)
22
(hexafluoruro-sulfurico OR SF6 OR SF-6 OR (sulphur hexafluoride*) 
OR (sulphur hexafluoride*) OR (sulfur hexafluoride*) OR (sulfur 
hexafluoride*)
(liver OR hepato* OR hepatic* OR FLL OR 
FLLS OR BFLL OR BFLLS OR HCC OR HCCs 
OR hepatoma* OR hemangiosarcoma* 
OR hemangio-sarcoma* OR 
haemangiosarcoma* OR haemangio-
sarcoma*)
8
Total 70
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metaRegister of Controlled Trials (Internet)
www.controlled-trials.com/
Searched 7 October 2011.
Search terms Results
CE-US OR CEUS 7
Sonovue OR sono-vue OR Sonavoid OR Sonogen OR sonagen OR Sonavist 4
(SF6US OR SF6-US OR SF-6US OR SF-6-US) and (liver or hepato or hepatic) 110
(SF6 OR SF6) AND (liver OR hepato OR hepatic OR FLL OR FLLS OR BFLL OR BFLLS OR HCC OR HCCs OR 
hepatoma* OR hemangiosarcoma OR hemangio-sarcoma OR haemangiosarcoma OR haemangio-sarcoma)
1
SF6 OR SF6 5
(sulphur hexafluoride) OR (sulphur hexafluoride) OR (sulfur hexa-fluoride) OR (sulfur hexa-fluoride) 2
hexafluoruro-sulfurico OR SF6 OR SF-6 OR (sulphur hexafluoride) OR (sulphur hexafluoride) OR (sulfur 
hexafluoride) OR (sulfur hexafluoride)
7
Total 136
World Health Organization International Clinical Trials Registry Platform 
(Internet)
www.who.int/ictrp/en/
Searched 7 October 2011.
Search terms Results
CE-US OR CEUS 11
Sonovue OR sono-vue OR Sonavoid OR Sonogen OR sonagen OR Sonavist 7
SF6US OR SF6-US OR SF-6US OR SF-6-US 0
SF6 OR SF6 0
(sulphur hexafluoride) OR (sulphur hexafluoride) OR (sulfur hexa-fluoride) OR (sulfur hexa-fluoride) 0
hexafluoruro-sulfurico OR SF6 OR SF-6 OR (sulphur hexafluoride) OR (sulphur hexafluoride) OR (sulfur 
hexafluoride) OR (sulfur hexafluoride)
1
Total 19
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EU Clinical Trials Register (Internet)
www.clinicaltrialsregister.eu/ctr-search/
Searched 10 October 2011.
Search terms Results
Sonovue OR sono-vue OR Sonavoid OR Sonogen OR sonagen OR Sonavist 21
SF6 3
SF-6 0
hexafluoruro-sulfurico 0
sulphur hexafluoride 5
sulfur hexafluoride 8
sulfur hexa-fluoride 0
sulphur hexa-fluoride 0
CE-US 2
CEUS 2
Total 41
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Conference abstract searches
EUROSON (European Federation of Ultrasound in Medicine and Biology) 
conference (Internet): 2007, 2008, 2011 only
Searched 10 November 2011 (2011 abstracts); 21 November 2011 (2007–8 abstracts).
2011 = www.wfumb2011.org/index.php?pid=70: searched title+abstract
2010 = Unable to access
2009 = Unable to access
2008 = www.thieme-connect.com/ejournals/toc/ultraschall/33697/grouping/54161: searched title
2007 = www.interplan.de/pages/euroson2007/front_content.php?idcat=82: searched title and abstract
2006 = Unable to access
Search terms 2011 2010 2009 2008 2007 2006
Sonovue or Sono-vue 35 – – 0 41 –
Sonavoid 0 – – 0 0 –
Sonogen 0 – – 0 0 –
sonagen 0 – – 0 0 –
Sonavist 0 – – 0 0 –
SF6 0 – – 0 0 –
hexafluoride 2 – – 0 2 –
Sulphur 0 – – 0 0 –
sulfur 3 – – 0 2 –
CEUS – – – 9 – –
Liver – – – 21 – –
Hepat – – – 27 – –
Total by year 40 – – 57 45 –
Total 142
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European Congress of Radiology (internet): 2006–11
Searched 10 November 2011.
2011 = www.myesr.org/cms/website.php?id=/en/past_congresses/ecr_2011/ecr_2011_book_of_abstracts.
htm
2010 = www.myesr.org/cms/website.php?id=/en/ecr_2010/book_of_abstracts.htm
2009 = www.myesr.org/cms/website.php?id=/en/ecr_2009/ecr_2009_book_of_abstracts.htm
2008 = www.abstractsonline.com/viewer/?mkey={9AF35541-5128-444B-9D15-447022358A3F}
2007 = www.abstractsonline.com/viewer/?mkey={9A26688A-5BBE-4366-AE14-5AC99DF8F8E4}
2006 = www.abstractsonline.com/viewer/?mkey={6748FA35-D7A5-44B0-B8D4-4E2E51850B06}
Search terms 2011 2010 2009 2008 2007 2006
Sonovue or Sono-vue 10 11 19 22 28 24
Sonavoid 0 0 0 0 0 0
Sonogen 0 0 0 0 0 0
sonagen 0 0 0 0 0 0
Sonavist 0 0 0 0 0 0
SF6 0 0 0 0 0 0
hexafluoride 1 0 1 3 3 4
Sulphur 1 0 1 0 1 2
sulfur 0 0 0 3 2 2
Total by year 12 11 21 28 34 32
Total 138
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Radiological Society of North America conference (internet): 2006–10
Searched 10 November 2011.
2010 = http://rsna2010.rsna.org/search/search.cfm
2009 = http://rsna2009.rsna.org/search/search.cfm
2008 = http://rsna2008.rsna.org/program.cfm
2007 = http://rsna2007.rsna.org/rsna2007/v2007/conference/track.cvn
2006 = http://rsna2006.rsna.org/rsna2006/v2006/conference/track.cvn
Search terms 2010 2009 2008 2007 2006
Sonovue or Sono-vue 10 18 0 0 0
Sonavoid 0 0 0 0 0
Sonogen 0 0 0 0 0
sonagen 0 0 0 0 0
Sonavist 0 0 0 0 0
SF6 0 0 0 0 0
hexafluoride 4 1 0 0 0
Sulphur 2 1 0 0 0
sulfur 4 1 0 0 1
CEUS – – 6 3 2
Liver – – 84 76 87
Hepatic – – 34 49 34
Total by year 20 21 124 128 124
Total 417
Cost-effectiveness searches
MEDLINE (OvidSP): 2000–11 September Week 2
Searched 11 October 2011.
1. neoplasm metastasis/ or neoplasm seeding/ or neoplasms, unknown primary/ (79,582)
2. (Metasta$ or meta-sta$).ti,ab,ot,hw. (311,666)
3. or/1-2 (313,877)
4. (liver or hepato$ or hepatic$).ti,ab,ot,hw. (871,423)
5. 3 and 4 (46,193)
6. exp Liver Neoplasms/ (112,995)
7. exp Bile Duct Neoplasms/ (11,958)
8. Carcinoma, Hepatocellular/ (51,056)
9. (FLL or FLLs).ti,ab,ot. (95)
10. Cholangiocarcinoma/ (4146)
11. ((liver$ or hepat$) adj3 (cancer$ or met$ or malignan$ or carcinoma$ or tumo?r$ or neoplas$ or 
adeno$ or angiom$ or sarcoma$ or angiosarcoma$)).ti,ab,ot,hw. (169,576)
12. (hepatoma$ or h?emangiosarcoma$ or h?emangio-sarcoma$).ti,ab,ot,hw. (27,800)
13. (Focal liver lesion$ and (cancer$ or met or mets or metasta$ or malignan$ or carcinoma$ or tumo?r$ 
or neoplas$ or adeno$ or angiom$ or sarcoma$ or angiosarcoma$)).ti,ab,ot,hw. (712)
14. (BFLL or BFLLS).ti,ab,ot. (3)
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15. (HCC or HCCs).ti,ab,ot. (18,801)
16. (Cholangiocarcinoma$ or Cholangio-carcinoma$).ti,ab,ot,hw. (6205)
17. (Bile duct$ adj3 (cancer$ or met$ or malignan$ or lesion$ or carcinoma$ or tumo?r$ or neoplas$ or 
adeno$ or angiom$ or sarcoma$)).ti,ab,ot,hw. (14,499)
18. or/5-17 (200,072)
19. tomography, emission-computed/ or exp tomography, x-ray computed/ (278,220)
20. exp Ultrasonography/ (220,625)
21. exp Tomography/ (530,496)
22. exp Magnetic Resonance Imaging/ (259,244)
23. exp Tomography, Emission-Computed/ (65,860)
24. Fluorodeoxyglucose F18/du (11,296)
25. (MSCT or MDST or MRI or FDGPET or FDG-PET or MDCT or IOUS or MRI or FMRI or NMRI or FNMRI).
ti,ab,ot. (131,472)
26. (pet or petscan$ or positron).ti,ot,ab,hw. (55,858)
27. (CAT or CTA or CT or cine-ct).ti,ab,ot. (241,703)
28. (3dcta or 3d-cta).ti,ab,ot. (189)
29. (64slice$ or 64-slice$ or 64row$ or 64-row$ or 64-detect$).ti,ab,ot,hw. (1580)
30. ((nmr or comput$ or mr) adj4 (scan$ or imag$ or tomogra$ or angiogra$ or angio-gra$ or xray$ or 
x-ray$)).ti,ab,ot,hw. (473,823)
31. (electron beam adj4 (scan$ or imag$ or tomogra$ or angiogra$ or angio-gra$ or xray$ or x-ray$)).
ti,ab,ot,hw. (1499)
32. Chemical shift imag$.ti,ot,ab,hw. (714)
33. ((ultrasonic$ or ultra-sonic$) adj4 (scan or imag$ or tomogra$ or echogram$ or sonogra$ or detect$ 
or diagnos$ or scintillat$ or exam$)).ti,ot,ab,hw. (7134)
34. MR imag$.ti,ot,ab,hw. (36,261)
35. (ultraso$ or ultra-so$ or sonogra$ or Echotomogra$ or Echo-tomogra$ or doptone or echoscope$ 
or echosound$ or tomogra$ or Echogra$ or zeugmatogra$ or echogra$ or tomoechogra$ or 
tomodensitomet$).ti,ot,ab,hw. (629,456)
36. “ultrasound without contrast”.ti,ot,ab,hw. (1)
37. (“ultrasonography without contrast” or “ultrasonograph without contrast”).ti,ot,ab,hw. (0)
38. ((Un-enhanced or Unenhanced) adj4 (sonogra$ or ultra-so$ or ultraso$ or Echotomogra$ or Echo-
tomogra$ or doptone or echoscope$ or echosound$ or tomogra$ or Echogra$ or zeugmatogra$ or 
echogra$ or tomoechogra$ or tomodensitomet$)).ti,ot,ab,hw. (367)
39. Positron emission tomogra$.ti,ot,ab,hw. (38,028)
40. or/19-39 (1,087,651)
41. 18 and 40 (29,857)
42. exp Liver Neoplasms/us [Ultrasonography] (2714)
43. Carcinoma, Hepatocellular/us [Ultrasonography] (1268)
44. exp Bile Duct Neoplasms/us (375)
45. Cholangiocarcinoma/us [Ultrasonography] (137)
46. Neoplasm Metastasis/us [Ultrasonography] (51)
47. Neoplasm Seeding/ra [Radiography] (1)
48. Neoplasms, Unknown Primary/us [Ultrasonography] (21)
49. or/42-48 (3101)
50. 41 or 49 (30,149)
51. economics/ (26,431)
52. exp “costs and cost analysis”/ (160,527)
53. economics, dental/ (1886)
54. exp “economics, hospital”/ (17,621)
55. economics, medical/ (8758)
56. economics, nursing/ (3854)
57. economics, pharmaceutical/ (2288)
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58. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).
ti,ab. (348,545)
59. (expenditure$ not energy).ti,ab. (14,733)
60. (value adj1 money).ti,ab. (20)
61. budget$.ti,ab. (14,850)
62. or/51-61 (463,424)
63. ((energy or oxygen) adj cost).ti,ab. (2377)
64. (metabolic adj cost).ti,ab. (624)
65. ((energy or oxygen) adj expenditure).ti,ab. (13,655)
66. or/63-65 (16,028)
67. 62 not 66 (459,787)
68. letter.pt. (728,700)
69. editorial.pt. (285,457)
70. historical article.pt. (282,970)
71. or/68-70 (1,283,982)
72. 67 not 71 (434,958)
73. animals/ not (animals/ and humans/) (3,606,824)
74. 72 not 73 (409,921)
75. 50 and 74 (506)
76. limit 75 to yr=”2000 -Current” (293)
Economics filter: Centre for Reviews and Dissemination. NHS EED economics filter: MEDLINE (Ovid) 
monthly search. York: CRD; 2010. URL: www.york.ac.uk/inst/crd/intertasc/nhs_eed_strategies.html 
(accessed 28 September 2010).
MEDLINE In-Process & Other Non-Indexed Citations (OvidSP): 2000–10 
October 2011
MEDLINE Daily Update (OvidSP): 2000–10 October 2011
Searched 11 October 2011.
1. neoplasm metastasis/ or neoplasm seeding/ or neoplasms, unknown primary/ (84)
2. (Metasta$ or meta-sta$).ti,ab,ot,hw. (12,775)
3. or/1-2 (12,776)
4. (liver or hepato$ or hepatic$).ti,ab,ot,hw. (21,579)
5. 3 and 4 (1452)
6. exp Liver Neoplasms/ (174)
7. exp Bile Duct Neoplasms/ (7)
8. Carcinoma, Hepatocellular/ (125)
9. (FLL or FLLs).ti,ab,ot. (21)
10. Cholangiocarcinoma/ (8)
11. ((liver$ or hepat$) adj3 (cancer$ or met$ or malignan$ or carcinoma$ or tumo?r$ or neoplas$ or 
adeno$ or angiom$ or sarcoma$ or angiosarcoma$)).ti,ab,ot,hw. (5022)
12. (hepatoma$ or h?emangiosarcoma$ or h?emangio-sarcoma$).ti,ab,ot,hw. (493)
13. (Focal liver lesion$ and (cancer$ or met or mets or metasta$ or malignan$ or carcinoma$ or tumo?r$ 
or neoplas$ or adeno$ or angiom$ or sarcoma$ or angiosarcoma$)).ti,ab,ot,hw. (22)
14. (BFLL or BFLLS).ti,ab,ot. (0)
15. (HCC or HCCs).ti,ab,ot. (1380)
16. (Cholangiocarcinoma$ or Cholangio-carcinoma$).ti,ab,ot,hw. (322)
17. (Bile duct$ adj3 (cancer$ or met$ or malignan$ or lesion$ or carcinoma$ or tumo?r$ or neoplas$ or 
adeno$ or angiom$ or sarcoma$)).ti,ab,ot,hw. (131)
18. or/5-17 (6064)
19. tomography, emission-computed/ or exp tomography, x-ray computed/ (339)
20. exp Ultrasonography/ (229)
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State 
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17160 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 16
139
21. exp Tomography/ (827)
22. exp Magnetic Resonance Imaging/ (433)
23. exp Tomography, Emission-Computed/ (109)
24. Fluorodeoxyglucose F18/du (25)
25. (MSCT or MDST or MRI or FDGPET or FDG-PET or MDCT or IOUS or MRI or FMRI or NMRI or FNMRI).
ti,ab,ot. (7477)
26. (pet or petscan$ or positron).ti,ot,ab,hw. (3355)
27. (CAT or CTA or CT or cine-ct).ti,ab,ot. (10,016)
28. (3dcta or 3d-cta).ti,ab,ot. (15)
29. (64slice$ or 64-slice$ or 64row$ or 64-row$ or 64-detect$).ti,ab,ot,hw. (174)
30. ((nmr or comput$ or mr) adj4 (scan$ or imag$ or tomogra$ or angiogra$ or angio-gra$ or xray$ or 
x-ray$)).ti,ab,ot,hw. (10,787)
31. (electron beam adj4 (scan$ or imag$ or tomogra$ or angiogra$ or angio-gra$ or xray$ or x-ray$)).
ti,ab,ot,hw. (121)
32. Chemical shift imag$.ti,ot,ab,hw. (33)
33. ((ultrasonic$ or ultra-sonic$) adj4 (scan or imag$ or tomogra$ or echogram$ or sonogra$ or detect$ 
or diagnos$ or scintillat$ or exam$)).ti,ot,ab,hw. (369)
34. MR imag$.ti,ot,ab,hw. (1078)
35. (ultraso$ or ultra-so$ or sonogra$ or Echotomogra$ or Echo-tomogra$ or doptone or echoscope$ 
or echosound$ or tomogra$ or Echogra$ or zeugmatogra$ or echogra$ or tomoechogra$ or 
tomodensitomet$).ti,ot,ab,hw. (21,818)
36. “ultrasound without contrast”.ti,ot,ab,hw. (0)
37. (“ultrasonography without contrast” or “ultrasonograph without contrast”).ti,ot,ab,hw. (1)
38. ((Un-enhanced or Unenhanced) adj4 (sonogra$ or ultra-so$ or ultraso$ or Echotomogra$ or Echo-
tomogra$ or doptone or echoscope$ or echosound$ or tomogra$ or Echogra$ or zeugmatogra$ or 
echogra$ or tomoechogra$ or tomodensitomet$)).ti,ot,ab,hw. (12)
39. Positron emission tomogra$.ti,ot,ab,hw. (1414)
40. or/19-39 (38,105)
41. 18 and 40 (841)
42. exp Liver Neoplasms/us [Ultrasonography] (4)
43. Carcinoma, Hepatocellular/us [Ultrasonography] (3)
44. exp Bile Duct Neoplasms/us (0)
45. Cholangiocarcinoma/us [Ultrasonography] (0)
46. Neoplasm Metastasis/us [Ultrasonography] (0)
47. Neoplasm Seeding/ra [Radiography] (0)
48. Neoplasms, Unknown Primary/us [Ultrasonography] (0)
49. or/42-48 (4)
50. 41 or 49 (842)
51. economics/ (29)
52. exp “costs and cost analysis”/ (206)
53. economics, dental/ (0)
54. exp “economics, hospital”/ (43)
55. economics, medical/ (1)
56. economics, nursing/ (0)
57. economics, pharmaceutical/ (1)
58. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).
ti,ab. (24,833)
59. (expenditure$ not energy).ti,ab. (706)
60. (value adj1 money).ti,ab. (2)
61. budget$.ti,ab. (1368)
62. or/51-61 (26,315)
63. ((energy or oxygen) adj cost).ti,ab. (150)
64. (metabolic adj cost).ti,ab. (43)
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65. ((energy or oxygen) adj expenditure).ti,ab. (582)
66. or/63-65 (752)
67. 62 not 66 (26,100)
68. letter.pt. (17,183)
69. editorial.pt. (10,629)
70. historical article.pt. (603)
71. or/68-70 (28,394)
72. 67 not 71 (25,702)
73. animals/ not (animals/ and humans/) (2838)
74. 72 not 73 (25,645)
75. 50 and 74 (7)
76. limit 75 to yr=”2000 -Current” (7)
Economics filter: Centre for Reviews and Dissemination. NHS EED economics filter: MEDLINE (Ovid) 
monthly search. York: CRD; 2010. URL: www.york.ac.uk/inst/crd/intertasc/nhs_eed_strategies.html 
(accessed 28 September 2010).
EMBASE (OvidSP): 2000–11 Week 40
Searched 12 October 2011.
1. metastasis/ (155,985)
2. (Metasta$ or meta-sta$).ti,ab,ot,hw. (396,806)
3. or/1-2 (396,806)
4. (liver or hepato$ or hepatic$).ti,ab,ot,hw. (1,004,150)
5. 3 and 4 (65,370)
6. exp liver tumor/ (135,580)
7. FLL.ti,ab,ot. (107)
8. FLLs.ti,ab,ot. (43)
9. bile duct carcinoma/ (9937)
10. ((liver$ or hepat$) adj3 (cancer$ or met$ or malignan$ or carcinoma$ or tumo?r$ or neoplas$ or 
adeno$ or angiom$ or sarcoma$ or angiosarcoma$)).ti,ab,ot,hw. (211,624)
11. (hepatoma$ or h?emangiosarcoma$ or h?emangio-sarcoma$).ti,ab,ot,hw. (25,072)
12. (Focal liver lesion$ and (cancer$ or met or mets or metasta$ or malignan$ or carcinoma$ or tumo?r$ 
or neoplas$ or adeno$ or angiom$ or sarcoma$ or angiosarcoma$)).ti,ab,ot,hw. (854)
13. (BFLL or BFLLS).ti,ab,ot. (5)
14. (HCC or HCCs).ti,ab,ot. (25,363)
15. (Cholangiocarcinoma$ or Cholangio-carcinoma$).ti,ab,ot,hw. (6601)
16. (Bile duct$ adj3 (cancer$ or met$ or malignan$ or lesion$ or carcinoma$ or tumo?r$ or neoplas$ or 
adeno$ or angiom$ or sarcoma$)).ti,ab,ot,hw. (18,319)
17. or/5-16 (253,318)
18. exp Tomography/ (524,140)
19. exp Echography/ (399,873)
20. exp Nuclear-Magnetic-Resonance-Imaging/ (385,701)
21. Fluorodeoxyglucose-F-18/du (0)
22. (MSCT or MDST or MRI or FDGPET or FDG-PET or MDCT or IOUS or MRI or FMRI or NMRI or FNMRI).
ti,ab,ot. (175,669)
23. (pet or petscan$ or positron).ti,ot,ab,hw. (88,701)
24. (CAT or CTA or CT or cine-ct).ti,ab,ot. (295,625)
25. (3dcta or 3d-cta).ti,ab,ot. (261)
26. (64slice$ or 64-slice$ or 64row$ or 64-row$ or 64-detect$).ti,ab,ot,hw. (2721)
27. ((nmr or comput$ or mr) adj4 (scan$ or imag$ or tomogra$ or angiogra$ or angio-gra$ or xray$ or 
x-ray$)).ti,ab,ot,hw. (554,605)
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28.  (electron beam adj4 (scan$ or imag$ or tomogra$ or angiogra$ or angio-gra$ or xray$ or x-ray$)).
ti,ab,ot,hw. (2528)
29. Chemical shift imag$.ti,ot,ab,hw. (822)
30. ((ultrasonic$ or ultra-sonic$) adj4 (scan or imag$ or tomogra$ or echogram$ or sonogra$ or detect$ 
or diagnos$ or scintillat$ or exam$)).ti,ot,ab,hw. (7723)
31. MR imag$.ti,ot,ab,hw. (41,562)
32. (ultraso$ or ultra-so$ or sonogra$ or Echotomogra$ or Echo-tomogra$ or doptone or echoscope$ 
or echosound$ or tomogra$ or Echogra$ or zeugmatogra$ or echogra$ or tomoechogra$ or 
tomodensitomet$).ti,ot,ab,hw. (906,553)
33. “ultrasound without contrast”.ti,ot,ab,hw. (2)
34. (“ultrasonography without contrast” or “ultrasonograph without contrast”).ti,ot,ab,hw. (0)
35. ((Un-enhanced or Unenhanced) adj4 (sonogra$ or ultra-so$ or ultraso$ or Echotomogra$ or Echo-
tomogra$ or doptone or echoscope$ or echosound$ or tomogra$ or Echogra$ or zeugmatogra$ 
or echogra$ or tomoechogra$ or tomodensitomet$)).ti,ot,ab,hw. (412)Positron emission tomogra$.
ti,ot,ab,hw. (67,261)
36. or/18-36 (1,418,654)
37. 17 and 37 (42,839)
38. health-economics/ (30,583)
39. exp economic-evaluation/ (172,264)
40. exp health-care-cost/ (165,499)
41. exp pharmacoeconomics/ (140,625)
42. or/39-42 (395,230)
43. (econom$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).
ti,ab. (448,361)
44. (expenditure$ not energy).ti,ab. (17,805)
45. (value adj2 money).ti,ab. (974)
46. budget$.ti,ab. (18,892)
47. or/44-47 (467,436)
48. 43 or 48 (700,900)
49. letter.pt. (742,741)
50. editorial.pt. (383,238)
51. note.pt. (452,797)
52. or/50-52 (1,578,776)
53. 49 not 53 (628,549)
54. (metabolic adj cost).ti,ab. (670)
55. ((energy or oxygen) adj cost).ti,ab. (2591)
56. ((energy or oxygen) adj expenditure).ti,ab. (15,505)
57. or/55-57 (18,084)
58. 54 not 58 (624,471)
59. exp animal/ (1,655,604)
60. exp animal-experiment/ (1,467,831)
61. nonhuman/ (3,718,682)
62. (rat or rats or mouse or mice or hamster or hamsters or animal or animals or dog or dogs or cat or 
cats or bovine or sheep).ti,ab,sh. (4,119,669)
63. or/60-63 (5,951,308)
64. exp human/ (12,628,304)
65. exp human-experiment/ (293,772)
66. 65 or 66 (12,629,688)
67. 64 not (64 and 67) (4,686,921)
68. 59 not 68 (579,765)
69. 38 and 69 (895)
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70. limit 70 to yr=”2000 -Current” (667)
71. limit 71 to embase (604)
Economics filter: Centre for Reviews and Dissemination. NHS EED economics filter: EMBASE (Ovid) weekly 
search. York: CRD; 2010. URL: www.york.ac.uk/inst/crd/intertasc/nhs_eed_strategies.html (accessed 11 
October 2011). 
NHS Economic Evaluation Database (Wiley)
Search limited to 2000–11.
Searched 12 October 2011.
#1 MeSH descriptor Neoplasm Metastasis, this term only (1725)
#2 MeSH descriptor Neoplasm Seeding, this term only (25)
#3 MeSH descriptor Neoplasms, Unknown Primary, this term only (32)
#4 (Metasta* or meta-sta*):ti,ab,kw (10,876)
#5 (#1 OR #2 OR #3 OR #4) (10,908)
#6 (liver or hepato* or hepatic*):ti,ab,kw (30,235)
#7 (#5 AND #6) (1342)
#8 MeSH descriptor Liver Neoplasms explode all trees (1521)
#9 MeSH descriptor Bile Duct Neoplasms explode all trees (128)
#10 MeSH descriptor Carcinoma, Hepatocellular, this term only (769)
#11 MeSH descriptor Cholangiocarcinoma, this term only (41)
#12 (FLL or FLLs):ti,ab (0)
#13 ((liver* or hepat*) near/3 (cancer* or met* or malignan* or carcinoma* or tumor* or tumour* or 
neoplas* or adeno* or angiom* or sarcoma* or angiosarcoma*)):ti,ab,kw (5985)
#14 (hepatoma* or hemangiosarcoma* or hemangio-sarcoma* or haemangiosarcoma* or haemangio-
sarcoma*):ti,ab,kw (71)
#15 ((Focal NEXT liver NEXT lesion*) and (cancer* or met or mets or metasta* or malignan* 
or carcinoma* or tumor* or tumour* or neoplas* or adeno* or angiom* or sarcoma* or 
angiosarcoma*)):ti,ab,kw (20)
#16 (BFLL or BFLLS or HCC or HCCs):ti,ab (563)
#17 (Cholangiocarcinoma* or Cholangio-carcinoma*):ti,ab,kw (70)
#18 ((Bile NEXT duct*) near/3 (cancer* or met* or malignan* or lesion* or carcinoma* or tumor* or 
tumour* or neoplas* or adeno* or angiom* or sarcoma*)):ti,ab,kw (236)
#19 (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18) 
(6625)
#20 (#19), from 2000 to 2011 (85)
#21 MeSH descriptor Tomography, Emission-Computed, this term only (660)
#22 MeSH descriptor Tomography, X-Ray Computed explode all trees (2946)
#23 MeSH descriptor Ultrasonography explode all trees (6398)
#24 MeSH descriptor Tomography explode all trees (8806)
#25 MeSH descriptor Magnetic Resonance Imaging explode all trees (4171)
#26 MeSH descriptor Tomography, Emission-Computed explode all trees (2155)
#27 MeSH descriptor Fluorodeoxyglucose F18, this term only with qualifier: DU (397)
#28 (MSCT or MDST or MRI or FDGPET or FDG-PET or MDCT or IOUS or MRI or FMRI or NMRI or 
FNMRI):ti,ab (3437)
#29 (pet or petscan* or positron):ti,ab,kw (1958)
#30 (CAT or CTA or CT or cine-ct):ti,ab (5318)
#31 (3dcta or 3d-cta):ti,ab (4)
#32 (64slice* or 64-slice* or 64row* or 64-row* or 64-detect*):ti,ab,kw (52)
#33 ((nmr or comput* or mr) near/4 (scan* or imag* or tomogra* or angiogra* or angio-gra* or xray* or 
x-ray*)):ti,ab,kw (8723)
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#34 ((electron NEXT beam) near/4 (scan* or imag* or tomogra* or angiogra* or angio-gra* or xray* or 
x-ray*)):ti,ab,kw (56)
#35 (Chemical NEXT shift NEXT imag*):ti,ab,kw (12)
#36 ((ultrasonic* or ultra-sonic*) near/4 (scan or imag* or tomogra* or echogram* or sonogra* or 
detect* or diagnos* or scintillat* or exam*)):ti,ab,kw (147)
#37 (MR NEXT imag*):ti,ab,kw (614)
#38 (ultraso* or ultra-so* or sonogra* or Echotomogra* or Echo-tomogra* or doptone or echoscope* 
or echosound* or tomogra* or Echogra* or zeugmatogra* or echogra* or tomoechogra* or 
tomodensitomet*):ti,ab,kw (21,304)
#39 “ultrasound without contrast”:ti,ab,kw (0)
#40 (“ultrasonography without contrast” or “ultrasonograph without contrast”):ti,ab,kw (0)
#41 ((Un-enhanced or Unenhanced) near/4 (sonogra* or ultra-so* or ultraso* or Echotomogra* or Echo-
tomogra* or doptone or echoscope* or echosound* or tomogra* or Echogra* or zeugmatogra* or 
echogra* or tomoechogra* or tomodensitomet*)):ti,ab,kw (11)
#42 (Positron NEXT emission NEXT tomogra*):ti,ab,kw (1362)
#43 (#21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 
OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42) (31,232)
#44 (#20 AND #43), from 2000 to 2011 (27) (limited to NHS EED only)
NHS Economic Evaluation Database (Internet)
Top-up search to supplement search of NHS EED via The Cochrane Library (Wiley).
Records added to CRD databases between 1 January 2011 and 12 October 2011.
www.york.ac.uk/inst/crd/
Searched 12 October 2011.
1. ((liver or hepato* or hepatic* or FLL or FLLs)) OR ((hepatoma* or hemangiosarcoma* or hemangio-
sarcoma* or haemangiosarcoma* or haemangio-sarcoma*)) OR ((BFLL or BFLLS or HCC or HCCs)) OR 
((Cholangiocarcinoma* or Cholangio-carcinoma*) ) IN NHSEED WHERE PD FROM 01/01/2011 TO 
12/10/2011 (40)
2. ((Bile NEXT duct*)) IN NHSEED WHERE PD FROM 01/01/2011 TO 12/10/2011 (4)
3. #1 OR #2 (43)
Health Economic Evaluations Database (Internet): up to 12 October 2011
http://onlinelibrary.wiley.com/book/10.1002/9780470510933
Searched 12 October 2011.
Compound search (all data), unable to limit by date
ultraso* OR ultra-so* OR sonogra* OR Echotomogra*
AND
liver OR hepato* OR hepatic* OR FLL OR FLLs OR hepatoma* OR hemangiosarcoma* OR hemangio-
sarcoma* OR haemangiosarcoma* OR haemangio-sarcoma* OR BFLL OR BFLLS OR HCC OR HCCs OR 
Cholangiocarcinoma* OR Cholangio-carcinoma
N=78
MSCT OR MDST OR MRI OR FDGPET OR FDG-PET
AND
liver OR hepato* OR hepatic* OR FLL OR FLLs OR hepatoma* OR hemangiosarcoma* OR hemangio-
sarcoma* OR haemangiosarcoma* OR haemangio-sarcoma* OR BFLL OR BFLLS OR HCC OR HCCs OR 
Cholangiocarcinoma* OR Cholangio-carcinoma
N= 19
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MDCT OR IOUS OR MRI OR FMRI OR NMRI OR FNMRI
AND
liver OR hepato* OR hepatic* OR FLL OR FLLs OR hepatoma* OR hemangiosarcoma* OR hemangio-
sarcoma* OR haemangiosarcoma* OR haemangio-sarcoma* OR BFLL OR BFLLS OR HCC OR HCCs OR 
Cholangiocarcinoma* OR Cholangio-carcinoma
N= 17
pet OR petscan* OR positron OR CAT OR CTA
AND 
liver OR hepato* OR hepatic* OR FLL OR FLLs OR hepatoma* OR hemangiosarcoma* OR hemangio-
sarcoma* OR haemangiosarcoma* OR haemangio-sarcoma* OR BFLL OR BFLLS OR HCC OR HCCs OR 
Cholangiocarcinoma* OR Cholangio-carcinoma
N= 11
CT OR cine-ct OR 3dcta OR 3d-cta
AND 
liver OR hepato* OR hepatic* OR FLL OR FLLs OR hepatoma* OR hemangiosarcoma* OR hemangio-
sarcoma* OR haemangiosarcoma* OR haemangio-sarcoma* OR BFLL OR BFLLS OR HCC OR HCCs OR 
Cholangiocarcinoma* OR Cholangio-carcinoma
N=58
64slice* OR 64-slice* OR 64row* OR 64-row* OR 64-detect*
AND 
liver OR hepato* OR hepatic* OR FLL OR FLLs OR hepatoma* OR hemangiosarcoma* OR hemangio-
sarcoma* OR haemangiosarcoma* OR haemangio-sarcoma* OR BFLL OR BFLLS OR HCC OR HCCs OR 
Cholangiocarcinoma* OR Cholangio-carcinoma
N= 0
scan* OR imag* OR tomogra* OR angiogra* OR angio-gra* OR xray* OR x-ray*
AND
liver OR hepato* OR hepatic* OR FLL OR FLLs OR hepatoma* OR hemangiosarcoma* OR hemangio-
sarcoma* OR haemangiosarcoma* OR haemangio-sarcoma* OR BFLL OR BFLLS OR HCC OR HCCs OR 
Cholangiocarcinoma* OR Cholangio-carcinoma
N= 128
MR AND imag*
AND
liver OR hepato* OR hepatic* OR FLL OR FLLs OR hepatoma* OR hemangiosarcoma* OR hemangio-
sarcoma* OR haemangiosarcoma* OR haemangio-sarcoma* OR BFLL OR BFLLS OR HCC OR HCCs OR 
Cholangiocarcinoma* OR Cholangio-carcinoma
N= 5
Echo-tomogra* OR doptone OR Echogra* 
AND 
liver OR hepato* OR hepatic* OR FLL OR FLLs OR hepatoma* OR hemangiosarcoma* OR hemangio-
sarcoma* OR haemangiosarcoma* OR haemangio-sarcoma* OR BFLL OR BFLLS OR HCC OR HCCs OR 
Cholangiocarcinoma* OR Cholangio-carcinoma
N= 0
zeugmatogra* OR echogra* OR tomoechogra* OR tomodensitomet* OR echoscope* OR echosound*
AND 
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liver OR hepato* OR hepatic* OR FLL OR FLLs OR hepatoma* OR hemangiosarcoma* OR hemangio-
sarcoma* OR haemangiosarcoma* OR haemangio-sarcoma* OR BFLL OR BFLLS OR HCC OR HCCs OR 
Cholangiocarcinoma* OR Cholangio-carcinoma
N=0
HEED search retrieved 128 records.
Science Citation Index (Web of Science): 2000–7 October 2011
Searched 12 October 2011.
#34 432 #8 AND #22 AND #33
#33 407,965 #27 NOT #32
#32 1,077,839 #31 OR #30 OR #29 OR #28
#31 1,035,567 TS=(cat or cats or dog or dogs or animal or animals or rat or rats or hamster or 
hamster or feline or ovine or canine or bovine or sheep)
#30 14,241 TS=((energy or oxygen) SAME expenditure)
#29 4365 TS=(metabolic SAME cost)
#28 31,943 TS=((energy or oxygen) SAME cost)
#27 461,648 #23 OR #24 OR #25 OR #26
#26 27,939 TS=(budget*)
#25 561 TS=(value NEAR/1 money)
#24 9239 TS=(expenditure* not energy)
#23 435,234 TS=(economic* or cost or costs or costly or costing or price or prices or pricing 
or pharmacoeconomic*)
#22 616,323 #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 
OR #19 OR #20 OR #21
#21 37,784 TS=(Positron SAME emission SAME tomogra*)
#20 301 TS=((Un-enhanced or Unenhanced) near/4 (sonogra* or ultra-so* or ultraso* 
or Echotomogra* or Echo-tomogra* or doptone or echoscope* or echosound* 
or tomogra* or Echogra* or zeugmatogra* or echogra* or tomoechogra* 
or tomodensitomet*))
#19 318,584 TS=(ultraso* or ultra-so* or sonogra* or Echotomogra* or Echo-tomogra* or 
doptone or echoscope* or echosound* or tomogra* or Echogra* or zeugmatogra* 
or echogra* or tomoechogra* or tomodensitomet*)
#18 39,221 TS=(MR SAME imag*)
#17 3837 TS=((ultrasonic* or ultra-sonic*) near/4 (scan or imag* or tomogra* or echogram* 
or sonogra* or detect* or diagnos* or scintillat* or exam*))
#16 1747 TS=(Chemical SAME shift SAME imag*)
#15 19,251 TS=((electron SAME beam) SAME (scan* or imag* or tomogra* or angiogra* or 
angio-gra* or xray* or x-ray*))
#14 153,267 TS=((nmr or comput* or mr) near/4 (scan* or imag* or tomogra* or angiogra* or 
angio-gra* or xray* or x-ray*))
#13 1863 TS=(64slice* or 64-slice* or 64row* or 64-row* or 64-detect*)
#12 143 TS=(3dcta or 3d-cta)
#11 161,518 TS=(CAT or CTA or CT or cine-ct)
#10 82,730 TS=(pet or petscan* or positron)
#9 133,925 TS=(MSCT or MDST or MRI or FDGPET or FDG-PET or MDCT or IOUS or MRI or FMRI 
or NMRI or FNMRI)
#8 239,569 #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#7 9838 TS=((Bile SAME duct*) SAME (cancer* or met* or malignan* or lesion* or 
carcinoma* or tumor* or tumour* or neoplas* or adeno* or angiom* or sarcoma*))
#6 4832 TS=(Cholangiocarcinoma* or Cholangio-carcinoma*)
#5 1970 TI=(BFLL or BFLLS or HCC or HCCs OR FLL or FLLs)
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#4 1584 TS=((Focal SAME liver SAME lesion*) SAME (cancer* or met or mets or metasta* or 
malignan* or carcinoma* or tumor* or tumour* or neoplas* or adeno* or angiom* 
or sarcoma* or angiosarcoma*))
#3 10,317 TS=(hepatoma* or hemangiosarcoma* or hemangio-sarcoma* or 
haemangiosarcoma* or haemangio-sarcoma*)
#2 230,112 TS=((liver* or hepat*) SAME (cancer* or met* or malignan* or carcinoma* 
or tumor* or tumour* or neoplas* or adeno* or angiom* or sarcoma* 
or angiosarcoma*))
#1 24,461 TS=((Metasta* or meta-sta*) AND (liver or hepato* or hepatic*)) 
Additional NHS Economic Evaluation Database search (Wiley)
Search limited to 2000–11.
Searched 21 October 2011.
#1 MeSH descriptor Neoplasm Metastasis, this term only (1725)
#2 MeSH descriptor Neoplasm Seeding, this term only (25)
#3 MeSH descriptor Neoplasms, Unknown Primary, this term only (32)
#4 (Metasta* or meta-sta*):ti,ab,kw (10,876)
#5 (#1 OR #2 OR #3 OR #4) (10,908)
#6 (liver or hepato* or hepatic*):ti,ab,kw (30,235)
#7 (#5 AND #6) (1342)
#8 MeSH descriptor Liver Neoplasms explode all trees (1521)
#9 MeSH descriptor Bile Duct Neoplasms explode all trees (128)
#10 MeSH descriptor Carcinoma, Hepatocellular, this term only (769)
#11 MeSH descriptor Cholangiocarcinoma, this term only (41)
#12 (FLL or FLLs):ti,ab (0)
#13 ((liver* or hepat*) near/3 (cancer* or met* or malignan* or carcinoma* or tumor* or tumour* or 
neoplas* or adeno* or angiom* or sarcoma* or angiosarcoma*)):ti,ab,kw (5985)
#14 (hepatoma* or hemangiosarcoma* or hemangio-sarcoma* or haemangiosarcoma* or haemangio-
sarcoma*):ti,ab,kw (71)
#15 ((Focal NEXT liver NEXT lesion*) and (cancer* or met or mets or metasta* or malignan* 
or carcinoma* or tumor* or tumour* or neoplas* or adeno* or angiom* or sarcoma* or 
angiosarcoma*)):ti,ab,kw (20)
#16 (BFLL or BFLLS or HCC or HCCs):ti,ab (563)
#17 (Cholangiocarcinoma* or Cholangio-carcinoma*):ti,ab,kw (70)
#18 ((Bile NEXT duct*) near/3 (cancer* or met* or malignan* or lesion* or carcinoma* or tumor* or 
tumour* or neoplas* or adeno* or angiom* or sarcoma*)):ti,ab,kw (236)
#19 (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18) 
(6625)
#20 (#19), from 2000 to 2011 (85) (limited to NHS EED only)
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Additional health economics search: guidelines
Guidelines International Network (Internet)
www.g-i-n.net
Search limited to 2000–9 November 2011.
Searched 9 November 2011.
Terms searched Hits Filename
Free-text: FLL OR FLLS OR BFLL OR BFLLS OR HCC OR HCCs 0 –
Free-text: Liver OR hepato* OR hepatic* 111 GU_Gin_res1.end
Free-text: hemangio* 0 –
Free-text: Cholangiocarcinoma* 0 GU_Gin_res2.end
Free-text: Angiosarcoma* 0 –
Free-text: Bile AND duct* 1 GU_Gin_res3.end
MESH: Liver Neoplasms (C04.588.274.623) 20 GU_Gin_res3.end
Free-text: Hepatocellular 5 GU_Gin_res4.end
Total (before deduplication) 137 –
Total (after deduplication) 114 –
National Guidelines Clearinghouse (Internet)
www.guideline.gov/
Search limited to 2000–9 November 2011.
Searched 10 November 2011.
Advanced search
Terms searched Hits
FLL OR FLLS OR BFLL OR BFLLS OR HCC OR HCCs OR Liver OR hepato* OR hepatic* 343
hemangio*OR Cholangiocarcinoma*OR Angiosarcoma* OR (Bile AND duct*) 11
Total 354
National Institute for Health and Care Excellence guidance (Internet)
http://guidance.nice.org.uk/
Searched 10 November 2011.
Browsed: liver neoplasms = 11
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TRIP database (Internet)
www.tripdatabase.com/
Searched 10 November 2011.
Search limited to guidelines only, 2000–11.
Terms searched Hits
(FLL or BFLL or HCC) from:2000 to:2011 45
(title:Liver or hepato* or hepatic) (not FLL or BFLL or HCC) from:2000 to:2011 51
(title:hemangio* or Cholangiocarcinoma*)) (not FLL or BFLL or HCC) from:2000 to:2011 3
(title:bile duct) (not Liver or hepato* or hepatic) from:2000 to:2011 2
Total 101
Health Technology Assessment database (Internet)
www.york.ac.uk/inst/crd/
Search limited to 2000–11.
Searched 10 November 2011.
1. ((Bile NEXT duct*)) IN HTA (10)
2. ((liver or hepato* or hepatic* or FLL or FLLs)) OR ((hepatoma* or hemangiosarcoma* or hemangio-
sarcoma* or haemangiosarcoma* or haemangio-sarcoma*)) OR ((BFLL or BFLLS or HCC or HCCs)) OR 
((Cholangiocarcinoma* or Cholangio-carcinoma*)) IN HTA FROM 2000 TO 2011 (204)
3. #1 OR #2 (209)
4. (#3) IN HTA FROM 2000 TO 2011 (209)
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Appendix 2 Study-specific guide to completion of 
QUADAS-2
The version of QUADAS-2 used in this assessment splits domain 2 into ‘index test’ and ‘comparator’ and includes additional signalling questions to accommodate primary studies that assess multiple tests. 
Only the ‘patient selection’ domain includes an applicability domain as it was considered that the inclusion 
criteria matched the review question for the ‘index test’, ‘comparator’ and ‘reference standard’ domains. 
Before starting the risk of bias assessment we considered the relevance of each signalling question to 
our review, as well as the potential need for additional questions. Further criteria were then defined, as 
needed, to ensure consistent application of signalling questions and to help in the judgement of the risk of 
bias. Many signalling questions were not further specified and the answer was judged to be ‘yes’ if it was 
clearly reported in the study. If the answer to a signalling question was not clearly reported the question 
was judged as ‘unclear’ unless specified differently. ‘No’ was answered if it was clear from the reporting 
that an aspect was not fulfilled. Details of the assessment criteria used are reported below. 
Domain 1: patient selection
Risk of bias
Question 1: Was a consecutive or random sample of patients enrolled? 
 z ‘yes’ = low risk of bias 
 z ‘unclear’ = unclear risk of bias 
 z ‘no’ = high risk of bias.
Question 2: Was a case–control design avoided? 
 z ‘yes’ = low risk of bias 
 z ‘unclear’ = unclear risk of bias 
 z ‘no’ = high risk of bias.
Question 3: Did the study avoid inappropriate exclusions? 
 z ‘no’ for < 10% of patients or ‘yes’ = low risk of bias 
 z ‘unclear’ = unclear risk of bias 
 z ‘no’ for ≥ 10% of patients = high risk of bias.
Concerns regarding applicability
 z Included patients were adults with FLLs with uncertain diagnosis on standard US or other imaging 
modalities = ‘low concern’.
 z Included patients were adults with known liver malignancy who were being assessed for recurrence or 
response to treatment = ‘low concern’.
 z Included patients were adults with FLLs detected on standard US or other imaging, in which it was not 
clear if these examinations were diagnostic = ‘unclear concern’.
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Domain 2a: index test
Risk of bias 
Question 1: Were the index test results interpreted without knowledge of the results of the 
reference standard? 
Question 2: Were the index test results interpreted without knowledge of the comparator?
Question 3: Did the study prespecify the threshold for a positive result? 
The same criteria applied to each of the three signalling questions: 
 z ‘yes’ = low risk of bias 
 z ‘unclear’’ = unclear risk of bias 
 z ‘no’ = high risk of bias.
Domain 2b: comparator test
Risk of bias 
Question 1: Were the comparator test results interpreted without knowledge of the results of the 
reference standard? 
Question 2: Were the comparator test results interpreted without knowledge of the index test?
Question 3: Did the study prespecify the threshold for a positive result? 
The same criteria applied to each of the three signalling questions: 
 z ‘yes’ = low risk of bias 
 z ‘unclear’ = unclear risk of bias 
 z ‘no’ = high risk of bias.
Domain 3: reference standard 
Risk of bias
Question 1: Is the reference standard likely to correctly classify the target condition? 
 z ‘yes’ if ≥ 90% of test results were confirmed using the reference standard specified by the inclusion 
criteria (pathology for test positive and pathology or minimum 6 months’ follow-up for test 
negative) = low risk of bias 
 z ‘unclear’ = unclear risk of bias 
 z ‘no’ if < 90% of test results were confirmed using the reference standard specified by the inclusion 
criteria (pathology for test positive and pathology or minimum 6 months’ follow-up for test 
negative) = high risk of bias.
Question 2: Were the reference standard results interpreted without knowledge of the results of the 
index test? 
Question 3: Were the reference standard results interpreted without knowledge of the results of the 
comparator test? 
The same criteria applied to signalling questions 2 and 3: 
 z ‘yes’ = low risk of bias 
 z ‘unclear’ = unclear risk of bias 
 z ‘no’ = high risk of bias.
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Domain 4: flow and timing 
Question 1: Was there an appropriate interval between index test and reference standard? 
The time interval between index and reference standard (pathology) had to be ≤ 1 month to be judged as 
‘adequate’ and follow-up had to be ≥ 6 months to be judged as ‘adequate’. 
 z ‘no’ for < 10% of patients or ‘yes’ = low risk of bias 
 z the answer was judged to be ‘unclear’ if the time interval was not reported or if it was unclear 
what proportion of patients had an inadequate time interval between index test and reference 
standard = unclear risk of bias
 z ‘no’ for ≥ 10% of patients = high risk of bias.
Question 2: Was there an appropriate interval between comparator test and reference standard? 
The time interval between index and reference standard (pathology) had to be ≤ 1 month to be judged as 
‘adequate’ and follow-up had to be ≥ 6 months to be judged as ‘adequate’. 
 z ‘no’ for < 10% of patients or ‘yes’ = low risk of bias 
 z the answer was judged to be ‘unclear’ if the time interval was not reported or if it was unclear 
what proportion of patients had an inadequate time interval between index test and reference 
standard = unclear risk of bias
 z ‘no’ for ≥ 10% of patients = high risk of bias.
Question 3: Was there an appropriate interval between index test and comparator test? 
The time interval between index and comparator had to be ≤ 1 month to be judged as ‘adequate’.
 z ‘no’ for < 10% of patients or ‘yes’ = low risk of bias 
 z the answer was judged to be ‘unclear’ if the time interval was not reported or if it was unclear 
what proportion of patients had an inadequate time interval between index test and reference 
standard = unclear risk of bias
 z ‘no’ for ≥ 10% of patients = high risk of bias.
Question 4: Did all patients receive a reference standard? 
 z ‘no’ for < 10% of patients or ‘yes’ = low risk of bias 
 z ‘unclear’ = unclear risk of bias 
 z ‘no’ for ≥ 10% of patients = high risk of bias.
Question 5: Did all patients receive the same reference standard?
Acceptable reference standards were defined separately for test-positive and test-negative patients. The 
following criteria are therefore applied separately to test-positive and test-negative patients:
 z ‘no’ for < 10% of test-positive patients and < 10% of test-negative patients, or ‘yes’ = low risk of bias 
 z ‘unclear’ = unclear risk of bias 
 z ‘no’ for ≥ 10% of test-positive or test-negative patients = high risk of bias.
Question 6: Were all patients included in the analysis? 
 z ‘no’ for < 10% of patients or ‘yes’ = low risk of bias 
 z ‘unclear’ = unclear risk of bias 
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 z ‘no’ for ≥ 10% of patients = high risk of bias.
The following criteria were used to reach a per-domain judgement of risk of bias: 
 z if at least one of the signalling questions of a domain had an answer associated with a high risk of 
bias the domain was judged to have a high risk of bias
 z if the answer to any of the signalling questions was ‘unclear’ and the answers to the remaining 
questions were ‘yes’, the risk of bias was judged to be unclear
 z the answer to all the signalling questions had to be ‘yes’ for the domain to be judged as having a low 
risk of bias.
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Appendix 3 Quality assessment: QUADAS-2 
results
T his appendix presents completed QUADAS-2 assessments for all included studies.
Blondin 201148
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection:
Retrospective selection of patients with liver cirrhosis from a database (radiological information system) of patients who 
underwent CEMRI and CEUS 
Was a consecutive or random sample of patients enrolled? No
Was a case–control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Risk: high
B. Concerns regarding applicability
Describe included patients (previous testing, presentation, intended use of index test and setting):
Patients with liver cirrhosis and FLLs diagnosed with CEUS and CEMRI
Is there concern that the included patients do not match the review 
question?
Concern: high
Domain 2a: index test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
CEUS and CEMRI results were interpreted by two experts who were blinded (no more details given on blinding); index and 
comparator tests were conducted with maximum 4 weeks in between
Were the index test results interpreted without knowledge of the results of the 
reference standard?
Unclear
Were the index test results interpreted without knowledge of the comparator? Unclear
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? Risk: unclear
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Domain 2b: comparator test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
CEUS and CEMRI results were interpreted by two experts who were blinded (no more details given on blinding); index and 
comparator test were conducted with maximum 4 weeks in between 
Were the comparator test results interpreted without knowledge of the results of the 
reference standard?
Unclear
Were the comparator test results interpreted without knowledge of the index test? Unclear
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the comparator test have introduced 
bias?
Risk: unclear
Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted:
Histology was carried out for all FLLs, before imaging results were analysed
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the 
index test?
Yes 
Were the reference standard results interpreted without knowledge of the results of the 
comparator test?
Yes
Could methods used to conduct or interpret the reference standard have 
introduced bias?
Risk: low
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded 
from the 2 × 2 table(s):
All patients received each test.
Describe the time interval and any interventions carried out between index, comparator(s) and reference standard:
Time between index and comparator tests and reference standard was not reported. Time between index and comparator 
tests was maximum 4 weeks.
Was there an appropriate interval between index test and reference standard? Unclear
Was there an appropriate interval between comparator test and reference standard? Unclear
Was there an appropriate interval between index test and comparator test? Yes
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Risk: low
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Catala 200752
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection:
Patients ≥ 18 years with FLLs detected on standard US. A total of 213 patients assessed for inclusion, with 77 enrolled
Excluded if pregnant or nursing, if more than 1 month between CEUS and spiral computed tomography (unclear if these 
patients may be systematically different) and if positive lesions not confirmed by pathology
Was a consecutive or random sample of patients enrolled? No
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Risk: high 
B. Concerns regarding applicability
Describe included patients (previous testing, presentation, intended use of index test and setting):
Adult patients with FLLs detected at standard US. Not clear if standard US was diagnostic
Is there concern that the included patients do not match the review question? Concern: unclear
Domain 2a: index test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
Independently, by experienced radiologists, who were unaware of the diagnosis and the results of other imaging tests
Were the index test results interpreted without knowledge of the results of the reference 
standard?
Yes
Were the index test results interpreted without knowledge of the comparator? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? Risk: low 
Domain 2b: comparator test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
Independently, by experienced radiologists, who were unaware of the diagnosis and the results of other imaging tests
Were the comparator test results interpreted without knowledge of the results of the reference 
standard?
Yes
Were the comparator test results interpreted without knowledge of the index test? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the comparator test have introduced bias? Risk: low 
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Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted:
All index test-positive FLLs were confirmed pathologically following biopsy or surgery. Index test-negative lesions were 
confirmed by MRI and a minimum of 12 months’ follow-up
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index 
test?
Unclear
Were the reference standard results interpreted without knowledge of the results of the 
comparator test?
Unclear
Could methods used to conduct or interpret the reference standard have 
introduced bias?
Risk: unclear 
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded 
from the 2 × 2 table(s):
A total of 213 patients were originally recruited; 77 were included in the analysis. Patients were excluded if there was 
> 1 month between CEUS and SCT, or if positive lesions were not confirmed by pathology
Describe the time interval and any interventions between index, comparator(s) and reference standard:
Time between index test and comparator was ≤ 1 month; time between tests and pathology reference standard not 
specified; follow-up period appropriate
Was there an appropriate interval between index test and reference standard? Unclear
Was there an appropriate interval between comparator test and reference standard? Unclear
Was there an appropriate interval between index test and comparator test? Yes
Did all patients receive a reference standard? No
Did patients receive the same reference standard? No
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Risk: high 
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State 
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17160 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 16
157
Clevert 200951
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection:
Prospective cohort of 100 consecutive patients with suspected hepatic tumours
Exclusion criteria were lesion > 5 cm, more than five lesions, strong allergic reactions, liver or kidney disease with confirmed 
elevation of laboratory parameters, acute heart failure, acute myocardial infarction, subcutaneous emphysema, meteorism, 
tachypnea and aerobilia
The majority of test-positive patients were diagnosed with liver metastases, but previous investigations and diagnostic 
status with respect to primary tumours were unclear
Was a consecutive or random sample of patients enrolled?
Was a case–control design avoided?
Yes
Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Risk: low 
B. Concerns regarding applicability
Describe included patients (previous testing, presentation, intended use of index test and setting):
Previous investigations and diagnostic status with respect to primary tumours were unclear
Is there concern that the included patients do not match the review question? Concern: unclear
Domain 2a: index test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
CEUS interpreters blinded. Reference standard performed after both tests
Were the index test results interpreted without knowledge of the results of the reference standard?
Were the index test results interpreted without knowledge of the comparator?
If a threshold was used, was it prespecified?
Yes
Yes
Yes
Could the conduct or interpretation of the index test have introduced bias? Risk: low 
Domain 2b: comparator test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
Interpreted blind to index test; reference standard performed after both tests
Were the comparator test results interpreted without knowledge of the results of the reference 
standard?
Yes
Were the comparator test results interpreted without knowledge of the index test? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the comparator test have introduced bias? Risk: low 
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Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted:
No details of blinding or interpretation reported
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Were the reference standard results interpreted without knowledge of the results of the comparator 
test?
Unclear
Could methods used to conduct or interpret the reference standard have introduced 
bias?
Risk: unclear 
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded 
from the 2 × 2 table(s):
100 patients, with one lesion per patient. Positive tests were confirmed histologically and negative tests by imaging follow-
up over 2 years. A total of 21 patients were excluded from the CT analysis (eight did not undergo CT and 13 had non-
diagnostic CT results)
Describe the time interval and any interventions between index, comparator(s) and reference standard:
Imaging tests were performed on the same day. Follow-up was > 6 months but time between imaging and histological 
confirmation was not reported
Was there an appropriate interval between index test and reference standard? Unclear
Was there an appropriate interval between comparator test and reference standard? Unclear
Was there an appropriate interval between index test and comparator test? Yes
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Risk: high
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Dai 200843
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection:
498 consecutive patients with cirrhosis; study included 72 patients with 103 indeterminate liver nodules detected on 
surveillance US
Nine patients had been previously treated for HCC
Was a consecutive or random sample of patients enrolled? Yes
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Risk: low 
B. Concerns regarding applicability
Describe included patients (previous testing, presentation, intended use of index test and setting):
Adult patients with cirrhosis and indeterminate FLLs detected at surveillance US 
Is there concern that the included patients do not match the review question? Concern: low
Domain 2a: index test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
In consensus, by two experienced sonologists, who were unaware of the diagnosis and the results of other imaging tests
Were the index test results interpreted without knowledge of the results of the reference 
standard?
Yes
Were the index test results interpreted without knowledge of the comparator? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? Risk: low 
Domain 2b: comparator test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
In consensus, by two experienced radiologists, who were unaware of the diagnosis and the results of other imaging tests
Were the comparator test results interpreted without knowledge of the results of the 
reference standard?
Yes
Were the comparator test results interpreted without knowledge of the index test? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the comparator test have introduced bias? Risk: low 
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Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted:
All patients underwent biopsy (malignant and benign FLLs) within 15 days after CEUS; a negative biopsy was followed up 
for at least 6 months, including US, CT and testing for AFP
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index 
test?
Unclear
Were the reference standard results interpreted without knowledge of the results of the 
comparator test?
Unclear
Could methods used to conduct or interpret the reference standard have 
introduced bias?
Risk: unclear 
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded 
from the 2 × 2 table(s):
498 patients with cirrhosis; 72 with indeterminate liver nodules on US were included in the study
Describe the time interval and any interventions between index, comparator(s) and reference standard:
All patients underwent biopsy within 15 days after CEUS; all patients underwent CECT within 15 days before or after CEUS
Was there an appropriate interval between index test and reference standard? Yes
Was there an appropriate interval between comparator test and reference standard? Yes
Was there an appropriate interval between index test and comparator test? Yes
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Risk: low
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Feng 200757
Chinese-language paper.
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection:
Prospective cohort of 23 patients with 26 malignant lesions (23 HCC and three metastases) undergoing cryosurgery
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Risk: unclear 
B. Concerns regarding applicability
Describe included patients (previous testing, presentation, intended use of index test and setting):
Patients being assessed for treatment response
Is there concern that the included patients do not match the review question? Concern: low
Domain 2a: index test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
No details of interpretation reported. Reference standard followed imaging
Were the index test results interpreted without knowledge of the results of the reference 
standard?
Yes
Were the index test results interpreted without knowledge of the comparator? Unclear
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? Risk: unclear 
Domain 2b: comparator test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
No details of interpretation reported. Reference standard followed imaging
Were the comparator test results interpreted without knowledge of the results of the reference 
standard?
Yes
Were the comparator test results interpreted without knowledge of the index test? Unclear
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the comparator test have introduced bias? Risk: unclear 
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Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted:
Unclear if those making the diagnosis were aware of imaging results
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index 
test?
Unclear
Were the reference standard results interpreted without knowledge of the results of the 
comparator test?
Unclear
Could methods used to conduct or interpret the reference standard have 
introduced bias?
Risk: unclear 
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded 
from the 2 × 2 table(s):
All patients underwent imaging tests within 2 weeks of each other and within 1 week to 3 months after treatment. All 
diagnoses were confirmed by histopathology
Describe the time interval and any interventions between index, comparator(s) and reference standard:
Time between imaging tests and reference standard was not reported
Was there an appropriate interval between index test and reference standard? Unclear
Was there an appropriate interval between comparator test and reference standard? Unclear
Was there an appropriate interval between index test and comparator test? Yes
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Risk: unclear
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State 
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17160 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 16
163
Flor 201039
Abstract only.
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection:
Prospective cohort of 18 patients with known primary cancer and indeterminate liver lesions (< 1.5 cm) detected at MDCT
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Risk: unclear
B. Concerns regarding applicability
Describe included patients (previous testing, presentation, intended use of index test and setting):
Patients with known primary cancer and indeterminate liver lesions (< 1.5 cm) detected at MDCT
Is there concern that the included patients do not match the review question? Concern: low
Domain 2a: index test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
No details reported
Were the index test results interpreted without knowledge of the results of the reference 
standard?
Unclear
If a threshold was used, was it prespecified? Unclear
Could the conduct or interpretation of the index test have introduced bias? Risk: unclear 
Domain 2b: comparator test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
Not applicable
Were the comparator test results interpreted without knowledge of the results of the 
reference standard?
Were the comparator test results interpreted without knowledge of the index test?
If a threshold was used, was it prespecified?
Could the conduct or interpretation of the comparator test have introduced bias? Risk: not applicable
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Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted:
Biopsy or 3- to 6-month follow-up was used as the reference standard. No further details were reported
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index 
test?
Unclear
Were the reference standard results interpreted without knowledge of the results of the 
comparator test?
Not applicable
Could methods used to conduct or interpret the reference standard have 
introduced bias?
Risk: unclear 
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded 
from the 2 × 2 table(s):
All 18 patients appear to have received a reference standard. Numbers confirmed by biopsy/follow-up were not reported
Describe the time interval and any interventions between index, comparator(s) and reference standard:
Time between index test and biopsy was not reported
Was there an appropriate interval between index test and reference standard? Unclear
Was there an appropriate interval between comparator test and reference standard? Not applicable
Was there an appropriate interval between index test and comparator test? Not applicable
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Unclear
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Risk: unclear
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Forner 200844
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection:
Prospective cohort of 89 patients with Child–Pugh A/B cirrhosis and a new solid (5–20 mm) nodule detected on surveillance 
US
No patients had history of HCC
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Risk: unclear 
B. Concerns regarding applicability
Describe included patients (previous testing, presentation, intended use of index test and setting):
Adult patients with cirrhosis and new FLLs detected at surveillance US. Diagnostic status following conventional US was 
not specified
Is there concern that the included patients do not match the review question? Concern: unclear
Domain 2a: index test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
Interpreted by two experienced radiologists. Article states ‘blindly’, but nature of blinding is unspecified
Were the index test results interpreted without knowledge of the results of the reference 
standard?
Unclear
Were the index test results interpreted without knowledge of the comparator? Unclear
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? Risk: unclear 
Domain 2b: comparator test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
Interpreted by two experienced radiologists who were unaware of biopsy results
Were the comparator test results interpreted without knowledge of the results of the reference 
standard?
Yes
Were the comparator test results interpreted without knowledge of the index test? Unclear
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the comparator test have introduced bias? Risk: low 
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Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted:
All index test-positive FLLs were confirmed pathologically following biopsy or surgery. Index test-negative lesions were 
confirmed by MRI and a minimum of 12 months’ follow-up
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index 
test?
Unclear
Were the reference standard results interpreted without knowledge of the results of the 
comparator test?
Unclear
Could methods used to conduct or interpret the reference standard have 
introduced bias?
Risk: unclear 
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded 
from the 2 × 2 table(s):
89 patients all received index test, comparator and a reference standard
Describe the time interval and any interventions between index, comparator(s) and reference standard:
Times between index test, comparator and reference standard were not reported
Was there an appropriate interval between index test and reference standard? Unclear
Was there an appropriate interval between comparator test and reference standard? Unclear
Was there an appropriate interval between index test and comparator test? Unclear
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Risk: unclear
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Westwood et al. under the terms of a commissioning contract issued by the Secretary of State 
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17160 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 16
167
Georgio 200745
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection:
Prospective cohort of 73 consecutive patients with cirrhosis and a single nodule (≤ 30 mm) detected on US
Patients with a history of heart disease excluded (because of a rare side effect of SonoVue)
Was a consecutive or random sample of patients enrolled? Yes
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Risk: low 
B. Concerns regarding applicability
Describe included patients (previous testing, presentation, intended use of index test and setting):
Adult patients with cirrhosis and single FLL detected at US. Diagnostic status following conventional US was not specified
Is there concern that the included patients do not match the review question? Concern: unclear
Domain 2a: index test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
Interpreted by one operator with 20 years’ experience. Index test performed before comparator and reference standard
Were the index test results interpreted without knowledge of the results of the reference 
standard?
Yes
Were the index test results interpreted without knowledge of the comparator? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? Risk: low 
Domain 2b: comparator test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
Interpreted by one radiologist who was unaware of index test results. Comparator test performed before reference 
standard
Were the comparator test results interpreted without knowledge of the results of the reference 
standard?
Yes
Were the comparator test results interpreted without knowledge of the index test? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the comparator test have introduced bias? Risk: low 
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Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted:
Biopsy performed in all patients the day after both imaging studies were complete. No details of blinding were reported
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index 
test?
Unclear
Were the reference standard results interpreted without knowledge of the results of the 
comparator test?
Unclear
Could methods used to conduct or interpret the reference standard have introduced 
bias?
Risk: unclear 
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded 
from the 2 × 2 table(s):
73 patients all received the index test, comparator and a reference standard; same reference standard was used in all 
patients
Describe the time interval and any interventions between index, comparator(s) and reference standard:
Comparator was performed the day after the index test and the reference standard the day after that
Was there an appropriate interval between index test and reference standard? Yes
Was there an appropriate interval between comparator test and reference standard? Yes
Was there an appropriate interval between index test and comparator test? Yes
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Risk: low
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Gierbli ´nski 200853
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection:
Prospective cohort of 100 patients with incidentally detected liver lesions and inconclusive unenhanced US and/or CT. 
Patients with current or previous malignancy, with lesions with features of haemangioma or who were unable to undergo 
biopsy were excluded
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? Risk: high
B. Concerns regarding applicability
Describe included patients (previous testing, presentation, intended use of index test and setting):
Adult patients with incidentally detected FLLs in whom US and/or CT could not rule out malignancy. Not clear how many 
patients had CT
Is there concern that the included patients do not match the review question? Concern: unclear
Domain 2a: index test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
Interpreted by two experienced gastroenterologists; blinding unspecified
Were the index test results interpreted without knowledge of the results of the reference 
standard?
Unclear
Were the index test results interpreted without knowledge of the comparator? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? Risk: unclear 
Domain 2b: comparator test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
Not applicable
Were the comparator test results interpreted without knowledge of the results of the reference 
standard?
Were the comparator test results interpreted without knowledge of the index test?
If a threshold was used, was it prespecified?
Could the conduct or interpretation of the comparator test have introduced bias? Risk: not applicable
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Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted:
All FLLs were confirmed pathologically following biopsy. Biopsy-negative lesions were confirmed by clinical and imaging 
follow-up
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index 
test?
Yes
Were the reference standard results interpreted without knowledge of the results of the 
comparator test?
Not applicable
Could methods used to conduct or interpret the reference standard have introduced 
bias?
Risk: low 
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded 
from the 2 × 2 table(s):
89 patients all received index test, comparator and a reference standard
Describe the time interval and any interventions between index, comparator(s) and reference standard:
Time between index test and reference standard was not reported
Was there an appropriate interval between index test and reference standard? Unclear
Was there an appropriate interval between comparator test and reference standard? Not applicable
Was there an appropriate interval between index test and comparator test? Not applicable
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Risk: unclear
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Jonas 201150
Abstract only.
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection:
Prospective cohort of 20 consecutive patients with CRC liver metastases who could be rendered tumour free by a single-
stage surgical intervention and who underwent complete preoperative workup
Note: study states aim as determining the sensitivity and specificity for detection of metastases, but all included patients 
appear to have metastases
Patients with concomitant resectable extrahepatic disease and previous hepatobiliary surgery, other than cholecystectomy, 
were excluded
Was a consecutive or random sample of patients enrolled? Yes
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? Risk: high 
B. Concerns regarding applicability
Describe included patients (previous testing, presentation, intended use of index test and setting):
Adult patients with CRC liver metastases. Initial diagnostic status unclear (see previous note)
Is there concern that the included patients do not match the review question? Concern: high
Domain 2a: index test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
No details of blinding or interpretation reported
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
Were the index test results interpreted without knowledge of the comparator? Unclear
If a threshold was used, was it prespecified? Unclear
Could the conduct or interpretation of the index test have introduced bias? Risk: unclear 
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Domain 2b: comparator test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
No details of blinding or interpretation reported
Were the comparator test results interpreted without knowledge of the results of the reference 
standard?
Unclear
Were the comparator test results interpreted without knowledge of the index test? Unclear
If a threshold was used, was it prespecified? Unclear
Could the conduct or interpretation of the comparator test have introduced bias? Risk: unclear 
Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted:
No details of blinding or interpretation reported
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Were the reference standard results interpreted without knowledge of the results of the 
comparator test?
Unclear
Could methods used to conduct or interpret the reference standard have introduced 
bias?
Risk: unclear 
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded 
from the 2 × 2 table(s):
20 patients, 48 lesions, by lesion analysis. All patients appear to have received index test and both comparators. All 
resected, imaging-positive lesions were confirmed histologically and all patients had at least 36 months’ imaging follow-
up. Per 2 × 2 patient data were not reported/derivable and the number of lesions per patient was unclear
Describe the time interval and any interventions between index, comparator(s) and reference standard:
No details of the timing of the tests were reported
Was there an appropriate interval between index test and reference standard? Unclear
Was there an appropriate interval between comparator test and reference standard? Unclear
Was there an appropriate interval between index test and comparator test? Unclear
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Unclear
Could the patient flow have introduced bias? Risk: unclear
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Leoni 201042
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection:
Prospective consecutive cohort of cirrhotic patients with one to three hepatic nodules between 1 and 3 cm on US 
surveillance. Included both newly detected and recurrence of nodules
Patients in whom the nodules to be included in the study had been pretreated, those with contraindications to imaging 
and those with neoplastic portal thrombosis or extrahepatic metastases were excluded
Was a consecutive or random sample of patients enrolled? Yes
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? Risk: high 
B. Concerns regarding applicability
Describe included patients (previous testing, presentation, intended use of index test and setting):
Diagnostic status following unenhanced imaging unclear
Is there concern that the included patients do not match the review question? Concern: unclear
Domain 2a: index test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
Unclear if those interpreting CEUS had knowledge of other imaging test results
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
Were the index test results interpreted without knowledge of the comparator? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? Risk: low 
Domain 2b: comparator test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
Interpreted blind to other imaging test results, and biopsy/follow-up occurred after imaging
Were the comparator test results interpreted without knowledge of the results of the reference 
standard?
Yes
Were the index test results interpreted without knowledge of the comparator? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the comparator test have introduced bias? Risk: low 
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Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted:
Non-invasive positive diagnoses were interpreted without knowledge of other imaging studies. No details of interpretation 
of biopsy and follow-up were reported
Is the reference standard likely to correctly classify the target condition? No
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Were the reference standard results interpreted without knowledge of the results of the comparator 
test?
Unclear
Could methods used to conduct or interpret the reference standard have introduced 
bias?
Risk: high
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded 
from the 2 × 2 table(s):
Prospective cohort of 60 cirrhotic patients with at least one to three hepatic nodules (1–3 cm) on US (75 nodules). Positive 
nodules confirmed by two concordant imaging test results, FNB or follow-up at 3-month intervals. Negative nodules 
confirmed by FNB or follow-up at 3-month intervals. Seven nodules (< 10%) were not examined by SPIO-MRI and were 
excluded from the analysis of test performance
Describe the time interval and any interventions between index, comparator(s) and reference standard:
No details of the timing of examinations were reported
Was there an appropriate interval between index test and reference standard? Unclear
Was there an appropriate interval between comparator test and reference standard? Unclear
Was there an appropriate interval between index test and comparator test? Unclear
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? No
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Risk: high
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Li 200754
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection:
Prospective cohort of 109 patients examined with unenhanced US and unenhanced CT. Exclusions not specified
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Risk: unclear 
B. Concerns regarding applicability
Describe included patients (previous testing, presentation, intended use of index test and setting):
Diagnostic status following baseline imaging unclear
Is there concern that the included patients do not match the review question? Concern: unclear
Domain 2a: index test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
Interpreted blind to comparator; reference standard performed after both tests
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
Were the index test results interpreted without knowledge of the comparator? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? Risk: low 
Domain 2b: comparator test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
Interpreted blind to index test; reference standard performed after both tests
Were the comparator test results interpreted without knowledge of the results of the reference 
standard?
Yes
Were the comparator test results interpreted without knowledge of the index test? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the comparator test have introduced bias? Risk: low 
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Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted:
No details of blinding or interpretation reported
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Were the reference standard results interpreted without knowledge of the results of the comparator 
test?
Unclear
Could methods used to conduct or interpret the reference standard have introduced 
bias?
Risk: unclear 
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded 
from the 2 × 2 table(s):
109 patients, one lesion per patient. All patients appear to have received the index test, comparator and reference 
standard. Reference standard was histology in all patients. Seven lesions could not be visualised by CECT and three could 
not be visualised by CEUS. For our analysis, non-visualised lesions were classified as negative (false-negative or true-
negative according to final diagnosis)
Describe the time interval and any interventions between index, comparator(s) and reference standard:
Reference standard was performed within 2 weeks of the index test and comparator
Was there an appropriate interval between index test and reference standard? Yes
Was there an appropriate interval between comparator test and reference standard? Yes
Was there an appropriate interval between index test and comparator test? Yes
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Risk: low
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Lüttich 200640
Abstract only.
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection:
Cohort of 15 patients with HCC lesions undergoing RFA treatment
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Risk: unclear 
B. Concerns regarding applicability
Describe included patients (previous testing, presentation, intended use of index test and setting):
Patients being assessed for response to treatment
Is there concern that the included patients do not match the review question? Concern: low
Domain 2a: index test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
No details of interpretation reported. Reference standard followed CEUS
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
Were the index test results interpreted without knowledge of the comparator? Unclear
If a threshold was used, was it prespecified? Unclear
Could the conduct or interpretation of the index test have introduced bias? Risk: unclear 
Domain 2b: comparator test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
No details of interpretation reported. Reference standard followed CEUS
Were the comparator test results interpreted without knowledge of the results of the reference 
standard?
Unclear
Were the comparator test results interpreted without knowledge of the index test? Unclear
If a threshold was used, was it prespecified? Unclear
Could the conduct or interpretation of the comparator test have introduced bias? Risk: unclear 
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Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted:
Unclear if those making the diagnosis were aware of imaging results
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Were the reference standard results interpreted without knowledge of the results of the comparator 
test?
Unclear
Could methods used to conduct or interpret the reference standard have introduced 
bias?
Risk: unclear 
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded 
from the 2 × 2 table(s):
All patients underwent both imaging tests within 4 weeks of treatment. All patients had results confirmed by biopsy
Describe the time interval and any interventions between index, comparator(s) and reference standard:
Time between tests and reference standard was not reported
Was there an appropriate interval between index test and reference standard? Unclear
Was there an appropriate interval between comparator test and reference standard? Unclear
Was there an appropriate interval between index test and comparator test? Yes
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Risk: unclear
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Mainenti 201049
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection:
Prospective cohort of 34 consecutive patients with histologically proven CRC who were scheduled for surgery
Patients who refused to participate and those who had contraindications to one of the examinations were excluded
Was a consecutive or random sample of patients enrolled? Yes
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Risk: low 
B. Concerns regarding applicability
Describe included patients (previous testing, presentation, intended use of index test and setting):
Diagnostic status following unenhanced imaging unclear
Is there concern that the included patients do not match the review question? Concern: unclear
Domain 2a: index test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
Interpreted blind to comparator; reference standard performed after both tests
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
Were the index test results interpreted without knowledge of the comparator? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? Risk: low 
Domain 2b: comparator test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
Interpreted blind to index test; reference standard performed after both tests
Were the comparator test results interpreted without knowledge of the results of the reference 
standard?
Yes
Were the comparator test results interpreted without knowledge of the index test? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the comparator test have introduced bias? Risk: low 
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Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted:
No details of blinding or interpretation reported
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Were the reference standard results interpreted without knowledge of the results of the 
comparator test?
Unclear
Could methods used to conduct or interpret the reference standard have introduced 
bias?
Risk: unclear 
Domain 4: flow and timing
A. Risk of Bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded 
from the 2 × 2 table(s):
34 patients, 57 lesions; both per-lesion and per-patient data reported. Positive tests were confirmed by biopsy or resection. 
All patients were followed up for 6 and 12 months, either to confirm negative tests or to detect newly developed 
metastases
Describe the time interval and any interventions between index, comparator(s) and reference standard:
Surgery was performed within 10 days of imaging and imaging tests were performed over a 4- to 8-day period
Was there an appropriate interval between index test and reference standard? Yes
Was there an appropriate interval between comparator test and reference standard? Yes
Was there an appropriate interval between index test and comparator test? Yes
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Risk: low
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Quaia 200946
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection:
Prospective cohort of cirrhotic patients with at least one hepatic nodule on US surveillance
Only those nodules ≤ 3 cm that underwent biopsy after CT were included
Nodules with peripheral enhancement at CECT were excluded because of a high probability of haemangioma diagnosis
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? Risk: high 
B. Concerns regarding applicability
Describe included patients (previous testing, presentation, intended use of index test and setting):
Diagnostic status following unenhanced imaging unclear
Is there concern that the included patients do not match the review question? Concern: unclear
Domain 2a: index test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
Interpreted blind to comparator, reference standard and clinical details
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
Were the index test results interpreted without knowledge of the comparator? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? Risk: low 
Domain 2b: comparator test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
Interpreted blind to index test, reference standard and clinical details
Were the comparator test results interpreted without knowledge of the results of the reference 
standard?
Yes
Were the comparator test results interpreted without knowledge of the index test? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the comparator test have introduced bias? Risk: low 
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Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted:
No details of blinding or interpretation reported
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Were the reference standard results interpreted without knowledge of the results of the 
comparator test?
Unclear
Could methods used to conduct or interpret the reference standard have introduced 
bias?
Risk: unclear 
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded 
from the 2 × 2 table(s):
Prospective cohort of 180 cirrhotic patients with at least one hepatic nodule on US surveillance (195 nodules)
74 nodules were excluded because of a lack of histological diagnosis (n = 60), technical inadequacy of CT (n = 10) or 
inadequacy of CEUS examination (n = 4); 106 patients with 121 nodules finally included
Reference standard biopsy in all nodules
Describe the time interval and any interventions between index, comparator(s) and reference standard:
CT was performed 2–30 days after CEUS. Biopsy was within 15 days of CT
Was there an appropriate interval between index test and reference standard? Yes
Was there an appropriate interval between comparator test and reference standard? Yes
Was there an appropriate interval between index test and comparator test? Yes
Did all patients receive a reference standard? No
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Risk: high
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Sangiovanni 201047,61
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection:
Prospective cohort of cirrhotic patients with at least one hepatic nodule on US surveillance
Only 1- to 2-cm nodules were included in the analysis
Patients with a pre-existing liver nodule, poor liver function indicating transplantation regardless of HCC, or no defined 
nodule were excluded
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? Risk: high 
B. Concerns regarding applicability
Describe included patients (previous testing, presentation, intended use of index test and setting):
Diagnostic status following unenhanced imaging unclear
Is there concern that the included patients do not match the review question? Concern: unclear
Domain 2a: index test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
Interpreted blind to reference standard
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
Were the index test results interpreted without knowledge of the comparator? Unclear
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? Risk: unclear 
Domain 2b: comparator test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
Interpreted blind to reference standard
Were the comparator test results interpreted without knowledge of the results of the reference 
standard?
Yes
Were the comparator test results interpreted without knowledge of the index test? Unclear
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the comparator test have introduced bias? Risk: unclear 
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Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted:
Reference standard interpreted without knowledge of clinical or imaging results
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Yes
Were the reference standard results interpreted without knowledge of the results of the comparator 
test?
Yes
Could methods used to conduct or interpret the reference standard have introduced 
bias?
Risk: low 
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded 
from the 2 × 2 table(s):
Prospective cohort of 64 cirrhotic patients with at least one hepatic nodule (67 nodules). All nodules confirmed by biopsy
Describe the time interval and any interventions between index, comparator(s) and reference standard:
Biopsy was performed within 2 months of nodule detection
Was there an appropriate interval between index test and reference standard? Yes
Was there an appropriate interval between comparator test and reference standard? Unclear
Was there an appropriate interval between index test and comparator test? Unclear
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Risk: high
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Seitz 200955
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection:
The study used a cohort of 267 out of 1349 patients of a prospective study of consecutive patients with newly detected 
FLLs identified on US. The 267 patients were divided into subgroups A and B. Subgroup A had mainly benign diagnoses 
and subgroup B had mainly malignant diagnosis; 2 × 2 data with an appropriate reference standard were extractable only 
for subgroup B
Patients with specific liver lesions diagnosed by typical US echomorphology, such as cysts or haemangiomas, in a non-
steatotic liver without clinical signs and symptoms, as well as malignant tumours with infiltration into hepatic vessels, 
were excluded; patients who were critically ill or who suffered from pulmonary hypertension or unstable angina, as well as 
pregnant and nursing women, were also excluded.
Was a consecutive or random sample of patients enrolled? No
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? Risk: high
B. Concerns regarding applicability
Describe included patients (previous testing, presentation, intended use of index test and setting):
Patients with newly detected FLLs on US; primary diseases not specified
Is there concern that the included patients do not match the review question? Concern: unclear
Domain 2a: index test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
The definitive CEUS diagnosis was made at the time of the US examination by the physician performing CEUS; US carried 
out by the local investigators; US investigator not blinded to the results of the preceding CT in eight cases
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
Were the index test results interpreted without knowledge of the comparator? Yes
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? Risk: unclear
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Domain 2b: comparator test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
No details of blinding reported. Reporting radiologists had access to the patients’ clinical information
Were the comparator test results interpreted without knowledge of the results of the reference 
standard?
Unclear
Were the comparator test results interpreted without knowledge of the index test? Unclear
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the comparator test have introduced bias? Risk: unclear
Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted:
Subgroup B: diagnosis was based on US-guided FNB; no definitive diagnosis could be obtained in four patients
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Were the reference standard results interpreted without knowledge of the results of the comparator 
test?
Unclear
Could methods used to conduct or interpret the reference standard have introduced 
bias?
Risk: unclear
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded 
from the 2 × 2 table(s):
Four patients with inconclusive histology were excluded from the analyses (< 10% of patients)
Describe the time interval and any interventions between index, comparator(s) and reference standard:
Times between index and comparator tests and reference standard were not reported
Was there an appropriate interval between index test and reference standard? Unclear
Was there an appropriate interval between comparator test and reference standard? Unclear
Was there an appropriate interval between index test and comparator test? Unclear
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Risk: unclear
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Seitz 201056
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection:
The study used a cohort of 269 out of 1349 patients of a prospective study of consecutive patients with newly detected 
FLLs identified on US. The 269 patients were divided into subgroups A and B. Subgroup A had mainly benign diagnoses 
and subgroup B had mainly malignant diagnosis; 2 × 2 data with an appropriate reference standard were extractable only 
for subgroup B
Patients with specific liver lesions diagnosed by typical US echomorphology, such as cysts or haemangiomas, in a non-
steatotic liver without clinical signs and symptoms, as well as malignant tumours with infiltration into hepatic vessels, were 
excluded
Was a consecutive or random sample of patients enrolled? No
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? Risk: high
B. Concerns regarding applicability
Describe included patients (previous testing, presentation, intended use of index test and setting):
Patients with newly detected FLLs on US; primary diseases not specified
Is there concern that the included patients do not match the review question? Concern: unclear
Domain 2a: index test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
The definitive CEUS diagnosis was made at the time of the US examination by the physician performing CEUS; US carried 
out by the local investigators
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
Were the index test results interpreted without knowledge of the comparator? Unclear
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? Risk: unclear 
Domain 2b: comparator test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
No details of blinding reported. Reporting radiologists had access to the patients’ clinical information
Were the comparator test results interpreted without knowledge of the results of the reference 
standard?
Unclear
Were the comparator test results interpreted without knowledge of the index test? Unclear
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the comparator test have introduced bias? Risk: unclear
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Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted:
All index test-positive and -negative FLLs were confirmed pathologically following biopsy in subgroup B
Is the reference standard likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Were the reference standard results interpreted without knowledge of the results of the 
comparator test?
Unclear
Could methods used to conduct or interpret the reference standard have introduced 
bias?
Risk: unclear
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded 
from the 2 × 2 table(s):
Two patients with inconclusive histology were excluded from the analyses (< 10% of patients)
Describe the time interval and any interventions between index, comparator(s) and reference standard:
Times between index and comparator tests and reference standard were not reported
Was there an appropriate interval between index test and reference standard? Unclear
Was there an appropriate interval between comparator test and reference standard? Unclear
Was there an appropriate interval between index test and comparator test? Unclear
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Risk: unclear
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Solbiati 200641
Abstract only.
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection:
Retrospective cohort of patients with incidentally detected FLLs on unenhanced US
Was a consecutive or random sample of patients enrolled? No
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Risk: high 
B. Concerns regarding applicability
Describe included patients (previous testing, presentation, intended use of index test and setting):
Diagnostic status following unenhanced imaging unclear
Is there concern that the included patients do not match the review question? Concern: unclear
Domain 2a: index test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
Unclear if those interpreting CEUS had knowledge of other imaging test results. Biopsy performed after imaging
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
Were the index test results interpreted without knowledge of the comparator? Unclear
If a threshold was used, was it prespecified? Unclear
Could the conduct or interpretation of the index test have introduced bias? Risk: unclear 
Domain 2b: comparator test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
Unclear if those interpreting CECT had knowledge of other imaging test results. Biopsy performed after imaging
Were the comparator test results interpreted without knowledge of the results of the reference 
standard?
Unclear
Were the comparator test results interpreted without knowledge of the index test? Unclear
If a threshold was used, was it prespecified? Unclear
Could the conduct or interpretation of the comparator test have introduced bias? Risk: unclear 
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Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted:
Reference standard was a combination of CEUS and CT in most cases. No details of interpretation of biopsy and follow-up 
were reported
Is the reference standard likely to correctly classify the target condition? No
Were the reference standard results interpreted without knowledge of the results of the index test? No
Were the reference standard results interpreted without knowledge of the results of the comparator 
test?
No
Could methods used to conduct or interpret the reference standard have introduced 
bias?
Risk: high
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded 
from the 2 × 2 table(s):
Retrospective cohort of 694 lesions in 686 patients. Reference standard was concordant imaging test results in most 
(n = 656) lesions and FNB in case of discordance (n = 38). One lesion was missing from the analysis
Describe the time interval and any interventions between index, comparator(s) and reference standard:
No details of the timing of examinations were reported
Was there an appropriate interval between index test and reference standard? Unclear
Was there an appropriate interval between comparator test and reference standard? Unclear
Was there an appropriate interval between index test and comparator test? Unclear
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? No
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Risk: high
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Zhou 200758
Chinese-language paper.
Domain 1: patient selection
A. Risk of bias
Describe methods of patient selection:
Retrospective analysis of data from 56 patients with 64 HCC lesions undergoing non-surgical treatment
Was a consecutive or random sample of patients enrolled? Unclear
Was a case–control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Risk: unclear 
B. Concerns regarding applicability
Describe included patients (previous testing, presentation, intended use of index test and setting):
Patients being assessed for response to treatment
Is there concern that the included patients do not match the review question? Concern: low
Domain 2a: index test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
No details of interpretation reported. Reference standard followed imaging
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
Were the index test results interpreted without knowledge of the comparator? Unclear
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the index test have introduced bias? Risk: unclear 
Domain 2b: comparator test
A. Risk of bias
Describe how the index test and any comparator tests were conducted and interpreted:
No details of interpretation reported. Reference standard followed imaging
Were the comparator test results interpreted without knowledge of the results of the reference 
standard?
Yes
Were the comparator test results interpreted without knowledge of the index test? Unclear
If a threshold was used, was it prespecified? Yes
Could the conduct or interpretation of the comparator test have introduced bias? Risk: unclear 
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Domain 3: reference standard
A. Risk of bias
Describe the reference standard and how it was conducted and interpreted:
Unclear if those making the diagnosis were aware of imaging results; 3-month follow-up may not be adequate to confirm 
tumour response
Is the reference standard likely to correctly classify the target condition? Unclear
Were the reference standard results interpreted without knowledge of the results of the index test? Unclear
Were the reference standard results interpreted without knowledge of the results of the comparator 
test?
Unclear
Could methods used to conduct or interpret the reference standard have introduced 
bias?
Risk: unclear 
Domain 4: flow and timing
A. Risk of bias
Describe any patients who did not receive the index test, comparator(s) and/or reference standard or who were excluded 
from the 2 × 2 table(s):
All patients underwent both imaging tests within 1 week of treatment. Patients with a positive response on imaging 
were followed up for 3 months. Patients with a negative response on imaging (residual tumour detected) had diagnosis 
confirmed by FNB
Describe the time interval and any interventions between index, comparator(s) and reference standard:
See above. Note: 3-month follow-up may not be adequate to confirm tumour response
Was there an appropriate interval between index test and reference standard? Unclear
Was there an appropriate interval between comparator test and reference standard? Unclear
Was there an appropriate interval between index test and comparator test? Yes
Did all patients receive a reference standard? Yes
Did patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Risk: unclear
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Appendix 5 Table of excluded studies with 
rationale
The following is a list of studies excluded at the full-paper screening stage of the review, along with the primary reasons for their exclusion. For simplicity, studies were assigned a single reason for exclusion; 
however, many studies failed more than one inclusion criterion. Studies listed in submissions from the 
manufacturer of SonoVue are labelled ‘M’. Studies provided in submissions from manufacturers that 
related solely to clinical applications outside the scope of the current assessment (i.e. anatomy other than 
the liver) are not listed.
The reasons for study exclusion are coded as follows:
Population: The study did not consider characterisation of FLLs (incidentally detected by unenhanced 
US or detected by surveillance US in patients with cirrhosis), detection of liver metastases in patients with 
known primary tumours or assessment of response to treatment/recurrence in patients with liver cancer.
Index test: The study did not assess the effectiveness of CEUS using SonoVue.
Comparator: The study did not compare the effectiveness of CEUS using SonoVue with that of CEMRI 
and/or CECT.
Reference standard: For test accuracy studies, the study did not use histology following biopsy or 
surgical excision or clinical/radiological follow-up for a minimum of 6 months for patients who had a 
negative index test result. For studies on the characterisation of FLLs only (suspected HCC), the EASL/AASLD 
non-invasive diagnostic criteria (two concordant imaging test results) were also considered an acceptable 
reference standard. 
Outcomes: The study did not report any of the outcomes specified in Chapter 3, Inclusion and exclusion 
criteria or, for DTA studies, insufficient data were reported to allow the construction of 2 × 2 contingency 
tables (numbers of true-positive, false-negative, false-positive and true-negative test results).
Study design: The study design was not one of those specified in Chapter 3, Inclusion and exclusion 
criteria or the study included < 10 participants in the relevant patient groups.
Duplicate: The study was a duplicate publication.
Authors contacted: The study did not report sufficient information for inclusion assessment and authors 
were contacted for additional information but no response was received.
1. Albrecht T, Hohmann J, Oldenburg A, Skrok J, Wolf KJ. Detection and characterisation of liver 
metastases. Eur Radiol 2004;14:P25–33. (Reference standard)
2. Andreano A, Meneghel E, Bovo G, Ippolito D, Salvioni A, Filice C, et al. Contrast-enhanced 
ultrasound in planning thermal ablation of liver metastases: should the hypervascular halo be 
included in the ablation volume? J Ultrasound 2010;13:158–63. (Outcomes)
3. Aube C, Lebigot J. [Contrast ultrasonography: value in diagnosis and characterisation of hepatic 
tumors.] Gastroenterol Clin Biol 2003;27:B63–70. (Study design)
4. Banghui P, Chiche L, Alkofer B, Salame E, Bouvard N, Lepennec V. Imaging modalities before liver 
resection for colorectal metastases: which, when and how many? Paper presented at the 9th World 
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Congress of the International Hepato-Pancreato-Biliary Association, Buenos Aires, Argentina, 18–22 
April 2010. HPB 2010;12(Suppl. 1):100. (Authors contacted)
5. Bartolotta TV, Taibbi A, Galia M, Runza G, Matranga D, Midiri M, et al. Characterization of 
hypoechoic focal hepatic lesions in patients with fatty liver: diagnostic performance and confidence 
of contrast-enhanced ultrasound. Eur Radiol 2007;17:650–61. (Comparator)
6. Bartolotta TV, Sandonato L, Taibbi A, Latteri S, Soresi M, Lombardo G, et al. [Focal liver lesions: 
clinical usefulness of contrast-enhanced ultrasound in the selection of surgical patients.] Chir Ital 
2009;61:295–307. (Comparator)
7. Bartolotta TV, Taibbi A, Midiri M, La Grutta L, De Maria M, Lagalla R. Characterisation of focal liver 
lesions undetermined at grey-scale US: contrast-enhanced US versus 64-row MDCT and MRI with 
liver-specific contrast agent. Radiol Med 2010;115:714–31. (Reference standard)
8. Bartolotta TV, Taibbi A, Midiri M, Matranga D, Solbiati L, Lagalla R. Indeterminate focal liver lesions 
incidentally discovered at gray-scale US: role of contrast-enhanced sonography. Invest Radiol 
2011;46:106–15. (Reference standard)
9. Bauditz J, Schade T, Wermke W. [Sonographic diagnosis of hilar cholangiocarcinomas by the use of 
contrast agents.] Ultraschall Med 2007;28:161–7. (Index test)
10. Bauditz J, Quinkler M, Beyersdorff D, Wermke W. Improved detection of hepatic metastases of 
adrenocortical cancer by contrast-enhanced ultrasound. Oncol Rep 2008;19:1135–9. (Index test)
11. Bauditz J, Zeitz M, Wermke W. Malignant liver tumors: monitoring of local ablation by contrast 
enhanced ultrasound and computed tomography. Paper presented at the 61st Annual Meeting 
of the American Association for the Study of Liver Diseases: the Liver Meeting, Boston, MA, 29 
October–2 November 2010. Hepatology 2010;52:963A. (Outcomes)
12. Beaton C, Cochlin D, Kumar N. Contrast enhanced ultrasound should be the initial radiological 
investigation to characterise focal liver lesions. Eur J Surg Oncol 2010;36:43–6. (Reference 
standard, M)
13. Bernardini I, Mucciarini C, Razzini G, Guerzoni R, Blanzieri S, Bellentani S, et al. The role of contrast-
enhanced ultrasound in detection of liver metastases from colorectal cancer: 2 years update 
results. Paper presented at the 35th ESMO Congress, Milan, Italy, 8–12 October 2010. Ann Oncol 
2010;21:viii215. (Population)
14. Bleuzen A, Huang C, Olar M, Tchuenbou J, Tranquart F. Diagnostic accuracy of contrast-enhanced 
ultrasound in focal lesions of the liver using cadence contrast pulse sequencing. Ultraschall Med 
2006;27:40–8. (Reference standard)
15. Cantisani V, Ricci P, Erturk M, Pagliara E, Drudi F, Calliada F, et al. Detection of hepatic metastases 
from colorectal cancer: prospective evaluation of gray scale US versus SonoVue low mechanical 
index real time-enhanced US as compared with multidetector-CT or Gd-BOPTA-MRI. Ultraschall Med 
2010;31:500–5. (Reference standard, M)
16. Caturelli E, Ghittoni G, Roselli P, Anti M. Sensitivity rates in characterizing hepatocellular carcinomas. 
AJR Am J Roentgenol 2005;185:1079–80. (Study design)
17. Chami L, Lassau N, Malka D, Ducreux M, Bidault S, Roche A, et al. Benefits of contrast-enhanced 
sonography for the detection of liver lesions: comparison with histologic findings. AJR Am J 
Roentgenol 2008;190:683–90. (Comparator)
18. Chen LD, Xu HX, Xie XY, Lu MD, Xu ZF, Liu GJ, et al. Enhancement patterns of intrahepatic 
cholangiocarcinoma: comparison between contrast-enhanced ultrasound and contrast-enhanced 
CT. Br J Radiol 2008;81:881–9. (Population)
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19. Chen MH, Dai Y, Yan K, Fan ZH, Yin SS, Yang W, et al. The role of contrast-enhanced ultrasound 
on the diagnosis of small hepatocellular carcinoma (≤ 3 cm) in patients with cirrhosis. Hepatol Res 
2006;35:281–8. (Population)
20. Chen MH, Yang W, Yan K, Dai Y, Wu W, Fan ZH, et al. The role of contrast-enhanced ultrasound 
in planning treatment protocols for hepatocellular carcinoma before radiofrequency ablation. Clin 
Radiol 2007;62:752–60. (Duplicate)
21. Chiesara F, Baccini F, Merola E, Rinzivillo M, Panzuto F, Capurso G, et al. Contrast enhanced 
ultrasonography (CEUS) and quantitative perfusion analysis in the assessment of neuroendocrine 
liver metastases. Gastroenterology 2011;140:S875. (Population)
22. Cijevschi Prelipcean C, Pintilei I, Nedelciuc O, Chirita D, Dranga M, Mihai C. Liver tumors: the 
vascularisation pattern assessed by contrast-enhanced ultrasound. Paper presented at the 21st 
Conference of the Asian Pacific Association for the Study of the Liver (APASL), Bangkok, Thailand, 
17–20 February 2011. Hepatol Int 2011;5:480–1. (Reference standard)
23. Cokkinos DD, Blomley MJ, Harvey CJ, Lim A, Cunningham C, Cosgrove DO. Can contrast-enhanced 
ultrasonography characterize focal liver lesions and differentiate between benign and malignant, 
thus providing a one-stop imaging service for patients? J Ultrasound 2007;10:186–93. (Outcomes)
24. Dai Y, Chen MH, Yin SS, Yan K, Fan ZH, Wu W, et al. Focal liver lesions: can SonoVue-enhanced 
ultrasound be used to differentiate malignant from benign lesions? Invest Radiol 2007;42:596–603. 
(Comparator)
25. De Sanctis R, Quadrini S, Tedeschi M, Stumbo L, Gori B, Del Signore E, et al. Early response 
evaluation of antiangiogenic therapy: use of contrast-enhanced ultrasonography (CE-US) in 
hepatocellular carcinoma. Ann Oncol 2009;20:92. (Study design)
26. Dietrich CF, Kratzer W, Strobel D, Danse E, Fessl R, Bunk A, et al. Assessment of metastatic liver 
disease in patients with primary extrahepatic tumors by contrast-enhanced sonography versus CT & 
MRI. World J Gastroenterol 2006;12:1699–705. (Reference standard)
27. Ding H, Wang WP, Huang BJ, Wei RX, He NA, Qi Q, et al. Imaging of focal liver lesions: low-
mechanical-index real-time ultrasonography with SonoVue. J Ultrasound Med 2005;24:285–97. 
(Comparator)
28. D’Onofrio M, Rozzanigo U, Caffarri S, Zogno A, Procacci C. Contrast-enhanced US of hepatocellular 
carcinoma. Radiol Med 2004;107:293–303. (Population)
29. D’Onofrio M, Martone E, Faccioli N, Zamboni G, Malago R, Mucelli RP. Focal liver lesions: sinusoidal 
phase of CEUS. Abdom Imaging 2006;31:529–36. (Reference standard)
30. D’Onofrio M, Faccioli N, Zamboni G, Malago R, Caffarri S, Fattovich G, et al. Focal liver lesions in 
cirrhosis: value of contrast-enhanced ultrasonography compared with Doppler ultrasound and 
alpha-fetoprotein levels. Radiol Med 2008;113:978–91. (Reference standard)
31. Dumitru E, Dumitru IM, Alexandrescu L, Rugina S. Contrast enhanced ultrasonography (CEUS) 
helps characterization of focal liver lesions in HIV positive patients. Paper presented at the 21st 
Conference of the Asian Pacific Association for the Study of the Liver (APASL), Bangkok, Thailand, 
17–20 February 2011. Hepatol Int 2011;5:482. (Comparator)
32. Ercolani G, Zanello M, Rojas L, Ravaioli M, Cescon M, Gaudio MD, et al. A prospective comparative 
evaluation of pre-and intraoperative imaging techniques in chemo-pretreated or not pretreated 
patients with colorectal liver metastases. Paper presented at the 9th Congress of the European-
African HPBA (E-AHPBA), Cape Town, South Africa, 12–16 April 2011. HPB 2011;13:25–6. 
(Authors contacted)
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33. Fan ZH, Chen MH, Dai Y, Wang YB, Yan K, Wu W, et al. Evaluation of primary malignancies of 
the liver using contrast-enhanced sonography: correlation with pathology. AJR Am J Roentgenol 
2006;186:1512–19. (Outcomes)
34. Fracanzani AL, Maraschi A, Burdick L, Bertelli C, Fatta E, Bonelli N, et al. Contrast-enhanced 
ultrasonography (CEUS) and spiral computed tomography (CT) in the assessment of efficacy of 
percutaneous ablation treatments of hepatocellular carcinoma in cirrhosis. J Hepatol 2008;48:S145. 
(Reference standard)
35. Frieser M, Kiesel J, Lindner A, Bernatik T, Haensler JM, Janka R, et al. Efficacy of contrast-enhanced 
US versus CT or MRI for the therapeutic control of percutaneous radio-frequency ablation in the 
case of hepatic malignancies. Ultraschall Med 2011;32:148–53. (Reference standard)
36. Gaiani S, Celli N, Piscaglia F, Cecilioni L, Losinno F, Giangregorio F, et al. Usefulness of contrast-
enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at 
spiral computed tomography. J Hepatol 2004;41:421–6. (Outcomes)
37. Galassi M, Granito A, Piscaglia F, Borghi A, Lucidi V, Golfieri R, et al. Impact of gadoxetic acid 
(Gd-EOB-DTPA)-enhanced MR on the non-invasive diagnosis of small hepatocellular carcinoma. 
Paper presented at the Italian Association for the Study of the Liver (AISF) Annual Meeting, Rome, 
Italy, 24–25 February 2011. Dig Liver Dis 2011;43:S82. (Outcomes)
38. Gallotti A, D’Onofrio M, Ruzzenente A, Martone E, De Robertis R, Guglielmi A, et al. Contrast-
enhanced ultrasonography (CEUS) immediately after percutaneous ablation of hepatocellular 
carcinoma. Radiol Med 2009;114:1094–105. (Reference standard)
39. Gheorghe L, Carabelea A, Vadan R, Becheanu G. QUIZ HQ 54. Contrast-enhanced ultrasound 
(CEUS) for the detection and assessment of treatment efficacy in focal liver lesions. J Gastrointestin 
Liver Dis 2009;18:473–4. (Study design)
40. Giangregorio F, Comparato G, Marinone MG, Di Stasi M, Sbolli G, Aragona G, et al. Imaging 
detection of new HCCs in cirrhotic patients treated with different techniques: comparison of 
conventional US, spiral CT, and 3-dimensional contrast-enhanced US with the navigator technique 
(Nav 3D CEUS). J Ultrasound 2009;12:12–21. (Reference standard)
41. Giangregorio F, Aragona G, Marinone G, Comparato G, Fanigliulo L, Di Stasi M, et al. Contrast-
enhanced US (CEUS) in early evaluation of non-surgical treatment of HCC can change the patient’s 
follow-up and survival. Paper presented at the 45th Annual Meeting of the European Association 
for the Study of the Liver (EASL) International Liver Congress, Vienna, Austria, 14–18 April 2010. J 
Hepatol 2010;52:S90–1. (Outcomes)
42. Giangregorio F, Marinone M, Aragona G, Comparato G, Fanigliulo L, Sbolli G, et al. Echographic 
detection of hepatocellular carcinoma (HCC) during followup in cirrhotic patients with previous 
HCC: comparison among US, CT and a new panoramic 3-dimensional contrast-enhanced US with 
navigator system (3-D NAV CEUS). Paper presented at the 16th National Congress of Digestive 
Diseases – Italian Federation of Societies of Digestive Diseases (FISMAD), Verona, Italy, 6–9 March 
2010. Dig Liver Dis 2010;42:S77. (Reference standard)
43. Giangregorio F. Contrast-enhanced ultrasound (CEUS) for echographic detection of hepato 
cellular carcinoma in cirrhotic patients previously treated with multiple techniques: comparison 
of conventional US, spiral CT and 3-dimensional CEUS with navigator technique (3DNav CEUS). 
Cancers 2011;3:1763–76. (Reference standard)
44. Giesel FL, Delorme S, Sibbel R, Kauczor HU, Krix M. [Contrast-enhanced ultrasound for the 
characterization of incidental liver lesions – an economical evaluation in comparison with multi-
phase computed tomography.] Ultraschall Med 2009;30:259–68. (Study design, M)
45. Giorgio A, Di Sarno A, Nunzia F, De Stefano G, Scognamiglio U, Coppola C, et al. Value of contrast 
enhanced ultrasound in the characterization of small nodular lesions in cirrhotic livers. Paper 
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presented at the 45th Annual Meeting of the European Association for the Study of the Liver 
(EASL) International Liver Congress, Vienna, Austria, 14–18 April 2010. J Hepatol 2010;52:S219. 
(Comparator)
46. Giorgio A, Di Sarno A, Farella N, De Stefano G, Scognamiglio U, Coppola C, et al. Small nodular 
lesions in cirrhotic livers: characterization with contrast enhanced ultrasound. Paper presented at 
the 43rd Annual Meeting of the Italian Association for the Study of the Liver (AISF), Rome; Italy, 
25–26 February 2010. Dig Liver Dis 2010;42:S23–4. (Comparator)
47. Giorgio A. Diagnostic algorithm of hepatocellular carcinoma on cirrhosis: CEUS or no CEUS, that is 
the problem. Dig Liver Dis 2011;43:499. (Study design)
48. Gomez Rodriguez RA, Artaza Varasa T, Gonzalez de Frutos C, Sanchez Ruano JJ, Repiso Ortega 
A, Perez-Grueso Macias MJ, et al. [Value of contrast-enhanced ultrasound in the diagnosis of 
hepatocarcinoma in focal lesions detected in patients with liver disease.] Gastroenterol Hepatol 
2007;30:381–6. (Reference standard)
49. Guo J, Liang Y, Yan JY, Liu Y. [Clinical value of real time contrast-enhanced ultrasound in 
differentiating benign and malignant liver lesions.] Chin J Med Imaging Technol 2008;24:1434–7. 
(Comparator)
50. Hanle MM, Thiel R, Saur G, Mason RA, Pauls S, Kratzer W. Screening for liver metastases in women 
with mammary carcinoma: comparison of contrast-enhanced ultrasound and magnetic resonance 
imaging. Clin Imaging 2011;35:366–70. (Outcomes)
51. Hohmann J, Skrok J, Puls R, Albrecht T. [Characterization of focal liver lesions with contrast-
enhanced low MI real time ultrasound and SonoVue.] Rofo 2003;175:835–43. (Reference 
standard)
52. Iavarone M, Sangiovanni A, Forzenigo LV, Massironi S, Fraquelli M, Aghemo A, et al. Diagnosis of 
hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: the importance of tumor cell 
differentiation. Hepatology 2010;52:1723–30. (Outcomes)
53. Ignee A, Livraghi T, Tranquart F, Bolondi L, Dietrich CF, Albrecht T. Revised detection of liver lesions 
by ultrasound-contrast medium of the second generation, compared to conventional sonography. 
Endosk Heute 2009;22:105–9. (Reference standard)
54. Jang HJ, Kim TK, Wilson SR. Small nodules (1–2 cm) in liver cirrhosis: characterization with contrast-
enhanced ultrasound. Eur J Radiol 2009;72:418–24. (Index test)
55. Janica JR, Lebkowska U, Ustymowicz A, Augustynowicz A, Kamocki Z, Werel D, et al. Contrast-
enhanced ultrasonography in diagnosing liver metastases. Med Sci Monit 2007;13(Suppl. 
1):111–15. (Reference standard)
56. Jung EM, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, et al. Evaluation of quantitative 
contrast harmonic imaging to assess malignancy of liver tumors: a prospective controlled two-
center study. World J Gastroenterol 2007;13:6356–64. (Comparator)
57. Jung EM, Schreyer AG, Schacherer D, Menzel C, Farkas S, Loss M, et al. New real-time image fusion 
technique for characterization of tumor vascularisation and tumor perfusion of liver tumors with 
contrast-enhanced ultrasound, spiral CT or MRI: first results. Clin Hemorheol Microcirc 2009;43:57–
69. (Index test)
58. Kisaka Y, Hirooka M, Kumagi T, Uehara T, Hiasa Y, Kumano S, et al. Usefulness of contrast-enhanced 
ultrasonography with abdominal virtual ultrasonography in assessing therapeutic response in 
hepatocellular carcinoma treated with radiofrequency ablation. Liver Int 2006;26:1241–7. (Index 
test)
NIHR Journals Library
AppENDIx 5
214
59. Kobayashi Y, Nakamura S, Toshikuni N, Tanaka H, Matsumoto E, Ohnishi H, et al. Contrast-enhanced 
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correlation with histological grading. Gastroenterology 2004;126:A494. (Index test)
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(CEUS) to predict final outcome within 1 week after transarterial chemoembolization (TACE) for 
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as a predictor of treatment efficacy within 2 weeks after transarterial chemoembolization of 
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ultrasound: comparison to intraoperative findings.] Ultraschall Med Suppl 2005;26:107–13. 
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2010;31:283–8. (Reference standard)
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68. Larsen LPS, Rosenkilde M, Christensen H, Bang N, Bolvig L, Christiansen T, et al. Can contrast-
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Title 
Title 1 Identify the report as a systematic review, meta-
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Title page 
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Structured 
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systematic review registration number 
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and Chapter 2, Comparators, 
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being addressed with reference to participants, 
interventions, comparisons, outcomes and study 
design (PICOS) 
Chapter 1, objective
Methods 
Protocol and 
registration 
5 Indicate if a review protocol exists, if and where it 
can be accessed (e.g. web address) and, if available, 
provide registration information including registration 
number
PROSPERO: CRD42011001694 (www.
crd.york.ac.uk/prospero/)
NICE (http://guidance.nice.org.uk/
DT/6)
Eligibility criteria 6 Specify study characteristics (e.g. PICOS, length 
of follow-up) and report characteristics (e.g. years 
considered, language, publication status) used as 
criteria for eligibility, giving rationale
Chapter 3, Inclusion and exlusion 
criteria, 
Information 
sources 
7 Describe all information sources (e.g. databases with 
dates of coverage, contact with study authors to 
identify additional studies) in the search and date last 
searched
Chapter 3, Search strategy,
Search 8 Present full electronic search strategy for at least one 
database, including any limits used, such that it could 
be repeated
Appendix 1
Study selection 9 State the process for selecting studies (i.e. screening, 
eligibility, included in systematic review and, if 
applicable, included in the meta-analysis)
Chapter 3, Inclusion screening and 
data extraction, 
Data collection 
process 
10 Describe method of data extraction from reports (e.g. 
piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from 
investigators
Chapter 3, Inclusion screening and 
data extraction, 
Data items 11 List and define all variables for which data were 
sought (e.g. PICOS, funding sources) and any 
assumptions and simplifications made
Chapter 3, Inclusion screening and 
data extraction, 
Risk of bias in 
individual studies 
12 Describe methods used for assessing risk of bias of 
individual studies (including specification of whether 
this was carried out at the study or outcome level) 
and how this information is to be used in any data 
synthesis
Chapter 3, Quality assessment, 
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Section/topic No. Checklist item Reported on page
Summary 
measures 
13 State the principal summary measures (e.g. risk ratio, 
difference in means)
Chapter 3, Methods of analysis/
synthesis,
Synthesis of 
results 
14 Describe the methods for handling data and 
combining results of studies, if carried out, including 
measures of consistency (e.g. I2) for each meta-analysis
Chapter 3, Methods of analysis/
synthesis,
Risk of bias 
across studies 
15 Specify any assessment of risk of bias that may 
affect the cumulative evidence (e.g. publication bias, 
selective reporting within studies)
Not applicable
Additional 
analyses 
16 Describe methods of additional analyses (e.g. 
sensitivity or subgroup analyses, meta-regression), if 
carried out, indicating which were prespecified 
Chapter 3, Results of the assessment 
of clinical effectiveness, Accuracy 
of SonoVue contrast-enhanced 
ultrasound for the characterisation of 
incidentally detected focal liver lesions
Results 
Study selection 17 Give numbers of studies screened, assessed for 
eligibility and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram
Chapter 3, Results of the assessment 
of clinical effectiveness, Figure 3 and 
Appendix 5
Study 
characteristics 
18 For each study, present characteristics for which data 
were extracted (e.g. study size, PICOS, follow-up 
period) and provide the citations
Appendix 4
Risk of bias 
within studies 
19 Present data on risk of bias of each study and, if 
available, any outcome-level assessment (see item 12)
Appendix 3 and Table 11
Results of 
individual studies 
20 For all outcomes considered (benefits or harms), 
present, for each study: (a) simple summary data for 
each intervention group; (b) effect estimates and CIs, 
ideally with a forest plot 
Chapter 3, Results of the assessment 
of clinical effectiveness, Tables 4, 6, 8, 
10 and 12
Synthesis of 
results 
21 Present results of each meta-analysis carried out, 
including CIs and measures of consistency
Chapter 3, Results of the assessment 
of clinical effectiveness, Figures 4 and 
5
Risk of bias 
across studies 
22 Present results of any assessment of risk of bias across 
studies (see item 15)
Not applicable
Additional 
analysis 
23 Give results of additional analyses, if carried out (e.g. 
sensitivity or subgroup analyses, meta-regression; see 
item 16)
Chapter 3, Results of the assessment 
of clinical effectiveness, Accuracy 
of SonoVue contrast-enhanced 
ultrasound for the characterisation of 
incidentally detected focal liver lesions
Discussion 
Summary of 
evidence 
24 Summarise the main findings including the strength 
of evidence for each main outcome; consider their 
relevance to key groups (e.g. health-care providers, 
users and policy-makers)
Chapter 5, Statement of principal 
findings, 
Limitations 25 Discuss limitations at the study and outcome 
level (e.g. risk of bias) and at the review level (e.g. 
incomplete retrieval of identified research, reporting 
bias)
Chapter 5, Strengths and limitations 
of the assessment and Uncertainties,
Conclusions 26 Provide a general interpretation of the results in the 
context of other evidence, and implications for future 
research
Chapter 6,
Funding 
Funding 27 Describe sources of funding for the systematic review 
and other support (e.g. supply of data); role of 
funders for the systematic review
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Appendix 8 Protocol
Diagnostic Assessment Report commissioned by the NIHR HTA Programme on behalf of the 
National Institute for Health and Clinical Excellence – Protocol
1. Title of project
SonoVue® (sulphur hexafluoride microbubbles) – contrast agent for contrast enhanced ultrasound in 
liver imaging.
2. Name of External Assessment Group (EAG) and project lead
Kleijnen Systematic Reviews Ltd Assessment Group.
Project lead:
Marie Westwood
Kleijnen Systematic Reviews Ltd
Unit 6, Escrick Business Park
Riccall Road
Escrick
York YO19 6FD
Email: marie@systematic-reviews.com
Second contact:
Jos Kleijnen
Kleijnen Systematic Reviews Ltd
Unit 6, Escrick Business Park
Riccall Road
Escrick
York YO19 6FD
Email: jos@systematic-reviews.com
Health economics lead:
Manuela Joore
Department of Clinical Epidemiolgy and Medical Technology Assessment
Maastricht University Medical Centre & CAPHRI School for Public Health and Primary Care
Department of Health Services Research
Maastricht University
P.O. Box 5800
6200 AZ Maastricht
The Netherlands
Email: m.joore@mumc.nl
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Plain English Summary
Medical imaging, including ultrasound scanning, is important in diagnosing and planning treatment for a 
wide range of conditions including liver disease. Liver imaging will sometimes identify focal abnormalities 
in the liver which cannot be characterised initially and may need another test to fully explain the 
abnormality. The main aim of this subsequent liver imaging is to distinguish between liver cancers and 
benign abnormalities, which is not likely to require further treatment. Cancer in the liver is relatively rare 
and expert opinion suggests that 70 to 75% of liver abnormalities investigated in the NHS are found to be 
benign. One important factor in selecting an imaging test is ability to provide a rapid diagnosis, both to 
facilitate prompt treatment in patients who do have cancer and to minimise anxiety in the majority who do 
not. Most liver lesions are found at an initial ultrasound scan. If the liver abnormality is not characterised 
by this test, the patient is usually referred for additional imaging using magnetic resonance imaging (MRI) 
and/or computed tomography (CT). This can lead to waits of several months with consequent distress to 
patients and families. In addition, there are potential drawbacks in using these other imaging techniques. 
CT uses ionising radiation and the intravenous contrast agent can, on rare occasions, cause kidney 
damage. Some patients cannot have an MRI scan due to pacemakers and others find the examination 
causes claustrophobia.
Imaging technology has developed very rapidly in recent years and contrast agents have been developed 
for use with ultrasound scanning. These contrast agents are injected, but remain in the patient’s blood 
and are broken down by the body after a few minutes and breathed out as a gas. The use of contrast 
agents may improve the ability of ultrasound to distinguish between cancer in the liver and benign liver 
abnormalities and, because contrast enhanced ultrasound can be performed at the same appointment as 
conventional ultrasound, more rapid diagnoses may be possible and some CT and MRI examinations may 
be avoided.
The purpose of this project is to assess the benefits, risks and cost-effectiveness of contrast enhanced 
ultrasound using SonoVue® (Bracco UK Ltd) for the assessment of liver damage in adult patients.
3. Decision problem
3.1 Objectives
To evaluate the clinical and cost effectiveness of contrast enhanced ultrasound (CEUS) using the contrast 
agent SonoVue® for the assessment of adults with focal liver lesions (FLL), in whom un-enhanced 
ultrasound or other liver imaging is inconclusive.
4.2 Intervention technologies
SonoVue® (Bracco UK Ltd) is a contrast agent involving sulphur hexafluoride microbubbles for contrast 
enhanced ultrasound (CEUS) imaging in adults. It is used to enhance the echogenicity of the blood and 
can thus improve the signal to noise ratio in ultrasound. SonoVue® should only be used in patients where 
un-enhanced ultrasound is inconclusive.
SonoVue® product information lists its applications as:
 z Echocardiography – provision of opacification of cardiac chambers and enhancement left ventricular 
echocardial border delineation in patients with suspected or known cardiovascular disease.
 z Doppler ultrasound of the macrovasculature – detection or exclusion of abnormalities in the cerebral 
arteries, extra-cranial carotid arteries, or peripheral arteries.
 z Doppler ultrasound of the microvasculature – visualising the vascularity of liver and breast lesions for 
lesion characterisation.
The focus of this assessment is CEUS of the liver.
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SonoVue® consists of a kit containing a vial of sulphur hexafluoride gas and phospholipid powder, a pre-
filled syringe of solvent (sodium chloride solution) and a transfer and ventilation system (mini spike). The 
saline is introduced into the vial by the mini spike delivery system and once reconstituted, microbubbles 
are formed. These microbubbles are the contrast agent which is injected into a peripheral vein at the 
ante cubital fossa. When the ultrasound probe is placed on the abdomen, ultrasound waves cause the 
microbubbles to resonate so that a signal is picked up by a transducer and an image is formed on a screen. 
As this contrast agent is a pure blood pool agent it remains within the patient’s blood vessels and, 
depending on the type of lesion, it shows a pattern of uptake similar to that of CT or MRI contrast 
agents. Generally for benign lesions the lesion will remain bright or isoechoic with the rest of the liver. For 
malignant lesions the area will wash out and leave a black hole. 
The contrast agent is broken down by the body after a few minutes and the sulphur hexafluoride gas 
is exhaled through the lungs and the phospholipid component of the microbubble shell is metabolised 
(re-entering the endogenous phospholipid metabolic pathway). The adverse event rate associated with the 
use of SonoVue® for liver imaging is likely to be similar to or lower than that associated with other imaging 
modalities (CECT or CEMRI); a post-marketing study, published in 2006, included 23,188 abdominal 
investigations and reported adverse events in 29 cases, of which only two were graded as serious.1
SonoVue® is a second generation contrast agent. These agents have a flexible shell which allows 
continuous imaging (at a low mechanical index) without early destruction of the microbubble. First 
generation agents have now been superseded by second generation agents and are no longer available 
in Europe.
Other similar ultrasound contrast agents (e.g. Luminity®, Lantheus Medical Imaging and Optison®, 
GE Healthcare) are indicated for use in echocardiography only. Therefore, no equivalent alternative 
technologies will be considered in this assessment.
4.3 Population
The indication for this assessment is the detection and characterisation of FLLs in adults and the target 
condition is malignancies of the liver.
In this context, the term focal lesion in the liver refers to any focal area of perceived difference seen on an 
imaging study occurring in one specific area of the liver. FLLs can be broadly as benign (haemangioma, 
focal nodular hyperplasia, focal fatty infiltration or sparing and adenoma) or malignant (primary 
hepatocellular carcinoma, cholangiocarcinoma or liver metastases), with the detection or exclusion of 
malignancy being the primary aim of diagnostic imaging. The distinction between benign and malignant 
determines the individual’s prognosis and the subsequent treatment strategy.  Benign, asymptomatic 
liver lesions usually do not require any treatment. Depending on the specific type of lesion, the individual 
may be monitored and the lesion rescanned in 6 to 12 months. Once a malignant lesion is identified 
it is important to distinguish between primary and secondary cancers as this is likely to impact how 
the individual is managed. Malignant lesions may be treated by a range of interventions including 
chemotherapy, liver resection (surgery), and local ablative therapy. The treatment of primary hepatocellular 
carcinoma has been addressed in published guidelines,2,3 and NICE has issued guidance on a number 
of individual interventions for primary hepatocellular carcinoma and liver metastases (see Appendix 1). 
However, expert opinion suggests that practice within the NHS may vary significantly across regions based 
on clinician preference.
Although liver cancer is rare in the UK, (age-standardised rates are 4.7 per 100,000 males and 2.9 per 
100,000 females)4 it is the second fastest increasing cancer in males and the third fastest in females, 
(increases of 38% and 28%, respectively, in the last decade).5 In addition, expert opinion suggests that 
as many as 70 to 75% of FLLs assessed in the NHS may be benign. One possible benefit of CEUS may 
therefore be rapid rule-out of malignancy, with associated reduction in anxiety for patients and families; 
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current practice of referring patients with inconclusive un-enhanced ultrasound for contrast enhanced 
magnetic resonance imaging (CEMRI) and/or contrast enhanced computed tomography (CECT), may result 
in a wait of several months.
The European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) produced 
guidelines and good clinical practice recommendations for CEUS in 2004. The latest version of the 
guidelines was published in 2008.6 The 2008 version of the EFSUMB guidelines are currently being 
updated. The 2008 EFSUMB guidelines recommend the use of CEUS for the characterisation of FLL in the 
following indications:
 z patients with incidental findings on routine ultrasound
 z investigation of lesions or suspected lesions in chronic hepatitis or liver cirrhosis
 z investigation of lesions or suspected lesions in patients with a history of malignancy
 z patients with inconclusive MRI/CT or cytology/histology results
 z characterisation of portal vein thrombosis
and for the detection of FLL in the following indications:
 z to rule-out liver metastases
 z in selected cases, when clinically relevant for treatment planning and as a complement to CECT and/or 
CEMRI, to assess the number and location of liver metastases
 z surveillance of patients with known malignancy
 z suspected cholangiocarcinoma, where other imaging is inconclusive
 z suspected liver trauma (in some situations)
Because SonoVue® should be used only where un-enhanced ultrasound is inconclusive, we consider its 
primary application to be for the characterisation of lesions (benign or malignant) in patients with known 
FLLs; most patients who have already undergone un-enhanced ultrasound and who have proceeded to 
CEUS are likely to have FLLs (seen at un-enhanced ultrasound), the nature of which remains uncertain.  
Other, relevant applications include the detection of specific types of malignant FLL (e.g. liver metastases, 
recurrent or residual disease following treatment of a known malignancy). CEUS may also identify addition 
FLLs over and above those detected on un-enhanced ultrasound. A recent systematic review reported 
Conventional US
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ranges for the sensitivity and specificity of SonoVue® CEUS for the detection of liver metastases as 79% to 
100% and 95% to 100% respectively,7 and initial scoping searches have identified studies assessing the 
accuracy of SonoVue® CEUS for the detection of residual disease post-treatment.8,9
4.4 Relevant comparators
Patients with inconclusive un-enhanced ultrasound are currently referred for CECT and/or CEMRI. The 
comparators for this assessment are therefore CECT and CEMRI. A recent systematic review compared 
the accuracy of SonoVue® CEUS, CECT and CEMRI for the differentiation of malignant and benign liver 
lesions. The reported sensitivities were 88% (95% CI 79% to 84%), 90% (95% CI 88% to 92%) and 
86% (95% CI 83% to 88%), respectively, and the corresponding specificities were 81% (95% CI 79% to 
84%), 77% (95% CI 71% to 82%) and 81% (95% CI 76% to 85%).10 However, these data were based on 
indirect comparisons. CEUS could be included in the diagnostic pathway as a replacement for CECT/CEMRI 
(Figure 1), or as a triage step to reduce the use of CECT/CEMRI (Figure 2).
Expert opinion has indicated that biopsy would not be performed on the basis of un-enhanced ultrasound 
examination alone, therefore, biopsy alone is not a relevant comparator for CEUS.
5. Report methods for assessing clinical effectiveness
A systematic review will be conducted to summarise the evidence on the clinical effectiveness of SonoVue® 
CEUS for the assessment of focal liver lesions in adults in whom liver imaging with un-enhanced 
ultrasound has been inconclusive. Systematic review methods will follow the principles outlined in the 
Centre for Reviews and Dissemination (CRD) guidance for undertaking reviews in health care11 and NICE 
Diagnostic Assessment Programme interim methods statement.12
5.1 Inclusion and exclusion criteria
Participants
Study populations eligible for inclusion will be:
FIGURE 2 Diagnostic algorithm for liver imaging – CEUS as a triage test to reduce the use of CECT/CEMRI.
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Adults (≥ 18 years) in whom liver imaging with un-enhanced ultrasound or other liver imaging has been 
inconclusive, including patients being assessed for:
 z Suspected primary hepatocellular carcinoma
 z Suspected secondary malignancy (liver metastases)
 z Response to treatment/recurrence of known liver malignancy
Setting
Relevant settings are secondary or tertiary care.
Interventions (index test(s))
SonoVue® CEUS
Comparators
Comparators eligible for inclusion will be:
 z Contrast enhanced computed tomography (CECT)
 z Contrast enhanced magnetic resonance imaging (CEMRI)
Reference standard
The reference standard for a positive diagnosis will be histology following biopsy or surgical excision. 
Patients who test negative on the index test will generally not undergo biopsy or surgical treatment; 
clinical/radiological follow-up for a minimum of six months will therefore be considered an acceptable 
reference standard in these patients.
This criterion has been extended, for studies on the characterisation of FLLs only (suspected HCC), to 
include studies which use EASL/AASLD non-invasive diagnostic criteria (two concordant imaging test 
results) as the reference standard. This modification does not apply to test accuracy studies on the 
detection of liver metastases. This extension of the inclusion criteria was made because clinical opinion 
indicated that biopsy of small test positive lesions may be considered un-ethical in this population and that 
the original criterion (biopsy for imaging test positive patients/lesions and 6 months follow-up for imaging 
test negative patients/lesions) may, therefore, result in important studies being excluded.
Outcomes
The following outcomes will be considered:
 z Effect of testing on treatment plan (e.g. surgical or medical management, or palliative care), where 
information on the appropriateness of the final treatment plan is also reported
 z Effect of testing on clinical outcome, (e.g. overall survival, progression free survival)
 z Prognosis – the ability of test result to predict clinical outcome (e.g. overall survival, progression free 
survival, response to treatment)
 z Test accuracy and number of patients/lesions classified as non-diagnostic by SonoVue® CEUS.
For included studies reporting any of the above outcome measures, the following outcomes will also be 
considered if reported:
 z Acceptability of tests to patients or surrogate measures of acceptability (e.g. waiting time and 
associated anxiety).
 z Adverse events associated with testing (e.g. claustrophobia, reaction to contrast media).
 z Additional FLLs detected by CEUS, over and above those seen on un-enhanced ultrasound.
Radiation exposure is not considered a relevant outcome, as the population is mostly older adults in whom 
additional incident cancers due to imaging-related radiation are likely to be minimal. In addition a previous 
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technology assessment (new generation CT for cardiac imaging) showed that including radiation exposure 
in modelling did not influence the results of cost-effectiveness analyses.13
Study design
The following types of studies will be included:
 z Randomised or non-randomised controlled trials, where participants are assigned to the intervention 
or comparator tests, for treatment planning, and outcomes are compared at follow-up.
 z Observational studies which report the results of multi-variable regression modelling with clinical 
outcome (e.g. survival, response to treatment) as the dependent variable and index test and 
comparator test results as independent variables. Included studies should control adequately for 
potential confounders (e.g. age, tumour stage, previous treatment, results of other imaging).
 z Test accuracy studies, where the index test is compared with one or more of the comparators and the 
reference standard. Test accuracy studies of the index test alone will be included if they are conducted 
in patients who have previously undergone one or more of the comparator tests (e.g. a study of the 
accuracy of Sonovue for the diagnosis of HCC in patients with inconclusive findings on CECT), as these 
studies may inform cost-effectiveness modelling.
Test accuracy studies, will be required to report the absolute numbers of true-positive, false-negative, false-
positive, and true-negative index test results, or sufficient information to allow their calculation. If data are 
incomplete, study authors will be contacted to seek clarification, where practical.
The following study/publication types will be excluded:
 z Pre-clinical and  animal 
 z Reviews, editorials, and opinion pieces
 z Case reports
 z Studies reporting only technical aspects of the test, or image quality
 z Studies with < 10 participants
5.2 Search strategy
Search strategies will be based on target condition and intervention, as recommended in the Centre for 
Reviews and Dissemination (CRD) guidance for undertaking reviews in health care and the Cochrane 
Handbook for Diagnostic Test Accuracy Reviews.11,14,15
Additional supplementary searches will be carried out as necessary. Searches for studies for cost and 
quality of life will also be included, see Section 6 for further detail.
The following databases will be searched for relevant studies from 2000 to the present:
 z MEDLINE (OvidSP) 
 z MEDLINE In-Process Citations and Daily Update (OvidSP)
 z EMBASE (OvidSP)
 z Cochrane Database of Systematic Reviews (CDSR) (Internet)
 z Cochrane Central Register of Controlled Trials (CENTRAL) (Internet)
 z Database of Abstracts of Reviews of Effects (DARE) (Internet)
 z Health Technology Assessment Database (HTA) (Internet)
 z Science Citation Index (SCI) (Web of Science)
 z NIHR Health Technology Assessment Programme (Internet)
Completed and ongoing trials will be identified by searches of the following resources (2000–2011):
 z NIH ClinicalTrials.gov (http://www.clinicaltrials.gov/)
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 z Current Controlled Trials (http://www.controlled-trials.com/)
 z WHO International Clinical Trials Registry Platform (ICTRP) (http://www.who.int/ictrp/en/)
 z EU Clinical Trials Register (https://www.clinicaltrialsregister.eu/)
Key conference proceedings, to be identified in consultation with clinical experts, will be screened for the 
last five years. These may include British Medical Ultrasound Society, European Federation of Societies for 
Ultrasound in Medicine and Biology (EFSUMB) EUROSON congress.
Identified references will be downloaded in Endnote X4 software for further assessment and handling. 
References in retrieved articles and relevant systematic reviews will be checked.
Search strategies will be developed specifically for each database and the keywords associated with liver 
malignancies shall be adapted according to the configuration of each database. 
No restrictions on language or publication status will be applied. Limits will be applied to remove 
animal and phantom studies. Searches will take into account generic and other product names for the 
intervention. Examples of the search strategies to be used are presented in Appendix 1; these will be 
adapted as necessary following consultation with clinical experts.
5.3 Data extraction strategy
Two reviewers will independently screen titles and abstracts of all reports identified by searches and 
discrepancies will be discussed. Full copies of all studies deemed potentially relevant, after discussion, will 
be obtained and two reviewers will independently assess these for inclusion; any disagreements will be 
resolved by consensus or discussion with a third reviewer.
Data relating to study details, participants, intervention and comparator tests, reference standard, and 
outcome measures will be extracted by one reviewer, using a piloted, standard data extraction form. 
A second reviewer will check data extraction and any disagreements will be resolved by consensus or 
discussion with a third reviewer.
5.4 Quality assessment strategy
The methodological quality of included studies will be assessed using standard tools.11 The QUADAS 
tool,16,17 has been recommended for assessing the methodological quality of test accuracy studies.11,14 A 
revised version of QUADAS (QUADAS-2) has recently been released www.QUADAS.org.18 QUADAS-2 more 
closely resembles the approach and structure of the Cochrane risk of bias tool. The QUADAS-2 tool will be 
used in this assessment.
The results of the quality assessment will be used for descriptive purposes to provide an evaluation of 
the overall quality of the included studies and to provide a transparent method of recommendation for 
design of any future studies. In addition, if enough data are available from the included studies, quality 
components will be included as covariates in SROC models, to investigate their possible association with 
test performance. Based on the findings of the quality assessment, recommendations will be made for the 
conduct of future studies.
5.5 Methods of analysis/synthesis
The results of initial scoping searches suggest that trial data and prognostic data are likely to be sparse or 
non-existent. This section therefore focuses on the synthesis of data from test accuracy studies. If other 
studies are identified, we anticipate that these will be summarised in a narrative synthesis.
Where meta-analysis is considered unsuitable for some or all of the data identified (e.g. due to the 
heterogeneity and/or small numbers of studies), we will employ a narrative synthesis. Typically, this will 
involve the use of text and tables to summarise data. These will allow the reader to consider any outcomes 
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in the light of differences in study designs and potential sources of bias for each of the studies being 
reviewed. Studies will be organised by clinical application (diagnosis of primary hepatocellular carcinoma, 
diagnosis of liver metastases, assessment of treatment response/recurrence).  
Any data included on the following outcome measures: effects of testing on treatment planning and/
or clinical outcome; adverse events associated with testing; acceptability to patients will be summarized 
according to the size and range of the outcomes reported. For test accuracy data, absolute numbers of 
true-positive, false-negative, false-positive and true-negative test results, as well as sensitivity and specificity 
values, with 95% confidence intervals will be presented for each study and patient group reported.
Where appropriate, and where sufficient accuracy data are available, summary receiver operating 
characteristic (SROC) curves will be calculated to summarise test accuracy data. SROC modelling will use 
the bivariate approach.19–21 Potential sources of heterogeneity will be investigated by extending SROC 
models to include study level covariates, (e.g. participant age, tumour stage, hepatitis status, cirrhosis 
status); the bivariate approach to modelling allows investigation of the effects of covariates on sensitivity 
and specificity separately.
Where data are insufficient to support meta-analyses, the following graphical representations will be 
presented: plots in ROC space (without summary curves) for test accuracy data; forest plots for any 
trial data. 
A detailed commentary on the major methodological problems or biases that affected the studies 
will also be included, together with a description of how this may have affected the individual study 
results. Recommendations for further research will be made based on any gaps in the evidence or 
methodological flaws.
6. Report methods for synthesising evidence of cost-
effectiveness
6.1 Identifying and reviewing published cost-effectiveness studies
Exploration of the literature regarding published economic evaluations, utility studies and cost studies will 
be performed in the literature databases listed above. In addition, specific health economic databases will 
be searched (e.g. NHSEED (NHS Economic Evaluation Database), and HEED (Health Economic Evaluation 
Database); an example search strategy is included in Appendix 1. Searches will focus on original papers 
that report on cost, cost-accuracy, cost-effectiveness or cost-utility analyses, either studying the diagnostic 
phase (patients with FLLs and inconclusive un-enhanced ultrasound), therapeutic phase (patients with 
liver malignancy), or a combination. For our assessment cost studies, utility studies and full economic 
evaluations, i.e. those that explicitly compare different decision options will be selected. Clinical trials as 
well as modelling studies and cohort studies will be relevant within the frame of our project. The intention 
is not to perform a systematic review, but to use the studies identified to support the development of an 
economic model and estimation of model input parameters that will aim to answer the research questions 
of this project. 
The results and the methodological quality of the studies selected will be summarised. Assessment of 
methodological quality will follow the criteria for economic evaluations in health care as described in 
the NICE methodological guidance.12 Data extraction will focus on technologies compared, indicated 
population, main results in terms of costs and consequences of the alternatives compared, and the 
incremental cost-effectiveness, but also on methods of modelling used (if applicable), analytical methods 
and robustness of the study findings.
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6.2 Evaluation of costs, quality of life and cost-effectiveness
Decision analytic modelling will be undertaken to determine the cost-effectiveness of SonoVue® CEUS for 
the assessment of focal liver lesions in adults in whom liver imaging with un-enhanced ultrasound has 
been inconclusive.  The analysis will consider the consequences of diagnostic accuracy, treatment planning, 
and QALYs.
Potential diagnostic strategies
Depending on the nature of the FLL and local practice within the NHS a range of typical diagnostic 
strategies may emerge as current practice, which may include CECT and/or CEMRI. 
The following possible diagnostic strategies arise when assessing the role of CEUS for the assessment of 
focal liver lesions in adults in whom liver imaging with un-enhanced ultrasound has been inconclusive:
 z CEUS
 z CEUS* → CECT
 z CEUS* → CEMRI
*Additional examination, to be conducted if previous one was not conclusive.
Comparators to be included in the model may depend on the availability of data.
Model structure 
Published studies that measure the clinical utility of SonoVue® CEUS from initial diagnosis through to 
final health outcomes have not been identified during the scoping phase. Consequently, it is likely that a 
linked evidence approach will need to be used in the modelling. That is, outcomes of the diagnostic tests 
to be assessed will need to be related to changes in treatment decisions, any delays in diagnosis and final 
heath outcomes. Necessary choices and definitions regarding the structure of the model will depend on 
the findings from the literature review and consultation with clinical experts. In addition, the existence/
availability of any other electronic models that reflect the cost-effectiveness of treatment pathways for 
these patients, and are representative of current care within the NHS, will be determined.
Issues relevant to analyses: 
 z Longer term costs and consequences will be discounted using the UK discount rates of 3.5% of both 
costs and effects. 
 z One way sensitivity analyses will be performed for all key parameters, especially for parameters in the 
models which are based on expert opinion. 
 z Probabilistic sensitivity analyses will be performed using parameter distributions instead of fixed values. 
 z Decision uncertainty regarding mutually exclusive alternatives will be reflected using cost-effectiveness 
planes and cost-effectiveness acceptability curves. 
A simple draft model structure is presented (Appendix 3); this may be developed/expanded as indicated 
(Appendix 3) and as available data allow.
Health outcomes
Utility values, based on literature or other sources, will be incorporated in the economic model. QALYs will 
be calculated from the economic modelling. 
Costs
Resource utilisation will be estimated for the diagnostic tests and treatments. Data for the cost analyses 
will be drawn from routine NHS sources (e.g. NHS reference costs, Personal Social Services Research 
Unit (PSSRU), British National Formulary (BNF)), discussions with individual hospitals and with the 
manufacturers of the comparators.
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7. Handling of information from the companies
All data submitted by the manufacturers/sponsors will be considered if received by the EAG no later than 
05/12/2011. Data arriving after this date will not be considered. If the data meet the inclusion criteria 
for the review they will be extracted and quality assessed in accordance with the procedures outlined in 
this protocol.
Any ‘commercial in confidence’ data provided by manufacturers, and specified as such, will be highlighted 
in blue and underlined in the assessment report (followed by company name in parentheses). Any 
‘academic in confidence’ data provided by manufacturers, and specified as such, will be highlighted 
in yellow and underlined in the assessment report. Any confidential data used in the cost-effectiveness 
models will also be highlighted.
8. Competing interests of authors
None
9. Timetable/milestones
Milestones Completion data
Draft protocol 16/09/2011
Final protocol 14/10/2011
Progress report w/c 05/12/2011
Draft assessment report 27/01/2012
Final assessment report 27/02/2012
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APPENDIX 1
Clinical effectiveness search 
Medline (OvidSP): 2000–2011/09/wk 1
Searched 15.9.11
1. neoplasm metastasis/ or neoplasm seeding/ or neoplasms, unknown primary/ (78927)
2. (Metasta$ or meta-sta$).ti,ab,ot,hw. (309063)
3. or/1-2 (311269)
4. (liver or hepato$ or hepatic$).ti,ab,ot,hw. (864813)
5. 3 and 4 (45882)
6. exp Liver Neoplasms/ (112164)
7. exp Bile Duct Neoplasms/ (11889)
8. Carcinoma, Hepatocellular/ (50647)
9. (FLL or FLLs).ti,ab,ot. (95)
10. Cholangiocarcinoma/ (4109)
11. ((liver$ or hepat$) adj3 (cancer$ or met$ or malignan$ or carcinoma$ or tumo?r$ or neoplas$ or 
adeno$ or angiom$ or sarcoma$ or angiosarcoma$)).ti,ab,ot,hw. (168313)
12. (hepatoma$ or h?emangiosarcoma$ or h?emangio-sarcoma$).ti,ab,ot,hw. (27634)
13. (Focal liver lesion$ and (cancer$ or met or mets or metasta$ or malignan$ or carcinoma$ or tumo?r$ 
or neoplas$ or adeno$ or angiom$ or sarcoma$ or angiosarcoma$)).ti,ab,ot,hw. (711)
14. (BFLL or BFLLS).ti,ab,ot. (3)
15.  (HCC or HCCs).ti,ab,ot. (18590)
16.  (Cholangiocarcinoma$ or Cholangio-carcinoma$).ti,ab,ot,hw. (6158)
17.  (Bile duct$ adj3 (cancer$ or met$ or malignan$ or lesion$ or carcinoma$ or tumo?r$ or neoplas$ or 
adeno$ or angiom$ or sarcoma$)).ti,ab,ot,hw. (14419)
18. or/5-17 (198600)
19. ultrasonography/ or ultrasonography, doppler/ or exp ultrasonography, doppler, duplex/ or exp 
ultrasonography, doppler, pulsed/ (89506)
20. ((ultrasonic$ or ultra-sonic$) adj4 (scan or imag$ or echogram$ or sonogra$ or detect$ or diagnos$ or 
exam$)).ti,ot,ab,hw. (6793)
21. (ultraso$ or ultra-so$ or sonogra$ or Echotomogra$ or Echo-tomogra$ or echoscope$ or echosound$ 
or Echogra$ or tomoechogra$ or tomo-echogra$).ti,ot,ab,hw. (274775)
22. or/19-21 (279114)
23. Sulfur Hexafluoride/ (1474)
24. (hexafluoruro-sulfurico or SF6 or SF-6 or sulphur hexafluoride$ or sulphur hexafluoride$ or sulfur 
hexafluoride$ or sulfur hexafluoride$).af. (2133)
25. or/23-24 (2133)
26. 22 and 25 (658)
27. (Sonovue or sono-vue or Sonavoid or Sonogen or sonagen or Sonavist).af. (499)
28. (CE-US or CEUS).ti,ab,ot. (516)
29. ((hexafluoruro-sulfurico or SF6 or SF-6) adj4 (US or ultraso$ or ultra-so$ or sonogra$ or Echotomogra$ 
or Echo-tomogra$ or echoscop$ or echosound$ or Echogra$ or tomoechogra$ or tomo-echogra$ or 
imag$)).af. (7)
30. ((Sulfur or Sulphur) adj2 (hexafluoride$ or hexa-fluoride$) adj4 (US or ultraso$ or ultra-so$ or 
sonogra$ or Echotomogra$ or Echo-tomogra$ or echoscop$ or echosound$ or Echogra$ or 
tomoechogra$ or tomo-echogra$ or imag$)).af. (28)
31. (SF6US or SF6-US or SF-6US or SF-6-US).af. (0)
32. ((SF6 or SF6 or sulphur hexafluoride$ or sulphur hexafluoride$ or sulfur hexafluoride$ or sulfur 
hexafluoride$) adj4 (bubbl$ or microbubbl$ or micro-bubbl$ or micropartic$ or micro-partic$)).af. 
(213)
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33. or/27-32 (991)
34. 26 or 33 (1183)
35. 18 and 34 (365)
36. exp Liver Neoplasms/us (2702)
37. Carcinoma, Hepatocellular/us (1258)
38. exp Bile Duct Neoplasms/us (375)
39. Cholangiocarcinoma/us (137)
40. Neoplasm Metastasis/us (51)
41. Neoplasm Seeding/ra (1)
42. Neoplasms, Unknown Primary/us (21)
43. or/36-42 (3089)
44. 25 and 43 (162)
45. 35 or 44 (366)
46. limit 45 to yr=”2000 -Current” (361)
47. animals/ not (animals/ and humans/) (3586762)
48. 46 not 47 (340)
Economic evaluations search 
Medline (OvidSP): 2000–2011/09/wk 1
Searched 15.9.11
1. economics/ (26160)
2. exp “costs and cost analysis”/ (159824)
3. economics, dental/ (1851)
4. exp “economics, hospital”/ (17418)
5. economics, medical/ (8505)
6. economics, nursing/ (3853)
7. economics, pharmaceutical/ (2276)
8. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).
ti,ab. (345758)
9. (expenditure$ not energy).ti,ab. (14613)
10. (value adj1 money).ti,ab. (20)
11. budget$.ti,ab. (14766)
12. or/1-11 (459756)
13. ((energy or oxygen) adj cost).ti,ab. (2351)
14. (metabolic adj cost).ti,ab. (614)
15. ((energy or oxygen) adj expenditure).ti,ab. (13513)
16. or/13-15 (15852)
17. 12 not 16 (456159)
18. letter.pt. (726087)
19. editorial.pt. (283742)
20. historical article.pt. (279927)
21. or/18-20 (1276679)
22. 17 not 21 (431461)
23. neoplasm metastasis/ or neoplasm seeding/ or neoplasms, unknown primary/ (78927)
24. (Metasta$ or meta-sta$).ti,ab,ot,hw. (309063)
25. or/23-24 (311269)
26. (liver or hepato$ or hepatic$).ti,ab,ot,hw. (864813)
27. 25 and 26 (45882)
28. exp Liver Neoplasms/ (112164)
29. exp Bile Duct Neoplasms/ (11889)
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30. Carcinoma, Hepatocellular/ (50647)
31. (FLL or FLLs).ti,ab,ot. (95)
32. Cholangiocarcinoma/ (4109)
33. ((liver$ or hepat$) adj3 (cancer$ or met$ or malignan$ or carcinoma$ or tumo?r$ or neoplas$ or 
adeno$ or angiom$ or sarcoma$ or angiosarcoma$)).ti,ab,ot,hw. (168313)
34. (hepatoma$ or h?emangiosarcoma$ or h?emangio-sarcoma$).ti,ab,ot,hw. (27634)
35. (Focal liver lesion$ and (cancer$ or met or mets or metasta$ or malignan$ or carcinoma$ or tumo?r$ 
or neoplas$ or adeno$ or angiom$ or sarcoma$ or angiosarcoma$)).ti,ab,ot,hw. (711)
36. (BFLL or BFLLS).ti,ab,ot. (3)
37. (HCC or HCCs).ti,ab,ot. (18590)
38. (Cholangiocarcinoma$ or Cholangio-carcinoma$).ti,ab,ot,hw. (6158)
39. (Bile duct$ adj3 (cancer$ or met$ or malignan$ or lesion$ or carcinoma$ or tumo?r$ or neoplas$ or 
adeno$ or angiom$ or sarcoma$)).ti,ab,ot,hw. (14419)
40. or/27-39 (198600)
41. ultrasonography/ or ultrasonography, doppler/ or exp ultrasonography, doppler, duplex/ or exp 
ultrasonography, doppler, pulsed/ (89506)
42. ((ultrasonic$ or ultra-sonic$) adj4 (scan or imag$ or echogram$ or sonogra$ or detect$ or diagnos$ or 
exam$)).ti,ot,ab,hw. (6793)
43. (ultraso$ or ultra-so$ or sonogra$ or Echotomogra$ or Echo-tomogra$ or echoscope$ or echosound$ 
or Echogra$ or tomoechogra$ or tomo-echogra$).ti,ot,ab,hw. (274775)
44. or/41-43 (279114)
45. Sulfur Hexafluoride/ (1474)
46. (hexafluoruro-sulfurico or SF6 or SF-6 or sulphur hexafluoride$ or sulphur hexafluoride$ or sulfur 
hexafluoride$ or sulfur hexafluoride$).af. (2133)
47. or/45-46 (2133)
48. 44 and 47 (658)
49. (Sonovue or sono-vue or Sonavoid or Sonogen or sonagen or Sonavist).af. (499)
50. (CE-US or CEUS).ti,ab,ot. (516)
51. ((hexafluoruro-sulfurico or SF6 or SF-6) adj4 (US or ultraso$ or ultra-so$ or sonogra$ or Echotomogra$ 
or Echo-tomogra$ or echoscop$ or echosound$ or Echogra$ or tomoechogra$ or tomo-echogra$ or 
imag$)).af. (7)
52. ((Sulfur or Sulphur) adj2 (hexafluoride$ or hexa-fluoride$) adj4 (US or ultraso$ or ultra-so$ or 
sonogra$ or Echotomogra$ or Echo-tomogra$ or echoscop$ or echosound$ or Echogra$ or 
tomoechogra$ or tomo-echogra$ or imag$)).af. (28)
53. (SF6US or SF6-US or SF-6US or SF-6-US).af. (0)
54. ((SF6 or SF6 or sulphur hexafluoride$ or sulphur hexafluoride$ or sulfur hexafluoride$ or sulfur 
hexafluoride$) adj4 (bubbl$ or microbubbl$ or micro-bubbl$ or micropartic$ or micro-partic$)).af. 
(213)
55. or/49-54 (991)
56. 48 or 55 (1183)
57. 40 and 56 (365)
58. exp Liver Neoplasms/us (2702)
59. Carcinoma, Hepatocellular/us (1258)
60. exp Bile Duct Neoplasms/us (375)
61. Cholangiocarcinoma/us (137)
62. Neoplasm Metastasis/us (51)
63. Neoplasm Seeding/ra (1)
64. Neoplasms, Unknown Primary/us (21)
65. or/58-64 (3089)
66. 47 and 65 (162)
67. 57 or 66 (366)
68. limit 67 to yr=”2000 -Current” (361)
69. animals/ not (animals/ and humans/) (3586762)
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70. 68 not 69 (340)
71. 22 and 70 (19)
Economics filter:
Centre for Reviews and Dissemination. NHS EED Economics Filter: Medline (Ovid) monthly search [Internet]. 
York: Centre for Reviews and Dissemination; 2010 [cited 28.9.10]. Available from: http://www.york.ac.uk/
inst/crd/intertasc/nhs_eed_strategies.html
APPENDIX 2
NICE guidelines on interventions for the treatment of liver 
malignancies.
1. Cryotherapy for the treatment of metastases. NICE interventional procedure guidance 369 (2010). 
Available from http://guidance.nice.org.uk/IPG369
2. Ex-vivo hepatic resection and reimplantation for liver cancer. NICE interventional procedure 
guidance 298 (2009). Available from http://guidance.nice.org.uk/IPG298
3. Laparoscopic liver resection. NICE interventional procedure guidance 135 (2005). Available from 
http://guidance.nice.org.uk/IPG135
4. Microwave ablation for the treatment of liver metastases.  NICE interventional procedure guidance 
406 (2011). Available from http://guidance.nice.org.uk/IPG406
5. Microwave ablation of hepatocellular carcinoma.  NICE interventional procedure guidance 214 
(2007). Available from http://guidance.nice.org.uk/IPG214
6. Radiofrequency ablation of hepatocellular carcinoma. NICE interventional procedure guidance 2 
(2003). Available from http://guidance.nice.org.uk/IPG2
7. Radiofrequency-assisted liver resection. NICE interventional procedure guidance 211 (2007). 
Available from http://guidance.nice.org.uk/IPG211
8. Selective internal radiation therapy for non-resectable colorectal metastases in the liver.  NICE 
interventional procedure guidance 401 (2011). Available from http://guidance.nice.org.uk/IPG401
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APPENDIX 3
Draft model structure
Different types of FLL have not yet been included in this structure. This information could be added, if 
evidence is available.
There seems to be reasonable possibility of detecting false test results in the course of treatment/
follow up. This is not yet incorporated in the model, but may potentially influence the outcomes of the 
analysis considerably.
Direct health effects of the diagnostic procedures are not yet included, this could be done if relevant.
CE MR (similar to CE US structure)
CE CT (similar to CE US structure)
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Palliative treatment
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